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For the foreseeable future, public health professionals can expect fiscal concerns to heavilyinfluence health and prevention policies. Without a thorough understanding of the costs and
the impact of health services, we run the risk of losing resources to provide these services.
No matter how compelling the arguments of need, equity, or compassion are, policymakers will need
evidence of economic efficiency to accompany information on health improvement. Without such
cost-related data, those of us who advocate for the health and well-being of women and children will
be diminished in our effectiveness.
To address this need, the Division of Reproductive Health, National Center for Chronic Disease
Prevention and Health Promotion, Centers for Disease Control and Prevention, has assembled
relevant literature on economic issues in reproductive health. This annotated bibliography covers
published reports from 1980 to 1993 and includes 266 abstracted articles and 238 additional
references. It addresses a wide range of concerns in women's and children's health and presents
studies on cost-benefit, cost-effectiveness, cost utility, and other economic analyses. Along with
studies of specific conditions, it includes articles related to methodology in economic analysis that will
aid us all in becoming more informed users of economic reports. Although our literature search may
not have identified all relevant material, we believe that this bibliography provides useful information
on the state of knowledge in this field as it relates to reproductive health.
A review of the articles presented in this bibliography indicates that much information is already
available on the economics of women's and children's health. For example, some topics, such as
neonatal intensive care and birth defects screening services, have received extensive attention and
analyses. But many gaps still exist. Pediatric passive smoke exposure, for example, is only
beginning to be examined from an economic perspective. We hope that this bibliography will aid in
highlighting both the depth and the gaps in our current knowledge and will prepare us to make use of
what is known and to investigate what remains to be learned.
Readers are cautioned to examine these studies with care because the methods of analysis are not yet
standardized—papers with different findings may represent quite different approaches to the issue
under investigation. The challenges facing researchers who study the economic health issues
concerning women and children include defining the measurements of costs, identifying the services
whose costs will be assessed, and defining the duration over which outcomes will be measured.
Variations in definitions for each of these variables can produce different conclusions.
As public health workers have always known, we must also recognize that decisions regarding the
best use of public resources are not based solely on economic concerns. The most sophisticated
techniques of cost measurement cannot describe all the benefits and disadvantages of a specific health
program. Furthermore, such decisions must take into account the public's will to act on a health
problem even if money is not saved or an intervention is costly. Economic analyses may usefully
inform these decisions but are unlikely to provide the complete answer to the question, "Is this health
service appropriate?" Even if some highly regarded preventive interventions are found costly for a
given impact, such analysis can point researchers toward finding more efficient and less costly
approaches.
in
We hope public health professionals in both practice and academia, clinicians, insurers, and others
concerned with the health of women and children will find this a useful compilation. As advocates,
we need to give decision makers the factual basis upon which to decide with confidence that fiscal
prudence, along with altruistic concern, favors a woman- and child-oriented approach to health care.
IV
How to Use This Publication
Arrangement of Items
Items in this publication are arranged in seven sections: (1) Infant and Child Health; (2) Birth
Defects, Mental Retardation, and Chronic Conditions; (3) Maternal Health; (4) Family Planning and
Women's Reproductive Health; (5) Nutrition; (6) International Health; and (7) Methods. The sections
are divided into several parts. Items in each part are listed in alphabetical order by author. The
items are numbered sequentially, beginning with 001.
Space considerations did not allow for abstracting of every item we chose to include in this
publication. The nonabstracted items are contained in the Reference Lists at the end of their relevant
section and are denoted with an "R" before their sequential number.
Indexes
This publication contains three indexes. The Title Index lists document titles. The Author Index lists
personal and corporate authors. The Subject Index lists selected key words describing the content of
publications. If you know the title of a publication, use the Title Index. If you are looking for a
publication produced by a particular person or agency, use the Author Index. If you want to identify
items in a specific subject area, such as smoking education programs, use the Subject Index.
Data Elements
A citation and abstract are listed for each item in this publication. Data elements include the item
number, title, form, author or corporate author, source, and abstract.
Sample Description:
Item Number 109
Title Costs and Benefits of Screening for PKU in Wisconsin.
Form Journal article.
Author Barden, H.S.; Kessel, R.; Schuett, V.E.
Source Social Biology . 31(1-2): 1-17, Spring-Summer 1984.
Abstract Researchers conducted a comprehensive cost-benefit analysis of a screening program to detect
newborns with phenylketonuria (PKU) in Wisconsin. Classic PKU is a genetic disorder which, if
undetected and untreated during the first few weeks of life, generally results in mental retardation and
a variety of other abnormal conditions. Researchers compared monetary costs of the detection and
treatment program with the projected benefits (avoided costs) that result from the prevention of the
mental retardation associated with the disorder. Investigators determined future costs and benefits
using a 4 percent, 7 percent, and 10 percent rate of discount to achieve comparability between the
present and future costs. The estimated costs of the State Laboratory of Hygiene for PKU testing for 1
year were $104,740 for 78,050 samples. Actual costs of collecting a blood specimen for testing were
estimated at $4.60 per collection. Treatment costs for PKU for a 20-year period (discounted at 7
percent) were estimated at $40,830. Net benefits (benefits minus costs) for detecting and treating one
person with PKU were $208,000 ($292,000 minus $84,000) using the 7 percent rate of discount. Net
benefits for detecting four persons with PKU per year in Wisconsin totaled $832,000, a large rate of
return on a relatively small investment. 10 tables, 42 references.
Obtaining Additional Information
Questions about this publication may be directed to:
Division of Reproductive Health
National Center for Chronic Disease Prevention and Health Promotion
Centers for Disease Control and Prevention
4770 Buford Hwy, NE, Mailstop K-22
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Guidelines for Health Technology
Assessment: The Efficacy, Effectiveness,
and Efficiency of Neonatal Intensive Care.
Form: Journal article.
Author: Bennett, K.J.; Feeny, D.;
Guyatt, G.H.; Tugwell, P.; Drummond, M.F.
Source: International Journal of Technology
Assessment in Health Care.
l(4):873-892, 1985.
Abstract: Researchers discussed the efficacy,
community effectiveness, and efficiency of
neonatal intensive care (NIC). They used the
Technology Assessment Iterative Loop (TAIL)
as a comprehensive framework for evaluating
health care technologies and their impact on
community health. TAIL contained seven
steps: (1) Burden of illness, (2) efficacy
(therapeutic potential), (3) diagnosis and
screening, (4) community effectiveness, (5)
efficiency, (6) synthesis and implementation,
and (7) monitoring and reassessment. Efficacy
and community effectiveness guidelines
determined (1) the appropriateness of the
question, (2) whether the design of the studies
was sufficiently rigorous for making policy
decisions, (3) whether the intervention avoided
bias, (4) the accuracy of the measurement of
all relevant outcomes, (5) whether the results
were applicable to the setting, and (6) the
validity of the data analysis. The authors
evaluated current studies on NIC using
guidelines in relation to morbidity and
mortality and quality of life years (QALY).
They stated that a study by Boyle et al. that
evaluated NIC for infants less than or equal to
1,500 grams, was the best evidence upon
which to base estimates of impact. Boyle et
al. showed an overall decrease from 58.7 to
39.2 percent in neonatal mortality for very low
birthweight infants, and a 19.5 percent
absolute decrease or a 33 percent risk
reduction in mortality. Examination of the
results by birthweight group showed that the
mortality reduction was greater in the 1 ,000-
1 ,499 gram group than the 500-999 gram
group (1,000-1,4999 gram group: 36.6 to
21.6 percent or 41 percent risk reduction; 500-
999 gram group: 88.1 to 69.4 percent or 21
percent risk reduction). Efficiency guidelines
determined (1) the appropriateness of the
choice of level of approach, (2) the definition
of the viewpoint for the analysis, (3) the
appropriateness of the relevant range of
alternatives, (4) the appropriateness of the
selection of the form of economic evaluation,
(5) the identification of the relevant range of
costs and benefits, (6) the comprehensiveness
and accuracy of the estimation of costs and
benefits, (7) the distinction between average
and marginal costs and benefits, (8)
consideration of an allowance for differential
timing of costs and benefits, (9) consideration
of an allowance for uncertainty in costs and
benefits, and (10) the presentation of the
results. The authors used the study by Boyle
et al. to review efficiency and economic
outcomes according to birth class. Total
economic outcomes in undiscounted 1978
Canadian dollars were $92,500 without NIC
and $100,100 with NIC for birthweight 1,000
to 1,499 grams and $11,000 without NIC and
$43,600 with NIC for birthweight 500 to 999
grams. Measures of economic evaluation of
NIC according to birthweight class in 1978
Canadian dollars were for 1 ,000 to 1 ,499
grams: $59,500 per additional survivor to
hospital discharge, $4,100 per year of life
gained to age 15, $5,100 per QALY to age 15,
$900 per life-year and QALY gained to death,
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and $24,700 net economic benefit per live
birth. For birthweight class 500 to 999 grams,
the measures were $102,500 per additional
survivor to hospital discharge, $9,400 per year
of life gained to age 15, $30,900 per QALY to
age 15, $5,100 per life-year and $9,000
QALY gained to death, $3,700 net economic
loss per live birth, $600 net economic cost per
year of life gained, and $1,000 per QALY
gained. Discounted at 5 percent in 1978
Canadian dollars, for 1,000 to 1,499 grams,
the net economic loss was $2,600 per life
gained, $900 net economic cost per life-year
gained, and $1,000 net economic cost per
QALY gained. For 500 to 999 grams, the net
economic loss was $16,100 per life gained,
$7,300 net economic cost per life-year gained,
and $17,500 net economic cost per QALY
gained. The authors conclude that NIC is an
effective intervention for the care of low
birthweight neonates, especially for the 1,000
to 1,499 gram group. For the 500 to 999 gram
group increased survival rates are less and
NIC is less effective in terms of the resulting
quality of life for survivors.
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Economic Evaluation of Neonatal Intensive
Care of Very-low-birth-weight Infants.
Form: Journal article.
Author: Boyle, M.H.; Torrance, G.W.;
Sinclair, J.C.; Horwood, S.P.
Source: New England Journal of Medicine.
308(22): 1330-1337, June 2, 1983.
Abstract: Researchers evaluated the economic
aspects of neonatal intensive care of very-low-
birthweight infants (less than 1,500 grams)
using outcomes and costs of care before and
after the introduction of a regional neonatal
intensive care program. The study made
comparisons from birth to the time of hospital
discharge, to age 15, and to the time of death.
The study included (1) 373 very-low-
birthweight infants born live to residents of
Hamilton-Wentworth County in Ontario,
Canada, from July 1964 to December 1969
and (2) 265 very-low-birthweight infants born
live in the same county from January 1973 to
December 1977. Researchers calculated the
incremental costs, effects, and earnings
associated with the provision of neonatal
intensive care in the county. Costs included
neonatal intensive care costs and followup
costs to the health care sector and other
sectors. All costs were expressed in 1978
Canadian dollars. Effects included numbers of
lives saved, life-years gained, and quality-
adjusted life years (QALY) gained.
Researchers subtracted earnings from costs to
yield a net economic cost. Data analysis
indicated neonatal intensive care increased both
survival rates and costs. Among infants
weighing 1,000 to 1,499 grams, 133 of 213
(62.4 percent) survived without intensive care
as compared with 129 of 167 infants (77.2
percent) who survived in the intensive-care
era. Among infants weighing 500 to 999
grams, the survival rate with intensive care
increased from 17 of 160 (10.6 percent) to 22
of 98 (22.4 percent). The projected survival
rate to age 15 per live birth for infants
weighing 1 ,000 to 1 ,499 grams who survived
without intensive care was 9.0 and for infants
who received the intensive care was 11.1. The
projected survival rate to age 15 per live birth
for infants weighing 500 to 999 grams who
survived without intensive care was 1.46 and
for infants who received the intensive care was
3.37. Projected QALY's per live birth to
death for infants weighing 1 ,000 to 1 ,499
grams who survived without intensive care
were 27.4 as compared with 36.0 for infants
who received intensive care. Projected
QALY's per live birth to death for infants
weighing 500 to 999 grams who survived
without intensive care were 5.5 as compared
with 9.1 for infants who received intensive
care. Projected earnings per live birth to death
for infants weighing 1,000 to 1,499 grams
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who survived without intensive care were (in
1978 Canadian dollars) $122,200 as compared
with $154,500 for infants who received
intensive care. Among infants weighing 500
to 999 grams, projected earnings per live birth
to death before intensive care were $19,200
and after intensive care were $48,100. By
every measure of economic evaluation, the
impact of neonatal intensive care was more
favorable among infants weighing 1 ,000 to
1 ,499 grams than among those weighing 500
to 999 grams. 2 figures, 4 tables, 36
references.
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Source: Canadian Medical Association
Journal. 139(10):943-946, November 1988.
Abstract: During the past decade, the rate of
death among newborns weighing less than
1,500 grams at birth has decreased by
approximately half. The reduction is due in
part to the application of research findings and
technological advances, but it is very
expensive. The overall prevalence of
disabilities in infants is relatively unchanged.
Recently, researchers have begun viewing
neonatal intensive care as a possible area for
cost containment. Based on a cost-benefit
analysis, Walker and colleagues concluded that
neonatal intensive care for infants weighing
less than 900 grams at birth may not be
justified. A review of literature on the cost of
neonatal intensive care and the limited
information available on other expensive
medical programs found that the cost of
neonatal intensive care compares favorably
with that of other expensive medical programs,
especially for infants weighing 1,000 to 1,500
grams at birth. According to one Ontario
study, for newborns weighing 1000 to 1500
grams the neonatal cost was $59,500 for each
additional survivor, $2,900 for each life-year
gained and $3,200 for each life-year gained
adjusted for quality of life. The corresponding
costs for newborns weighing 500 to 999 grams
were $102,500, $9,300, and $22,400. On the
basis of cost per quality-adjusted life-year, the
neonatal intensive care for infants weighing
between 1 ,000 and 1 ,499 grams at birth
compared favorably with (1) screening for
thyroid disorders, (2) treatment of men with
hypertension, (3) coronary artery bypass
surgery for patients with single-vessel disease
and moderate-to-severe angina, (4) continuous
ambulatory peritoneal dialysis, and (5) in-
hospital hemodialysis. The extent of increase
in survival rates frequently seems to be
overlooked in considerations of the restriction
of neonatal intensive care application. In
Sweden, the application of modern perinatal
intensive care increased the overall survival
rate of infants weighing less than 1,500 grams
at birth by 3.8 per 1,000 live births; however,
the increase was accompanied by an increase
of 0.1 children with cerebral palsy per 1,000
live births. Before health professionals make
decisions to limit neonatal intensive care on
the basis of gestational age or birthweight,
they (1) should obtain better information on
the outcome of infants of very low
birthweight, (2) should conduct comparable
rigorous studies of the cost effectiveness of
other expensive medical programs, and (3)
should consider other, less easily quantified
factors. Decision makers should use the best
available information to make choices on
behalf of newborns. 1 table, 21 references.
Infant and Child Health
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Citywide Neonatal Program. Ten Years
Experience.
Form: Journal article.
Author: Chiu, T.; Garrison, R.D.;
Lilly, V.S.; Lim, M.O.; Rawlings, D.J.
Source: Journal of the Florida Medical
Association. 77(2): 101-104, February 1990.
Abstract: Researchers describe a citywide
neonatal program initiated in Jacksonville,
Florida, in July 1978 and its progress through
December 1988. The program instituted
contractual agreements with all hospitals
providing obstetrical services in the
metropolitan area to provide neonatal coverage
for the city in a cooperative rather than
competitive fashion, mainly to insure the
availability of Level Two stepdown neonatal
care. Admissions, occupancy rate, and patient
care days served by the Regional Perinatal
Intensive Care Center (RPICC) and the Level
Two nurseries had increased to capacity.
More stepdown care beds were made available
by this cost-effective program. In 10 years,
7,337 infants were transferred to the affiliated
Level Two nurseries in Jacksonville for care.
Estimated average cost for 237 infants in the
RPICC would have amounted to $2,031,120
for 14 days in 1988. Actual cost after transfer
from the RPICC to the stepdown care units
was $1,638,600, a total estimated savings of
$392,520, or $1,808 per patient. In
comparison, in 1981 the savings was $923 per
patient for 116 infants, demonstrating the rise
in cost savings from the program. Major
achievements of the program include the
physician extender coverage system;
standardization of forms, charts, and
protocols; and better understanding of the
program by the health maintenance and
preferred provider organizations so that
patients can be freely transferred between the
participating hospitals based on medical needs
rather than insurance guidelines. The program
is more cost-effective than traditional
competitive models and helps decrease the
liability exposure of individual hospitals.
Cities with only one Level Three center should
explore the possibility of establishing this type
of program. 3 tables, 6 references.
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Surfactant Replacement Therapy in
Neonates Less Than 32 Weeks Gestation:
Effect on Neonatal Intensive Care Resource
Utilization.
Form: Journal article.
Author: Diwaker, K.; Roberts, S.; John, E.
Source: Journal of Paediatrics and Child
Health. 29(6):434-437, December 1993.
Abstract: Researchers studied the effect of
synthetic surfactant (Exosurf) replacement on
complications from hyaline membrane disease
(HMD) in infants less than 32 weeks gestation
and their resource utilization within a neonatal
intensive care unit at Westmead Hospital, New
South Wales, Australia during 1991-1992. A
control group was selected from infants
admitted to the same unit during the preceding
3 years when Exosurf was not available. The
study group consisted of all infants (192) less
than 32 weeks gestation treated with Exosurf
for HMD at Westmead Hospital during 1991-
1992. One hundred fifty-five different
procedures in 192 infants were studied; the
majority of procedures were studied on 10
different occasions. The cost of each level of
care for each of the 192 infants was calculated
based on the activities around the infant,
documented over 24-hour periods. Cost of
medical care was determined by observing the
level of activity around a cohort of patients of
varying gestation and disease states, by an
independent observer (SR). Each activity was
timed and the equipment and consumable items
used documented. The cost of each procedure
was calculated based on actual time spent by
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personnel doing the procedure, the cost of
consumables, and the depreciation of capital
equipment used. Researchers calculated the
average cost per day per infant in 1990
Australian dollars at four levels of nursing care
in nurse:patient ratio: (1) for an unstable
infant, level 1:1, $1,286.94; (2) for a
stabilized infant, level 1:2, $622.83; (3) for an
infant who had been extubated but required
constant monitoring and total parenteral
nutrition, level 1:3, $376.67; and (4) for an
infant who required no life support but needed
cardio-respiratory monitoring, level 1:4,
$265.57. The cost of care for an unstable
infant was twice the cost of care of an infant
who had stabilized and nearly four times the
cost of care of the infant who had been
extubated. A total of 82 infants with moderate
to severe HMD were studied, 41 of whom
were born in 1991 and were given Exosurf.
The 41 control infants were born during 1988-
90 and had not received any form of artificial
surfactant. Infants given Exosurf had a
significant reduction in the incidence of
pulmonary interstitial emphysema (PIE), and a
marginal decrease in the incidence of
pneumothorax. In assessing benefits of
Exosurf in infants born between 24-26 weeks,
27-29 weeks, and 30-31 weeks, it was evident
that the benefit was more marked in the older
gestational groups. In the infants born
between 24-26 weeks (4), the number of days
in intermittent mandatory ventilation (IMV)
was 11.5 for the Exosurf study group and 16.5
for the control group, and the costs per group
in 1990 Australian dollars were $40,467 for
the Exosurf group and $48,359 for the control
group. In the infants born between 27-29
weeks (19), the number of days in IMV was
7.5 for the Exosurf study group and 11 for the
control group, and the costs per group in 1990
Australian dollars were $28,079 for the
Exosurf group and $38,818 for the control
group. In the infants born between 30-31
weeks (12), the number of days in IMV was
4.5 for the Exosurf study group and 6 for the
control group, and the costs per group in 1990
Australian dollars were $13,973 for the
Exosurf group and $20,166 for the control
group. The older infants required fewer days
on the ventilator and consumed less of the
scarce financial resources. There was no
difference in the mortality rate among the two
groups. Exogenous surfactant is effective in
reducing short-term morbidity and cost of
intensive care in preterm infants with HMD.
5 tables, 17 references.
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Increasing the Survival of Extremely-
immature (24 to 28 Weeks' Gestation)
Infants: At What Cost?
Form: Journal article.
Author: Doyle, L.W.; Murton, L.J.;
Kitchen, W.H.
Source: Medical Journal of Australia.
150(10):558-563, 567-568, May 15, 1989.
Abstract: Researchers at the Royal Women's
Hospital in Melbourne, Australia, studied live-
born infants of 24-28 weeks' gestation during
1977-1983 (616 infants) and during 1984-1986
(193 infants) to determine the cost-
effectiveness of intensive care up to the time of
hospital discharge over two separate eras of
stable consumption of resources for assisted
ventilation. Researchers also compared costs
(consumption of nursery resources) and
outcomes (survival) among three eras: 1971-
1974, 1977-1983, and 1984-1986. For each
infant who was born during 1977-1986, the
number of patient days that were consumed for
assisted ventilation, the number of patient days
of stay in the intensive care unit, and the
number of patient days of stay in the special
care nursery were recorded. The number of
patient days in the intensive care unit without
assisted ventilation and the number of patient
days in the special care nursery were
converted into equivalent numbers of patient
Infant and Child Health
days of assisted ventilation by assuming their
worth in proportion to the nurse-patient ratios
that are usually assigned to the respective
levels of care: One patient day of assisted
ventilation equals two patient days in the
intensive care unit with no ventilation, which
equals three patient days in the special care
nursery. Dollar costs, in Australian dollars for
1986-1987, were multiplied by the equivalent
number of patient days of assisted ventilation
that were consumed to estimate the expenses.
During 1977-1983, compared with producing
one survivor at 28 weeks' gestation, producing
one survivor at 24 weeks' gestation consumed
14.4 times the number of patient-days of
assisted ventilation (168.25 patient days for
one survivor at 24 weeks' gestation versus
34.32 patient days for one survivor at 28
weeks' gestation); the cost-effectiveness of
intensive care during this period decreased
with decreasing maturity. The overall cost-
effectiveness up to the time of hospital
discharge for infants of 24 to 28 weeks'
gestation during 1977-1983 (an era of
moderate assisted ventilation) compared with
1971-1974 (when assisted ventilation was rare)
was A$62,268 per additional survivor. After
1983, the consumption of resources for
assisted ventilation more than doubled in
infants of 24 to 28 weeks' gestation.
However, there was a diminishing return with
respect to the gains in survival during 1984-
1986 and the costs per additional survivor
averaged A$99,574, which was 60 percent
more than costs for 1977-1983. Researchers
speculate that improving survival further in the
most immature infants by increasing resources
for assisted ventilation only can be more
difficult and more expensive, and even less
cost-effective. 1 figure, 6 tables, 12
references.
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Financial Impact of the High Technology
Newborn.
Form: Journal article.
Author: Edell, D.S.; Banton, D.L.;
Browning, I.B.
Source: North Carolina Medical Journal.
52(2):97-99, February 1991.
Abstract: Each year, 50,000 high-risk infants
are born in the United States and are treated at
a cost of $1.5 billion. The cost for specialized
health care of low birthweight babies ranges
from $16,000-$250,000 per infant. Medical
costs for the morbidity of those who survive
the neonatal period are astronomical. The
average medical care costs of raising a child
from birth to age three range from $22 a
month to $26.80 a month for the
northeastern/north central United States and
the urban western United States, respectively.
Estimated average medical care costs of raising
a neonatal intensive care unit graduate until
age three are as follows: With no disability,
$62.60/month; with mild developmental
disability, $414.20/month; with moderate/
severe developmental disability,
$650.90/month; and with developmental
disability and institutionalization,
$l,216/month. In one study, of 60 children
released from intensive care and followed until
age three, 35 had developmental deficits. The
total health care cost after discharge from the
intensive care unit was $336,654. Costs that
contributed to this amount included primary
health care, hospital emergency room visits,
radiological studies, blood tests, specialty
clinic visits, and the cost of specialized
equipment. When adjusted for birthweight,
the neonatal mortality rate in the United States
is among the lowest in the world, but at the
greatest cost. Society is faced with a situation
in which advanced technology has produced
the high-tech, high-priced neonate. The
burden of the neonatal intensive care graduate
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is draining the health care system and will
eventually break it, if changes are not
instituted immediately. The authors conclude
that prevention of low birthweight infants and
the resulting high cost mortality and morbidity
must become the directive of all concerned.
10 references.
008
Estimated Costs of Different Treatments of
the Respiratory Distress Syndrome in a
Large Cohort of Preterm Infants of Less
Than 30 Weeks of Gestation.
Form: Journal article.
Author: Egberts, J.
Source: Biology of the Neonate.
61 (Supplement 1): 59-65, 1992.
Abstract: Researchers used data from a well-
defined population of preterm infants to
calculate the costs of various types of
treatment to prevent or alleviate respiratory
distress syndrome (RDS) in preterm neonates.
The study population included 468 preterm
babies less than 30 weeks' gestation who were
born in the Netherlands in 1983. Of these,
309 (66 percent) developed RDS, of whom
159 (51 percent) babies died; 65 of the 155
infants who did not develop RDS died of other
causes. Researchers derived estimates of the
effects of corticosteroids or surfactant on the
incidence of RDS and the mortality due to
RDS from overviews and expressed them as
typical odds ratios with 95 percent confidence
limits. Daily costs were care-related and the
price per day was based on the year-price per
bed reported in 1990 by the Central
Organization for Tariffs of Health Care in the
Netherlands, then corrected for an 80 percent
occupancy. The 1990 cost of intensive care
and high dependence care was Dfl 1,164 per
day and the special care cost was Dfl 510 per
day ($1.00 equals Dfl 1.85). Within a model
cohort of 1 ,000 preterm infants of less than 30
weeks' gestation, the incidence and mortality
of RDS change if corticosteroids are used
prenatally and surfactant prophylactically or
therapeutically after birth. Combined prenatal
and postnatal therapies give the best results
(approximately 125 extra survivors).
Therapeutic surfactant administration even in
combination with prenatal corticosteroids has
cost implications (Dfl 67,700; $36,595)
because extra intensive care beds (7-11
percent) are needed. More special care places
(12-24 percent) are required after each type of
intervention. Estimated costs per extra
survivor are the lowest for prenatal
corticosteroid administration. The combination
of corticosteroids prenatally and surfactant
postnatally seems to be most cost-effective
because it produces the most survivors and the
lowest number of intensive and high
dependency care days in hospital. 1 figure, 2
tables, 16 references.
009
Cost of Neonatal Care Across a Regional
Health Authority.
Form: Journal article.
Author: Fordham, R.; Field, D.J.;
Hodges, S.; Normand, C; Mason, E.;
Burton, P.; Yates, J.; Male, S.
Source: Journal of Public Health Medicine.
14(2): 127-130, June 1992.
Abstract: Researchers in Great Britain studied
17 hospitals in one regional health authority to
examine (1) the relative cost of intensive care
and special care for newborns and (2)
economies of scale. They collected clinical
data for 1987 in two parts, first gathering
workload information on a day-to-day basis
from each neonatal unit, and then collecting
hospital cost information using a 3-stage postal
questionnaire with telephone followup.
Investigators used multiple regression models
to separate out the effects on costs of scale (as
Infant and Child Health
measured by the total numbers of cot days in
the unit) from the case mix (measured by the
proportion of the days in intensive care). The
dependent variable was average cost per cot
days (size) and the independent variables were
the number of cot days (size) and the
proportion of intensive care cases (case mix).
The expected costs for a unit providing 1 ,000
cot days in total were (in 1988 pounds sterling)
467 pounds for intensive care and 181 pounds
for special care; for larger units with 3,000 cot
days, costs were 380 pounds for intensive care
and 113 pounds for special care. There is
clear evidence of economies of scale: The
quadratic form showed average cost per cot
day falling by 50 pounds between 1,000-2,000
cot days, 40 pounds between 2,000-3,000 cot
days, but only by 10 pounds per day between
5,000-6,000 cot days. The study lends support
to a previous study that found that intensive
care is three times as expensive as special care
in a typical large hospital. Economies of scale
became small above 4,000 cot days (around
13-14 cots). 4 tables, 11 references.
010
Cost of Care of the Less-Than-1000-Gram
Infant.
Form: Journal article.
Author: Hernandez, J. A.; Offutt, J.;
Butterfield, L.J.
Source: Climes in Perinatology.
13(2):461-476, June 1986.
Abstract: Researchers report their
experiences in the management and cost of
hospital care of preterm infants weighing less
than 1 ,000 grams who were cared for at the
Newborn Center of The Children's Hospital in
Denver, Colorado. Between January 1984 and
June 1985, 128 outborn infants weighing less
than 1 ,000 grams were admitted to the center
and received all their care there until time of
discharge. Birthweight ranged from 435 to
1 ,000 grams and gestational ages ranged from
23-31 weeks. Researchers reviewed patients'
records and collected data referring to (1)
mortality, (2) duration of hospitalization, and
(3) hospital charges. Researchers reviewed
hospital records of infants with a birthweight
less than 1,000 grams from 1981-1984 to
establish survival rate, age at time of death,
and length of stay. Provision of care was
arbitrarily divided into levels of care: During
high intensity and intermediate intensity care
(level three), infants received full ventilatory
and nutritional support and the nurse-patient
ratio was 1:1 or 1:2; during low intensity
intensive care and convalescent care (level
two), the nurse-patient ratio was 1:2 or 1:3.
Charges were identified for level two and level
three care in nine categories: (1) Daily room
charges, (2) nursing charges, (3) respiratory
therapy, (4) blood gas analysis, (5) pharmacy,
(6) laboratory, (7) radiology, (8) central
supply, and (9) miscellaneous. Physicians'
fees were not included. Total and daily
charges (bills sent out by the hospital for
services) and costs (financial resources the
hospital required to provide neonatal care) for
all infants (survivors and nonsurvivors) were
calculated. The average length of survival for
neonatal deaths was 19 days, ranging between
1-162 days. The average length of
hospitalization for surviving infants was 89
days, with a range of 49 to 197 days. Costs
increased significantly as birthweight decreased
and length of stay increased. The average cost
for survivors was $902 and for nonsurvivors
$1,183. Daily average level three care cost
$1,000 per day; of that, approximately 37
percent was for nursing care, 26 percent was
for support and management of ventilation and
oxygenation, and 20.3 percent was for direct
room charges. Daily average level two care
cost was $441 per day; changes in cost derived
from nursing care acuity and decreased cost
from respiratory therapy, laboratory, and
ancillary services. 6 figures, 5 tables, 60
references.
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Cost Efficiency of Neonatal Nurseries: The
Significance of Unit Size.
Form: Journal article.
Author: John, E.; Hind, N.; Roberts, V.;
Roberts, S.
Source: Australian Journal of Public Health.
15(3):242-244, September 1991.
Abstract: Using data from a larger study in
which cost analysis of neonatal intensive care
was done prospectively from July 1988
through June 1989, researchers in Australia
examined the relationship of neonatal intensive
care unit (NICU) size to cost and determined
the optimum and minimum size of the unit in
terms of cost efficiency. They identified
categories of costs within the nursery
considered essential for patient care, including
costs of (1) personnel, (2) equipment, (3)
disposable items, (4) drugs, and (5) food.
Requirements for units with 1-16 ventilator
cots were determined from published data and
discussions with peers. All cost calculations
were based on a 100-percent occupancy rate.
The major pieces of equipment (i.e., mobile
radiographic equipment and blood gas
analyzer) were costed at 1989 value and
divided by the life span of the equipment to
achieve yearly depreciation, which was
summed with the maintenance cost and used as
the cost of the equipment for the year. Costs
were examined for Level three NICU's
(ventilator and nonventilator) and Level two's
(high-dependency neonatal care). Findings
suggest that units with fewer than 6 ventilator
cots were less cost-efficient than those with
more cots while those with 12 ventilator cots
were the most efficient. The calculations were
done only up to 16 ventilator cots. Similarly,
Level two units were most cost-efficient when
attached to an intensive-care unit and had more
than 16 cots. Optimal cost efficiency was
achieved with 12 ventilator cots, 8 Level three
nonventilator cots, 16-20 Level two cots, and a
unit size of 36-40 cots. When incremental
costs were considered, the most cost-efficient
establishment involved 11-12 ventilator cots
with all the required stepdown cots. Larger
numbers would be cost-efficient, but the unit
could become too large to be clinically
efficient. The source document does not
provide specific cost information. 2 figures, 2
tables, 11 references.
012
Cost of Neonatal Intensive Care.
Form: Journal article.
Author: John, E.; Lee, K.; Li, G.M.
Source: Australian Paediatrics Journal.
19(3): 152-156, September 1983.
Abstract: Researchers in Australia analyzed
the costs of providing intensive care to inborn
babies in an inner city hospital equipped to
deal with high-risk obstetrics. Costs included
all services, materials, and maintenance related
to nursing and medical care for inborn babies
in 1981; the hospital had 4,000 births that
year. Of 136 babies admitted to the intensive
care nursery in 1981, 16 were transferred,
leaving 120 babies for consideration. Costs
showed the expected inverse proportion to
birthweight. Total cost of care for the 120
babies was $1 million. Average cost per baby
was $8,644. The cost per survivor, adjusted
to reflect the fact that survivors are the
beneficiaries of the total outlay, was greater
($10,170) than the average cost, and the cost
per year of life saved was $145. A larger
number of more mature babies nevertheless
contributed almost two-thirds of the total cost.
The adjusted cost per survivor (adjusted to
reflect the fact that only the survivors benefit)
was $39,845 for babies less than 801 grams;
$26,100 for those between 801 grams and
1,000 grams; $14,137 between 1,001 grams
and 1,500 grams; and $4,782 over 1,500
grams. The largest single expense was in
Infant and Child Health
nursing salaries, which constituted 60-80
percent of the total outlay. No data are
available for precise comparison. Researchers
present these figures as a basis on which to
begin forming judgments of the cost
effectiveness of newborn intensive care. 6
tables, 18 references.
therapy decreased $901 per day spent in utero
and decreased $3,776 per 100 grams of weight
gained in utero. Researchers conclude that the
noted decrease in hospital costs should not
justify prenatal glucocorticoid administration
but should stimulate examination of long-term
effects of the drug on surviving infants. 3
tables, 2 figures, 28 references.
013
Effect of Antenatal Administration of
Betamethasone on Survival of Premature
Infants.
Form: Journal article.




Abstract: Prenatal administration of
glucocorticoids has been shown to decrease the
incidence and severity of respiratory distress
syndrome in premature infants, but little is
known regarding the immediate economic
impact of this reduction in respiratory
morbidity. This study retrospectively
examined 342 infants born during 1978 and
1979 and hospitalized in the University of
Minnesota Hospitals. Comparison of survival
and the hospital charges for infants whose
mothers had not received prenatal
glucocorticoid therapy showed that
administration of glucocorticoids has a
significant effect in lowering mortality in
infants with birthweights between 750 and
1,249 grams (27 to 29 gestational weeks).
Glucocorticoid therapy was also effective in
decreasing morbidity as reflected by hospital
charges of surviving infants with birthweights
between 1,250 and 1,749 grams (30 to 32
gestational weeks). In both steroid-treated and
nontreated mothers, prolongation of gestation
decreases hospital charges in a linear fashion.
The total hospital charges for infants whose
mothers received no antenatal glucocorticoid
014
Costs of Neonatal Intensive Care by Day of
Stay.
Form: Journal article.
Author: Kaufman, S.L.; Shepard, D.S.
Source: Inquiry. 19(2): 167-178,
Summer 1982.
Abstract: Researchers developed and tested a
methodology for calculating the cost of care
for a stay in the neonatal intensive care unit
(NICU) at a Boston hospital specializing in
obstetrics and gynecology. The subjects
consisted of a random sample of 10 infants
weighing between 751 and 1,000 grams who
were discharged in 1977. Only four infants
survived. Analysis incorporated all medical
costs incurred by the infants during their
hospital stay including physician's services and
hospital overhead. The data consisted of
medical records, medical bills, internal
hospital cost reports, hospital financial reports,
information from the group practice
supervising the medical care in the NICU, and
interviews with physicians and hospital
employees. Costs were divided into three
types: (1) Infant direct costs, (2) unit direct
costs, and (3) hospital overhead. Infant direct
costs were further divided into four types: (1)
Direct nursing care, (2) attending physician
care, (3) certain selected supplies, and (4)
ancillary services delivered in departments
outside the neonatal intensive care unit. Three
levels of care (intensive, intermediate, and
growth and recovery) within the NICU
10
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accounted for unit direct costs. Within each
level, the amounts allocated at each cost
component were summed to determine a total
unit direct cost by level. These totals were
then divided by the total annual number of
patient days for all infants in the NICU.
Hospital overhead allocated to the NICU was
divided among the three levels of care, and
total overhead costs and overhead costs per
day were computed in the same manner as the
unit direct costs. The 10 infants incurred a
total cost of $102,944 over 330 days, for an
average cost per day of $312. The total cost
of care for the four surviving infants ranged
from $14,654 to $40,752 with lengths of stay
from 62 to 100 days. Among the six
nonsurvivors, five did not survive more than
four hours. Total costs for individual infants
in this group ranged from $0 to $505. A sixth
infant survived nine days and accumulated
$7,594 in total costs. Results indicate that the
total cost per day declines over the course of
an infant's stay and the time spent at a
particular level of care. Analysis of infant
direct cost showed a similar decline over time,
indicating that the pattern of declining costs
did not result solely from the stepped
allocation of unit direct and overhead costs. 3
tables, 5 figures, 26 references.
015
Cost Analysis of Extremely Low Birthweight
Infants: An Update (Editorial Response).
presented in the previous study may give a
misleading impression of how expensive it is
to keep an ELBW infant alive. Costs are
based on establishing a new neonatal intensive
care unit of 43 cots in an existing hospital with
available floor space, including operating costs
for an average year in the life of the unit.
Additional costs of new equipment and
increases in the medical and nursing staff
salaries were added to the fixed and variable
costs and the average cost of each level of
patient care was updated. All costs are
presented in 1987 Australian dollars for the
years studied. In 1989-1990, of the 122
ELBW infants who were either live born at the
Mater Mothers' Hospital in Brisbane or
admitted to the Intensive Care Nursery, 84
(68.8 percent) survived to hospital discharge
compared with a survival rate of 51.9 percent
(53 of 102) in 1986-1987. Due to marked
improvements in the survival rates for these
ELBW infants in the last 5 years, the average
cost per survivor decreased from $68,355 in
1986-1987 to $56,707 in 1989-1990. The
most dramatic change occurred for infants less
than 800 grams birthweight ($120,164 in
1986-1987 to $87,313 in 1989-1990). The
New Life Centre at the Mater Mothers'
Hospital opened for clinical use in April 1991
and has an entirely different infrastructure than
the previous nursery, so the above method for
cost analysis will not be appropriate for further
accounting exercises. 1 table, 4 references.
Form: Journal article.
Author: Khadilkar, V.V.; Tudehope, D.I.
Source: Journal of Paediatrics and Child
Health. 28(5):410, October 1992.
Abstract: The authors respond to a study
which conducted a cost analysis for the care of
extremely low birthweight (ELBW) infants in
Australia for the years 1986 and 1987. They
present updated information on the cost per
surviving ELBW infant, stating that costs
11
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Cost of Improving the Outcome for Infants
of Birthweight 500-999 g in Victoria.
Form: Journal article.
Author: Kitchen, W.H.; Bowman, E.;
Callanan, C; Campbell, N.T.; Carse, E.A.;
Charlton, M.; Doyle, L.W.; Drew, J.;
Ford, G.W.; Gore, J.; Kelly, E.A.;
Lumley, K.J.; McDougall, P.;
Rickards, A.L.; Watkins, A.; Woods, H.;
Yu, V.
Source: Journal of Paediatrics and Child
Health. 29(l):56-62, February 1993.
Abstract: Researchers conducted an economic
evaluation of neonatal intensive care for
extremely low birthweight (ELBW) infants,
between 500 and 999 grams, born in Victoria,
Australia. In Victoria, the outcome to 2 years
of age for infants of birthweight 500 to 999
grams improved between 1979-80 to 1985-87,
with not only a higher survival rate, but also a
lower rate of neurological morbidity in
survivors at 2 years of age. Followup data at
2 years of age were available for all 89
survivors from the 351 live births in 1979-80
and for 211 of the 212 survivors from the 560
live births in 1985-87. Researchers assigned
the following utilities to neurological
disabilities: (1) No disability, 1.0; (2) mild,
0.8; (3) moderate, 0.6; (4) severe, 0.4; and (5)
non-survivor at 2 years of age, 0. Life years
gained per live birth and quality-adjusted life
years gained per live birth were calculated by
multiplying the survival rate and the quality-
adjusted survival rate, respectively, by the life
expectancy. A life expectancy of 70 years was
assumed, except for multiple-severely disabled
children, whose life expectancy was assumed
to be 40 years; a discount rate of 5 percent
was applied to life years gained. For each live
born ELBW infant, the number of patient-days
of assisted ventilation and of stay in the
tertiary hospital were recorded. The dollar
costs were determined by multiplying the
equivalent patient-days of assisted ventilation
by the calculated cost to the community of one
patient-day of assisted ventilation at $1,140 (in
1987 Australian dollars). Researchers
calculated cost-effectiveness and cost-utility
analyses and performed sensitivity analyses to
determine robustness. The overall cost-
effectiveness in 1987 Australian dollars for
ELBW infants during 1985-87 compared with
1979-80 was $104,990 per additional survivor,
or $5,390 per additional life year gained. The
costs per 2-year survivor in 1987 Australian
dollars in 1985-87 and 1979-80, respectively,
by birthweight range were $131,690 and
$121,220 for 600-699 grams, $113,080 and
$96,420 for 700-799 grams, $75,280 and
$64,470 for 800-899 grams, $62,460 and
$55,270 for 900-999 grams, and $80,620 and
$68,600 for the overall total 500-999 grams.
The overall cost-utility ratios in 1987
Australian dollars indicated that the cost per
additional quality-adjusted survivor in 1985-87
was $98,570 and the cost per additional
quality-adjusted life year gained in 1985-87
was $5,090. Cost-effectiveness improved with
increased birthweight. If the quality of life of
the survivors was considered, the economic
outlook was more favorable. The cost per
quality-adjusted life year in 1987 Australian
dollars was $5,090, approximately one-tenth of
that obtained from the only previous full
economic evaluation of neonatal intensive care.
The authors suggest that although neonatal
intensive care is expensive, it compares
favorably with some other health care
programs, particularly as the outcome for
ELBW infants continues to improve.
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Cost of Neonatal Care.
Form: Journal article.
Author: Malan, A.F.; Ryan, E.;
Van Der Elst, C.W.; Pelteret, R.
Source: South African Medical Journal.
82(6):417-419, December 1992.
Abstract: Researchers conducted a medical
and financial assessment of the Neonatal Unit
at Groote Schuur Hospital in Cape Town,
South Africa. The study included 482
admissions over a 3-month period.
Researchers evaluated two aspects: (1) The
level of care and length of hospital stay for
infants, and (2) the cost of such care. Levels
of care included intensive, high, low, or
general care, and each infant was assigned to a
level on a daily basis until discharged. Cost
was determined in South African rands for the
neonatal unit for November 1990 and included
costs of personnel (R 146, 842), services
(R56,004), consumable supplies (R8,841),
overhead (R50,719), equipment (R35,576),
and the mortgage on the building (R 14,400).
Using data' for 1 month, researchers trebled
the costs to cover the 3-month study period.
Calculated at a rate of per patient per day
(ppd), intensive care (3.5 percent of patient
days) cost R530 ppd, high care (38.7 percent
of patient days) cost R265 ppd, low care (55.6
percent of patient days) cost R88 ppd, and
general care (2.2 percent of patient days) cost
R88 ppd. The average was R172 ppd. Very
low birthweight infants (under 1,500 grams)
accounted for 58 percent of expenditures.
Half of this amount was spent on infants
weighing below 1,000 grams; the cost was
R14,621 per survivor and R344 per quality-
adjusted life-year. The cost declined
progressively for infants of greater
birthweight. There is a paucity of comparable
local data, but researchers considered the cost
of care at Groote Schuur Hospital to be
reasonable. 4 tables, 8 references.
018
Impact of Surfactant Treatment on Cost of
Neonatal Intensive Care: A Cost-Benefit
Analysis.
Form: Journal article.
Author: Merritt, T.A.; Hallman, M.;
Vaucher, Y.; McFeeley, E.; Tubman, T.
Source: Journal of Perinatology.
10(4):416-419, December 1990.
Abstract: Exogenous surfactant treatment is
often used to reduce morbidity and mortality
among very low birthweight infants with
respiratory distress syndrome (RDS) or those
at high risk for bronchopulmonary dysplasia
(BPD). One group of researchers analyzed the
overall effectiveness of postnatal surfactant
administration from multiple studies involving
over 5,000 infants, and found that surfactant
recipients had odds ratios of 0.61 and 0.55
respectively for reducing RDS severity and
death before discharge. Surfactant treatment
costs upwards of $500 a dose and many infants
require multiple doses for a treatment course.
Surfactant use may reduce the costs of
neonatal intensive care. For instance, a study
showed that at any gestational age, infants
requiring assisted ventilation had hospital
charges that averaged nearly $10,000 per
infant more than those for nonventilated
infants, and surfactant use can decrease the
need for assisted ventilation. Surfactant use
has been shown to reduce the prevalence of
chronic lung disease in some studies but not in
others. Hospital costs of treating chronic lung
disease averaged $125,688 per infant in one
study, with additional outpatient costs for
oxygen, medications, and clinic visits of
$8,250 per infant during the first year.
Abundant evidence now supports the efficacy
of surfactant treatment for infants manifesting
the early stages of RDS with selective or the
so-called rescue approach. Neonatologists
should reserve this therapy for those under 30
weeks' gestation with indices of surfactant
13
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deficiency, and treat only those infants above
30 weeks' gestation with clinical, biochemical,
and radiographic evidence of moderately
severe RDS. 34 references.
019




Source: Community Medicine. 10(2):99-111,
May 1988.
Abstract: A researcher reviews the economics
of caring for very low birthweight (VLBW)
infants (less than 1,500 grams) by outlining
methodological issues and reviewing published
studies under three headings: (1) The cost of
hospital care, (2) hospital cost differences
arising from specific interventions, and (3)
costs and benefits of regional organization of
care. Studies are summarized in chart form
and include the following: The costs of
hospital care for VLBW newborns; effects of
selected interventions on neonatal hospital
costs; measures of economic evaluation of
neonatal intensive care, according to
birthweight class (5 percent discount rate); and
comparative cost-utility results for selected
programs. The review affirms that caring for
VLBW babies is costly and that costs (on
average) increase with decreasing birthweight.
Many studies also support the view that access
to neonatal intensive care facilities improves
survival chances. The evidence about
impairment is less clear. The research
reviewed further indicates that regional
organization of neonatal intensive care with
efficient referral and transport mechanisms is
more cost-effective for health care providers
than attempting to provide a full intensive care
service at every hospital where births occur.
For wealthier countries, neonatal intensive care
could be seen as a rational decision, where
considerable resources are already committed
to the health and well-being of all childbearing
women and their babies. The cost per quality-
adjusted life-year gained in 1983 currency for
selected health care programs include (1) PKU
screening, less than $0; (2) postpartum anti-D,
less than $0; (3) antepartum anti-D, $1,220;
(4) coronary artery bypass surgery, $4,200;
(5) neonatal intensive care, $4,500; (6) T4
screening, $6,300; (7) treatment of severe
hypertension, $9,400; (8) treatment of mild
hypertension, $19,100; (9) estrogen therapy,
$27,000; (10) neonatal intensive care,
$31,800; (11) coronary artery bypass surgery
for single vessel disease, $36,000; (12) school
tuberculin testing programs, $43,700; (13)
continuous ambulatory peritoneal dialysis,
$47,000; and (14) hospital hemodialysis,
$54,000. 5 tables, 47 references.
020
Cost Implications of Different Approaches
to the Prevention of Respiratory Distress
Syndrome.
Form: Journal article.
Author: Mugford, M.; Piercy, J.;
Chalmers, I.
Source: Archives of Disease in Childhood.
66(7):757-764, July 1991.
Abstract: Because the incidence of both
neonatal respiratory distress syndrome and
neonatal mortality can be reduced by giving
corticosteroids to women expected to deliver
preterm and by giving surfactant to infants at
high risk of developing hyaline membrane
disease, British researchers have considered
what effects the adoption of one or both of
these preventive policies would have on the
costs of neonatal care. They estimated the
effects of treatment from overviews of the
relevant controlled trials and estimated costs
from observations of care at one neonatal unit.
The cost of caring for the 70 infants of less
14
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than 35 weeks' gestation was estimated to have
been 269,085 pounds. The use of antenatal
corticosteroids for women with gestations up
to 35 weeks would have reduced the number
of cases of respiratory distress syndrome by 28
percent, and the number of deaths by 22
percent. The researchers estimated that the
costs of caring for the whole cohort of 70
infants would have been reduced from 269,085
pounds to 240,985 pounds, which means a
reduction in the average cost per infant by 10
percent; the cost per survivor would have been
reduced from 4,561 pounds to 3,927 pounds, a
reduction of 14 percent. Results suggest that
if either of these policies is adopted for all
infants under 35 gestational weeks at a drug
cost of 150 pounds or less per infant, the
overall costs of care would be reduced by 1 to
10 percent. The cost per survivor would be
reduced by as much as 16 percent even if the
drug cost per infant was 550 pounds. If the
policies were to be adopted only for infants
under 31 gestational weeks, both policies
would result in a cost reduction per survivor of
5 to 16 percent, although the increased
survival resulting from the policies would lead
to an increase in overall costs of 7 to 32
percent for infants of less than 3 1 gestational
weeks. 4 tables, 4 figures, 32 references.
1500 grams birthweight), to 5500 pounds (for
infants 1000 to 1499 grams birthweight), to
10,000 pounds (for infants less than 1000
grams birthweight). The mean cost of caring
for non-survivors is 1000 pounds or less, with
little difference between the birthweight
groups. These figures are based on the lengths
of stay in three treatment regimens: (1)
Intensive care, (2) high dependency care, and
(3) special care; the average daily costs of
which are estimated to be 235 pounds, 122
pounds, and 43 pounds, respectively. The
survival of very low birthweight infants (less
than 1500 grams) at this hospital has improved
from 42 percent to 73 percent since the
introduction of regional funding for neonatal
intensive care. This increase in survival has
been brought about without undue disability in
the survivors. 4 tables, 1 figure, 4 references.
022
Costs and Benefits of Neonatal Intensive
Care.
Form: Journal article.
Author: Pharoah, P.O.; Stevenson, R.C.;
Cooke, R.W.; Sandu, B.
Source: Archives of Disease in Childhood.
63(7):715-718, July 1988.
021
Costs and Outcomes in a Regional Neonatal
Intensive Care Unit.
Form: Journal article.
Author: Newns, B.; Drummond, M.F.;
Durbin, G.M.; Culley, P.
Source: Archives of Disease in Childhood.
59(11): 1064-1067, November 1984.
Abstract: At the Birmingham Maternity
Hospital in Great Britain, the mean cost of
caring for surviving infants who require
neonatal intensive care ranges from
approximately 2500 pounds (for infants above
Abstract: Researchers in England present
estimates of the cost of producing quality
adjusted life years (QALYs) in a neonatal
intensive care unit over a 3-year period during
which there was a considerable change in
clinical practice following the appointment of a
consultant neonatologist. Researchers followed
a cohort of 152 very low birthweight infants
(weighing less than 1,500 grams) born from
1979-1981 in a geographically defined area
and made a costing of the initial admission to
the neonatal intensive care unit. Researchers
examined the infants between ages 3 and 4 for
disabilities and use of medical services. A
4-point scale measured the severity of each
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child's disability. Adjusting for differences in
quality of life, researchers made an estimation
of the costs of education and full-time
residential care over the children's projected
life spans. Researchers calculated the cost per
survivor for the years 1979, 1980, and 1981 to
be 14,623 pounds, 23,161 pounds, and 20,574
pounds, respectively. Costs per QALY for the
three years were 766 pounds, 1,366 pounds,
and 1,152 pounds, respectively. Results
indicated a progressively increasing proportion
of infants survived in the 3 years of the
cohort, and there was an increasing incidence
of disability among the survivors. When
researchers related costs to outcome up to the
age of 4, the cost per QALY became
progressively less over the 3-year study
period. After the age of 4, the costs of special
education and residential care dominated, and
the cost trend reversed. 3 tables, 10
references.
023
Cost Effects of Surfactant Therapy for
Neonatal Respiratory Distress Syndrome.
Form: Journal article.
Author: Phibbs, C.S.; Phibbs, R.H.;
Wakeley, A.; Schlueter, M.A.; Sniderman, S.;
Tooley, W.H.
Source: Journal of Pediatrics.
123(6):953-962, December 1993.
Abstract: Researchers examined the cost
effects of a single dose (5ml/kg) of a protein-
free synthetic surfactant, Exosurf, as therapy
for neonatal respiratory distress syndrome
(RDS). They conducted two nonblinded,
randomized clinical trials, a prophylactic
therapy trial and a rescue therapy trial, and
compared the studies' short-term (until hospital
discharge) costs of neonatal care and the in-
hospital and first year mortality rates. They
used regression analyses to estimate the effects
of surfactant on total hospital cost, cost per
day, duration of stay, and mortality rate for
both treatment nodes, controlling for the
independent effects such as birthweight,
gestational age, multiple birth, type of
delivery, maternal glucocorticoid therapy, and
discharge to another hospital for recovery
care. Researchers conducted the prophylactic
trial at the University of California at San
Francisco (UCSF) medical center only; the
rescue trial was conducted at UCSF and Mount
Zion Hospital Medical Center, a tertiary
community hospital. Infants in the
prophylactic trial were not eligible for the
rescue trial. The cost of the surfactant was
$450 per bottle in each trial. With a dose of 5
milligrams/kilogram of Exosurf, infants with
birthweights greater than 1,600 grams required
two bottles of surfactant. Infants were entered
into studies from 1985 to 1989. To adjust for
inflation, researchers used the actual annual
changes in average charges at each hospital to
convert each infant's hospital charges to equal
those of the study hospitals during the 1989-
1990 fiscal year. They used the Medicare
ratio of costs to charges for each institution to
adjust charges in order to obtain estimates of
the actual cost of hospitalization for each
infant. The prophylactic trial included 74
infants born at UCSF with birthweights
between 700 and 1,350 grams, and gestational
ages of less than 34 weeks. The infants were
randomly assigned to surfactant treatment and
control (no surfactant treatment) groups with
stratification by sex and two birthweight
categories (700 to 1,100 grams and 1,101 to
1,350 grams). All infants were given
surfactant within 11 minutes after birth.
Prophylaxis was administered immediately
after birth to 36 infants. Infants were eligible
for the rescue trial if they weighed more than
650 grams and had RDS severe enough to
require assisted ventilation with a mean airway
pressure of greater than or equal to 7
centimeters water and a fraction of inspired
oxygen greater than or equal to 0.40 for those
infants with birthweights less than or equal to
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1,250 grams, or greater than or equal to 8
centimeters water and oxygen greater than or
equal to 0.50, respectively for larger infants.
Infants could be entered into the study at any
time between 4 and 24 hours after birth (mean,
12 hours). The rescue trial included 104
infants randomly assigned to treatment or
control groups, stratified by hospital and three
birthweight categories: (1) 650 to 1,250
grams, (2) 1,251 to 1,750 grams, and (3)
greater than 1,750 grams. All treated infants
received a single dose of 5 milligrams/
kilogram of Exosurf, administered into the
trachea. Rescue therapy was administered to
53 infants with established respiratory distress
syndrome and birthweights greater than 650
grams. For the prophylactic trial, hospital
costs were larger for treated infants versus
control subjects who weighed less than 1,100
grams and lower for treated infants versus
control subjects who weighed more than 1,100
grams at birth. For the prophylactic sample,
the in-hospital mortality rate was 13.9 percent
for the treated population and 18.4 percent for
the control; the mortality rate for the first year
of life was 13.9 percent for the treated
population and 21.1 percent for the control.
Means (with standard deviation and median
costs) per infant of hospital stay respectively,
were $40,525, ($30,333 and $31,143) for the
treated and $28,034 ($22,884 and $24,536) for
the control. Means (with standard deviation
and median costs) per day per infant
respectively, were $794 ($311 and $750) for
the treated and $972 ($571 and $738) for the
control. Researchers compared durations of
stay in study hospitals to stays at other
hospitals. Mean durations of stay in the study
hospitals and all hospitals in days per infant
were for the treated infants, 51.9 days for
study hospitals and 67.9 days for all hospitals;
for the control infants, 37.9 days for study
hospitals and 53.8 for all hospitals. Mean
birthweight was 976 grams for the treated
population and 1 ,008 grams for the control
population. Costs to achieve survival per
infant for the rescue trial were $47,061 for the
treated population and $35,510 for the control
population. For the prophylactic trial, there
was an average cost per life saved of $71,500.
For the rescue trial, the in-hospital mortality
rate was 17 percent for the treated population
and 29.4 percent for the control; the mortality
rate for the first year of life was 17 percent for
the treated population and 33.3 percent for the
control. Mean (with standard deviation and
median costs) per infant of hospital stay
respectively, were $49,909, ($51,512 and
$32,302) for the treated and $67,216 ($89,040
and $33,192) for the control. Mean (with
standard deviation and median costs) per day
per infant respectively, were $1,368 ($652 and
$1,292) for the treated and $1,554 ($1,131 and
$1,252) for the control. Mean durations of
stay in the study hospitals and all hospitals in
days per infant were for the treated infants,
43.2 days for study hospitals and 56.8 days for
all hospitals; for the control infants, 52.4 days
for study hospitals and 54.5 for all hospitals.
Mean birthweight was 1,317 grams for the
treated population and 1,332 grams for the
control population. Costs to achieve survival
per infant for the rescue trial were $59,515 for
the treated population and $100,824 for the
control population. For the rescue trial, there
was a $16,600 per infant reduction in average
hospital costs, which was larger than the cost
of the surfactant, yielding a probable net
savings. Summary results indicate that single-
dose rescue surfactant therapy is a cost-
effective therapy that reduces mortality rates
relative to other commonly used health care
interventions. Single-dose prophylactic
therapy for smaller infants (less than or equal
to 1,350 grams) appeared to yield a reduction
in mortality rate for a small additional cost.
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024
Newborn Risk Factors and Costs of
Neonatal Intensive Care.
Form: Journal article.
Author: Phibbs, C.S.; Williams, R.L.;
Phibbs, R.H.
Source: Pediatrics. 68(3): 3 13-321,
September 1981.
Abstract: To understand the sources of the
high costs of neonatal intensive care,
researchers gathered financial and medical
information on admissions to the intensive care
nursery at the University of California San
Francisco H.C. Moffitt Hospital between July
1976 and January 1979. Researchers excluded
from analysis data on infants weighing less
than 500 grams and those with unknown
birthweights or incomplete records, resulting
in data on 1,185 admissions. Researchers
divided the patients into six mutually exclusive
diagnostic categories based on the major type
of medical problem present: (1) Primary
medical, which included infants who required
no surgery or only minor surgical procedures;
(2) cardiac medical, which included infants
with primary cardiac problems that required no
surgery; (3) anomaly medical, which included
infants who had major anomalies other than
cardiac malformations and that required no
surgery; (4) medical surgery, which included
infants who required some medical and
surgical management; (5) cardiac surgery,
which included infants who required surgery
for a cardiac lesion; and (6) anomaly surgery,
which included infants who had major
anomalies other than cardiac malformations
and that required surgery. Three levels of
care are provided, depending on the state of
the patient: (1) Maximum care, which
provides one nurse per patient; (2)
intermediate care, which provides one nurse
for every two or three patients; and (3)
recovery care, which provides one nurse for
every four patients. The daily hospital bill is
made up of a basic charge to which a
surcharge is added depending on the level of
care provided during the day and charges for
nursing, house officers, monitoring equipment,
laboratory and radiologic studies, medicines,
inhalation therapy, and specialized facilities.
Researchers combined total hospital and
physician bills to estimate the cost of care for
each subject. Although the average cost was
$8,069, the median total cost was only $3,610.
The average cost per day was $545 and the
median cost per day was $346. Multiple
regression analysis showed that a significant
portion of the variation in individual costs was
explained by three measures of risk: Low
birthweight, surgical intervention, and assisted
ventilation. There was a highly skewed
distribution of costs. Nearly half of all
admissions had none of the above risk factors,
had an average cost of about $2,000, and
accounted for only 13 percent of the total costs
for the whole sample. In contrast, less than 25
percent of the admissions had two or more of
the risk factors, had an average cost of
$19,800, and accounted for nearly 60 percent
of the total costs. The average cost to produce
a survivor was $9,089 for the entire sample
but increased to $31,621 for infants whose
birthweights were under 1,000 grams. Models
that predict costs and length of stay were
developed on a basis of seven categories of
risk (no risk factors, ventilation, medical
surgery, anomaly surgery, cardiac surgery,
1,000-1,5000 grams, 501-1,000 grams, and
1,501-2,000 grams) to allow for differences in
patient populations. 9 tables, 8 references.
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Author: Pomerance, J.J.; Schifrin, B.S.;
Meredith, J.I.
Source: American Journal of Obstetrics and
Gynecology. 137(4):486-490, June 15, 1980.
Abstract: Researchers analyzed the
relationship between gestational age at delivery
and the cost of neonatal care for 137 infants
ranging from 24 to 34 weeks' gestation born
between 1973 and 1977. The infants were
patients from Cedars-Sinai Medical Center
(Los Angeles, California). The study defined
costs as hospital charges actually collected,
adjusted to 1977 rates, and weighted according
to a smoothed survival curve. Researchers
calculated percent survival for each gestational
age from the smoothed survival curve and
determined weighted costs according to a
specific formula. Data analysis indicated the
cost estimates varied according to gestational
age and development of respiratory distress
syndrome, and both in turn related to survival.
The estimated cost per infant without regard to
survival status was (1) $7,000 per infant at 24
weeks' gestation (none of whom survived), (2)
a bimodal peak cost of $36,000 per infant at
26 and again at 29 weeks' gestation, and (3)
$9,000 per infant at 34 weeks' gestation.
Between 29 and 34 weeks' gestation, the
average cost of hospital care fell about $5 ,400
per week or $772 per day. At certain periods
of gestation, safe postponement of delivery for
even a few days may result in significant
financial benefits. 6 figures, 1 table, 8
references.
026
Cost of Neonatal Care.
Form: Journal article.
Author: Ryan, S.; Sics, A.; Congdon, P.
Source: Archives of Disease in Childhood.
63(3):303-306, March 1988.
Abstract: In 1985, researchers in England
conducted a 6-month evaluation of the costs of
a regional neonatal medical and surgical unit
that opened in 1984. The study looked at (1)
direct treatment costs, (2) patient treatment
costs, and (3) general service costs. Direct
treatment costs were the salaries for the
medical, nursing, and other professional staff
and the costs of supplies and equipment.
Patient treatment costs included the costs of (1)
drugs, (2) intravenous feeding solutions, (3)
investigations by the pathology laboratories,
(4) blood transfusions, (5) radiology, and (6)
operating room time. The general service
costs reflected the general operating costs of
the hospital, such as payment to ancillary staff,
services, power, heat, and lighting. Each
patient day was allocated to one of three
categories: Intensive care, special care
(preterm babies awaiting discharge home), and
surgical care. Nursing costs were allocated in
proportion to rostered staffing in each
category. The total cost for 6 months was
972,000 pounds over 4,349 inpatient days and
282 admissions. For medical cases, the mean
daily cost for different infant weight groups
ranged from 187 pounds to 274 pounds. The
average daily cost for regional referral patients
(258 pounds) was greater than for district
patients (199 pounds), probably due to the
greater number of very low birthweight babies
among the regional admissions. The neonatal
unit admitted 23 medical patients weighing less
than 1,000 grams at birth. The total cost for
nine of the infants who died was 30,991
pounds, which is about 3 percent of the unit's
total budget. 6 tables, 5 references.
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027
Cost of Neonatal Intensive Care for Very-
Low-Birthweight Infants.
Form: Journal article.
Author: Sandhu, B.; Stevenson, R.C.;
Cooke, R.W.; Pharoah, P.O.
Source: Lancet. l(8481):600-603,
March 1986.
Abstract: Researchers in England studied the
relationship between birthweight and the cost
of care, creating a detailed costing of the
Mersey regional neonatal intensive care unit
(NICU) for 1983 (at 1984 prices) for (1)
intensive care, (2) special care, and (3) nursery
care. The study included all infants who
received treatment, some of whom received
neither intensive nor special care. In the
observed time frame, the NICU provided
7,193 days of inpatient care. Researchers
divided the cost of care for each level by
inpatient days to give an average day cost.
Multiplying the day costs by the number of
days that 182 very low birthweight (VLBW)
infants spent at each care level rendered a
patient-specific cost estimate for each infant.
Researchers observed the medical and nursing
time spent at each level . The estimate of cost
of capital equipment included items donated by
charities and took into account capital
consumption and maintenance. Researchers
estimated annual consumption of consumables
from quantities of 55 items used in 1 week.
They based the estimate of annual consumption
of drugs and pharmaceuticals on a 6-week
sample period. Researchers also determined
the cost of diagnostic tests and overhead. Data
analysis indicated costs per inpatient day were
297, 138, and 71 pounds for intensive, special,
and nursery care, respectively. Regression of
ungrouped patient-specific costs against
birthweight indicated the explanatory power of
birthweight was negligible. The average cost
per VLBW infant was 4,490 pounds for a
survivor and 3,446 pounds for a nonsurvivor.





Source: Family Planning Perspectives.
21(4): 170-174, July-August 1989.
Abstract: In 1985, researchers (1) focused on
a sample of infants representing over one-third
of all urban births in the United States during
1985, (2) quantified the cost of hospital care
for low birthweight (LBW) infants, and (3)
identified the magnitude of the immediate
savings of in-hospital costs that could result
from a small shift in the birthweight
distribution. Researchers examined immediate
in-hospital costs of 360 urban tertiary hospitals
for 80,282 neonates, 11 percent of whom
weighed less than 2,500 grams. The hospitals
provided clinical and financial data on all
neonates and their mothers. The analysis
estimated the cost of risk screening and
prenatal care for high risk mothers needed to
improve the birthweight distribution. Data
used in the analysis come from a stratified
sample of 28 urban neonatal intensive care
centers that participated in a national study on
the impact of diagnosis related groups on
perinatal regionalization. A cost analysis
focusing on all infants who survived and went
home from the hospitals revealed that those
weighing from 500-2,500 grams represented
only 9 percent of the neonatal patient load but
cost $911,223,389 to care for, or 57 percent
of the total acute inpatient cost for all infants.
Neonates in the 500-1,499 gram range
accounted for 1.6 percent of the infants cared
for and over 33 percent of related costs in the
urban facilities. If only 20 percent of infants
moved from one birthweight group to the next,
the upward shift would result in an immediate
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savings of $70-$95 million. Programmatic
expenditures for prenatal care needed to cause
the shift would be $9-$28 million less than the
immediate savings. 5 tables, 18 references.
029
Medical Care Costs of High-Risk Infants
After Neonatal Intensive Care: A
Controlled Study.
Form: Journal article.
Author: Shankaran, S.; Cohen, S.N.;
Linver, ML; Zonia, S.
Source: Pediatrics. 81(3):372-378,
March 1988.
Abstract: Researchers at the Children's
Hospital of Michigan Developmental
Assessment Clinic examined the medical costs
of high risk infants following discharge from a
neonatal intensive care unit (NICU) until the
children were 3 years old. The study looked
at costs incurred for (1) primary health care,
(2) subspecialty care, (3) diagnostic care, (4)
therapeutic care, and (5) rehabilitation.
Researchers compared costs with those of
developmentally disabled infants
institutionalized following NICU discharge
during the same time period and with existing
medical costs available from the U.S.
Department of Agriculture estimates of raising
a child from birth to age 3. Researchers
considered infants high risk if they had (1) low
birthweight, (2) intracranial hemorrhage, (3)
chronic lung disease, or (4) a disadvantaged
social background. The parents of 60 infants
agreed to participate in the study. There were
23 children who served as controls because the
results of their neurologic and developmental
evaluations were normal (group A). Group B
consisted of 15 children with mild neurologic
and/or developmental abnormalities, and group
C consisted of 22 children with moderate to
severe developmental disabilities. Researchers
collected medical outpatient and inpatient cost
data and data on health insurance, public
assistance, and parental employment. Infants
received developmental assessments at term
age and 3, 6, 12, 24, and 36 months postterm.
Testing included a physical and neurologic
exam, an interim medical history, and the
Denver Developmental Screening Test. At 12
and 24 months researchers administered the
Bayley Scales of Infant Development, and at
30 and 36 months researchers administered the
McCarthy Scales of Children's Abilities. Of
the 60 study children 34 were hospitalized for
a total of 98 hospitalizations. In group A, 7 of
the 23 infants were hospitalized once. Among
the infants in group B, 9 of 15 were
hospitalized; the range of hospitalizations was
1 to 4, resulting in 19 hospitalizations. In
group C, 18 of 22 infants were hospitalized,
and the number of hospitalizations per patient
ranged from 1 to 13. The average cost of an
inpatient day was $428 for a child in group A,
$657 in group B, and $641 in group C.
Among the 34 hospitalized children the
average cost of one inpatient day was $635;
the total cost of the 72 hospitalizations was
$336,654. Data analysis indicated that
following NICU discharge, children with and
without neurodevelopmental deficits had
significantly higher medical costs than children
who were not in the NICU. 5 tables, 16
references.
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030
Cost of Surfactant Replacement Treatment
for Severe Neonatal Respiratory Distress
Syndrome: A Randomized Controlled Trial.
Form: Journal article.
Author: Tubman, T.; Halliday, H.L.;
Normand, C.
Source: British Medical Journal.
30 1(6756): 842-845, October 13, 1990.
pounds, and the cost per QALY was 710
pounds. When the costs are weighed against
the benefits of the baby's surviving with a low
probability of neurological abnormality and the
potential for a healthy, productive life span of
up to 70 years, surfactant replacement
treatment for severe respiratory distress
syndrome is fairly inexpensive and cost
effective. 3 tables, 20 references.
Abstract: During 1985-1987, researchers in
the neonatal unit of Belfast's Royal Maternity
Hospital (Northern Ireland) conducted a
retrospective, controlled survey to estimate the
cost of treating infants with severe respiratory
distress syndrome with natural porcine
surfactant. The study included 33 preterm
babies with severe respiratory distress
syndrome who were part of a European
multicenter trial; 19 infants received the
surfactant replacement treatment and 14
matched infants served as controls. The
treatment group received a dose of the
surfactant intratracheally and then 2 minutes of
manual ventilation. The control group
received only manual ventilation for 2 minutes.
Both groups received identical medical and
nursing care before and after randomization
except for the replacement treatment.
Researchers calculated the total cost of
neonatal intensive care and special care using a
detailed survey of the staffing, equipment, and
facilities at the hospital. To calculate the cost
per bed day, researchers gathered data on the
number of infants treated, the length of stay,
and the proportion of the total number of bed
days spent at each level of care. Researchers
calculated the cost associated with surfactant
replacement treatment per extra survivor in the
treatment group and the cost per quality-
adjusted life year (QALY) for each surviving
baby in the treatment group. A total of 15 of
the 19 treated infants and 5 of the 14 control
infants survived. The cost per additional
survivor in the treatment group was 13,720
031
Cost-analysis of Neonatal Intensive and
Special Care.
Form: Journal article.
Author: Tudehope, D.I.; Lee, W.;
Harris, F.; Addison, C.
Source: Australian Paediatrics Journal.
25(2):61-65, April 1989.
Abstract: Australian researchers assessed the
inhospital costs of neonatal intensive care in
Mater Mothers' Hospital, Brisbane,
Queensland, Australia. For the year 1985,
investigators calculated fixed and variable costs
for services and uses of an Intensive/Special
Care Nursery and corrected these to 1987
Australian dollar equivalents. Yearly costs
included (1) total charges for staff
(A$2,454,532); (2) total furnishings
(A$l 14,911); (3) equipment (A$l,287,941);
(4) council rates for electricity, water,
maintenance, and telephones (A$50,882); (5)
stationary (A$9,760); (6) costs of 330
disposable items (A$l,359,811); (7) pathology
(A$535,020); (8) radiology (A$126,183); (9)
surgical procedures (A$16,085); (10) neonatal
transport (A$16,122); (11) laundry
(A$44,720); (12) pharmacy (A$392,118); and
(13) instrument sterilization (A$230,240).
After analyzing the data, researchers estimated
that to establish a new neonatal intensive care
unit of 43 cots in an existing hospital with
available floor space, including operating costs
for 1 year, would cost $6,408,000 in 1987
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Australian dollars. Daily costs per baby for
each level of care were A$ 1,282 for ventilator
care, A$481 for intensive care, A$293 for
transitional care, and A$287 for recovery care.
The cost per survivor managed in the
Intensive/Special Care Nursery in 1985
showed the expected inverse relationship to
birthweight, being A$2,400 for greater than
2,500 grams, A$4,050 for 2,000-2,500 grams,
A$9,200 for 1,500-1,999 grams, A$23,900 for
1,000-1,499 grams and A$63,450 for less than
1,000 grams. Further analysis for extremely
low birthweight infants managed in 1986 and
1987 demonstrated costs per survivor of
A$128,400 for infants less than 800 grams
birthweight and A$43,950 for those 800-999
grams. Researchers conclude that this
methodology might serve as a basis for further
accounting and cost-evaluation exercises. 1
figure, 7 tables, 20 references.
032
Cost-Benefit Analysis of Neonatal Intensive
Care for Infants Weighing Less Than 1,000
Grams at Birth.
Form: Journal article.
Author: Walker, D.B.; Feldman, A.;
Vohr, B.R.; Oh, W.
Source: Pediatrics. 74(l):20-25, July 1984.
Abstract: Researchers performed cost benefit
analysis on the care of 247 infants weighing
between 500 and 999 grams at birth, admitted
to Women and Infants Hospital of Rhode
Island between January 1977 and December
1981. The neonatal mortality was 68 percent.
Eighty-seven percent of the survivors were
evaluated neurodevelopmentally for 1 to 5
years; 74 percent were normal or minimally
impaired; 10 percent were moderately
impaired; and 16 percent were severely
handicapped. Using these data in conjunction
with cost information obtained from the
hospital and therapeutic care facilities for
handicapped children, total lifetime costs for
the care of these infants were estimated. In
1982 dollars, present values of costs ranged
from $362,992 per survivor for those weighing
between 600 and 699 grams to $40,647 per
survivor for those weighing between 900 and
999 grams, resulting in an inverse correlation
between cost per survivor and birthweight.
Researchers estimated present values of
expected lifetime earnings per survivor, with a
range of zero earnings for infants between 500
and 699 grams, to $77,084 for those with
birthweight of 900 to 999 grams. The
evaluators concluded that from the standpoint
of cost benefit analysis as was used for this
study population, neonatal intensive care may
not be justifiable for infants weighing less than
900 grams at birth. 5 tables, 20 references.
033
Economic Analysis of Regionalized Neonatal
Care for Very Low-Birth-Weight Infants in
the State of Rhode Island.
Form: Journal article.
Author: Walker, D.B.; Vohr, B.R.; Oh, W.
Source: Pediatrics. 76(l):69-74, July 1985.
Abstract: Researchers conducted a cost
benefit analysis to evaluate the economic
outcome of regionalized neonatal care in
Rhode Island, with specific reference to
newborns weighing less than 1,500 grams at
birth. Regionalization of neonatal care in the
state began in 1974, with a single tertiary care
center (the Women and Infants Hospital of
Rhode Island (WIHRI)) and eight community
hospitals offering primary neonatal care. The
study analyzed two time periods: 1974-1975
(initiation of perinatal regionalization) and
1979-1980 (regionalization established). For
the very low birthweight infants admitted to
the WIHRI, researchers collected data about
(1) mortality, (2) duration of hospitalization,
(3) hospital charges, and (4) neuro-
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developmental outcome observed during
followup assessment of survivors. Researchers
calculated hospital charges for all infants from
hospital billing, converting them to April 1982
dollar values. The study analyzed the data in
two birthweight categories (501-1,000 grams
and 1,001-1,500 grams). Data analysis
indicated that the neonatal mortality for infants
weighing between 501 and 1,500 grams
decreased significantly between the two time
periods. Neurodevelopmental morbidity was
unchanged. The costs per survivor were
consistent over the time periods studied. The
estimated benefits per survivor increased
between the time periods (though it was not a
statistically significant increase), and benefits
outweighed costs in both study periods. When
the data for the two weight categories were
examined, it became apparent that the cost-
benefit analysis was negative for infants
weighing between 501 and 1,000 grams (a
$74,310 and a $378,774 net economic loss
from 1974 to 1975 and 1979 to 1980,
respectively). The large portion of economic
benefit, however, was observed in infants
weighing between 1,001 and 1,500 grams (a
$1,269,281 and a $3,705,988 net economic
gain for 1974 to 1975 and 1979 to 1980,
respectively). 2 figures, 5 tables, 19
references.
034
Medical Expenses of Neonatal Intensive
Care for Very Low Birthweight Infants.
in-hospital medical expenses for 90 VLBW
infants weighing 1,500 grams or less at birth,
whose parents had private health insurance;
they also gathered data on all 375 VLBW
infants born at this hospital in the 4-year
period studied. Researchers reviewed each
infant's financial account to determine total
and average daily charges as well as charges
from all hospital departments and specialists,
hospital bed rates, neonatologist, pediatrician,
surgeon, cardiologist, radiologist, and
pathologist. Seventy-five (83 percent) of the
90 study population infants survived. Overall
survival was 297 of 375 infants (79 percent).
Median total and daily charges per survivor
were $5,883 and $70, respectively. Median
total and daily charges per nonsurvivor were
$1,113 and $450, respectively. Medical
expenses per VLBW survivor calculated for all
375 VLBW infants admitted for neonatal
intensive care over the 4-year period were
$6,813. This ranged from $10,000 per
survivor for the 11 survivors in the 501 gram-
750 gram birthweight group to $5,363 per
survivor for the 145 survivors in the 1,251
gram- 1,500 gram birthweight group. As these
charges were a small proportion of the
resource costs in providing a neonatal intensive
care service, society at large was bearing most
of the cost. Researchers believe that with the
present decline in neonatal mortality and
morbidity in VLBW infants, the outcome of
neonatal intensive care justifies the cost. 3
tables, 7 references.
Form: Journal article.
Author: Yu, V.; Bajuk, B.
Source: Australian Paediatrics Journal.
17(3): 183-185, September 1981.
Abstract: Researchers reviewed the medical
expenses to parents of neonatal intensive care
for their very low birthweight (VLBW) infants
under the current medical benefits scheme in
Australia. Investigators gathered data on the
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Source: Weekly Epidemiological Record.
65(36):275-279, September 7, 1990.
Abstract: Researchers compared the cost
effectiveness of diarrheal disease treatment for
children under age 5 at the Queen Elizabeth II
Hospital in Maseru, Lesotho (Africa), 1 year
before establishment of an Oral Rehydration
Therapy Unit (ORTU) and 1 year after its
establishment (1985 and 1987, respectively).
The study also examined the cost effectiveness
of alternative options for extending the
operation of the ORTU beyond its weekday
schedule. Researchers estimated costs (both
recurrent and capital) using the methods
proposed by the CDD Program of the World
Health Organization (WHO) with some
adaptations to the Lesotho setting. The
methods for estimating costs were not given in
detail. The cost per outpatient with diarrhea
declined from Maloti (M) 14.26 in 1985 to M
11.21 in 1987 (in 1987, M 2.4 equaled one
United States dollar). In this 2-year period,
the number of diarrhea-related hospital
admissions decreased from 376 to 218,
representing a savings of M 36,166. In 1985,
12 percent of those under age 5 seen at this
hospital required hospitalization compared with
only 6 percent in 1987. The overall cost of
diarrhea treatment of children under age 5 at
the hospital declined from 1.31 percent of the
hospital's total budget in 1985 to 0.57 percent
in 1987. When comparing the savings created
by the decrease in hospital admissions with the
initial cost of establishing the unit (M 8,000),
and an annual maintenance cost of M 2,270,
there was a net gain of M 25,857. If the
ORTU were kept open at all times rather than
its current Monday-Friday hours, the savings
of M 21,360 in reduced hospital admissions
would be offset by staffing costs. The most
cost-effective strategy would be to operate the
ORTU 7 days a week during the high diarrhea
season only. 4 figures, 1 table.
036
Efficacy of Early Newborn Discharge in a
Middle-class Population.
Form: Journal article.
Author: Britton, H.L.; Britton, J.R.
Source: American Journal of Diseases of
Children. 138(11): 1041-1046,
November 1984.
Abstract: From November 1981 through
March 1982, researchers assessed the safety
and cost benefit of early newborn discharge by
determining the incidence, time of onset, and
nature of problems requiring hospitalization
that appeared in the first 2 weeks of life
among 1,735 consecutively born term infants
in Tucson (Arizona) Medical Center, a private
metropolitan hospital. Researchers divided the
infants into two groups: Those who required
physician attention during the initial 6-hour
transitional period and those who did not.
During the transitional period, infants were
observed and nursing staff notified the
physicians about positive laboratory test results
for hypoglycemia, polycythemia, or clinical
problems such as (1) respiratory distress, (2)
cyanosis, (3) heart rate irregularities, (4)
apnea, (5) persistent temperature instability,
(6) continuous lethargy, (7) abdominal
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distention, (8) vomiting, (9) feeding
intolerance, (10) jaundice, or (11) major
congenital anomalies. Of 1,583 initially well
infants, 11 (0.7 percent) had problems other
than jaundice develop that required
hospitalization in the first 3 days of life;
infants with abnormal transition periods had a
28 percent chance of requiring hospitalization
for problems other than jaundice. A total of
46 (30 percent) of the 152 infants with
abnormal transitional periods required inpatient
care after 6 hours of age; in 43 (28 percent)
the problem necessitating hospitalization was a
continuation of a transitional period
abnormality. The cost-effectiveness of
discharge at 6 hours of age was compared with
that of a traditional 72-hour hospital stay for
the 1,583 initially well infants. Cost-benefit
analysis demonstrated that the total hospital
and physician fees for a 72-hour hospitalization
were $404 per infant ($348 hospital and $56
physician). For a 6-hour stay the total figure
per infant was $164 ($116 hospital and $48
physician). If the 34 initially well infants in
whom problems later developed had remained
in the hospital from birth and been transferred
to intermediate or intensive care nurseries
when they became sick, they would have
incurred an additional cost of $1,103;
however, the additional cost to readmit them if
they had been discharged early would have
been $7,069. As a whole, early discharge of
initially well infants with readmission of those
who became ill within 72 hours would have
saved an average of $236 per infant. The
babies in whom problems did occur before 72
hours of age primarily had jaundice, rarely an
urgent problem, which occurs with equal
frequency in the second 72 hours after birth
among those who did and did not require
physician attention in the first 6 hours after
birth. Most illnesses requiring hospitalization
in the first 3 days of life could have been
safely detected during an outpatient visit; these
findings, in addition to a cost-benefit estimate,
suggest that early discharge of initially well
infants with careful followup may be an
effective alternative to a traditional 3-day stay.
4 figures, 3 tables, 9 references.
037
Randomized Clinical Trial of Early Hospital
Discharge and Home Follow-up of Very-
Low-Birth-Weight Infants.
Form: Journal article.
Author: Brooten, D.; Kumar, S.;
Brown, L.P.; Butts, P.; Finkler, S.A.;
Bakewell-Sachs, S.; Gibbons, A.;
Delivoria-Papadopoulos, M.
Source: New England Journal of Medicine.
315(15):934-939, October 1986.
Abstract: Researchers conducted a study to
examine whether it was safe and economical to
discharge very-low-birthweight infants (under
1,500 grams) early if they met certain
conditions. The study involved randomly
assigning infants from the Hospital of the
University of Pennsylvania to one of two
groups. The 40 infants in the control group
went home according to routine nursery
criteria, which included a weight of about
2,200 grams. The 39 infants in the early
discharge group went home before they
weighed 2,200 grams if they (1) were
clinically well and able to feed by nipple every
4 hours, (2) were able to maintain their body
temperature in an open crib, (3) had no
evidence of serious apnea or bradycardia, (4)
had a mother who demonstrated satisfactory
caretaking skills, and (5) had an adequate
physical home environment with facilities for
care. Infants and families in the early
discharge group received home followup care
by a nurse. The home care included
instruction, counseling, home visits, and daily
on-call availability of a hospital-based nurse
for 18 months. Results indicated infants in the
early discharge group left the hospital a mean
of 11 days earlier, weighed 200 grams less,
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and were 2 weeks younger at discharge than
the control group infants. The mean hospital
charge for the early discharge group was 27
percent less than that for the control group,
and the mean physician's charge was 22
percent less. The mean cost of the home
followup care in the early discharge group was
$576, yielding a net savings of $18,560 for
each infant. The two groups did not differ in
the number of rehospitalizations and acute care
visits or in measures of physical and mental
growth. 3 tables, 30 references.
038
Medical Care Use Among US Children.
Form: Journal article.
Author: Butler, J. A.; Winter, W.D.;
Singer, J.D.; Wenger, M.
Source: Pediatrics. 76(4):495-507,
October 1985.
Abstract: Researchers present and discuss
some of the baseline data obtained on the
subsample of all children ages 0-18 years from
the 1980 National Medical Care Utilization
and Expenditure Survey (NMCUES).
Collecting data on health insurance coverage
and on financial aspects of contacts with health
care providers, NMCUES involved
interviewing members of 6,600 households
five times between 1980 and 1981 regarding
health care services; 5,662 people younger
than age 19 completed the survey.
Researchers addressed four issues to determine
whether the data reveal persistent gaps in
access to care or use of services for certain
groups of children and youth. Issue one
concerned the proportion of subjects having a
regular source of medical care, according to
sociodemographic variables. Issue two
involved how frequently the subjects saw a
doctor and how this and the presence of a
regular care source varied by poverty status,
race, and ethnicity. Issue three addressed the
proportion of subjects covered by private or
public health insurance and how the pattern
varied according to family background
characteristics. Issue four concerned the total
1980 medical care charges and charges paid
out-of-pocket by parents for the total group
and for various subgroups of subjects and how
the charges vary by sociodemographic
characteristics. Fifty percent of all children
had $99 or less spent on their medical care
during the year. Researchers calculated costs
for two model subgroups, those children
covered for the full year by private medical
insurance and those children covered by public
medical insurance. Average total medical
charges for the privately insured are $339,
compared with $396 for the publicly insured.
Out-of-pocket expenditure for the former
group averaged $104, compared with $63 for
the latter group. Analysis indicated that in
1980, 92 percent of American children and
youth had a regular care source, and the same
percentage had coverage for the full year or
part of the year by some form of public or
private health insurance. Approximately 75
percent of all children and youth had coverage
for the full year and more than 75 percent had
at least one medical care visit in the calendar
year. Use rates and patterns of expenditure
differed dramatically according to family
background factors, particularly race,
ethnicity, poverty status, and location of
residence. Minority group and near-poor
children were at highest risk for limited use of
services and inadequate insurance coverage.
Approximately 33 percent of African
American and Hispanic children did not see a
medical care provider during the year,
compared with 21 percent of white children.
Children living in central cities were less likely
to have received any medical care than their
counterparts living in suburban areas, smaller
cities, or rural areas. Approximately 8 percent
of infants and toddlers had no physician visits
during the calendar year. 9 tables, 24
references.
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039
Earlier Discharge With Community-Based
Intervention for Low Birth Weight Infants:
A Randomized Trial.
Form: Journal article.
Author: Casiro, O.G.; McKenzie, E.;
McFadyen, L.; Shapiro, C; Seshia, M.;
MacDonald, N.; Moffatt, M.; Cheang, M.S.
Source: Pediatrics. 92(1): 128-134,
July 1993.
Abstract: Researchers investigated the
feasibility of earlier discharge of low
birthweight infants with community-based
followup of 100 infants with a birthweight of
less than or equal to 2000 grams, without the
use of home apnea monitors. Prolonged
hospitalization of low birthweight infants
appeared to increase the risk of medical and
psychosocial complications. Subjects included
100 infants admitted to the neonatal units of
either the Health Sciences Centre or St.
Boniface General Hospital in Winnipeg,
Manitoba, Canada between October 27, 1988
and June 30, 1990. Subjects were randomized
to either an intervention (50 infants) or control
group (50 infants) when they met five
discharge-readiness criteria: (1) Clinically
well, i.e., normal vital signs and in no distress
while breathing room air; (2) free of
apneic/bradycardie episodes, while not
receiving apnea medications, during 3
consecutive days of continuous electronic
monitoring and 2 days of observation; (3) able
to maintain normal body temperature in an
open crib; (4) able to feed satisfactorily by
breast and/or bottle and requiring no
supplementary gavage feedings; and (5) the
safety of the home environment and the
parents' readiness to care for the infant having
been evaluated as adequate by the study public
health nurse. The infant's physician, not the
investigators, was responsible for deciding
when an infant was to be discharged. The
intervention used in this study was designed to
complement existing physician, hospital, and
community followup programs. Thus,
inhospital care to intervention group infants
and their families did not differ from that for
other infants. Community-based services were
provided by a public health nurse and
homemakers over the 8-week period following
an infant's discharge from the hospital. The
study assessed all infants at age 1 year using
the Bayley and Home Observation for
Measurement of the Environment (HOME)
scales. There were no statistically significant
group differences in baseline infants'
characteristics or in neonatal complications.
The minimum cost of care per patient per day
was $873 in 1990 Canadian dollars, which
included hospital charges but not physician
costs. Public health nursing services provided
to the entire intervention group accounted for
50 hours predischarge, 300 hours
postdischarge, and an estimated 150 hours for
direct administration and travel time (500
hours multiplied by $18.87 per hour in 1990
Canadian dollars) for a total cost $9,435 or
$189 per infant. Indirect administration and
system costs were not factored in.
Homemaker services (at $9.50 per hour in
1990 Canadian dollars) provided to the
intervention group totaled 2,298 hours for the
8-week period for a total cost of $21,831, or
$437 per infant. Infants in the intervention
group were discharged from the hospital at an
a mean postconceptional age of 36.6 weeks;
the mean age of the control group was 37.3
weeks. Infants in the intervention group were
discharged from the hospital after a median of
23 days versus 31.5 days for the control
infants. Among subjects with 1,501 to 2,000
grams birthweight, there was a statistically
significant difference in (1) the median length
of hospital stay, 17 days for the intervention
group and 24 days for the control group; and
(2) the mean discharge weight, 2,122 grams
for the intervention group and 2,259 grams for
the control group. During the first year of
life, there were no significant differences
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between the intervention and control groups in
terms of rehospitalization rates and use of
ambulatory care services. The public health
nurse made a mean total of 185 home visits
and 410 phone contacts to the intervention
group families; 27 families (55 percent) in the
intervention group required and received
homemaker services. A total of 2,298
homemaker hours were provided. The public
health nurse made a mean total of 66 home
visits and 89 phone contacts to the control
group. Intervention families had significantly
higher 1-year HOME scores. The community-
based program designed to provide
individualized support and education for
families of low birthweight infants was cost-
effective and saved the equivalent of $153,381
by shortening the hospital stay of the 29
infants of 1,501 to 2,000 gram birthweight in
the intervention group by a average of 1 week.
5 tables, 38 references.
040
Costs and Benefits of a Community Special
Care Baby Service.
Form: Journal article.
Author: Couriel, J.M.; Davies, P.
Source: British Medical Journal.
296(6628): 1043-1046, April 1988.
Abstract: British researchers analyzed the
activity of the Manchester Community Special
Care Baby Service from January 1981-
December 1986. Researchers collected
prospective data weekly and included (1) the
numbers and sources of all referrals,
birthweight, and weight at discharge from
hospital of all infants referred; (2) the number
of visits made by the special care sisters; (3)
the number of home assessments; and (4) the
number of infants who required readmission to
hospital while still under care of the service.
The service works with (1) low birthweight
babies, (2) babies discharged from the neonatal
surgical unit, (3) babies with problems on the
postnatal wards, and (4) babies who lived in a
special care nursing unit for more than 48
hours. The service consists of 10 specialist
nursing sisters who are registered general
nurses, state certified midwives, and certified
neonatal nurses. The nurses work in three
teams, with primary responsibility for a
particular geographic region. They (1) attend
neonatal ward rounds, (2) contact local clinics
and physicians, (3) work with community
midwives, (4) visit special care baby units, and
(5) visit new mothers (at the hospital and at
home). A total of 5,809 babies received
referrals to the service over the 6 study years,
about 14 percent of the live births in
Manchester. Each referral resulted in an
average of 11 visits. A total of 1,159 of the
babies weighed under 2,000 grams, and 3,829
weighed under 2,500 grams. Over the 6 year
period, 4 percent of all referrals were
readmitted to hospital while under care of the
service. Readmittance was related to
birthweight: 19 percent of infants with a
birthweight under 1,500 grams needed to be
readmitted, compared to 3.3 percent of infants
with a birthweight over 1,500 grams. Four
infants died while under the care of the service
between January 1985 and December 1986; all
four infants had severe congenital or perinatal
problems. The total annual cost for the
service in 1985 was 126,638 pounds; the cost
of each visit was approximately 11.18 pounds.
With the improving survival rate for low
birthweight infants and the growing
recognition that they have an increased risk of
dying or becoming seriously ill far beyond the
neonatal period, the case for providing
continuing support for the infants after they
are discharged from the hospital has become
clearer. A community specialist nursing
service for low birthweight infants and infants
at high risk allows more efficient use of
overstretched hospital neonatal services and is
highly cost effective. 3 tables, 20 references.
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Abstract: In a letter to the editor, a physician
discusses the cost effectiveness of home
management of bronchopulmonary dysplasia
and documents the cost effectiveness of the
Women's Hospital in Ann Arbor Michigan's
program. Based on increasing numbers of
infants requiring prolonged hospitalization for
oxygen therapy for neonatal respiratory
distress syndrome, he outlines the feasibility
and efficacy of home management of infants
using as examples the Women's Hospital
program and studies by Pinney et al. (Home
Management of Bronchopulmonary Dysplasia,
Pediatrics 58:856, 1976); Philip et al.
(Transcutaneous P02 Monitoring in the Home
Management of Bronchopulmonary Dysplasia,
Pediatrics 61:655, 1978); and Glassanos et al.
(Infants Who Are Oxygen-dependent: Sending
Them Home, American Journal of Maternal
and Child Nursing 5:42, 1980). In the
Women's Hospital program, through
December 1981, 18 infants were sent home
oxygen dependent. The first 12 infants no
longer require supplemental oxygen and are
symptom-free. The 12 infants ranged in
birthweight from 900 to 4,040 grams;
gestational age ranged from 27 to 43 weeks.
Eleven initially had respiratory distress
syndrome and one had meconium aspiration
pneumonitis; all had clinical and radiographic
evidence of bronchopulmonary dysplasia. The
length of hospitalization varied from 49 to 255
days. At the time of discharge all infants were
receiving oxygen by nasal cannula; none
required continuous positive airway pressure.
The duration of the home oxygen therapy
ranged from 2 months to 8 months. During
the period of oxygen dependence all infants
were seen weekly in the Neonatology Clinic
and were seen approximately monthly by their
primary physicians. Six infants had no
rehospitalization. Four infants were
readmitted for management of upper
respiratory infections; one infant was
readmitted for pneumonia; one infant was
electively rehospitalized for an inguinal
heriorraphy. The average daily inpatient
charges were $627, which included (1)
hospitalization, $493; (2) physician fees, $93;
(3) respiratory therapy; $20; and (4) laboratory
fees, $21. The nursery utilizes a graduated
system of daily hospital charges, and all
infants had progressed to the minimum daily
charge of $493 . The maximum daily
outpatient charge including clinic visit
($30/week) $4.29, primary physician
($30/month) $1.00, oxygen therapy
($250/month) $8.33, and medications
($30/month) $1.00, totals $14.62. The
determination of the hospital patient days
saved was based on the assumption that
discharge from the hospital would have
occurred at approximately the same time as the
infant was weaned from oxygen. Thus, patient
days saved reflect the time from early hospital
discharge through discontinuance of oxygen at
home. Any rehospitalization days were
subtracted from this figure. For the 12
patients, total hospital days saved were 1,281;
there were 91 rehospitalization days, giving a
net savings of 1,190 patient days. The overall
savings for the group is the product of patient
days saved and daily cost differential (1,190
multiplied by $612), which is a total cost of
$728,280 or $60,690 per patient. All figures
are savings based on charges; actual
reimbursements from third party payers are
generally 65 percent to 85 percent of the
charges. Although the author supports home
management, he emphasized that home
management of oxygen-dependent infants
entails additional risks, less intense
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observation, equipment failure, and a greater
potential for medication error. In addition to
the increased responsibilities and demands,
parents must be taught suctioning techniques,
assessment of infant well-being, and
cardiopulmonary resuscitation. 4 references.
042




Author: Fields, A.I.; Rosenblatt, A.;
Pollack, M.M.; Kaufman, J.
Source: American Journal of Diseases of
Children. 145(7):729-733, July 1991.
Abstract: Researchers evaluated home care
costs and cost effectiveness versus alternative
institutional care for children who were
respiratory technology-dependent, enrolled in
Maryland's Model Home and Community-
based Services Waiver Program, and who had
been discharged from short-term or long-term
care hospitals between April 1985 and June
1987. Data were collected by the
Coordinating Center for Home and
Community Care, a consortium of public and
private institutions, agencies, and organizations
that (1) provided case management for children
with respiratory disabilities living at home or
in alternate living facilities, (2) monitored the
plan of care, and (3) determined the cost-
effectiveness of the program for each
participant. Data were available on 10
children, 6 of whom were dependent on
mechanical ventilation and 4 of whom had
tracheostomies and received oxygen.
Researchers evaluated the cost effectiveness
eligibility by comparing the projected costs of
home care to the projected costs of an
alternative setting. The study projected annual
costs for each patient's care at home or in an
alternative institutional setting from an
individualized care plan developed by a
multidisciplinary team. Researchers calculated
savings by the program for the first year as
estimated alternative institutional expenses
minus home care reimbursements. Data
analysis indicated the annual home care costs
were approximately $109,836 for ventilator
dependent children and $63,650 for oxygen
dependent children with tracheostomy,
representing annual savings of $79,000 per
patient and $83,000 per patient, respectively,
using individualized home care plans. The
largest portion of home care reimbursements
was for nursing care. The full program has
the potential for saving $4 million per year. 1
figure, 4 tables, 12 references.
043
Quality of Outcome and Cost in an
Obstetric and Neonatal Service.
Form: Journal article.
Author: Gunn, T.R.; Nightingale, A.;
Cable, G.D.
Source: New Zealand Medical Journal.
102(864): 136-140, March 22, 1989.
Abstract: Researchers reviewed the outcome
and efficiency of the obstetric and neonatal
service at St. Helen's Hospital, Auckland,
New Zealand. The review of perinatal
outcome encompassed calendar years 1981
through 1987 and included all births at the
hospital. Hospital statistics were collected in a
standard manner during this period.
Researchers reviewed the records of morbidity
and case review committee meetings, and
obtained the number of full-time staff working
in the hospital in all fields. Analysis showed
that in the 7-year period there was a 33
percent fall in perinatal mortality rates (from
slightly less than 14 per 1,000 births in 1981
to 5.88 per 1,000 births in 1987). The early
neonatal death rate has fallen from
approximately 5 per 1,000 births in 1981 to
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1.12 per 1,000 in 1987. The average perinatal
death rate for Maori infants was low, 4.81 per
1,000 compared to 7.43 per 1,000 for
Europeans over this period. There was a 38
percent increase in births, to 3,597 a year,
while the total hospital staffing rose only 9
percent. Thus the ratio of births to staff has
increased from 12.35 in 1981 to 15.6 in 1987.
The cost per infant delivered in constant
dollars has fallen 18.7 percent in the same
period to NZ$2,432. The postnatal bed
occupancy was 101 percent in 1987 and the
average day stay fell to 5.7 days. An extra 61
full-time staff would be needed to reduce the
workload to that of 1981; the staff is now
unable to give each family the necessary
focused, holistic care it needs. 2 figures, 3
tables, 10 references.
044
Cost-Effectiveness Analysis of Strategies to
Reduce Infant Mortality.
Form: Journal article.
Author: Joyce, T.; Corman, H.;
Grossman, M.
Source: Medical Care. 26(4): 348-360,
April 1988.
estimate infant health production functions
across large counties in the United States in
1977. Estimates of costs came from a variety
of published sources; one study estimated the
cost of initial hospitalization in a neonatal
intensive care unit to be $13,616, assuming an
average stay of 13 days. The results indicated
that initiation of prenatal care in the first
trimester was the most cost-effective means of
reducing the neonatal mortality rate for
African American and white infants. For
those who initiated prenatal care in the second
and third trimesters, researchers estimated that
they must obtain an additional three and six
physician visits, respectively, with the cost of
each visit averaging $176-187. With respect
to African Americans, prenatal care ranked
second to WIC in reducing race-specific
neonatal mortality or death in the first 27 days
of life when the lower-bound cost estimate is
used and first when less conservative estimates
are used. African American infants benefitted
more per dollar of input use than white
infants. Neonatal intensive care, although the
most effective means of reducing neonatal
mortality rates, was one of the least cost-
effective strategies. The same pattern of cost-
effectiveness existed with respect to low
birthweight. 4 tables, 21 references.
Abstract: Researchers compared the cost
effectiveness of various health inputs and
government programs in reducing race-specific
neonatal mortality or death in the first 27 days
of life (when approximately two-thirds of all
infant deaths occur). The programs and inputs
included (1) teenage family planning use; (2)
the Special Supplemental Food Program for
Women, Infants and Children (WIC); (3) use
of community health centers and maternal and
infant care projects; (4) abortion; (5) prenatal
care; and (6) neonatal intensive care. Using
an economic model of the family as the
analytic framework, the study determined
effectiveness via ordinary least squares
analysis and 2-stage least squares analysis to
045
Costs of Multiple Pregnancy.
Form: Journal article.
Author: Keith, L.G.; Papiernik, E.; Luke, B.
Source: International Journal of Gynecology
and Obstetrics. 36(2): 109-1 14, October 1991.
Abstract: Researchers review United States
vital statistics to describe the increase in
multiple births between 1977 and 1987. The
epidemic of multiple pregnancy, which has an
increased rate of preterm birth, is of concern
because of the need to provide high quality
intensive neonatal support to large numbers of
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low-birthweight infants. The paper focuses on
three issues related to multiple gestation: (1)
The extent and nature of the explosive increase
in numbers of twins and higher order multiple
births, (2) the inevitability of preterm delivery
in substantial numbers of mothers of multiples,
and (3) the growing awareness of the true
costs of such events and how the costs impact
upon society. Between 1977 and 1987, twin
and multiple births rose approximately 30
percent each. There was a 47 percent increase
in multiple births among women over age 35
.
A possible explanation for the increase in
multiple births related to changing patterns of
childbearing: The highest rates of dizygotic
twinning normally occur in adolescents (who
experienced a 30 percent decline in multiple
childbirth rates during the same period,
possibly due to increased numbers of induced
abortions) and women over age 35, the age
group that is experiencing increased, delayed
childbearing. Presently there is no published
United States national data comparing
multiples and singletons on a weight for
gestational age basis; however, a higher
proportion of twins are born at low
birthweight compared to singletons. Multiples
versus singleton infants have a relative risk of
perinatal mortality of at least 4.25. According
to a study conducted at Johns Hopkins
Hospital in Baltimore, Maryland, the length of
neonatal intensive care unit (NICU) stay
among twins doubles for each 500 gram
increment below birthweights of 2000 grams.
Among survivors, the risk of moderate to
severe handicap is vastly increased as
birthweight decreases. Low-birthweight and
length of NICU stay are intimately associated
with risk of future handicap (and costs
attendant to the condition). Potential solutions
include (1) provision of adequate methods to
diagnose multiple pregnancy and provide
comprehensive prenatal care, (2) provision of
nutritional evaluation and support in the
pregravid and pregnant state, (3) elimination of
inappropriate uses of fertility-enhancing agents
and assisted reproductive technologies that lead
to iatrogenic multiple gestation, and (4)
consideration of selective reduction in some
cases of higher order multiple gestation. 4
figures, 4 tables, 14 references.
046
Outpatient Oral Rehydration in the United
States.
Form: Journal article.
Author: Listernick, R.; Zieserl, E.;
Davis, A.T.
Source: American Journal of Diseases of
Children. 140(3):21 1-215, March 1986.
Abstract: To compare the safety, efficacy,
and costs of oral versus intravenous
rehydration, researchers enrolled in a
prospective, randomized study 29 well-
nourished infants between ages 3-24 months
who had acute gastroenteritis and were
dehydrated. The study assessed the use of a
holding room in a hospital emergency room
for the outpatient rehydration of dehydrated
infants. Infants with fluid deficits of less than
100 mL/kg were placed in a holding room for
8-12 hours for observation and oral hydration
with a solution containing sodium, potassium
chloride, citrate, glucose, and fructose.
Patients who failed to return to a normal state
of hydration in 12 hours or who failed to
achieve adequate oral intake due to vomiting
or refusal to drink were admitted to the
hospital for parenteral rehydration. Medical
personnel successfully rehydrated 13 of 15
patients orally as outpatients; 2 patients who
were subsequently discovered to have urinary
tract infections required hospitalization due to
persistent vomiting. Orally rehydrated
outpatients spent a mean of 10.7 hours in the
holding room, as compared with intravenously
rehydrated inpatients, who were hospitalized
for a mean of 103.2 hours. Outpatient oral
rehydration therapy was significantly less
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costly than inpatient intravenous therapy
($272.78 versus $2,299.50 per patient), and
somewhat less costly than intravenous therapy
in the holding area ($379.20 per patient).
Results indicate that oral rehydration is a safe
and cost-effective way to treat dehydrated
children in an outpatient setting in the United
States. The use of a holding room for
observation in the emergency room can
markedly decrease health care costs and






Source: Lancet. 1(8428): 591,
March 9, 1985.
Abstract: This report is derived from a
lecture at a symposium on cot deaths (crib
deaths) at the London School of Hygiene and
Tropical Medicine, and describes the benefits
of medical intervention to prevent sudden
infant death in terms of cost per quality-
adjusted life-years (QALY). With preventable
infant deaths in Britain at 3-4 per 1 ,000 live
births out of a total of 10 deaths per 1,000 in
1985, the author estimates that intervention
could reduce the death rate by between a
quarter and a third, thus saving 600-1,000
infants a year. Medical intervention would
consist of a system of scoring, applied at birth
and at 1 month, which would identify the 10-
15 percent of infants most at risk for
unexpected death. These would receive six
extra visits by health visitors to improve infant
care and identify early symptoms of illness.
The estimated total cost of a national
prevention scheme would be between 5-7
million pounds sterling a year: 2 million
pounds for a central coordination monitoring
unit and 1.5 administrators per 5,000 live
births, plus 3-5 million pounds for health
visitors' time, giving an assumed mean cost of
8,000 pounds per death avoided. If an ensuing
lifespan of 70 years were assumed, the annual
cost per QALY of a prevented infant death
came to 114 pounds, compared with 750
pounds for a hip replacement, 5,000 pounds
for a heart transplant, and 14,000 pounds for
kidney dialysis in a hospital. This suggests
that programs designed to identify the risk of
unexpected infant death and prevent it by
health-visitor intervention would be highly
cost-beneficial compared with other
interventions in the health services.
048
Costs Incurred by Parents of Very Low
Birth Weight Infants After the Initial
Neonatal Hospitalization.
Form: Journal article.
Author: McCormick, M.C.; Bernbaum, J.C.;
Eisenberg, J.M.; Kustra, S.L.; Finnegan, E.
Source: Pediatrics. 88(3):533-541,
September 1991.
Abstract: By comparing costs incurred in the
first year of life by 32 very low birthweight
(VLBW) infants with the costs incurred by 34
term infants, researchers assessed the
economic impact of posthospitalization care of
VLBW infants. The researchers obtained
prospective data on the quarterly charges and
expenditures for care of a cohort of VLBW
survivors and for the term infants from
Children's Hospital of Philadelphia from July
1983 to October 1984. Parents recorded
medical expenditures for each month in a
diary. Quarterly, the parents were telephoned
by a research assistant who used a structured
questionnaire to obtain expenditure data. The
diary plus questionnaire technique was adapted
from methods used in national medical
expenditure surveys. Interviewers collected
(1) sociodemographic characteristics, (2) direct
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medical costs, (3) related nonmedical direct
costs, (4) other costs, (5) social support data,
and (6) family impact data. The mean
differences between NICU graduates and the
comparison groups were compared using
analysis of variance. Discrimination between
charges covered by insurance and out-of-
pocket expenditures could not be made; total
costs for hospital care were difficult to
ascertain because parents were unable to
separate the individual charges due to
prolonged billing periods. Researchers
estimated patient costs by approximating the
daily hospital charges for three children to be
$1,500 per child, based on the average at
Children's Hospital of Philadelphia. Diaries
and quarterly interviews revealed that VLBW
infants averaged $10,139 per infant in direct
medical charges compared with $1,179 for the
term infants; the differential in charges was
greatest in the first three quarters ($3,653,
$2,509, and $2,426 compared to $212, $126,
and $54, respectively). By the fourth quarter
the difference was $415 to $459, with the
VLBW infants charges $44 less that the term
infants. Transportation costs for VLBW
infants and term infants were $180 per year
and $23 per year, respectively. In terms of
nonmonetary costs, parents of the VLBW
children experienced greater restrictions in
social contacts, particularly in the first two
quarters. 4 tables, 27 references.
049
Evaluation of Interventions to Reduce Racial
Disparities in Infant Mortality: Case
Studies of Selected Interventions.
Form: Book chapter.
Corporate Author: US Department of Health
and Human Services.
Author: McManus, M.
Source: IN: Report of the Secretary's Task
Force on Black and Minority Health. Volume
VI: Infant Mortality and Low Birthweight.
Washington, DC, US Department of Health
and Human Services, pp. 159-181,
January 1986.
Abstract: Evaluation of Interventions to
Reduce Racial Disparities in Infant Mortality:
Case Studies of Selected Interventions provides
summaries of five demonstration projects
designed to reduce low birthweight (LBW) and
the infant mortality rate (IMR). The projects
are (1) the California OB Access Project; (2)
the New York Evaluation of the Cost
Effectiveness of an Intensive Program of
Prenatal Care; (3) the South Carolina High
Risk Perinatal Program; (4) the Washington,
D.C. Better Babies Project; and (5) the St.
Paul, Minnesota Adolescent Pregnancy
Prevention Services. These projects were
selected because of their evaluation designs,
their findings of effectiveness, and their focus
on financing as well as the delivery of
comprehensive services. The California
project (1) increased access to perinatal care in
underserved areas, (2) halved LBW in the
study population compared to the control
group, and (3) realized a cost savings of $250
a month over Medi-Cal cases. The New York
program expected to have cost data after
November 1985. South Carolina's program
had (1) half the rate of fetal and neonatal
deaths in the study population when compared
to the rate in the control group; (2) lesser rates
of postneonatal mortality; (3) more prenatal
care visits; and (4) its first significant infant
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mortality decrease in 4 years (in 1982 it was
16.1; in 1983 it was 15.0). The District of
Columbia's project expected to have findings
available after November 30, 1986. The St.
Paul program found (1) a 40 percent decline in
the rate of teenage pregnancies in the school
population and (2) that pregnant teenagers
were more likely to seek prenatal care.
1 table.
050
Pediatric Patients, Race, and DRG
Prospective Hospital Payment.
Form: Journal article.
Author: Munoz, E.; Barrios, E.;
Johnson, H.; Goldstein, J.; Mulloy, K.;
Chalfin, D.; Wise, L.
Source: American Journal of Diseases of
Children. 143(5):612-616, May 1989.
Abstract: Researchers analyzed resource
consumption for hospitalized minority pediatric
patients treated at the Long Island (New York)
Jewish Medical Center, an 805-bed academic
medical center, using the diagnosis-related
group (DRG) prospective hospital payment
format by race. The study analyzed all 14,489
hospitalized pediatric admissions over a 3-year
period at the center. Researchers analyzed six
characteristics by race for white, African
American, and Hispanic pediatric patients: (1)
Mean age; (2) hospital length of stay; (3) total
hospital cost; (4) number of International
Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9-CM) diagnosis
codes; (5) number of ICD-9-CM procedure
codes; and (6) total number of ICD-9-CM
diagnosis and procedure codes. The study
assessed (1) profit and loss under DRG all
payer reimbursement, (2) the number and
percentage of outlier payments (additional
payment for very expensive patients) for each
group, (3) diagnostic costs, (4) adjustment by
DRG index, and (5) route of admission. Mean
hospital cost per patient (adjusted for DRG
weight index) was significantly greater for
African American ($8408) and Hispanic
children ($8099) than for white children
($6744). The mean hospital length of stay was
also longer for African Americans (10.18
days) and Hispanics (9.55 days) than whites
(7.75 days). Financial risk as measured by
outliers and losses under DRG's was greater
for African Americans and Hispanics than
whites. African American and Hispanic
patients had a higher proportion of emergency
admissions to the hospital than whites, a
greater severity of illness, and higher
diagnostic costs for each episode of illness.
Because minority patients are more likely to be
admitted to the hospital through the
Emergency Room than whites (generally a
more expensive mode of admission than
nonemergency admittance), minority patients
may be a financially unattractive population
under DRG's. The data suggest that African
American and Hispanic pediatric patients have
a greater hospital resource consumption than
whites and may be vulnerable to decreased
access to quality medical care under DRG
prospective payment. 3 figures, 2 tables, 12
references.
051
Childhood Human Immunodeficiency Virus
Infection: The Spectrum of Costs.
Form: Journal article.
Author: Parrott, R.H.
Source: Journal ofAcquired Immune
Deficiency Syndromes. 4(2): 122-129,
February 1991.
Abstract: A physician reviews projections of
the prevalence, estimates of cost, and available
resources to cope with human
immunodeficiency virus (HIV) infection in
infants, children, and adolescents, and
discusses the politics of seeking support. The
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prevalence and number of new cases of HIV
infection in children depend on several factors,
some of which change from time to time and
place to place. In predicting incidence and
prevalence, planners must consider whether (1)
to base predictions only on reported cases; (2)
to account for factors that vary geographically
(e.g., amount of drug abuse, extent of HIV
infection in male and female drug users, and
extent of bisexual and heterosexual spread);
and (3) to use perinatal serosurveillance, which
can assist in prevalence estimates and
incidence prediction. There has been
considerable variation in prediction of HIV
infection in children, partially because the
pediatric surveillance definition of AIDS does
not adequately reflect national morbidity and
mortality due to HIV infection. No matter
what method is used for estimates of future
cases, it is important to fund resources to
follow and test infants whose status is
indeterminant in addition to infants who are
determined to be infected with HIV. Since the
infant's IgG antibody status reflects that of the
mother, estimates of the extent of HIV
infection, both in women and infants, can be
made by performing anonymous HIV antibody
testing on an aliquot of the blood of newborns
routinely obtained for mandated metabolic
screening. The observed prevalence rate can
be adjusted by 30-50 percent (the estimated
rate of vertical transmission of HIV to the
infant) to estimate the ultimate infection rate
among infants born to infected mothers. Far
more than hospital services are important in an
ideal HIV program in areas with moderate to
high prevalence, but to date, there are few
data available beyond hospital costs and
charges. Most caregivers believe that HIV-
infected children and adults are better served
outside the hospital when they are not critically
ill or when they are clearly dying. Though it
is assumed that out-of-hospital costs are less,
such costs have not been analyzed as
thoroughly as hospital costs. There are many
hidden costs of HIV infection, including
manpower costs, hospital costs, and lifetime
costs. Future funding strategies should include
further development of community services
and lobbying for HIV-infected children and
adolescents. 5 tables, 23 references.
052
Impact of Eligibility Criteria on
Phototherapy Program Size and Cost.
Form: Journal article.




Abstract: Researchers analyzed the impact of
eligibility criteria on phototherapy treatment,
in particular for home phototherapy treatment,
based on program size and cost. Subjects
included 786 births from two hospitals of the
Group Health Cooperative (GHC) of Puget
Sound, Washington, a large health
maintenance organization. Four sets of
admission criteria for home phototherapy were
compared from the following sources: (1) the
American Academy of Pediatrics, (2) Group
Health Cooperative, (3) Slater and Brewer,
and (4) Eggert et al. Infants were placed in
one of three groups: (1) Those infants with no
indication for phototherapy by any set of
criteria, (2) infants needing hospital-based
phototherapy indicated by all sets of criteria,
and (3) infants whose phototherapy treatment
would differ depending upon eligibility
criteria. Costs of phototherapy treatment were
estimated for 86 infants whose treatment could
vary by criteria set; 687 infants indicating no
phototherapy and 13 infants treated in the
hospital for all criteria sets were not included.
Treatment varied substantially according to the
criteria sets for the remaining 86 infants (10.9
percent). The treatment rates and home
phototherapy rates of the 86 infants varied:
(1) 51 infants (59 percent) under the American
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Academy of Pediatrics with 23 for home
treatment, (2) 12 infants (14 percent) under
GHC criteria with 6 for home treatment, (3)
61 infants (71 percent) under Slater and
Brewer with 18 for home treatment, and (4) 86
infants (100 percent) under Eggert et al. with
69 for home treatment. Only direct costs were
assessed; indirect and intangible costs were
excluded. Direct costs for one episode of
home phototherapy was $193 dollars and the
direct cost of one episode of hospital
phototherapy was $423 . Estimated annual
discretionary phototherapy costs, including
laboratory examination, home treatment, and
hospital treatment ranged from (1) $70,232 per
infant under the American Academy of
Pediatrics ($55,064 greater than the GHC), (2)
$15,168 under GHC criteria, (3) $90,800
under Slater and Brewer ($75,632 greater than
GHC) and (4) $82,032 under Eggert et al
($66,864 greater than GHC). Differences in
costs were mainly due to the number of infants
treated. Modest variations in standards of care
can potentially have a large effect on medical
care costs. The authors assert that although
most cost savings occurred due to a reduction
in the number of infants treated, health
maintenance organizations reduce costs by
substituting outpatient care for hospital care. 1
figure, 4 tables, 12 references, and appendix.
053
Home Oxygen Therapy in the Newborn:
Costs and Parental Acceptance.
Form: Journal article.
Author: Thilo, E.H.; Comito, J.;
McCulliss, D.
Source: American Journal of Diseases of
Children. 141(7):766-768, July 1987.
from Rose Medical Center intensive care
nursery (ICN) (Denver, Colorado) along with
supplemental oxygen therapy. The telephone
questionnaire assessed the social and economic
impact of home oxygen therapy on the family.
In all cases, the infants received oxygen via a
nasal cannula with prongs. Criteria for
discharge with supplemental oxygen were (1)
stable respiratory status with low-flow oxygen
for at least several days, (2) readiness for
hospital discharge in all other aspects, and (3)
willingness of parents and followup physicians
to cope with oxygen therapy at home. Results
of the questionnaire indicated the mean
birthweight was 1,988 grams, with a mean
gestational age of 33 weeks. The mean length
of time infants needed oxygen at home was 74
days. The financial impact of home oxygen
therapy was calculated for each infant by
determining the cost of oxygen and related
equipment and adding this figure to the cost of
any special followup outpatient visits or
laboratory tests, including outpatient
oxygenation studies and blood gas
determinations. Hospital costs were estimated
using the minimal rate charged by the Rose
Medical Center for an infant in the ICN
receiving oxygen per day multiplied by the
number of days receiving oxygen at home. In
most instances, weaning of oxygen therapy
was accomplished with the aid of periodic
transcutaneous oxygen monitoring performed
as an outpatient in the ICN. Savings for each
infant of treatment at home compared with
being hospitalized averaged $33,370. Despite
various problems and inconveniences (e.g.,
travel and babysitters), 94 percent of the
families stated they definitely would again take
a baby home while oxygen dependent if
necessary. 7 references.
Abstract: To assess the cost of and parental
response to home oxygen therapy in newborn
infants, researchers conducted a telephone
survey of 34 families of infants discharged
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054




Source: Modern Healthcare. 20(16): 18,
April 23, 1990.
Abstract: A study based on information from
44 children's hospitals revealed that children
with acquired immunodeficiency syndrome
(AIDS) stay in the hospital longer, need more
services, incur higher costs, and are associated
with higher hospital costs than adult AIDS
patients. The findings emphasize the need for
more community-based AIDS care, early
detection, and treatment programs to minimize
costly hospital stays. Providing hospital care
to children with AIDS cost more than $37
million in 1987, according to the study by the
National Association of Children's Hospitals
and the National Association of Public Health
and Hospital Institute. Medicaid paid for
nearly half that amount (45 percent). Private
insurance covered 39 percent, and the
remaining 16 percent was either self-pay or
uninsured. By contrast, 48 percent of all adult
patients with AIDS were covered by private
insurance, 34 percent by Medicaid, 13 percent
were self-pay or uninsured, 3 percent were
covered by Medicare, and prison systems paid
2 percent. Young AIDS patients also require
more frequent and lengthier hospital stays than
adult patients. Hospitals' average annual cost
for pediatric AIDS patients totaled $34,713,
but only 78 percent of that amount was
covered by revenue. The typical children's
hospital lost revenue on an average of $7,701
per patient each year, compared with a loss of
$1,472 for adult patients. These findings
indicate that more government and private
money needs to be directed to children's
hospitals that treat a large number of pediatric
AIDS patients. Costly hospital stays can be
reduced by community programs that
coordinate outpatient services, provide social
services (transportation, child care, housing),
and use a case-management system to meet a
range of medical and social-support needs. A
2-year-old program at a Michigan hospital that
provides outpatient services to both HIV
positive children and their mothers in the same
place has reduced admission rates to the
hospital, because barriers to receiving ongoing
medical care have been removed. 1 table.
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Abstract: Researchers conducted a cost-
benefit analysis of amniocentesis in an effort to
provide useful guidelines to policy makers.
Amniotic fluid can be used to assess the
developmental level of the fetus and indicate
the presence of certain genetic characteristics
or defects in certain metabolic processes. For
congenital anomalies in general, the incidence
rates initially decrease as the age of the mother
increases, reaching a minimum in the 25-29
year age range, and then rapidly increasing as
maternal age increases beyond 30. For the
purposes of this study, researchers looked at
amniocentesis in terms of the resources which
will be saved by society as a result of the
program. They defined as a benefit anything
that comes under the heading of resources not
consumed as a result of the prevention of
certain births. Costs dealt with the
amniocentesis program itself, i.e., costs
emanating more or less directly from the
program. Benefits determined by the
researchers included (1) saved cost of
institutional care for mentally retarded or
developmentally disabled persons, (2) saved
cost of hospital and medical care in cases of
neural tube defects and other conditions, (3)
saved cost of loss of parental income due to a
retarded or disabled child, and (4) benefits
from basic research and expanded knowledge
due to further development of amniocentesis.
Costs of an amniocentesis program include (1)
publicity to make the program known, (2)
administration of the program, (3) genetic
counseling, and (4) abortion and associated
care costs in the case of a positive test.
Researchers determined that the total benefit of
extending the program to all women at or
beyond age 35 would be $60 million, and the
total cost would be $31 million. The cost of
institutional care for mentally or
developmentally disabled persons ranges from
$12,775 to $30,588 annually. The estimates
for income of retarded workers ranged from
$5,891 for mild retardation to $5,233 for
moderate retardation. Researchers determined
that cost of the amniocentesis procedure
averaged about $200, ranging from $121 to
$400. Abortion procedures had an average
cost of $250-300. When considering
amniocentesis procedures, there are several
moral, ethical, and legal issues which must be
considered in addition to cost-benefit analysis.
093
Prenatal Cytogenetic Diagnosis: Medical
and Social Implications. Indications,
Acceptance By Doctors and Patients, Impact
and Cost: A 10-year Review.
Form: Journal article.
Author: Bell, J. A.; Pearn, J.H.
Source: Medical Journal of Australia.
143(2):76-79, July 22, 1985.
Abstract: Australian researchers review the
medical and social implications, indications,
and acceptance by physicians and patients of
prenatal cytogenetic diagnosis (PCD) over a
10-year period. Apart from the legal and
ethical questions, clinicians and cytogeneticists
have been involved in two distinct debates:
(1) Philosophical questions about what
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constitutes high risk for a couple having a
future child with a cytogenetic abnormality,
and (2) pragmatic questions concerned with
offering a diagnostic service to as many
couples as the cytogenetic support services can
cope with, without compromising standards.
By 1975, amniocentesis for early PCD had
become an established part of clinical genetic
practice and antenatal care. The two most
common indications have been maternal age
and a previous child with Down's Syndrome.
Other indications include a family history of
Down's Syndrome or other chromosomal
abnormality, repeated abortions, parental
carrier of a balanced translocation, and
maternal carrier of an X-linked disorder, in
order to determine fetal sex. The Human
Genetics Society of Australasia has a policy
stating that facilities for PCD should be
available in Australia for all women 37 years
of age or older. An assessment of the impact
of PCD on the birth incidence of major
chromosomal abnormalities, particularly
Down's Syndrome, indicates that the
maximum reduction which might be achieved
in current practice is 30 percent. In
acceptance by doctors and patients, the overall
interpretation of patient surveys indicated that
range of acceptance of PCD is between 60 and
80 percent and that the attitudes of
obstetricians towards PCD are a significant
factor affecting the acceptance of this test as a
routine procedure. Utilization rates of PCD
vary among physicians due to knowledge
difference, acceptance of innovation, perceived
risks, and personal beliefs. In studies
conducted between 1976 and 1982, utilization
rates range from 6.7 percent (Adams et al.,
1978, Nebraska, U.S.) to 72 percent
(Mikkelsen et al., 1981-82, Copenhagen,
Denmark). In 1973, it was estimated that the
cost of screening (with subsequent followup
procedures) was $64 million, but that the cost
of care for infants with serious chromosomal
abnormalities would be in excess of $2 billion
(an estimate approximately 32 times the cost of
prevention). The estimated cost of PCD in
1973 was $150 per test. In 1977, Hook and
Chambers estimated the per capita cost of PCD
to be $400 and that a PCD program would not
result in economic loss if the maternal age
limit for inclusion was 32 years of age. A
cost benefit analysis of 1981-82 prevention
programs in British Columbia for both Down's
Syndrome and neural tube defects concluded
that prenatal screening for Down's Syndrome
is cost-beneficial for women 34 years of age
and older. If all women in the study were
screened, the average cost (in 1982 Canadian
dollars) of detecting a fetus with Down's
Syndrome was $570 Canadian dollars. Access
to PCD has been determined by medical
attitudes towards what constitutes high risk and
by questions about the logistics of delivering a
new diagnostic test to as many couples as costs
will allow. The most common indication,
advanced maternal age, has led to different
access criteria in various parts of Australia.
Factors such as socioeconomic status,
education, and religion affect the acceptance of
PCD from the point of view both of patients
and of the doctors who care for them.
094




Author: Gafni, A.; Blanchette, V.S.
Source: Current Studies in Hematology and
Blood Transfusion. (54): 140-147, 1988.
Abstract: Neonatal alloimmune
thrombocytopenia (NAITP) is the platelet
counterpart of the red cell disorder hemolytic
disease of the newborn. The incidence of this
disorder in a Caucasian population is about 1
out of 2,000-3,000 live births. NAITP is
potentially treatable; therefore, should a policy
of screening for it be recommended for
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pregnant women in Canada? Economic
evaluation must be conducted to help in this
type of decision making. The evaluation of a
preventive measure is complicated, and
includes considerations of population and
frequency of the illness, size of risks
(including those associated with the prevention
measure), and time between adoption of a
preventive measure and the payoff in health.
Researchers conducted an economic analysis
under favorable assumptions toward the
screening program, and calculated that the
costs resulting from a screening program of
100,000 Caucasian pregnant women would be
$1,036,000 (Canadian dollars) or $745,920
(United States dollars). This made the cost per
quality-adjusted life-year (QALY) U.S.
$16,736. This is then compared with other
screening measures; for example, NAITP
screening would be 10 times more expensive
than Rh immunization prevention, 3 times
more expensive than thyroid screening, but
two and a half times less expensive than a
school tuberculin testing program. The
authors' main conclusion from this preliminary
economic evaluation is that an NAITP
screening program has the potential to compete
with other programs for the limited resources
available. No cost information is given for
each of the measures. 2 tables, 14 references.
which can only be applied when genetic
material is available from a CF-affected family
member; and (2) those based on probes for the
newly discovered CF gene, which can be
applied in the general population. When either
type is applied in families of CF-affected
children, even an expensive test produces
substantial net benefits. Existing direct gene
probe tests are not sensitive, although
eventually they may become less expensive
and more accurate than tests based on RFLPs.
Even if these tests become highly accurate, the
financial benefits of population-wide screening
for CF are likely to be small or negative,
particularly if testing does not lead to increases
in the number of normal children as it
decreases the number of births of CF-affected
children. Because few children born in
families without a history of CF have the
disease, tests that are not perfectly specific will
produce a large number of false-positive
results, leading to the abortion of many normal
fetuses. 2 tables, 6 figures, 35 references.
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Economic Appraisal of Screening for
Down's Syndrome in Pregnancy Using
Maternal Age and Serum Alpha Fetoprotein
Concentration.
095
Costs and Benefits of Prenatal Screening for
Cystic Fibrosis.
Form: Journal article.
Author: Gill, M.; Murday, V.; Slack, J.
Source: Social Science and Medicine.
24(9): 725-731, 1987.
Form: Journal article.
Author: Garber, A.M.; Fenerty, J. P.
Source: Medical Care. 29(5):473-489,
May 1991.
Abstract: Researchers examined the costs and
benefits of prenatal screening for cystic
fibrosis (CF) and selective abortion using two
types of tests: (1) Those based on restriction
fragment-length polymorphisms (RFLPs),
Abstract: Researchers calculated the direct
and indirect costs and benefits of expanding
the existing screening program for Down's
Syndrome by using maternal age and serum
alpha fetoprotein concentrations using a sample
of Down's Syndrome pregnancies from the
North East Thames Region of England in
1982. The North East Thames regional
screening policy for Down's Syndrome is to
offer amniocentesis to all women ages 38 or
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more at the expected date of delivery in whom
the risk of delivering a baby with Down's
Syndrome is at least 1 in 220. In 1982
through 1983, 64 Down's babies were born in
the North East Thames Region. These babies
were ascertained through the regional
cytogenetic laboratories and hospital
obstetricians and pediatricians. The costs of
the existing and extended programs were
calculated by adding the costs of (1) the
amniocenteses, including repeats; (2) the
cytogenetic laboratory costs; and (3) the
hospital costs of termination. Estimated cost
of detecting and terminating each fetus was
5,614 pounds. If the program had been
extended to all the women whose risk was 1 in
220 or more, the total cost for detecting and
terminating would have been 118,300 pounds
at 1983 prices, or $7,393 each. Estimated
total costs of the existing program were 61,755
pounds. The benefits included in this analysis
reside in the averted excess lifetime costs of
Down's compared with non-Down's
individuals. These are compared under the
following categories: (1) Lost parental output,
(2) affected individuals output, (3)
consumption of goods and services, (4) use of
health services, (5) education, and (6) fostering
and adoption. The life time costs of a Down's
birth are 156,660 (discounted at 5 percent) and
120,940 pounds. If each birth were replaced a
year later by a normal child, the costs amount
to 30,070 pounds and the excess costs for a
child with Down's Syndrome are 126,590
pounds. The estimated return on the 1,000
pounds spent on the screening program ranges
from 14,100 to 27,900 pounds for the existing
program and 13,600 and 21,200 pounds for
the proposed extended program. If the uptake
of the proposed screening program is maximal,
the replacement rate is zero and a discount rate
of 5 percent is used, the benefit cost ratio is
23.6. If the uptake of the program is 50
percent, the replacement rate is 100 percent
and a discount rate of 7 percent is used, the
benefit cost ratio is 12.2. The extra workload
involved in the proposed extension of the
program amounts to between one and two
amniocenteses per week in each district, and
the extra cytogenetic analyses. An increment
of this size at district level makes it unlikely
that unit costs will be increased. 3 figures, 5
tables, 12 references.
097
Studies of Various Aspects of Down
Syndrome in Denmark, and Their Use as an
Epidemiological Basis for a Cost Benefit
Analysis of Genetic Amniocentesis.
Form: Journal article.
Author: Goldstein, H.
Source: Danish Medical Bulletin.
39(6):489-508, December 1992.
Abstract: A researcher performed a cost
benefit analysis (CBA) of a program of
prenatal diagnosis by amniocentesis, analyzing
two alternatives: (1) The Danish society,
which has a program that offers amniocentesis
at no cost to all Danish pregnant women,
compared to (2) a society without the same
program. The investigator studied three
groups of persons with Down's Syndrome
(DS) representing three stages of life: (1) 16
people aged 3-7 (preschool group), (2) 43
people aged 14-20 (adolescent group), and (3)
38 people aged 40-50 (adult group). The
researcher collected data on their living
conditions and use of health and social services
by interviewing the DS person's caretakers
(such as parents, siblings, institution workers).
The study showed that living conditions of
persons with DS are different from those of
the background population. These differences
grow more marked with the age of the person
and comprise places of residence, educational
activities, and vocational activities. Additional
public sector costs due to the handicap of the
DS person are 133,919 Danish Kroner
(DKK)/year (equal to $13,549 United States
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dollars) for children ages 3-7; 219,750
DKK/year ($24,409) for DS adolescents; and
207,587 DKK/year ($18,436) for DS adults
ages 40-50. Results indicate that the tangible
benefits exceed tangible costs for most
calculations of this study, if all Danish women
were to be offered amniocentesis. 7 tables,
125 references.
098
Cost-benefit Analysis of Prenatal Diagnosis
by Amniocentesis in Denmark.
Form: Journal article.
Author: Goldstein, H.; Philip, J.
Source: Clinical Genetics. 37(4):24 1-263,
April 1990.
Abstract: Researchers in Denmark performed
a cost-benefit analysis of amniocentesis using
both the excess-cost method and the
replacement method and several replacement
and discount rates. In Denmark,
amniocentesis is offered at no cost to various
groups of pregnant women at risk for genetic
disorders of the fetus. The most important
risk factor is being over age 35. The analysis
is based on incidence and survival rates for
Down's Syndrome (trisomy 21), Patau's
syndrome (trisomy 13), and Edwards'
syndrome (trisomy 18), and on incidence and
survival rates of children with neural tube
defects (NTD's). Researchers calculated
prevalences of various chromosomal
aberrations such as NTD's and abdominal wall
defects (AWD's) on the basis of vital statistics
of the birth cohort for Denmark in 1985, and
adjusted financial figures to 1985 prices. The
following are annual costs to maintain an adult
with Down's Syndrome in Danish Kroner: (1)
298,958 in an institution, (2) 72,037 in a
private home, and (3) 67,572 in a sheltered
residence. If amniocentesis were offered to all
pregnant women independent of age, with a
supposed participation rate of 75 percent and if
only tangible costs and benefits were included,
the analysis shows a benefitxost ratio greater
than 1.0 using discount rates of 4 percent and
7 percent (both for the excess-cost method and
replacement method). Analysis shows a
benefitxost ratio less than 1.0 using 10
percent. The ratio is approximately 1.0, if
pregnant women between ages 15-19 and 20-
24 years are excluded, using the discount rate
10 percent. The ratios are independent of both
methods of calculation and rate of replacement
but clearly dependent on rate of discounting.
Researchers also performed calculations for
other participation rates. If intangible costs
and benefits are included, the results are more
uncertain because the evaluation of intangible
costs and benefits may vary between
individuals and countries. 1 figure, 17 tables,
30 references.
099
Can We Afford Screening for Neural Tube
Defects? The South Wales Experience.
Form: Journal article.
Author: Hibbard, B.M.; Roberts, C.J.;
Elder, G.H.; Evans, K.T.; Laurence, K.M.
Source: British Medical Journal.
290(6464): 293-295, January 26, 1985.
Abstract: Researchers estimated clinical and
financial gains and losses accruing from five
different options for screening for open neural
tube defects (ONTD), based principally on
results of detailed monitoring of inputs and
outcomes and of process costs in the South
Wales Anencephaly and Spina Bifida Study.
Between April 1977 and August 1979,
researchers obtained complete information for
15,687 pregnant women in Mid Glamorgan, a
nonteaching health authority in Wales. The
five screening options included (1) diagnostic
ultrasound scanning and amniocentesis for all
mothers with serum alpha fetoprotein
concentration confirmed to be above 95
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percent after ultrasound estimation of
gestational age and exclusion of multiple
pregnancy; (2) as option one, but for mothers
with a concentration above 97 percent; (3) as
option two, but also with ultrasound and
amniocentesis for pregnancies with close
family history of ONTD irrespective of
fetoprotein concentration; (4) as option two,
but with routine ultrasound scanning at first
hospital visit; and (5) ultrasound scanning, but
with no measurement of serum alpha
fetoprotein concentration, in all pregnancies
eligible for screening together with
amniocentesis in all pregnancies with a
suspicion of ONTD on ultrasound scanning.
Researchers calculated social gains and losses
associated with each of the options based on
assumptions primarily derived from the South
Wales field study. Long term gains, expressed
in avoidance of births or stillbirths of a child
with an open neural tube defect, were (1) 342
avoided births per 100,000 births for option
one; (2) 324 avoided births per 100,000 for
option two; (3) 351 avoided births per 100,000
for option three; (4) 340 avoided births per
100,000 for option four; and (5) 376 avoided
births per 100,000 for option five. Long term
losses produced by death or morbidity of a
normal fetus as a result of (1) amniocentesis
were, per 100,000 children, 100 cases of death
or morbidity of a normal fetus for option one,
60 for option two, 100 for option three, 60 for
option four, and 20 for option five; (2)
termination of a normal fetus due to diagnostic
error were, per 100,000 children, 20 abortions
of a normal fetus for option one, 20 for option
two, 20 for option three, 20 for option four,
and 20 for option five; and (3) incorrect
reassurance after a false negative screening test
and subsequent birth of an affected child were,
per 100,000 children, 124 births of an affected
child for option one, 144 for option two, 114
for option three, 126 for option four, and 86
for option five. Financial costs per 100,000
population, in 1981 prices, were 707,500
pounds for option one, 656,100 pounds for
option two, 696,200 pounds for option three,
735,600 pounds for option four, and 677,900
pounds for option five. Results show option
five to be the most cost effective option. If
the prevalence, including terminations, of
ONTD's is between 1.25 and 5 per 1,000
births, the financial cost of avoiding the birth
of a child with an open neural tube defect who
would survive for more than 24 hours ranges
from 9,400 pounds (option five at a prevalence
of 5 per 1,000) to 53,600 pounds (option four
at prevalence 1.25 per 1,000). Prevalence is
the biggest determinant of cost. 4 tables, 13
references.
100
Economic Considerations in Technology
Assessment: The Case of Genetic Disease.
Form: Journal article.
Author: Lairson, D.R.; Swint, J.M.
Source: Health Policy . 9(3):309-315, 1988.
Abstract: Researchers describe economic
issues pertinent to health care technology
assessment using allocation alternatives that
confront decision makers in screening for
intervention against genetic diseases. These
economic issues include (1) the allocation of
resources between health and other sectors of
the economy and between alternative services
within the health sectors, and (2) the costs of
producing the services that are selected. The
authors use allocative efficiency, production
efficiency, and cost benefit analysis to evaluate
efficiency. Both community and on-demand
hospital screening programs for Tay Sachs
disease, in combination with diagnostic and
therapeutic abortion services for couples at
risk, have positive economic consequences.
The cost benefit ratios range from 3:1 to 10:1
for community screening efforts and 1.6:1 to
3.2:1 for on-demand hospital screening.
Concerning intervention against Down's
Syndrome, the primary economic issue is
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whether or not to increase investment in fetal
detection programs, which have been shown to
be allocatively efficient. Empirical studies
found that benefit-cost ratio for Down's
Syndrome and other chromosomal trisomies
was 2:1; a Centers for Disease Control (CDC)
study found the benefit-cost ratio is 1.5:1 (for
maternal age greater than or equal to 35).
However, only 22 percent of Down's
Syndrome births in the United States are to
women over 34 years of age. Due to the
lower risks of amniocentesis and probability of
Down's Syndrome, studies suggest that an
expansion of service to pregnant women 33
and 34 would be allocatively efficient. Tests
for alpha-fetoprotein levels used to prenatally
detect neural tube defects can be used with risk
levels for all maternal ages to indicate
probability of an affected fetus. Alpha-
fetoprotein level tests increase the number of
affected fetuses that can be prenatally detected
by more than 50 percent. Results indicate that
investments in screening programs for Tay
Sachs disease and Down's Syndrome are
allocatively efficient, also for interventions
against neural tube defects; however, there are
complex ethical issues involved. The authors
concluded that as tests for genetic diseases
become available, each will have to be
evaluated on its own merits relative to
alternative health sector investments.
101
Cost-effectiveness Ratio of Chorionic Villi
Biopsy for the Prenatal Diagnosis of
Chromosomal Aberrations as Compared
With Amniocentesis.
Form: Journal article.
Author: Marchese, C.A.; Viora, E.;
Campogrande, M.; Carbonara, A.O.
Source: Ricerca in Clinica e In Laboratorio.
16(4):533-538, October-December 1986.
Abstract: Researchers evaluated whether
chorionic villi biopsy (CVB) for the prenatal
diagnosis of chromosomal aberrations may be
a cost-effective procedure as compared with
second trimester amniocentesis. The total cost
of amniocentesis was divided into three
categories: (1) Cost before amniocentesis,
80,000 Italian lira, which included two
obstetrical visits, genetic counseling, and one
ultrasound; (2) cost of amniocentesis, 216,000
lira, which included obstetrician's fee, one
ultrasound examination, amniocentesis kit, and
laboratory material and time; and (3) a second
trimester pregnancy termination, 858,000 lira,
which included psychiatric counseling and 5
days of hospital stay. The estimated cost of
CVB also was divided into three categories:
(1) Cost before biopsy, 72,000 lira, which
included one obstetrical visit, genetic
counseling, and one ultrasound examination;
(2) cost of biopsy, 163,000 lira, which
included two obstetricians' fees, one
ultrasound, CVB kit, and laboratory material
and time; and (3) cost of a first trimester
abortion, 170,000 lira, which included a 1-day
hospital stay. Since the most frequent
indication for the prenatal diagnosis of
chromosomal aberrations is advanced maternal
age, the study limited analysis to 100 women
of advanced maternal age who were 10 weeks
pregnant with a viable fetus. The cost of
second trimester abortion includes the fee for
the psychiatric counselling, which in Italy is
necessary for allowing a second trimester
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pregnancy termination. For CVB, researchers
considered the cost of 100 procedures, plus the
cost of 6 therapeutic abortions; for
amniocentesis, they calculated the cost of 5
spontaneous abortions, 95 amniocenteses, and
2 therapeutic abortions. Total costs for
amniocenteses for the entire subject group
were 31,536,000 lira and for CVB were
24,520,000. The costs for CVB were 22
percent less than amniocentesis. In addition to
its lower cost, if CVB is proven to be as safe
and accurate as amniocentesis for the prenatal
diagnosis of chromosomal aberrations, then it
might become a first-choice test in pregnancies
at risk because of advanced maternal age.
CVB had a lower cost primarily due to the
shorter time required by the laboratory to
process the specimens. Using the direct
method for the cytogenetic analysis of
chorionic villi, it was possible to avoid the
time-consuming tissue culture needed for
amniotic fluid. 4 tables, 8 references.
102
Cost-benefit Analysis of a Population
Screening Programme for Neural Tube
Defects.
Form: Journal article.
Author: Sadovnick, A.D.; Baird, P. A.
Source: Prenatal Diagnosis . 3(2): 117-126,
April-June 1983.
Abstract: British Columbia has approximately
39,000 births annually and the incidence of
neural tube defects (NTD's) is 1.55 per 1,000
births. Researchers performed a cost-benefit
analysis to determine if a population screening
program for NTD's would be cost effective for
British Columbia. In calculating costs and
obstetrical benefits of a screening program,
incidence figures for all births (i.e., livebirths
and stillbirths) are used as these are incurred
regardless of the pregnancy outcome.
However, in calculating the benefits from a
screening program associated with the
avoidance of the costs for lifetime care of
affected persons, only livebirth incidence rates
are used since the cost of lifetime care is not
an issue if an infant is stillborn. While there
are approximately 39,000 births annually in
British Columbia, researchers estimate that 20
percent of pregnant women would either fail to
seek medical attention early enough in the
gestation to allow them to participate in a
screening program for NTD's or else would
refuse to participate for personal reasons. A
screening program for NTD's has been found
to be 100 percent and 75 percent effective for
detecting anencephaly (AN) and spina bifida
(SB) respectively. Therefore, by screening
30,950 pregnancies, it is expected that 21 AN
fetuses and 20 SB fetuses would be detected.
Costs of prenatal diagnosis, such as
ultrasonography and removal of amniotic fluid,
are covered by the British Columbia
government through a provincial medical
insurance program. The protocol screening
for NTD's includes a maternal serum
alphafetoprotein (MSAFP) analysis ($21.50
1980 Canadian dollars plus a $0.74 mailing
cost per blood test), a second blood test for
women with raised MSAFP levels, and
counseling for women with two consecutively
raised MSAFP levels. Counselors explain
further diagnostic testing in the protocol,
including ultrasound to detect AN fetuses and
amniocentesis. The cost of a program
administrator also needs to be calculated into
the screening cost (approximately $30,000
annual salary). Costs for NTD screening were
calculated for two situations: (1) When
chromosomal analysis is done on all amniotic
fluid samples, and (2) when chromosomal
analysis is not done on all amniotic fluid
samples. Benefits from the avoidance of
lifetime costs of caring for persons with SB are
approximately $83,000 per person. It costs
approximately $700 less to terminate a
pregnancy after 16 weeks gestation than to
continue delivery and the savings in delivery
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costs is considered an obstetrical benefit of
screening. The costs of a screening program
for the entire cohort of 30,950 pregnant
women would be $871,800 if only amniotic
alphafetoprotein (AFP) levels are measured. If
fetal karyotyping is done in addition to the
measurement of amniotic AFP levels, the cost
would increase to $964,000 for the cohort of
30,950 pregnant women. The benefits from a
screening program for NTD would be
$1,537,000 for the cohort of 30,950 pregnant
women. The cost benefit ratio is 1.8:1 for
prescreening for NTD and 1.6:1 when
karyotyping is also done. The results of a cost
benefit analysis for a screening program for
NTD's show that such a program would be
cost-beneficial in British Columbia.
Calculations were based on the assumption that
2.3 percent of the cohort would initially have
elevated maternal serum AFP levels. This
figure has been reported to be as high as 7.4
percent, but results from recalculation of the
costs using this higher rate also show that such
a program would be cost effective in British
Columbia. 1 figure, 2 tables, 29 references.
103
Economic Assessment of Maternal Serum
Screening for Down's Syndrome Using
Human Chorionic Gonadotropin.
Form: Journal article.
Author: Seror, V.; Muller, F.; Moatti, J. P.;
Gales, C.L.; Boue, A.
Source: Prenatal Diagnosis. 13(4):281-292,
April 1993.
Abstract: The effectiveness and costs of
prenatal screening programs for Down's
Syndrome using maternal serum markers will
vary significantly depending on the biological
cut-off values chosen in order to select
women, at each maternal age, who will be sent
for amniocentesis. On the basis of the first
French prospective study of human chorionic
gonadotropin (hCG) measurement in maternal
serum, researchers show that the screening
protocol currently used in France, where hCG
cut-off values are defined in order to offer
amniocentesis to women of all ages with a 1
percent fetal risk of Down's Syndrome, would
detect approximately 64 percent of all cases of
trisomy 21 at birth and would provide cost
savings for the French health care and social
security system. On the basis of a
representative sample of 100,000 pregnant
women, the total costs of screening would
reach $8,302,000 American dollars but would
generate net potential savings of $32,186,000
in terms of life-long costs of care for trisomic
21 children which would be avoided by
termination of pregnancy following a positive
diagnosis of Down's Syndrome. Data about
the effectiveness of screening come from the
database of the Biochemistry Laboratory of
Ambroise Pare Hospital in Boulogne.
Economic assessment of screening strategies is
performed on the basis of 100,000 women
getting access to hCG testing and under the
following assumptions: (1) The age
distribution is identical to that of the French
general population of pregnant women; (2) all
women with hCG values equal to or higher
than the cut-off levels will agree to have an
amniocentesis and will choose abortion in the
case of a true-positive diagnosis; and (3) 15
percent of pregnancy terminations concern
affected fetuses who would have died anyway
before the end of pregnancy or at delivery,
implying no further costs for society. The
results are presented on the basis of a unit cost
of $14 American dollars (80 1980 French
Francs) for hCG testing and $700 American
dollars (4,070 1980 French Francs) for
amniocentesis. The estimated life-long costs
of care for a trisomic 21 child were between
$320,000 and $777,500 American dollars
(1,900,000 and 4,400,000 French Francs).
Extensive sensitivity analyses were performed
in order to take into account the remaining
uncertainties about these life-long costs.
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Researchers conclude that it is the ethical and
value-laden issues rather than economic and
financial arguments that set limits to the
utilization of screening for Down's Syndrome
using maternal serum markers like hCG. 1
figure, 4 tables, 37 references.
104
Economic Appraisal of Alternative Pre-natal
Screening Programmes for Down's
Syndrome.
Form: Journal article.
Author: Shackley, P.; McGuire, A.;
Boyd, P. A.; Fitchett, D.M.; Kay, J.;
Roche, M.; Wood, P.
Source: Journal of Public Health Medicine.
15(2): 175-184, June 1993.
Abstract: Researchers evaluated the cost-
effectiveness of alternative screening programs
for Down's Syndrome within the Oxford
Regional Health Authority in the United
Kingdom. The measure of outcome is the
average cost per Down's Syndrome birth
avoided. Researchers evaluated a serum
screening program for women of all ages,
which includes the triple test of alpha-
fetoprotein (AFP), unconjugated estriol (UE3),
and human chorionic gonadotrophin (HCG).
All women with a positive serum test would be
offered an amniocentesis. Researchers
compared this screening option with a
screening based on maternal age. Data were
collected on the current screening program
within the Oxford Regional Health Authority
and compared with the estimated cost-
effectiveness of the triple test. From 1989 to
1990, a 2-year period, there were 96 cases of
Down's Syndrome from 72,233 live births, or
an overall incidence of 1.33 per 1,000 live
births. Of the 96 cases, 39 (40 percent) were
to women over 35 years of age. Making the
assumption that there were 35,000 pregnancies
per year in the Oxford Region, with an
incidence of Down's Syndrome of 1.33 per
1,000 live births, therefore implying that there
will be 48 Down's Syndrome births per year
in the Region, researchers used the Oxford
data to estimate the triple test based on a 66
percent sensitivity, a 4.6 percent false positive
rate, and a 100 percent uptake of the triple test
and amniocentesis. Researchers estimated that
the triple test would detect 31.7 of 48 Down's
Syndrome fetuses. Replacement of the current
screening with the triple test, with a risk cut-
off point for amniocentesis of 1 in 250, would
result in 12.5 extra Down's Syndrome
detections. Researchers assumed that in
addition to the 36,500 patient samples, 7,300
standards and quality controls would also need
to be sampled. The estimated cost of the triple
test procedure was 13.63 pounds sterling per
person. Estimating the cost of each
amniocentesis at 250 pounds sterling and each
termination of pregnancy at 450 pounds
sterling, the total cost associated with the
introduction of the baseline serum screening
program was 938,885 pounds sterling, which
would result in an average cost of 29,618
pounds sterling per Down's Syndrome birth
avoided. Indirect costs, including (1) lost
parental output, (2) consumption impacts, (3)
education impacts, (4) additional National
Health Service (NHS) costs, (5) capital
impacts, (6) adoption and fostering costs, and
(7) lost individual output, were adjusted to
1990 prices and added. Researchers estimated
excess lifetime costs of an individual with
Down's Syndrome amount to 100,500 pounds
sterling discounted at 6 percent; 79,500
pounds sterling when Baird and Sadovnick's
life tables are applied. When incorporated into
the costs per Down's birth avoided, the excess
lifetime cost is 49,882 pounds sterling, or a
general resource saving of 49,882 per Down's
birth avoided from the introduction of a serum
screening program. Based on a sensitivity
analysis of the screening program, researchers
found that the cost-effectiveness of the triple
test is sensitive to assumptions concerning the
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costs and uptake of amniocentesis and
detection rate. Unless the uptake of
amniocentesis is very low, the triple test is a
more cost-effective means of screening. 4
figures, 3 tables, 12 references, and an
appendix.
105
Appraisal of a New Scheme for Prenatal
Screening for Down's Syndrome.
Form: Journal article.
Author: Sheldon, T.A.; Simpson, J.
Source: British Medical Journal.
302(6785): 1133-1 136, May 11, 1991.
Abstract: British evaluators appraised the
triple test which is a new method of prenatal
screening for Down's Syndrome based on
maternal serum concentrations of alpha
fetoprotein, unconjugated oestriol, and human
chorionic gonadotrophin combined with
maternal age. They determined the cost
effectiveness of this test relative to screening
only by maternal age over a range of
population detection rates. Costs per affected
fetus detected served as the outcome measure.
Results indicate that the triple test is more cost
effective than maternal age screening for
amniocentesis risk cut off points, resulting in a
detection rate for Down's Syndrome of over
45 percent. A detection rate of 60 to 65
percent is most cost effective, that is, the cost
per case detected is at its minimum (around
29,000 pounds), though screening with higher
detection rates is still likely to be cost
beneficial. The researchers concluded that
prenatal screening for Down's Syndrome based
on the triple test should replace screening
based only on maternal age. Individual
women's preferences should be elicited by the
use of structured decision analysis in order to
maximize utility and so increase the benefits of
the screening program. 3 tables, 1 figure, 23
references.
106
Cost-Justification Analysis of Prenatal
Maternal Serum Alpha-feto Protein
Screening.
Form: Journal article.
Author: Taplin, S.H.; Thompson, R.S.;
Conrad, D.A.
Source: Medical Care. 26(12): 1185-1202,
December 1988.
Abstract: Researchers examined whether
systematic use of maternal serum alpha-feto
protein (MSAFP) screening will result in a
positive or negative net cost to an insurer.
They used Group Health Cooperative (GHC)
of Puget Sound, Seattle, Washington, a closed
panel health maintenance organization as the
setting for the MSAFP protocol. Using a
decision analysis approach, the researchers
used the MSAFP test to detect neural tube
defects (NTD's) and Down's Syndrome,
identifying the possible outcomes and their
respective probabilities. The initial MSAFP
screening was 16 to 18 weeks after the first
day of the woman's last menstrual period.
After the screening, the protocol included the
following events as appropriate: (1) A repeat
MSAFP, (2) an ultrasound, (3) a genetic
amniocentesis, and (4) a termination of
pregnancy. The sensitivity of MSAFP was
between 75 and 90 percent depending on the
multiple of the median chosen to establish an
elevation and the specificity was between 95
and 99 percent. The proportion of the
population requiring genetic amniocentesis
varied from one to two percent. Studies
indicated that between 21 and 33 percent of
Down's Syndrome cases are found among
screened women under 35 years of age; an
additional 10 to 20 percent of all Down's
Syndrome cases were found by amniocentesis
among women over 35 years of age.
Generally, after the initial screening,
approximately eight percent of women will
have had a low MSAFP value (less than 0.5
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multiple of the median), whereas another five
percent will have had a high value (greater
than 2.5 multiple of the median). The
recommendation was that women with an
abnormal value obtain a repeat MSAFP.
Researchers assumed that 4.8 percent of the
screened population will obtain a repeat
MSAFP because of a high value, whereas 5.2
percent will obtain one because of a low value.
Approximately three percent of the screened
population will obtain an ultrasound as a result
of an elevated MSAFP, whereas five percent
will obtain one because of a low value. One
to two percent of screened women will need
amniocentesis to evaluate their risk of having a
child with a NTD, whereas two to five percent
will need one to check for Down's Syndrome.
The probabilities and costs (in 1987 dollars) of
events were analyzed on a computer
spreadsheet using a decision analytic approach.
A GHC chart audit provided baseline estimates
of the use of ultrasound and amniocentesis.
The prenatal population was 4,000 and
participation was 40 to 80 percent. The costs
were $8 to $12 for MSAFP, $100 for
ultrasound, $800 to $1,000 for genetic
amniocentesis, $595 for second trimester
abortion, $400 for prenatal care, $1,500 for
delivery, and $2,000 to $3,000 for
spontaneous abortion. The cost benefit
analysis considered only direct medical care
costs that would be experienced by the insurer.
Costs included were those associated with
having an MSAFP program in operation;
benefits were defined as health care costs
avoided. Avoided costs included the avoided
delivery and prenatal costs subsequent to a
pregnancy termination and medical care that
would have occurred following a delivery.
Lifetime medical costs at GHC alone were
used in the analysis. Researchers used
discount rates of 5 and 10 percent for the 10
year analysis, and 14 percent to obtain present
value for total lifetime benefits. Total costs
were $322,762 for each individual with
Down's Syndrome and $137,923 for each
individual with open spina bifida. The
analysis considered MSAFP screening for
NTD's alone, and then was repeated to
consider screening for both NTD's and
Down's Syndrome. Fewer than 1 percent of
the women had an MSAFP performed. Fifty-
four percent of women obtained at least one
ultrasound during their prenatal care and 8.4
percent had an amniocentesis. Among all
prenatal patients, 6.7 percent had at least one
ultrasound during the time when it might have
been indicated by MSAFP; 13 percent had
ultrasound done between 16 and 18 weeks.
Genetic amniocentesis was obtained by 8.4
percent of the sample. It would cost an
estimated $823,292 to perform NTD screening
in 3,200 women per year over 10 years
(assuming 80 percent participation) with a
resultant avoided cost of $456,332. The
current values of these costs and benefits
would be $636,211 and $347,218 using a 5
percent discount rate. Testing for both NTD's
and Down's Syndrome results in current
values of $1,475,635 and $574,392,
respectively for program and avoided costs
over the 10-year period. Thus, the current
value of the costs of screening exceeded the
current value of the avoided costs of care.
Using a 5 percent discount rate, the cost to the
insurer of a screening program for NTD's
alone over 10 years exceeded costs avoided by
$10 per person screened. Adding screening
for Down's Syndrome using the same MSAFP
test increased the net cost by $22 to a total of
$32 per screenee. Subtracting the cost of the
baseline use of ultrasound and amniocentesis
reduced this net cost by $1 per person for
NTD screening alone, and by $4 when
screening for both NTD's and Down's
Syndrome. The estimate of the cost to the
insurer was sensitive to assumptions regarding
costs of medical care avoided, the expense of
the MSAFP, the proportion of screened
women requiring a genetic amniocentesis, and
the cost of that procedure. Results indicated
that screening by MSAFP for NTD's and
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Down's Syndrome will result in a net cost to
the insurer within the 10-year screening period
and even when a lifetime of avoided direct
care costs were considered.
107
When Does Mass Screening for Open Neural
Tube Defects in Low-risk Pregnancies Result
in Cost Savings?
Form: Journal article.
Author: Tosi, L.L.; Detsky, A.S.;
Roye, D.P.; Morden, M.L.
Source: Canadian Medical Association
Journal. 136(3):255-265, February 1, 1987.
Abstract: Researchers estimated the cost
savings that might be derived from a mass
prenatal screening program aimed at detecting
open neural tube defects (NTDs) in low-risk
pregnancies. They determined whether the
costs of instituting a screening program would
be less than the savings that would result from
aborting fetuses with NTDs detected in utero.
The screening protocol model used decision
analysis to compare the costs of the two
strategies: (1) No screening, and (2) screening
all women at low-risk between 16 and 18
weeks of gestation. The costs associated with
the no-screening strategy arise from the cost of
caring for children with NTDs, which include
direct medical costs of hospital and outpatient
services, physician services, rehabilitation
services, medical appliances, and
institutionalization. The average cost for the
first 10 years of life for a child with spina
bifida was estimated to be $42,507, which
does not include indirect costs (e.g., costs of
special education and loss of income by
parents) or intangible costs (e.g., parental
anxiety, psychologic effects on siblings and the
child's own psychologic problems). The cost
of screening included physician visits, genetic
counseling, second trimester abortion, delivery
of an abnormal fetus, amniocentesis, and
ultrasound examination. Testing costs were
$7.50 per test for the maternal serum alpha-
fetoprotein (MSAFP) test. Direct costs
associated with the loss of a healthy fetus were
$3,000. Our baseline analysis showed that
screening versus no screening could be
expected to save approximately $8 per
pregnancy given a cost of $7.50 for the
MSAFP test and a cost of $42,507 (for the
first 10 years of life for a child with spina
bifida). When a more comprehensive estimate
including indirect and intangible costs for
caring for such a child was used, the savings
with the screening program were more
substantial. The average direct medical costs
per pregnancy for the entire cohort were
$20.28 when screening is done and $28.31
when screening is not done. For the
sensitivity analyses, the cost of amniocentesis
and the ultrasound examination were increased
to $250 and $150, respectively, which still
results in a saving of about $3.30 per
pregnancy in direct medical costs. The
sensitivity analyses showed that the savings
were somewhat sensitive to the cost of the
MSAFP test and highly sensitive to the
specificity (but not the sensitivity) of the test.
The test could cost as much as $15 and still
remain cost effective. Results indicated that a
screening program for NTDs in low-risk
pregnancies may result in substantial savings in
direct health care costs if the screening
protocol is followed rigorously and efficiently.
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Costs and Benefits of Screening for
Congenital Hypothyroidism in Wisconsin.
Form: Journal article.
Author: Barden, H.S.; Kessel, R.
Source: Social Biology . 3 1(3-4): 185-200,
Fall-Winter 1984.
Abstract: Researchers conducted a
comprehensive benefit-cost analysis of the
screening program to detect newborns with
congenital hypothyroidism in Wisconsin. The
Wisconsin Infant Health Screening Program
for congenital hypothyroidism follows a two-
tiered system of testing in which T4 (thyroxin)
is the primary marker and TSH (thyroid
stimulating hormone) is tested on those
individuals with a low T4 value. The costs of
the program to prevent the serious
developmental abnormalities associated with
congenital hypothyroidism included the cost of
screening and detection, $269,230, or a
laboratory cost per sample (78,050 samples) of
$3.45. Screening and detection costs included
the costs related to the collection of the blood
specimen and the costs incurred for laboratory
testing. The cost of collecting the blood
specimen in the hospital was estimated to be
$4.60 per patient. This cost included expenses
for drawing blood, administration costs,
medical record costs, supplies, billing costs,
and overhead. Because one collection
procedure provided the blood specimens for
four screening tests, the cost of the
hypothyroid portion was $1.15 per sample.
When the initial tests for congenital
hypothyroidism are positive, recall tests must
be done to verify the initial finding. The
recall rate in Wisconsin was estimated to be 2
percent; the cost of the recall was estimated to
add $1.60 to the cost of each sample tested.
The sum of the costs for collecting and testing,
including recall tests, was the cost for
processing each sample, which was estimated
to be $6.20 for the period July 1, 1981
through June 30, 1982. The incidence of
congenital hypothyroidism in Wisconsin was
1:6,500 and the discounted cost of detecting
each case of congenital hypothyroidism was
$40,300. Treatment costs of individuals with
congenital hypothyroidism included charges for
clinic visits, costs of periodic T4 and TSH
testing, and costs of the medication for thyroid
hormone replacement. Discounted treatment
costs were estimated to be approximately
$3,230 over the lifetime of the individual and
the combined costs of detection and treatment
were $43,530. The benefits that result from
the detection and successful treatment of an
individual with congenital hypothyroidism are
represented by the total cost of the disease if
left untreated. Total benefits included (1)
institutional care, foster care, and adult
residential care and services, $73,310; (2)
special education, $24,730; (3) foregone
maternal income, $13,000; and (4) lost
lifetime productivity, $30,730. The total
benefits were $141,770. Net benefits for
detecting and treating one individual with
congenital hypothyroidism were approximately
$98,200 using the 7 percent rate of discount
($141,770 minus 43,530). Net benefits for
detecting the 13 individuals with congenital
hypothyroidism in 1981-82 totaled $1,277,000.
In the case of congenital hypothyroidism, early
detection before clinical manifestations of the
disorder appear is essential to prevent the
mental retardation that is commonly associated
with this disorder. Future costs and benefits
were determined using a 4 percent, 7 percent,
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and 10 percent rate of discount. 1 figure, 10
tables, 36 references.
110
Screening Infants for Hearing Loss: An
Economic Evaluation.
109
Costs and Benefits of Screening for PKU in
Wisconsin.
Form: Journal article.
Author: Barden, H.S.; Kessel, R.;
Schuett, V.E.
Source: Social Biology. 31(1-2): 1-17,
Spring-Summer 1984.
Abstract: Researchers conducted a
comprehensive cost-benefit analysis of a
screening program to detect newborns with
phenylketonuria (PKU) in Wisconsin. Classic
PKU is a genetic disorder which, if undetected
and untreated during the first few weeks of
life, generally results in mental retardation and
a variety of other abnormal conditions.
Researchers compared monetary costs of the
detection and treatment program with the
projected benefits (avoided costs) that result
from the prevention of the mental retardation
associated with the disorder. Investigators
determined future costs and benefits using a 4
percent, 7 percent, and 10 percent rate of
discount to achieve comparability between the
present and future costs. The estimated costs
of the State Laboratory of Hygiene for PKU
testing for 1 year were $104,740 for 78,050
samples. Actual costs of collecting a blood
specimen for testing were estimated at $4.60
per collection. Treatment costs for PKU for a
20-year period (discounted at 7 percent) were
estimated at $40,830. Net benefits (benefits
minus costs) for detecting and treating one
person with PKU were $208,000 ($292,000
minus $84,000) using the 7 percent rate of
discount. Net benefits for detecting four
persons with PKU per year in Wisconsin
totaled $832,000, a large rate of return on a




Source: Journal of Epidemiology and
Community Health. 46(4):350-356,
August 1992.
Abstract: Using data from a prospective
cohort study of 1,990 children born between
August 1985 and April 1986, researchers
conducted an economic evaluation of the
program implemented in an English district
health authority for the screening of infants for
hearing loss. Researchers used the
methodology of decision analysis to model (1)
the conventional screening policy, which was
for a health visitor and colleague to screen at
8-9 months, and for each child to be seen
again by a clinical medical officer at 10
months for a developmental assessment plus
hearing screen if necessary; (2) screening to
take place at 10 months only if concern is
expressed (or if there is a clinical indication) at
the developmental assessment (alternative
screening policy); (3) issuing to the family a
checklist of the general signs indicating that a
baby is hearing normally; and (4) no
screening. The study focused mainly on
children screened before age 10 months. The
costs of screening included (1) clinic costs, (2)
salaries of test personnel, (3) average test
duration, (4) parent's travel costs, (5) parent's
travel time, (6) resource use, and (7) treatment
cost. When necessary, screening is conducted
in the family home; for this computation,
clinic and parent travel costs were excluded
but tester's travel was included. The annual
expected cost per unit output was 20.57
pounds for the conventional screening policy,
11.13 pounds (in-clinic cost and 11.23 pounds
in-home cost) for the screening to take place
only if concern is expressed, and 11.27 pounds
for the third option of no screening.
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Introducing the check list is likely to raise the
cost of the alternative screening policy by 52
pence per unit output, but the effects are
uncertain. The results suggest that the
alternative screening policy is more cost-
effective than the conventional policy, but has
little advantage over not screening at all. The
effects of introducing a check list need further
investigation. 2 figures, 7 tables, 21
references.
Ill
Economic Evaluation of Cost-Benefit Ratio
of Neonatal Screening Procedure for
Phenylketonuria and Hypothyroidism.
Form: Journal article.
Author: Dhondt, J.L.; Farriaux, J. P.;
Sailly, J.C.; Lebrun, T.
Source: Journal of Inherited Metabolic
Disease. 14(4):633-639, 1991.
Abstract: Researchers present an approach to
the cost-benefit analysis of the French neonatal
screening program, which aimed to prove an
expected positive cost-benefit ratio and to
serve as a model to develop an analytical
framework that can be applied to new
programs. Investigators established a
comparison between the cost of identification
and care of patients with phenylketonuria
(PKU) and congenital hypothyroidism (CH)
and the expenditure for the care of untreated
retarded patients. This comparison was based
on the activity of the Nord-Pas-de-Calais
Regional Screening Center, a screening center
that tests 80,000 newborns a year with a single
laboratory, and of interviews with patients'
families. To evaluate the cost-benefit ratio per
detected case, researchers calculated screening
costs on the basis of (1) the expenses of the
screening center and other economic data
obtained from the National Economic
Statistical Agency, (2) analysis of 153 medical
records (63 cases of PKU and 90 cases of CH)
to establish medical costs, and (3) interviews
with 60 families (30 with infants with PKU
and 30 with infants with CH) to evaluate
additional costs. The analysis yields a cost-
benefit ratio of 6.6 for PKU and 13.8 for CH
prophylaxis. The difference between the two
was expected because the incidence of CH is
five times higher than PKU and the cost of its
treatment is much lower (7.6 percent of the
medical costs versus 40 percent). The cost of
dietary foods for PKU patients is 4.5 million
FF and the annual mean cost per PKU infant
for this diet is estimated at 15,000 FF. In
CH, improvement in the therapeutic results is
believed to be obtained with a higher dosage
of L-thyroxine for the early treatment and
earlier followup. Mean age of infants at
diagnosis was 26 days. Screening logistics can
be accelerated by (1) taking blood earlier (on
day 3 instead of day 5), (2) speeding up mail
transport, and (3) modifying the working
schedule in the laboratory. Benefits of PKU
neonatal screening for (1) the child and family
were 981,841 FF; (2) the National Social
Security were 2,364,238 FF; and (3) state and
other administrators were 326,441 FF. For
CH, the benefits of neonatal screening for (1)
the child and family were 731,073 FF; (2) the
National Social Security were 1,727,119 FF;
and (3) state and other administrators were
465,624 FF; and the costs were 274,268 FF;
92,537 FF; and 100,609 FF, respectively. 1
figure, 3 tables, 6 references.
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112
Cost-benefit Evaluation of Systematic
Radiological Diagnosis of Congenital
Dislocated Hip.
Form: Journal article.
Author: Faure, C; Schmit, P.; Salvat, D.
Source: Pediatric Radiology. 14(6):407-412,
1984.
Abstract: Researchers evaluated the cost-
benefit ratio of radiological detection of
congenital hip displacement at the age of 3-4
months, taking into account the socioeconomic
cost and radiation risk. Investigators
retrospectively studied 163 cases of dislocation
of the hip that were treated in the orthopedic
surgery department of a hospital in Paris,
France. Researchers calculated for each
patient the cost of the treatment in francs
according to prices usually applied in April
1981 in university hospitals. Patients included
(1) 39 infants between and 31 days old
(group one), (2) 31 infants between ages 2 and
3 months (group two), (3) 56 infants between
ages 4 and 9 months (group three), (4) 20
children between ages 9 and 15 months (group
four), and (5) 17 children over age 15 months
(group five). Treatment for group one
involved ( 1 ) treatment by abduction and
radiological and clinical survey for 33 of the
39 infants and (2) several days of
hospitalization for 6 infants, which radically
affected treatment costs. Group one had an
average of 5.23 pelvic radiographs and
treatment costs averaged 5,142 FF (SD of
3,580). Treatment for group two included
hospitalization of 13 of the 31 infants for an
average of 11 days, and an average of 8 pelvic
radiographs per infant; treatment costs
averaged 14,613 FF (SD of 12,315).
Treatment for group three involved
hospitalization of 43 of the 56 infants for an
average of 28 days and an average of 14.44
pelvic radiographs; treatment costs averaged
38,953 FF (SD of 24,790). Treatment for
group four included (1) an average
hospitalization of 57 days, (2) traction in
abduction for 40 days, (3) surgical operations
in 14 out of 20 cases, and (4) an average of
20.57 pelvic radiographs; treatment costs
averaged 84,230 FF (SD of 17,108).
Treatment for group five involved (1)
hospitalization for an average of 175 days, (2)
1 or more surgical operations for 16 of 17
children, and (3) an average of 17.8 pelvic
radiographs; treatment costs averaged 149,100
FF (SD of 70,388). Assuming a frequency of
this disorder of 1 percent of the total
population, the average cost of treatment of
one case detected by X-ray screening at the
age of 3-4 months, including the price of X-
ray examinations of 99 normal babies, is
23,374 FF. The cost-benefit ratio of
radiologically detecting and treating congenital
hip displacement at the age of 3-4 months,
compared to detecting and treating the same
problem at the age of walking (12-15 months)
is 3.76. In countries where the frequency
reaches two percent, the cost benefit ratio is
4.57. Results show that the irradiation of the
patient is much smaller when the diagnosis is
made earlier. Comparing the slight irradiation
delivered to normal infants by mass screening
to the heavy irradiation received by a few
individuals whose treatment is started after 9
months, the calculated risk of leukemia or of
genetic disorder for the whole population still
favors a systematic X-ray film of the pelvis at
age 3-4 months. However, if a mass
radiological detection program during the
fourth month of life is made obligatory, this
would necessitate a serious effort to train all
radiologists to obtain adequate films with the





Screening for Congenital Dislocation of the
Hip: An Economic Appraisal.
Form: Journal article.
Author: Fulton, M.J.; Barer, M.L.
Source: Canadian Medical Association
Journal. 130(9): 1149-1 156, May 1, 1984.
Abstract: Researchers in British Columbia,
Canada, performed a cost-effectiveness
analysis that compared the direct costs of
screening for congenital dislocation of the hip
(CDH) with the treatment costs resulting from
no screening. Comprehensive screening
programs at selected hospitals formed the basis
for determining screening program costs.
Included in overall cost estimates were costs of
screening, conservative followup treatment,
surgery for missed cases, and direct costs to
families. Costs associated with screening and
subsequent conservative treatment for 6-15
positive cases of CDH per 1 ,000 infants were
about $6,000 ($6,111 to $7,225) less than the
costs of either open or closed reduction of the
hip for 1.5 infants with CDH per 1,000 infants
not screened ($15,267 and $12,655,
respectively). When researchers adjusted
assumptions about screening costs, rates with
which cases were missed, and hospital
treatment costs, only the assumptions thought
to be overly unfavorable to screening and
overly optimistic for no screening brought the
costs of no screening within the likely range of
costs of screening. Results strongly suggest
that screening for CDH is cost effective
relative to no screening when dealing with
large numbers of newborn infants and very
low false-negative rates. As for cost-
effectiveness of screening for CDH in British
Columbia: If one assumes conservative
savings of $3,000 per 1,000 screened infants,
screening the approximately 40,000 infants
born annually in British Columbia would imply
a savings of $120,000 (in Canadian dollars)
per year. 3 figures, 5 tables, 33 references.
114
Cost-Benefit Analysis of the Detection and
Treatment of Phenylketonuria (PKU) in
Newly-Born Babies, in Belgium.
Form: Journal article.
Author: Goss, S.
Source: Cahiers Economiques de Bruxelles.
(99):459-468, 1983.
Abstract: Using a cost-benefit analysis, a
researcher estimates whether or not the cost of
detection and treatment of phenylketonuria
(PKU) in newly-born babies in Belgium is
justified. Since 1972, more than 100,000
newborns have been examined for PKU
annually at a cost of approximately 8 million
Belgian francs (BF). The researcher uses two
discount rates: (1) 4.18 percent, derived from
the average of the interest rates of four
categories of private investment (housing,
other investment, consumption on credit, and
other consumption) weighted according to the
fraction of the public investment that diverts
funds from each of these four categories of
private investment; and (2) 7 percent, to
examine the sensitivity of the benefit and cost
ratios. Data on PKU screening includes the
annual number of examinations and cases
detected and the cost of one year's PKU
screening in the government-approved centers
from 1978-1981. The social costs, with 4.18
and 7 percent discount rates respectively,
include (1) screening, average cost per year
was 7.7 million 1981 BF, with 10 PKU per
year detected; (2) government contributions for
the dietary supplements Lofenalac and
Phenyldon, 9.5 and 7.2 million 1981 BF; and
(3) parental contributions toward the 30-year
phenylalanine diet and treatment, 8.6 and 9
million 1981 BF. Total social costs were 25.8
and 23.9 million 1981 BF. For the study, the
researcher assumes that without detection and
treatment, PKU children are raised at home for
the first 5 years of life then placed in an
institution for the rest of their lives, implying a
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loss of 10 adult life-values. The total social
benefits without detection and treatment, with
4.18 and 7 percent discount rates respectively,
are 174.5 and 99.7 million 1981 BF, which
included: (1) Upbringing at home, 6.6 and
6.3 million 1981 BF; (2) upbringing in an
institution, 24.9 and 17 million 1981 BF; (3)
supplementary allowance, 11.4 and 9 million
1981 BF; and (4) loss of life value of 76. 1 and
47.8 million 1981 BF for men and 55.5 and
19.6 million 1981 BF for women. The total
social benefits with detection and treatment
were 18 and 13.8 million 1981 BF, which
includes the expense of upbringing at home
only. The benefit: cost ratios for one year of
PKU screening of average adult life value are
6.1 and 3.6, with 4.18 and 7 percent discount
rates respectively. Assuming that treated PKU
children will have only half of the average
adult life-values yields benefit: cost ratios of
3.5 and 2.2, respectively.
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Source: Birth Defects. 19(5): 11 1-120, 1983.
Abstract: A researcher assesses the costs and
benefits of newborn screening, explores the
possible pitfalls of such screening, and
considers how they can be corrected. The
results of the U.S. Collaborative Study of
Children Treated for Phenylketonuria (PKU),
which followed 132 infants discovered to have
PKU by screening up to age 6, showed that
the benefits of PKU screening can be
documented. Although the mean IQ of these
children is lower than that of their unaffected
siblings, it is far higher than in untreated or
late-treated children with the disorder. As a
result of discoveries that followed this
screening, what appeared to be a simple,
homogeneous disorder turned out to be a
heterogeneous collection, requiring different
treatments, and a revision of diagnostic criteria
to avoid treating unnecessarily. The same
kind of problems could have been anticipated
for hypothyroid screening but have still not
been resolved. Reliably performed neonatal
screening for hypothyroidism will detect the
vast majority of infants destined to become
retarded because of the condition. However,
even infants who are treated early may still
have problems. It is possible that
asymptomatic infants discovered by screening
may be treated unnecessarily. Despite
problems of neonatal screening, the benefits of
such screening for PKU and hypothyroidism
exceed the costs, but probably not by as much
as some early studies suggested. Provided are
estimated costs of detecting and treating the 4
PKU infants and 10 hypothyroid infants
estimated to be born in Maryland in 1984:
Costs (in 1981 dollars) would be $514,250.
The benefit (averted cost) of Maryland's
Newborn Screening Program for PKU and
Hypothyroidism would be, at a 6 percent
discount rate, $1,270,000 ($630,000 at a 10
percent discount rate). Mechanisms for
resolving screening-related problems through
careful monitoring and long-term study are
still not firmly established. 8 tables, 24
references.
116
Cost-Effectiveness of Screening and
Cryotherapy for Threshold Retinopathy of
Prematurity.
Form: Journal article.
Author: Javitt, J.; Dei Cas, R.; Chiang, Y.
Source: Pediatrics. 91(5):859-866,
May 1993.
Abstract: Researchers examine whether
surveillance of a population to detect
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retinopathy of prematurity (ROP), a rare sight-
threatening disease and leading cause of
blindness among premature infants, can be
cost-saving from a governmental perspective.
The National Eye Institute-sponsored
prospective, multicenter trial investigating the
use of cryotherapy for treatment of ROP
demonstrates a significant reduction in
blindness and low vision for patients with
sight-threatening (stage 3) ROP. Researchers
developed a microsimulation model based on
Monte Carlo techniques to determine the cost-
effectiveness of cryotherapy for ROP. The
model included events such as disease
progression, screening, detection, treatment
outcomes, and mortality. Mortality, failure to
develop threshold disease, severe vision loss
following treatment, and severe neurologic
deficits were treated as terminal nodes of the
model. Simulations were performed on an
annual cohort of 28,321 premature infants
divided into three subpopulations: Premature
infants based on birthweights 500 through 749
grams, 750 through 999 grams, and 1,000
through 1,249 grams; and for three
ophthalmoscopic screening strategies: Weekly,
biweekly, and monthly starting 28 days after
birth. For this model, the researchers assumed
a sensitivity and specificity of 80 percent and
95 percent, respectively, based on data on
screening for diabetic retinopathy. The model
assumes that (1) of those progressing to
threshold disease, 82.5 percent develop
bilateral threshold disease; (2) cryotherapy
applied as soon as threshold disease is noted;
(3) 6.4 percent of treated eyes will require
additional cryotherapy; (4) no mortality
associated with cryotherapy; (5) both eyes are
treated; (6) that the outcome in the second eye
is biased 50 percent in the direction of the
outcome of the first treated eye; (7) treatment
assumed to be permanent; (8) compliance rate
for followup care at 100 percent; (9)
unfavorable functional visual outcome
consistent with severe vision loss in both eyes;
(10) benefit of treating subthreshold
retinopathy of prematurity not modeled; (11)
benefit of treating other birthweights not
modeled; (12) 27.5 percent of cryotherapy
done under anesthesia; (13) cost of screening
per patient is $84 for the first in-hospital visit
and $68 subsequent visits; (14) cost of
cryotherapy is $831 per eye; and (15) cost of
anesthesia is $222 per service. Researchers
also addressed the progression to threshold
ROP; symmetry of progression; outcome
following cryotherapy for threshold ROP; risk
of developing severe neurologic disabilities;
costs for screening and treatment; government
budgetary costs of infancy-acquired blindness,
such as federal insurance and entitlement
programs; and blindness and quality of life.
The annual government budgetary costs of
blindness, including special education, SSDI
and Medicare, SSI and Medicaid, and tax loss
are $7,497 per person for ages 3 through 5,
$7,088 for ages 6 through 20, $12,975 for
ages 21 to 64, and $90 for ages 65 and over.
Researchers estimate that an emotionally well-
adjusted blind person would have a health state
utility of 0.48, compared with utility of 1.00
for complete well-being. To account for the
time value of money, researchers discounted
benefits to the year of treatment for ROP at
three percent, the average cost of long-term
funds borrowed by the federal government.
The simulation predicts that approximately
1 ,000 infants from all three birthweight groups
will develop threshold ROP. Based on 1,000
cases per year of threshold ROP, a biweekly
screening and cryotherapy program is
predicted to save 321 infants from a lifetime of
blindness, while a monthly screening and
cryotherapy program can save 289, and a
weekly program can save 344. The weekly
program is estimated at $28.1 million, the
biweekly program is $15.7 million, and the
monthly program is $9.7 million. Predicted
annual savings for screening and treatment
range from $3.8 million to $64.9 million per
year, depending on the screening frequency,
discount rate, and costs of blindness chosen.
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Biweekly screening is associated with both
increased financial and medical savings. With
biweekly screening, an additional 29 children
per year are saved from blindness with $0.7
million in increased savings than the monthly
screening. Governmental savings directly
relate to the percentage of patients who have a
nongovernmental source of payment for health
care. If governmental sources paid for care
for only those uninsured individuals, the
biweekly screening strategy will be associated
with an additional $13.3 million governmental
savings. If private insurance covers all
screening and treatment costs, the additional
cost savings to the government would be $15.7
million. 6 figures, 6 tables, 33 references.
117
Epidemiological Assessment of Neonatal
Screening for Dislocation of the Hip.
Form: Journal article.
Author: Leek, I.
Source: Journal of the Royal College of
Physicians ofLondon. 20(l):56-62,
January 1986.
Abstract: A researcher attempts to assess the
deficiencies of neonatal screening for
dislocation of the hip (DH) by measuring it
against the main criteria that any population-
wide screening program should meet. These
criteria are: That the disorder to be detected
should be important and of known natural
history and be best treated early; the screening
test should be accurate and safe; the treatment
should be effective and its indications agreed;
and both test and treatment should be
practicable and worth the cost. Each topic is
examined epidemiologically. Regarding cost,
estimates of the current financial costs of
screening and splinting for neonatal instability
and of surgical treatment for established DH in
the United Kingdom are not readily available,
but figures were published for British
Columbia in 1981-1982 that can be used for an
approximate assessment of the relative health
service costs of screening versus not screening.
Per 100,000 persons, these costs were
$1,141,625 (Canadian dollars) to provide
surgical treatment for an estimated 125
recipients if screening was omitted, versus
$1,106,790 (Canadian dollars) for screening
100,000 people, splinting 1,935, and surgically
treating 65. Screening is marginally more
economical. Four main problems emerge in
the field of neonatal screening and treatment
for hip joint instability as currently practiced:
(1) False positives, (2) false negatives, (3)
treatment policies, and (4) questions on
outcome of early treatment. Further trials are
needed to answer these questions, and these
should be designed to enable the costs and
benefits of current screening and treatment
policies to be compared as comprehensively as
possible. Whether screening is justified will
remain an open question until this is done. 3
figures, 3 tables, 57 references.
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Hearing Loss Screening in the Neonatal
Intensive Care Unit: Auditory Brain Stem
Response Versus Crib-O-Gram; A Cost-
Effectiveness Analysis.
Form: Journal article.
Author: Prager, D.A.; Stone, D.A.;
Rose, D.N.
Source: Ear and Hearing. 8(4):213-216,
August 1987.
Abstract: Researchers used cost-effectiveness
analysis to compare two strategies for
screening for severe hearing loss in the
neonatal intensive care unit (NICU): The
auditory brain stem response (ABR) and the
Crib-O-Gram (COG). COG is an automated
extension of behavioral audiometry in which a
motion sensitive device replaces the human
observer in detecting infant movement in
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response to sound stimuli. In the ABR test, an
electrical waveform is registered from the
brain stem after reception of an emitted click.
Researchers studied hypothetical cohorts of
infants using data derived from the literature
on screening test characteristics. They
included the costs of initial screening ($20,000
for COG testing 1 ,000 infants (versus
$110,000 for ABR testing 1,000 infants)) and
those of further diagnostic testing for infants
who fail the screening test ($149,649 for 299
infants). There were two outcome measures:
The cost of correctly detecting a case of
hearing loss and the number per 1,000 infants
screened of infants with hearing loss not
detected before the end of the critical period of
language development. To estimate the
prevalence of hearing loss among NICU
infants, researchers defined hearing loss to be
permanent, bilateral, and of sufficient severity
to warrant amplification. The cost data are
derived from third party and operating costs in
a New York City hospital and from
manufacturers' estimates of charges. Costs are
stated in 1985 dollars. Results showed the
ABR to be more cost effective than the COG
because, although it cost more per test than
COG ($110 and $20, respectively), it had
higher sensitivity (100 percent and 75 percent,
respectively) and specificity to detect hearing
loss (86 percent and 71 percent, respectively).
The cost of diagnostic testing for infants who
fail the screening test is estimated at $65
1
each. Using best-estimate assumptions, ABR
cost $10,610 for each correctly detected case
of hearing loss while COG cost $14,310 for
each correctly detected case (due to the
incidence of false positives and their followup
diagnostic tests). Among every 1,000 NICU
infants screened, ABR detected all cases of
hearing loss, whereas COG failed to detect
hearing-impairment in five infants. 2 tables,
27 references.
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Cost-effectiveness of Neonatal Screening for
Duchenne Muscular Dystrophy: How Does
This Compare to Existing Neonatal
Screening for Metabolic Disorders?
Form: Journal article.
Author: Rosenberg, T.; Jacobs, H.K.;
Thompson, R.; Home, J.M.
Source: Social Science and Medicine.
37(4):541-547, 1993.
Abstract: Researchers in Canada examined
the costs of screening a series of 18,152
newborn males for Duchenne muscular
dystrophy (DMD), an X-linked genetic
disorder. The final aim of neonatal screening
for DMD is the avoidance of cases in
subsequent pregnancies in the families
identified. The Manitoba Pilot Project of
Neonatal Screening for DMD has existed on a
research basis since 1986. The neonatal
segment involves mass screening of newborn
males. A prenatal protocol also is offered to
affected families during subsequent
pregnancies. In 1986 and 1987, 18,152
newborn males were screened for DMD using
a drop of blood taken from their heels. This
sample was obtained at the same time, and on
the same card, as for the other metabolic
diseases routinely screened for in the newborn
period. The bioluminescent test for creatine
kinase (CK) on whole dried blood, as
formulated by Scheurerbrandt et al. was
performed on this sample. The cost of
specimen collection was based on an estimated
15 minutes of nursing time, consumables, as
well as mailing to the provincial laboratory.
This total was then divided by the number of
diseases screened for in this manner, and
which share the same resources. A value of 1
dollar per test was obtained. The cost per CK
test was calculated at $2.36 by the laboratory
scientist at the provincial laboratory. It
included shared cost of the specimen card,
clerical time, reagents, consumables,
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equipment servicing, and time of a medical
technologist. Unit costs for repeated tests
were $20 per test. Unit cost to confirm
positive cases was $590.50 per child. Average
genetic diagnosis costs were $250 per person
or $1,250 per family. Total cost for prenatal
diagnosis and intervention was $3,282. The
proportional total number of cases that could
be prevented by a screening program is 16.7
percent and the probability that a carrier will
have an affected child is one in four. Total
costs and incremental costs to avoid one case
of DMD were estimated in Canadian dollars at
$172,000 and $83,100; compliance with
genetic advice was identified as a factor crucial
for cost effectiveness. In Manitoba, Canada,
the annual total and incremental costs
amounted to $59,500 and $27,300,
respectively. Costs of neonatal screening for
DMD were compared with costs of neonatal
screening for inborn metabolic disorders. The
two programs were found to be similar in
costs. 6 tables, 25 references.
120
Economic Evaluation of Neonatal Screening
for Congenital Dislocation of the Hip.
Form: Journal article.
Author: Tredwell, S.J.
Source: Journal of Pediatric Orthopaedics.
10(3):327-330, May-June 1990.
Abstract: Researchers conducted a study to
determine the cost benefit of neonatal
screening for dislocatable and subluxable hips
at two hospitals in Vancouver, British
Columbia, Canada (Grace Hospital and
Children's Hospital). As a followup to
retrospective and prospective studies that
established the safety and efficacy of early
treatment to the newborn, researchers
examined the direct and significant economic
benefit to the participating institutions of a
neonatal hip screening program. Researchers
hypothesized that early treatment of the
condition, which worsens and becomes harder
to treat as the child develops, would lead to
indirect cost savings to the hospital. Medical
costs were based on the salary scales and fee
schedules existing in British Columbia in 1987
and 1988. Investigators assumed a constant
rate of 30 minutes for the screening process,
performed three times weekly. Orthopedic
surgeons were assisted by one registered nurse
during the process. No charge was levied on
behalf of the orthopedic surgeon for the
procedure. Researchers used 1.5/1,000 live
births as the incidence of congenital dislocation
in the unscreened population, and used an
incidence rate of 10/1,000 live births in the
screened population. The cost of neonatal
screening per thousand live births was C$468.
The hospitals experienced an economic benefit
of C$15,143.71 per 1,000 infants screened.
The economic benefit would fall to zero when
the false-negative rate reached 1.23/1,000 live
births. The actual cost to other institutions
would vary, but the results in British Columbia
indicate the effectiveness of this type of
program. 1 figure, 1 table, 10 references.
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Preventive Screening for the Fragile X
Syndrome.
Form: Journal article.
Author: Turner, G.; Robinson, H.;
Laing, S.; Purvis-Smith, S.
Source: New England Journal of Medicine.
315(10):607-609, September 4, 1986.
Abstract: To determine the number of
females at risk of being carriers of the fragile
X syndrome, researchers in Sydney, Australia,
physically and cytogenetically screened 921
intellectually handicapped persons for the X-
1 inked semidominant fragile X syndrome.
Subjects included (1) children ages 5-18 with a
moderate to severe handicap (IQ 20-55) who
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were enrolled in special schools; (2) children
ages 8-12 with a mild handicap (IQ 55-75)
who were in special classes; (3) children ages
8-18 with a mild handicap who were enrolled
in two special schools; and (4) persons of all
ages in institutions, day activity centers, and
sheltered workshops. Researchers excluded
subjects who had another known diagnosis.
Subjects whose parents consented to a limited
physical examination were physically examined
for (1) gait, (2) measurement of height and
head circumference, and (3) neurocutaneous
signs on the chest. Researchers counseled the
families of those subjects with abnormal
karyotypes and, when indicated, interviewed
and examined first-degree and second-degree
relatives. Subjects contributed 10 milliliters of
venous blood collected directly into sodium
heparin, enriched with fetal-calf serum,
cultured, and examined for the presence of the
fragile site at band q27 on the X chromosome.
Researchers found 40 probands (28 male and
12 female), representing 36 families. Twelve
of the probands had a fragile X-positive
second-degree or first-degree relative or both,
1 1 probands had a positive first-degree
relative, and 10 probands had no positive
relatives; other probands either refused further
participation or were adopted. Prevalence
rates for persons with an intellectual handicap
and the fragile X syndrome in the sample were
1 per 2610 for males and 1 per 4221 for
females. Family studies identified 84 women
who were either obligate carriers (fragile X-
positive) or at high risk of being carriers, who
were under the age of 35, and had no children.
These women were given genetic counseling,
and the availability of antenatal diagnosis was
explained to them. If each of these 84 women
had two children, there would be 27 affected
boys among their 168 future offspring. The
cost of identifying one female subject at high
risk of being a carrier was Australian $3,570.
If each at-risk woman would request antenatal
diagnosis, the cost to prevent the birth of one
intellectually handicapped boy would be
Australian $11,110 (or $14,200 if $500 is
included for each chorionic villus biopsy
investigation). A conservative estimate for
special schooling, invalid pension, and adult
hostel accommodations for one intellectually
handicapped person is Australian $1 million
over a lifetime. 2 tables, 6 references.
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Costs of Providing Residential and Related
Support Services to Individuals With Mental
Retardation.
Form: Journal article.
Author: Ashbaugh, J.; Nerney, T.
Source: Mental Retardation. 28(5):269-273,
October 1990.
Abstract: Researchers determined costs of
services in different types of residential
settings in two regions of the country
(Michigan and Nebraska) to persons with
mental retardation. Investigators studied
persons living in 160 group homes, 130 family
homes, and 41 apartments from July 1, 1984
through June 30, 1985. Project staff obtained
cost data from reports of service provider
expenditures on file in the regional offices and
checked the reports against audited statements
of expenditures completed for each residential
provider. Staff compiled information on the
total cost of services, cost of residential
services per resident, and cost of residential
services by type of expenditure. Researchers
used simple univariate analyses to indicate the
extent to which one variable of interest
appeared to be related to another. Analysis
showed that the per diem costs of providing
residential services for persons with mental
retardation in group homes, family homes, and
apartments in the Macomb-Oakland Region of
Michigan and in Region Five in eastern
Nebraska varied far more by type of living
arrangement than by resident level of need.
The average cost per resident ranged from
about $25,000 to $50,000 in group homes and
from $10,000 to $25,000 in family-care
homes. In Nebraska the average annual
operating cost per person was $3,084 in foster
care and $4,190 in adult family homes;
equivalent costs in group homes and in
apartments with live-in staff and with live-out
staff were $15,755, $11,098, and $7,094,
respectively. In Michigan the average
operating costs for staffed facilities and group
homes were $31,540 and $32,287 respectively;
the equivalent costs in the community training
and adult family homes were $10,757 and
$13,724, respectively. Nearly all of the
variation in the per diem costs of staffed, as
opposed to family-operated, living
arrangements could be explained in terms of
staff-to-resident ratios and staff compensation
levels. 23 references.
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Health Care Financing for Severe
Developmental Disabilities.
Form: Monograph.
Author: Birenbaum, A.; Guyot, D.;
Cohen, H.J.
Source: Washington, DC, American
Association on Mental Retardation, 150 p.,
1990.
Availability: American Association on Mental
Retardation, 1719 Kalorama Road, NW.,
Washington, DC 20009.
Abstract: Health Care Financing for Severe
Developmental Disabilities analyzes the
utilization and financing of health care for
children and young adults with two different
types of developmental disabilities: Autism
and severe or profound mental retardation.
The purpose of the study was to collect
reliable and accurate national data useful for
making public policy. Chapters include (1)
The Problem and the Aims of the Study; (2)
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Methodology; (3) The Children and Young
Adults in the Study (the criteria used to
determine eligibility for inclusion in the
sample); (4) Utilization of Health Care and
Medical Services; (5) Expenditures
(differences in expenditure patterns among the
two developmental disabilities under study);
(6) Third Party Coverage and the Uninsured;
(7) The Financing of Services; (8) Family Out-
of-Pocket Expenses; (9) Family Hardships;
(10) Policy Recommendations on the Financing
of Care; and (11) Summary and Conclusions.
Average annual total expenditures for basic
medical and other heath care, including
hospital charges, doctors' fees, emergency
room visits, and dental charges, were found to
be four times greater for children with severe
mental retardation ($4,000) than for those with
autism ($1,000). The average family makes
payments that appear manageable, but there
are some families who pay catastrophically
high amounts for the health care of their
disabled children. The average family with an
autistic child under age 18 at home spent about
$900 annually on health care and related
services, while the family with a severely
retarded child living at home paid out-of-
pocket an average of $1,700 for health care
and personal care. (Healthy children incur
about $414 for health care per year.) Proposals
to increase assistance to families with severely
and profoundly mentally retarded children
must seriously consider a targeted approach to
those with extreme medical needs, as some
families must pay more than 20 percent of
their income to meet these expenses. 9
figures, 54 tables, 135 references.
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Toward Timely Corrections of Mental
Retardation/Developmental Disabilities
Policy: Commentaries on Braddock et al.
Form: Journal article.
Author: Boggs, E.M.
Source: American Journal of Mental
Deficiency. 92(2): 134-135, September 1987.
Abstract: The author presents a commentary
on a 1987 article by Braddock et al., National
Study of Public Spending for Mental
Retardation and Developmental Disabilities,
concerning timely corrections and
improvements to mental retardation and
developmental disabilities policy. Braddock
and his colleagues at the University of Illinois
in Chicago have been breaking ground for
mental retardation in disciplines that were
unknown 25 years ago, particularly in the use
of computer science and systems theory for
public policy analysis. The article makes it
clear that it is the states, not the federal
government, that drive the community agenda.
Documentation of who pays for what services
to which children and adults is increasingly
difficult because of the number of agencies
involved at each level, the lack of uniformity
in the way in which state and local agencies
report their federal and demographic data, and
the fact that some very relevant data are not
collected at all. In the late 1970's, the
National Center for Health Statistics developed
a proposed broad-based long-term care
minimum data set designed to include persons
of all ages and types of impairment in all kinds
of long-term care settings, nonresidential as
well as residential. Recent policy decisions
have made clear, however, that this vehicle
will not be very useful to workers in the field
of developmental disabilities. An independent
effort is needed to develop a common
statistical framework encompassing the
characteristics, needs, and multiple service
systems that attempt to accommodate people
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with long-term disabilities. The Braddock
article's computations can enable us to make
still more timely course corrections in our
future policy trajectories. 6 references.
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Governmental Spending for Mental
Retardation and Developmental Disabilities,
1977-1984.
Form: Journal article.
Author: Braddock, D.; Hemp, R.
Source: Hospital and Community Psychiatry.
37(7):702-707, July 1986.
Abstract: In 1985, researchers examined the
impact of the Omnibus Budget Reconciliation
Act of 1981 and each state's response to it in
the context of federal, state, and local spending
for institutional and community services for
mental retardation and related developmental
disabilities, both before and after the passage
of the Budget Reconciliation Act. The study
had three components: State government
expenditure analysis, federal expenditure
analysis, and intergovernmental analysis. The
state government expenditure analysis
identified and described the financing of
community and institutional services for
mentally retarded and developmentally disabled
persons in each state and the District of
Columbia; nearly 200 official state budgets
spanning fiscal years 1977-1984 were
analyzed. The federal expenditure analysis
examined data pertaining to services, research,
training, income maintenance, construction,
and information coordination in 82 federal
programs between 1935 and 1985. The
intergovernmental analysis integrated financial
data emanating from the state and federal
analyses for fiscal years 1977-1984 with data
on local spending in fiscal year 1984 into a
unified intergovernmental data set. The data
were analyzed to determine how state and
federal funding of institutional operations
compared with that of community services
during fiscal years 1977-1984. Researchers
adjusted data for inflation. Results reveal that
combined state and federal government
spending grew by 23 percent (from $6.28
billion in 1977 to $13.36 billion in 1984)
despite diminished growth in federal spending
after passage of the Budget Reconciliation Act.
Combined state and federal expenditures for
community services grew by 40 percent (from
$1.56 billion in 1977 to $3,783 billion in
1984), primarily because of a rise in state
spending. Community services include
aggregate support for individual foster family
placements, small group homes, large
congregate care private facilities, and day
activities. Total state and federal spending for
institutional services plateaued during fiscal
years 1977-1984, as a 26 percent drop in state
appropriations was offset by an infusion of
federal dollars, mostly through the
Intermediate Care Facilities for the Mentally
Retarded program. Annually the average real
rate of growth of federal spending was 9.1
percent for fiscal years 1977-1980 and 2.8
percent for 1981-1984. State-source
expenditures exceeded the inflation rate by
0.64 percent per year. Local funds included
school district expenditures for special
education services to mentally retarded pupils
and funds provided by county and municipal
government for noneducational purposes, such
as local habilitation services and sheltered
workshops. Federal, state, and local
expenditures were estimated to total $16.49
billion in fiscal 1984. Specific cost figures
were not mentioned in the source document for
(1) total state and federal spending for
institutional services during fiscal years 1977-
1984, (2) the average real rate of growth of
federal spending for fiscal years 1977-1980
and 1981-1984, and (3) state-source
expenditures that exceed the inflation rate by
0.64 percent per year. 4 figures, 30
references.
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National Study of Public Spending for
Mental Retardation and Developmental
Disabilities.
Form: Journal article.
Author: Braddock, D.; Hemp, R.;
Fujiura, G.
Source: American Journal of Mental
Deficiency. 92(2): 121-133, September 1987.
Abstract: Researchers expanded on a 1981
study to analyze mental retardation and
developmental disabilities (MR/DD)
expenditures in each state government's
published executive budget. The more recent
analysis included budgets from fiscal year
(FY) 1977 through FY 1986. Investigators
obtained 250 published state government
budgets both from libraries and directly from
the states. Project staff photocopied relevant
material on MR/DD funding and agency
organization and prepared ledger sheets
summarizing MR/DD funding in the same
terms used in each state's budget. While
conducting telephone interviews, staff used
ledger sheet information that was sensitive to
each state's budgeting context. These
interviews enabled the study team to develop a
uniform fiscal classification system that
delineated (1) institutional and community
services spending, (2) spending by level of
government (state and federal), and (3)
statutory revenue sources. Trends identified
included (1) continuing growth in spending for
community services, (2) contraction of total
spending for institutional operations, and (3)
predominance of Intermediate Care Facilities
for the Mentally Retarded (ICF/MR) support
in large (more than 15 beds) congregate care
settings. Between 1977 and 1986, the
institutional census declined from 149,176 to
100,421. Costs of care in institutional settings
climbed from a national average of $44.54 per
day in FY 1977 to $126.79 per day in FY
1986. Total spending in the states for
community programs climbed rapidly,
advancing from $0,910 billion in FY 1977 to
$4,422 billion in FY 1986. Excluding federal
income maintenance payments, in FY 1986 the
nation was spending approximately equal sums
in both sectors, $4,647 billion in institutional
settings versus $4,422 billion in community
settings. Fully 87 percent of all
reimbursement budgeted under the ICF/MR
program in FY 1986 was associated with the
larger settings (more than 15 beds). Given the
potentially much larger constituencies for
MR/DD services existing outside large state-
operated institutions and the continuing decline
of the institutional census, analysis shows that
the contemporary budgeting of ICF/MR funds
predominantly inside institutions is
anachronistic. No additional cost information
is provided in the source document. 6 figures,
1 table, 38 references.
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Source: Journal of Health Economics.
10(3):291-311, October 1991.
Abstract: Using the 1988 Child Health
Supplement (CHS), a sub-sample of the
National Health Interview Survey, researchers
assessed the relationship between low
birthweight and special education in the U.S.
and the subsequent costs of educating a special
pupil. Researchers used a general measure of
enrollment in special education of any kind
and a second more limited measure of special
education participation, which included
children in special education because of a
developmental delay, emotional/behavioral
problem, or learning disability. The sample
consisted of 8,000 in-school children between
ages 6 and 15. Researchers calculated the
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probability of attending special education, and
held constant individual, family, and regional
variables. Survey data show that normal
birthweight babies have a 6.9 percent chance
of being in special education of any kind,
whereas low birthweight babies have an 11.3
percent chance of being in special education.
Under the multivariate estimation, researchers
used a logit function with a dichotomous
dependent variable, special education, and
several measures of the family's home
environment, the child's characteristics, and
regional differences. Children who weighed
less than 2,500 grams at birth were almost 50
percent more likely to be enrolled in any type
of special education than children who were of
normal weight at birth, controlling for
medical, family, social, and economic factors.
Children in low-income, single-parent
households were more likely to be in special
education than children in two-parent
households with a highly-educated head-of-
household; girls were less likely to be enrolled
in special education than boys and the
likelihood of enrollment in special education
increased with age. Researchers estimated the
average per pupil special education total
expenditures to be $6,335, 2.3 times the cost
of regular education ($2,780), or an
incremental cost of $3,555 per pupil annually.
The authors substituted the $3,555 per pupil
costs to estimate the effect of low birthweight
on enrollment in special education programs in
aggregate (i.e., assuming that low birthweight
affects all handicapping conditions on average
equally). In terms of 1989/1990 dollars, the
estimated per pupil cost was $4,350, derived
by inflating the $3,555 1985/1986 cost by the
Consumer Price Index between the two
periods, which was an increase of
approximately 16.5 percent, and by adding a
real growth rate of 1.25 percent annually. The
constant $4,350 estimate indicates a total
expenditure for special education in 1989/1990
of between $19 and $20 billion, depending on
caseload growth. Under the broader measure
of all types of special education, the simple
estimate is $466.1 million and the multivariate
estimate is $370.8 million. Under the learning
disabled, emotional problems, or
developmentally delayed, the simple estimate
is $317.8 million and the multivariate estimate
is $254.2 million. The authors conclude that
(1) approximately 85,000 children in special
education programs are enrolled due to
handicapping conditions that result primarily
from the fact that they were born at less than
2,500 grams, and (2) services for these
children required approximately $370 million
in expenditures in the 1989/1990 school year.
4 tables, 38 references.
128




Source: Basic Life Science. 36:35-59,1985.
Abstract: A researcher develops a model to
conduct economic analysis of aneuploidy and
presents some empirical estimates of the costs
of aneuploidy and the benefits of prevention.
Aneuploidy is one of a large number of
diseases, accidents, and genetic conditions that
adversely affect people's well-being by causing
impairments, handicaps, possible premature
death, and other ultimate effects such as loss
of productivity. The social cost of aneuploidy
is equal to the cost of the values of all the
ultimate effects caused by the condition, such
as loss of output, the value of psychic distress,
and the value of all the prevention and
treatment programs. Cost-benefit analysis is
directly related to social costs. Problems in
conducting economic studies include those of
missing data, variables without a market
(monetary) value, different weighting of
components of costs and benefits, joint
benefits, distribution, defining the appropriate
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decision units, and discounting; also
considered are technical cost problems,
technical problems of benefits, and ambiguity
of benefits of preventing aneuploidy.
Economic analyses can neither fully measure
costs and benefits nor resolve conflicts in the
ways in which people value various
components of costs and benefits. Most
people with aneuploidy have Down's
Syndrome. The researcher develops an
estimate of the reduction in social well-being
that results because a part of society has this
condition. In 1983, estimated social costs of
Down's Syndrome included loss of output
(among living persons, $841 million; due to
premature death, $1.75 billion); excess
educational expense ($295 million); excess
residential care expense ($590 million); adult
day care ($146 million); and prevention ($33
million), for a total of $3.65 billion. Lifetime
costs are also estimated. This is contrasted
with costs to prevent Down's Syndrome babies
from being born ($1,000 for abortion, $650
for amniocentesis). The total costs would be
$32,500,000 for amniocentesis and less than
$500,000 for abortion. Here, a breakeven
point is reached as long as at least one case of
Down's Syndrome is detected out of every 306
examinations. 5 tables, 17 references.
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One Year of Health and Social Services for
Children 3-7 Years Old With Down
Syndrome: A Calculation of Costs in Two
Danish Counties.
lived at home in two Danish counties. The
health service and financial support is
supposed to meet the needs of the handicapped
children and provide the families with
facilities. The total population of DS patients
included 16 in one county and 6 in the other.
Researchers interviewed the children's parents
or foster parents and their personal social
workers about the child's contacts with the
health and social security system in the 1-year
period before the interview. Some calculations
were made on the basis of fixed and known
prices, such as the cost of one child in a
kindergarten for handicapped children for 1
year. Other services were researched, such as
the number of consultations in outpatient
clinics and number of days in hospitals, and
services from social workers, school
psychologists, speech therapists, etc. In
addition to health services and social security
services, researchers considered transportation
costs. Twenty of the 22 children attended
some sort of day institution. The minimum
average cost of supporting one child (and his
or her family) during 1 year was calculated at
132,882 Danish Crowns, equal to 9,280
British pounds sterling or $13,436 American
dollars. In spite of the decentralized system,
the difference between the two counties in
terms of their support was very small and was
caused by differences in a number of
additional handicaps, especially in one child,
and not by different standards of support. 1
figure, 4 tables, 12 references.
Form: Journal article.
Author: Goldstein, H.; Philip, J.; Dupont, A.
Source: Social Psychiatry. 21(3): 134-138,
1986.
Abstract: Researchers conducted a study to
calculate the 1-year costs of health and social
security system support for children aged three
to seven with Down's Syndrome (DS), who
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Some Financial Costs of Caring for
Children With Down Syndrome at Home.
Form: Journal article.
Author: Gunn, P.; Berry, P.
Source: Australia and New Zealand Journal
of Developmental Disabilities. 1 3(4) : 1 87- 1 93
,
December 1987.
A$15), activities (A$9.30 versus A$17), and
specialists (A$24 versus A$5.75). The main
difference between families for holiday
expenses was in connection with transport
costs and child care. Findings suggested that
an allowance such as the Handicapped Child's
Allowance is a realistic acknowledgement of
the rights of families to financial support. 5
tables, 4 references.
Abstract: Researchers conducted a study to
determine the extent to which Australian
families with a Down's Syndrome child
incurred significant financial expenses in
caring for the child. Over a 4-week period,
37 families with a child with Down's
Syndrome (23 boys, 14 girls) and 20
comparison families (17 boys, 13 girls)
recorded the expenses involved in rearing their
children. When the study began, the children
ranged in age from 1 year 9 months to 8 years
9 months. The Handicapped Child's
Allowance was 85 Australian dollars (A$) per
month. Families completed a series of
questionnaires that determined weekly
expenses in addition to basic costs for food,
shelter, and clothing (such as regular
medication, special foods, transport, extra
lessons, specialist costs, and baby sitting).
Another questionnaire sought to estimate
holiday (vacation) costs for each family; a
third, at the end of the year, gathered
information on the major costs involved in
rearing these children that were additional to
those covered either by weekly or holiday
costs. Results showed that while all families
incur considerable financial costs in raising
children, there were additional expenses for
the families with the Down's Syndrome child,
and there was less participation in activities
such as dance, music, gymnastics, and sports
by these families. Sample costs, per week, for
each group (Down's Syndrome and
comparison) were as follows: Medication
(A$12 versus A$4.72), special foods (A$6.50
versus A$4.29), transport (A$33 versus
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Benefit-Cost Analysis of Supported
Competitive Employment for Persons With
Mental Retardation.
Form: Journal article.
Author: Hill, ML.; Banks, P.D.;
Handrich, R.R.; Wehman, P.H.; Hill, J.W.;
Shafer, M.S.
Source: Research in Developmental
Disabilities. 8(l):71-89, 1987.
Abstract: Researchers present a cost-benefit
analysis of placing persons with mental
retardation and other severe disabilities into
supported competitive employment, focusing
on the financial outcomes of supported
competitive employment through a program
evaluation of economic or financial variables.
The analysis is discussed from two
perspectives: (1) Benefits and costs to the
person with severe disabilities receiving
supported competitive employment services
(the consumer) and (2) benefits and costs to
the taxpayer. The supported competitive
employment model is presented as illustrative
of a habilitation program allowing greater
monetary returns to society than traditional
adult service programs. The analyses evaluate
services provided by the Rehabilitation
Research and Training Center (RRTC) from
1978 to 1986 to persons with severe
disabilities in several predominately urban
areas of Virginia. The majority of the 214
consumers placed in supported competitive
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employment were described as moderately
mentally retarded. The most frequent types of
jobs in which the consumers were placed were
entry-level nonskilled positions such as janitors
or dishwashers. The average length of time
that consumers were employed was 21 months.
Actual monetary outcomes incurred from the
supported competitive employment were
identified from permanent records and
information supplied by cooperating agencies.
These outcomes were conceptualized by their
effect on government expenditures and
consumer outcomes. All figures were
converted to constant 1986 dollars and a 5
percent discount rate was applied to all
figures. Results indicate that supported
competitive employment is a financially
prosperous venture from both perspectives.
Benefits included (1) increased revenue, of
which the consumer received the benefit of
total consumer income and fringe benefits and
the taxpayer received the benefit of taxes
collected from the consumer and employer tax
credit; (2) decreased service expenditures; and
(3) decreased supplemental security income
(SSI) payments. Total costs included (1)
operational costs to the taxpayer, (2) lost
workshop earnings to the consumer, (3)
decreased government subsidy to the
consumer, and (4) those taxes paid by the
consumer and those credited to the employer.
From the consumers' perspective, for every $1
relinquished in taxes, SSI, and foregone
workshop earnings, $1.97 was received in
increased income; the net benefit per year was
$3,894 per consumer. From the taxpayers'
perspective, for every $1 expended for the
funding of supported competitive employment
programs and in lost tax revenues realized by
the provision of targeted jobs tax credits,
$1.87 was accumulated in benefits; the net
yearly benefit to the taxpayer was $4,063 per
consumer. 5 tables, 19 references.
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Ventura Planning Model: A Proposal for
Mental Health Reform.
Form: Journal article.
Author: Jordan, D.D.; Hernandez, M.
Source: Journal of Mental Health
Administration. 17(l):26-47, Spring 1990.
Abstract: The Ventura Planning Model, a
proposal for public mental health reform,
addresses the decline in mental health funding
and offers a rationale for increased support
(and funding) for public mental health
services. The Planning Model grew out of the
experience of implementing and operating the
Ventura (California) Children's Demonstration
Project. The model has five characteristics, or
planning steps: (1) Multi-problem target
population; (2) systems goals; (3) interagency
coalitions; (4) services and standards; and (5)
systems monitoring and evaluation. The
Project implemented these planning steps with
an infusion of $1.54 million in funds from the
state legislature. The Project offset a portion
of its cost by reducing other public agency
costs. Specifically, the cost avoidance
achieved in group home, state hospital,
nonpublic school residential placements,
juvenile justice incarcerations, and special
education costs was $1,013,852, or 66 percent
of the annual direct expenses of $1,528,265
(annualized from 36 months of operations).
The Project also improved a variety of client-
oriented outcomes such as costs of (1) group
home care, (2) child and adolescent state
hospital programs, (3) nonpublic school
residential placement, (4) juvenile justice
incarceration, and (5) special education
placement. The success of the Project in
offsetting its costs has led the legislature to
provide additional funds for three more
California counties to implement the model for
children and youth, and $4 million a year for 4
years for Ventura County to test the model for
adults and senior citizens. Emphasizing cost
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offsets in addition to client-centered outcomes
provides a practical rationale for proposing
increases in public mental health funds. This
rationale also implies substantial changes in the
operations of many public mental health
agencies. 2 figures, 7 tables, 9 references.
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New Genetics: Will It Pay Its Way?
Form: Journal article.
Author: Chappie, J.C.; Dale, R.;
Evans, B.G.
Source: Lancet. 1(8543): 1189-1 192,
May 23, 1987.
Abstract: Using a broad-brush approach for
(1) the genetic disorders of cystic fibrosis,
beta-thalassemia, sickle-cell anemia,
hemophilia, and muscular dystrophy, and (2)
known 1985-1986 costs for inpatient hospital
care only, researchers compared possible
financial savings from a DNA diagnostic
service with the cost of setting up and running
a laboratory. The study area comprised the
North West (NW) and South East (SE) Thames
Regional Health Authorities (RHA), each of
which have a population of about 3.5 million
and 45,000 live births a year. The Hospital
Activity Analysis (HAA) figures for NW and
SE Thames in 1984 for various genetic
diseases were obtained to ascertain the number
of discharges, deaths, and occupied beds for
each disorder. Clinicians specializing in the
treatment of various genetic disorders advised
on their prevalence in the community, survival
and treatment rates, and the likely number of
cases each year in which antenatal diagnosis
could be made and an affected pregnancy
terminated. Researchers compared figures for
the regions to ascertain whether the method
was applicable to both, and used a computer
model to calculate costs for each case
prevented. The model applied the survival
factor for each disorder to give an estimated
number of cases in each future year arising
from a single year's births within the regions.
Researchers estimate that genetic screening
would prevent annually (1) two cases of cystic
fibrosis in NW, (2) 5 cases of beta-
thalassaemia in NW and SE, (3) 8 cases of
sickle-cell anemia in NW and SE, (4) 1.5
cases of haemophilia, and (5) 2.5 cases of
muscular dystrophy. Clinician geneticists
estimate the total costs of running a DNA
laboratory as 83,000 pounds. Results show
that there would be clear savings at the
hospital level if a DNA screening laboratory
were set up in each region. For example,
calculations using marginal costs for drug
treatments associated with hemophilia and
cystic fibrosis showed cost savings of 90,000
pounds over a 10-year period compared with
83,000-pound costs associated with termination
of these and other pregnancies. Additionally,
once a program is set up, new developments
will make it even more cost-effective.
Researchers concluded that RHA's should
attach high priority to the setting up of DNA






Author: Evans, B.G.; Chappie, J.C.
Source: Public Health. 102(4):323-328,
July 1988.
Abstract: With the large increase in the
numbers of genetic disorders capable of bein£
diagnosed antenatally, the demand on some
research-oriented services in Britain is
outstripping supply. The demand for these
tests from high-risk families is likely to
increase significantly. Regional or
supraregional laboratories need to ascertain
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whether a service offered to high-risk families
will be cost beneficial. Researchers
summarize the current options here. Four
approaches are possible: (1) A full cost-
benefit analysis (which is being undertaken at
certain centers); (2) an attempt at a cost-benefit
analysis based on guesstimates; (3) the use of
data from hospital activity analysis and
minimal hospital costs estimated to determine
if, in hospital savings alone, such a screening
program could be cost beneficial; and (4) an
estimate of the cost per case prevented for
certain genetic disorders, with some judgment
made as to how reasonable this expenditure is.
The authors present the fourth approach as the
simplest and considered it in detail. The cost
per case terminated using this method is
approximately 4,000 British pounds. Cost was
determined by estimating the following:
Running costs of a DNA screening service
(60,000 pounds); capital costs per year (23,000
pounds); chorionic villus sampling (CVS)
(3,640 pounds); counseling (14,000 pounds);
central register (1,150 pounds); and additional
terminations (abortions) (3,900 pounds), for a
total cost of 105,690 pounds. Divide this by
the estimated number of cases terminated (26,
which is the estimated number of cases picked
up by CVS in this example) and the result is
4,065 pounds. Compared with the high costs
of treating children with genetic disorders, the
costs of running a screening program for high-
risk families is small. No figures were given
for the expected increased demand from high-
risk families for genetic testing. 2 tables, 5
references.
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Source: Journal of Pediatric Health Care.
3(l):20-27, January-February 1989.
Abstract: The author notes that a patchwork
of financing programs and services exist to
meet the needs of the approximately 750,000
children in the United States with a severe
chronic illness, but from a national
perspective, (1) coverage is incomplete, (2)
eligibility criteria are uneven across states, and
(3) care is disjointed. The sources of financial
support for this care (i.e., private insurance,
philanthropic support, research funds, disease-
oriented voluntary associations, special state
programs, Medicaid, and Crippled Children's
Services) typically leave many gaps in
coverage. The families of these children face
many years of mounting medical bills with
little help in sight. For example, home care
for a severely disabled child costs $7,000-
$8,000 per year compared with a $40,000
annual cost for institutionalizing the child, yet
parents are given little encouragement
(financial or otherwise) to keep their disabled
children at home. Another area of concern is
early intervention and education. If
intervention for handicapped infants is delayed
until age 6, education costs to age 18 are
estimated at $53,350; if these same
intervention services begin at birth, education
costs are estimated at $37,272, a saving of
$16,078. Additionally, for every $1 invested
in high quality preschool programming there is
a $3 reduction in public special education
costs. Statistics show that money would be
well invested in prevention and health
promotion services such as prenatal care and
early screening. Research in Alabama shows
that for every $1 spent on preventive maternal
and child health care, the state saves between
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$5 and $10 on long-term institutional care for
a severely retarded child. In the author's
view, the nation must establish a national
policy to (1) provide an organized system of
health care for the nation's chronically ill
children; (2) address current inadequacies; and
(3) provide comprehensive, ongoing care for
these children and their families. Nurses can
be an effective voice in articulating the special
needs of such children to local communities
and agencies that provide funding and care.
Nurses must act as advocates for chronically ill
children and their families and encourage
public and private insurance companies to (1)
identify gaps in coverage for care and services
(e.g., Medicaid in some states does not
provide eyeglasses; physical therapy; speech,
hearing, and language disorder services;
occupational therapy; and dental services); (2)
define ways to increase the numbers of
handicapped children covered by insurance
(e.g., eliminate clauses restricting coverage for
preexisting conditions); and (3) improve the
extent and quality of services offered (e.g.,
covering home health care by specially trained
personnel). 3 tables, 24 references.
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Cost-Effectiveness of Different Strategies for
Prevention of Congenital Rubella Infection:
A Practical Example From Iceland.
Form: Journal article.
Author: Gudnadottir, M.
Source: Reviews of Infectious Diseases.
7(Supplement 1):S200-S209,
March-April 1985.
Abstract: From June 1979-June 1981 Iceland
conducted a nationwide program to vaccinate
females aged 12-40; the strategy chosen was
the selective vaccination of seronegative
women and teenage girls. The program
continues with vaccination of seronegative girls
age 12 every year. Researchers compared the
cost-effectiveness of this strategy with (1) the
vaccination of all children and seronegative
young adult women; (2) the vaccination of all
children in early childhood (age 18 months)
with combined vaccines for rubella, measles,
and mumps, and revaccination at age 12 of all
teenagers; and (3) vaccination of nonpregnant
seronegative women who are willing to use
contraceptives for 2-3 months afterward. The
cost of the program was compared with the
preprogram direct cost of congenital rubella
infection in Iceland. Thirty children with
normal intelligence were born with rubella-
associated deafness between 1955 and 1964;
the cost of educating them to the standard of
healthy children cost as much as educating 165
healthy children. The rubella epidemics of
1954-1955 and 1963-1964 left three persons
with multiple congenital defects, including
deafness and subnormal intelligence.
Researchers estimate that the cost to educate
and maintain one multiple defect rubella victim
reaching age 60 is almost equal to the total
cost of the rubella vaccine campaign that was
carried out between 1979-1981. During the
rubella epidemic of 1978-1979, total direct
costs of rubella infection during pregnancy
included (1) $24,515 for 14,709 diagnostic
tests, (2) $68,640 for 104 therapeutic
abortions, and (3) $20,000 for heart surgery
and hospital beds for patients with congenital
rubella syndrome (total costs: $113,155).
Total cost estimates for strategies for
protecting 50,000 females in Iceland against
rubella infection was (1) $250,000 for
vaccination without screening, (2) $84,000 for
screening and vaccinating seronegative
females, and (3) $226,000 for vaccine for
46,300 children between ages 2 and 12.
Previously unscreened females aged 12-40
were screened and nonpregnant seronegative
females were vaccinated for $83,000, or about
one-third the $226,000 cost of vaccinating all
children aged 2 to 12 years. Continuation of
this program by vaccinating all seronegative
12-year-old girls was two to three times more
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cost-effective than vaccination of all 2-year-old
children, saving an average of $10,000-
$14,000 per year. Use of rubella vaccine in
combined vaccines proved the most expensive
strategy ($24,000 for 4,000 doses of the
combination vaccine versus $20,000 for the
same amount of rubella vaccine), with or
without revaccination of teenagers. Specific
cost figures for the total cost of the rubella
vaccine campaign that was carried out between
1979-1981 were not mentioned in the
document. 5 tables, 37 references.
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Cost Savings and Economic Considerations
Using Home Intravenous Antibiotic Therapy
for Cystic Fibrosis Patients.
Form: Journal article.
Author: Kane, R.E.; Jennison, K.;
Wood, C; Black, P.G.; Herbst, J.J.
Source: Pediatric Pulmonology . 4(2): 84-89,
1988.
Abstract: A cystic fibrosis (CF) center used
home intravenous antibiotic therapy (HIVAT)
as an alternative to continued hospitalization
during a 1-year study between January and
December 1984. After thorough individual
clinical and financial evaluation, researchers
selected 27 of 41 CF patients who had been
admitted to the University of Utah Cystic
Fibrosis Center to complete a HIVAT
treatment course lasting from 14-21 days
(mean 15.1 days). The HIVAT treatment
involved at least three aerosol treatments and
chest physiotherapy daily at home with the aid
of family members. By arrangement, two
commercial home parenteral therapy
companies provided antibiotics, syringe
pumps, supplies, and at-home supervision of
the treatment. Physician followup was during
clinic weekly, or the first clinic day closest to
the end of therapy. The 27 patients (ages 6-
28, mean age 16) incurred a total of $698,587
in hospital charges and physician fees during
96 admissions. The average charge for 974
inpatient days was $717 per day ($7,280 per
admission). After an average of 10.2 days of
inpatient care, the 27 patients underwent 79
courses of HIVAT for an additional 8 days; 21
additional HIVAT courses in 6 of these
patients were initiated on an outpatient basis
between frequent readmissions. The 811 days
of HIVAT resulted in $85,027 total charges by
two home care companies. The charges per
day of HIVAT by one company were almost
twice that of the other. The source document
offered no explanation for the practice of one
company in compounding fees for antibiotics
and services at nearly twice the rate charged
by the other company. The average daily cost
of HIVAT was $108/day. If the HIVAT
patients had completed the course of
intravenous antibiotic therapy while
hospitalized, the projected total inpatient costs
would have been $589,271. Therefore, the
811 days of HIVAT over a 1-year period
resulted in total estimated direct cost savings
of $501,770. The average savings per course
of HIVAT were $5,017, or $618/day.
Researchers concluded that (1) HIVAT was a
safe, less expensive alternative to prolonged
hospitalization with few complications; and (2)
additional cost savings could have been
realized by cost comparison between home
health care companies offering comparable
services. 4 tables, 21 references.
86
Genetic Disorders and Chronic Conditions
138
Study of Medical Costs Associated With
Selected Genetic Disorders in Texas.
Form: Journal article.
Author: McCabe, E.; Patterson, P.J.;
Botsonis, H.; Day, D.W.; Lockhart, L.;
Martinec, J.D.; Weber, B.; Godbout, R.;
Malitz, D.
Source: Birth Defects. 26(2): 132-138, 1990.
Abstract: Researchers attempted to quantify
the medical costs associated with 1 1 selected
genetic disorders in Texas, using two data
sources: Medicaid and the program for
Chronically 111 and Disabled Children (CIDC).
There were 464,947 paid claims for services
identified with one of the 1 1 targeted diseases
during the study period for Medicaid data
(April 1, 1987-December 31, 1987). A total
of $115.6 million was billed and $66.1 million
was paid on behalf of claimants with one or
more of these 1 1 disorders. Of the $66.
1
million, 49.2 percent went towards congenital
heart disease, 34.5 percent for Down's
Syndrome, 6.2 percent for spina bifida, 4.8
percent for sickle cell disease, 3.2 percent for
cystic fibrosis, 2.4 percent for muscular
dystrophy, 2.3 percent for cleft palate, 1.4
percent for neurofibromatosis, 1.3 percent for
hemophilia, 0.6 percent for thalassemia/
Cooley's anemia, and 0.6 percent for
phenylketonuria. (Total is more than 100
percent because some claimants had more than
one disease.) Total payments for all services
by CIDC for 1987 equaled $10.65 million:
47.5 percent went towards congenital heart
disease, less than 0.1 percent for Down's
Syndrome, 10.6 percent for spina bifida, 0.4
percent for sickle cell disease, 18.5 percent for
cystic fibrosis, 16.9 percent for cleft palate,
5.4 percent for hemophilia, and 0.8 percent
for neurofibromatosis. Diseases not covered
by CIDC in 1987 were muscular dystrophy,
thalassemia/Cooley's anemia, and
phenylketonuria. Researchers conclude that
(1) their estimate of close to $100 million in
payments for these disorders in 1987
represents a low estimate of the true medical
costs for care of these patients; (2) these 11
disorders represent a disproportionate share of
Medicaid payments; (3) CIDC is a significant
source of support for the medical care of these
patients in Texas; and (4) referral for genetic
services represents a significant barrier for
persons who need these services. 1 table.
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Need for a Science of Community Genetics.
Form: Journal article.
Author: Modell, B.
Source: Birth Defects. 28(3): 131-141, 1992.
Abstract: A discipline of community genetics
(services based on population screening) is
needed with the following responsibilities: (1)
Describing the epidemiology of genetic
disorders; (2) educating the public and the
medical profession; (3) providing a liaison
with support associations; (4) auditing to
monitor service delivery and analyze costs and
benefits; and (5) providing a liaison with
health authorities to ensure delivery of
appropriate genetic services. The author
discusses each of these points in detail and
presents hypothetical calculations. Cost-
benefit analysis of genetic services is important
because (1) money represents peoples' work,
so one should account for the money spent on
health care; and (2) in practice, to get
screening services funded one is forced to
show that they save money. A general
approach for cost-benefit analysis of genetic
services must be developed that is based on the
objectives of ameliorating suffering and buying
health, and is equally acceptable to the medical
profession, patients, and the public. It should
consider both treatment and prevention, and
financial and nonfinancial costs and benefits.
This will require improved dialogue between
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economists and clinicians. As an example, a
flow chart is presented summarizing some of
the real costs and benefits of screening for
prenatal diagnosis, such as 1.80 pounds per
person tested and informed, 60 pounds per at-
risk couple, 670-700 pounds per prenatal
diagnosis, and 1,350-1,650 pounds per
homozygote detected and replaced. There is a
demonstrable need for a scientific framework
for community genetics, and a considerable
basis for consensus already exists. 5 figures,
3 tables, 11 references.
140
Financing Health Care for Disabled
Children.
Form: Journal article.
Author: Newacheck, P.W.; McManus, M.A.
Source: Pediatrics. 81(3):385-394,
March 1988.
Abstract: Researchers used data from the
1980 National Medical Care Utilization and
Expenditure Survey (NMCUES) to assess (1)
use of inpatient hospital services, physician
and nonphysician services, prescribed
medications, and health care equipment and
supplies by chronically ill children; (2) total
charges for the services; and (3) family out-of-
pocket medical care expenses and other
sources of medical care payment. The study
compared use and expenditure levels for the
population younger than age 2 1 with and
without limitation of activity due to chronic
health problems. Collecting data on health
insurance coverage and on financial aspects of
contacts with health care providers, NMCUES
involved interviewing members of 6,600
households five times over 1 year regarding
health care services. Of the 6,245 people
younger than age 21 who completed the
survey, only 249 were limited in their
activities. Since the NMCUES sample frame
excluded the institutional population, a large
segment of the most severely ill children and
youths were not included. Analysis revealed
that children with limitations in their activities
used more medical services than other
children, especially hospital-based services and
services provided by health professionals other
than physicians. Charges and out-of-pocket
expenses were two to three times higher on
average for children with disabilities; total
charges for health services averaged $760 per
child limited in activity compared with $263
for other children. In total dollars, disabled
children and youth accounted for $2.4 billion
of $21.9 billion in charges for health services
provided to the population younger than age
21 (4 percent of the children and youth, those
with disabilities, accounted for 11 percent of
total health care expenditures). Charges and
out-of-pocket expenses were found to vary
greatly from individual to individual; in fact,
most of the children with disabilities in 1980
had low charges and out-of-pocket expenses.
Prevalence of limitation of activity varied
according to the sociodemographic
characteristics of children and their families.
Disability was more common among teenagers
and young adults, boys, white children, and
children in families with incomes below the
poverty level. Compared with disabled
children with low medical charges, disabled
children with higher medical care charges
tended to be older and more likely to come
from low income families; no substantial
differences were apparent by sex or race.
Public and private third-parties paid 82 percent
of all charges for services provided to disabled
children and youth. 7 tables, 15 references.
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Cardiac Care for Infants: Determinants of
Hospital Charges for Acute Care.
Form: Journal article.
Author: Pearson, G.D.; Kidd, L.;
Beittel, T.M.; Neill, C.A.
Source: American Journal of Diseases of
Children. 145(12): 1397-1400,
December 1991. .
Abstract: Researchers analyzed hospital use
and inpatient charges at a tertiary referral
center for infants hospitalized for cardiac
disease in the first year of life. Patient data
included demographic information,
birthweight, source of medical insurance,
charges for inpatient care, type of surgery if
applicable, number of admissions, total
number of days in the hospital and intensive
care unit during the first year of life, cardiac
diagnoses, extracardiac defect(s), and outcome
at 1 year of age. Cardiac disease was
classified as complex or noncomplex based on
severity. Complex defects comprised those
cases in which functioning heart ventricles
were not adequate; extracardiac anomalies
included chromosomal abnormalities,
mendelian and other syndromes, and other
major anomalies. For 93 infants hospitalized
between August 1987 and June 1989, there
were 1.8 admissions per patient, with a median
stay of 14 days and 24.7 percent who required
more than 28 days of acute patient care. The
infant mortality rate in the total cohort was
25.8 percent (24 of 93 patients). Sixty-six
patients underwent 88 surgical procedures, or
0.9 per study patient and 1.3 per patient who
underwent surgery. Total hospital charges,
excluding professional fees, in the first year of
life were $3,417,612 which represents $36,749
per infant and $35,386 per survivor.
Reimbursement totaled 93.2 percent of
charges. Multivariate analysis revealed that
complex cardiac disease, surgery, and length
of stay in the intensive care unit were
significantly associated with increased charges,
while extracardiac anomalies, birthweight,
outcome, and type of insurance were not. For
children younger than 1 year, the present value
of lifetime earnings was estimated at
$191,184. Researchers estimated the
economic benefits of averting death in infancy
for the 69 survivors to be $13,191,696
compared with total hospital expenditures of
$2,441,634, yielding a benefit-to-cost ratio of
5.4 to 1. Results indicated that current
treatment of most infants with cardiac disease
was both effective and economically justified.
142
Predicting Hospital Charge and Length of
Stay for Congenital Heart Disease Surgery.
Form: Journal article.
Author: Silberbach, M.; Shumaker, D.;
Menashe, V.; Cobanoglu, A.; Morris, C.
Source: American Journal of Cardiology.
72(12):958-963, October 15, 1993.
Abstract: Researchers determined the
expenditures for children admitted to a single
tertiary referral center for the repair of low
surgical-risk congenital heart disease and
estimated the influence of age and other
preoperative factors on the hospital charge and
length of stay. They evaluated 322
consecutive operations between December
1985 and December 1989 for 10 types of low-
risk congenital cardiac malformation. Data
included total hospital charges for inpatient
care (excluding professional fees), source of
payment, home to hospital distance, and
inhospital mortality for children less than 17
years of age who had cardiac surgery during
the specified time period. Multiple regression
analysis of variance was used to predict the
influence of the primary diagnosis and various
preoperative parameters. Primary diagnoses,
hospital charges with standard deviation (SD),
and length of stay in days with SD per patient
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included (1) atrial septal defect, $18,030 (SD
$5,830), 5.9 (SD 1.2); (2) ventricular septal
defect, $27,488 (SD $22,885), 9.7 (SD 11.4);
(3) tetralogy of fallot, $37,290 (SD $34,854),
11.3 (SD 7.9); (4) coarctation, $22,527 (SD
$17,318), 9.7 (SD 6.9); (5) aortic stenosis,
$29,056 (SD $11,077), 8.0 (SD 2.7); (6)
complete atrioventricular canal, $37,545 (SD
$17,075), 11.1 (SD 6.9); (7) transposition of
great arteries, $29,303 (SD $11,566), 9.4 (SD
4.8); (8) membranous type subaortic stenosis,
$23,686 (SD $9,053), 7.6 (SD 3.1); (9) partial
atrioventricular canal, $32,195 (SD $30,167),
13 (19.1); and (10) abnormal tricuspid or
mitral valve canal, $42,194 (SD $24,406),
11.9 (SD 7.8). The average hospital charge
was $27,262 (SD $20,644) and the
postoperative length of stay was 9.3 days (SD
8.3). Age at operation alone did not influence
the dependent variables. The diagnosis of
atrial septal defect or coarctation of the aorta
decreased the mean charge, whereas the 8
other primary diagnoses did not significantly
influence the mean charge. Other preoperative
factors found to be predictive of increased
hospital charge were (1) the date of operation,
(2) previous thoracic surgery, (3) failure to
thrive, (4) associated major extra cardiac
anomalies, (5) oxygen requirement, and (6)
distance from home to hospital. A primary
diagnosis of atrial septal defect decreased the
mean postoperative length of stay by 3.1 days.
Other preoperative conditions that increased
the mean postoperative length of stay were:
(1) Major extracardiac malformation, (2)
failure to thrive, and (3) oxygen requirement.
Researchers generated charge and length of
stay equations to assist with the prediction of
resource utilization in this patient population.
Results indicated that the repair of cardiac
malformations at an earlier age should not be
limited since age at operation alone did not
influence the hospital charge or length of stay
and that the majority of children with
congenital heart disease can expect a lifetime
of productivity.
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Source: International Journal of Technology
Assessment in Health Care.
7(Supplement 1): 151-154, 1991.
Abstract: According to Swedish statistical
data, in 1981 about 7 percent of the total
Swedish population, or every fifteenth child,
had some degree of disability and 1.3 percent
had severe disabilities, often related to preterm
birth. In assessing the negative and positive
consequences of a specific neonatal treatment
policy, both with regard to saving lives (cost
effectiveness) and to the achievement of the
lowest possible incidence of disabilities among
survivors (cost efficiency), it is necessary to
include the family and society in a purely
economic (cost benefit) evaluation. Cost
estimates should cover the costs of neonatal
intensive care, the long-term medical care
costs, the socioeconomic costs of care of
children with disabilities, and the intangible
costs and benefits (e.g., the effects on the
child and family). Items to consider in
estimating the costs of a child with disabilities
for society include (1) the direct costs for
different levels of disabilities at different levels
of care; (2) the indirect costs to members of
the family; and (3) the intangible costs to
parents, other family members, medical
personnel, and social workers. Currently in
Sweden, most of the direct costs of child
rehabilitation efforts relate to outpatient clinic
care and home care. A 1977 study assessed
the costs of neonatal intensive care in a 1-year
Swedish neonatal care population. At that
time, estimates showed that the average annual
cost for rehabilitative care of a child with
mild, moderate, or severe disabilities was 5-11
times higher than the average cost per patient
for neonatal treatment in the hospital during
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that year. Another study in the 1970's showed
that, of every 40 lives saved among preterm
infants in one region of Sweden, one infant
would acquire some degree of cerebral palsy.
1 table, 9 references.
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Corporate Author: Cystic Fibrosis Neonatal
Screening Study Group.
Author: Farrell, P.M.; Mischler, E.H.
Source: Advances in Pediatrics.
39:35-70, 1992.
R162
Evaluation of New Services: Possibilities for
Preventing Congenital Toxoplasmosis.
Form: Journal article.
Author: Henderson, J.B.; Beattie, C.P.;
Hale, E.G.; Wright, T.
Source: International Journal of
Epidemiology. 13(l):65-72, March 1984.
R159
Maternal Serum Alpha-Fetoprotein
Screening for Neural Tube Defects.
R163
Reduction of RH (D) Sensitization: A Cost-
effective Analysis (Editorial).
Form: Journal article.
Author: Fuhrmann, W.; Weitzel, H.K.
Source: Human Genetics. 69(1):47-61, 1985.
Form: Journal article.
Author: Hensleigh, P. A.
Source: Obstetrics and Gynecology.
61(4):537-538, April 1983.
R160
Is Antenatal Screening for Syphilis Worth
While?
R164
Chronically 111 Children in America.
Form: Journal article.
Author: Garland, S.M.; Kelly, V.N.
Source: Medical Journal of Australia.
151(7):368, 370, 372, October 2, 1989.
Form: Journal article.
Author: Hobbs, N.; Perrin, J.M.;




Feasibility of Screening All Neonates for
Hearing Loss.
Form: Journal article.
Author: Hall, D.; Garner, J.
Source: Archives of Disease in Childhood.
63(6):652-653, June 1988.
R165
Health Maintenance Organizations vs.
Indemnity Insurance for Children With
Chronic Illness: Trading Gaps in Coverage.
Form: Journal article.
Author: Horwitz, S.M.; Stein, R.
Source: American Journal of Diseases of
Children. 144(5):581-586, May 1990.
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R166




Author: Mills, J.L.; Raymond, E.
Source: Annals of the New York Academy of
Sciences. 678:137-145, March 15, 1993.
R170








Cost-benefit Analysis of a Thalassemia
Disease Prevention Program.
R171
Thalassemia Disease Prevention: Genetic
Medicine Applied.
Form: Journal article.
Author: Ostrowsky, J.T.; Lippman, A.;
Scriver, C.R.
Source: American Journal of Public Health.
75(7):732-736, July 1985.
Form: Journal article.
Author: Scriver, C.R.; Bardanis, M.;
Cartier, L.; Clow, C.L.; Lancaster, G.A.;
Ostrowsky, J.T.
Source: American Journal of Human
Genetics. 36(5): 1024-1038, September 1994.
R168
State-Sponsored Genetic Services in
Maryland.
Form: Journal article.
Author: Panny, S.R.; Bernhardt, B.A.
Source: Maryland Medical Journal.
38(ll):925-932, November 1989.
R169
Costs and Benefits of Providing Early
Intervention to Very Young, Severely
Hearing-impaired Children in the United
States: The Conceptual Outline of a
Longitudinal Research Study and Some
Preliminary Findings.
R172
Feasibility of Chemical Screening of Urine
for Neuroblastoma Case Finding in Infancy
in Quebec.
Form: Journal article.
Author: Scriver, C.R.; Gregory, D.;
Bernstein, M.; Clow, C.L.; Weisdorf, T.;
Dougherty, G.E.; Auray-Blais, C;
Giguere, R.; Lemieux, B.; Laberge, C.
Source: Canadian Medical Association
Journal. 136(9):952-956, May 1, 1987.
Form: Journal article.
Author: Rittenhouse, R.K.; White, K.;
Lowitzer, C; Shisler, L.
Source: British Journal of Disorders of





Screening for Down Syndrome: Economic
Considerations.
Form: Journal article.
Author: Swint, J.M.; Greenberg, F.
Source: American Journal of Medical
Genetics. 31(l):231-245, September 1988.
R177







Assessing the Diagnostic Accuracy and
Efficacy of Selected Antepartum Fetal
Surveillance Techniques.
Form: Journal article.
Author: Thacker, S.B.; Berkelman, R.L.
Source: Obstetrical and Gynecological
Survey. 41(3): 121-141, March 1986.
R178
Containing Costs in the Treatment of
Congenital Heart Disease.
Form: Journal article.
Author: Waldman, J.D.; George, L.;
Lamberti, J.J.; Lodge, F.A.;
Pappelbaum, S.J.; Turner, S.W.;
Mathewson, J.W.; Kirkpatrick, S.E.
Source: Western Journal of Medicine.
141(1):123-126, July 1984.
R175
Cost Effectiveness of Antenatal Hepatitis B
Screening and Vaccination of Infants.
Form: Journal article.
Author: Thomas, I.L.
Source: Australian and New Zealand Journal
of Obstetrics and Gynaecology.
30(4):33 1-335, November 1990.
R176
Cost-effectiveness Analysis of Prenatal
Screening and Vaccination Against Hepatitis
B Virus: The Case of Belgium.
Form: Journal article.
Author: Tormans, G.; Van Damme, P.;
Carrin, G.; Clara, R.; Eylenbosch, W.
Source: Social Science and Medicine.
37(2): 173-181, July 1993.
R179
Costs and Results of Cardiac Operations in
Infants Less Than 4 Months Old: Are They
Worthwhile?
Form: Journal article.
Author: Watson, D.C.; Bradley, L.M.;
Midgley, F.M.; Scott, L.P.
Source: Journal of Thoracic and
Cardiovascular Surgery. 9 1(5): 667-673,
May 1986.
R180
Antepartum Rh Immune Globulin.
Form: Journal article.
Author: Wible-Kant, J.; Beer, A.E.
Source: Clinics in Perinatology.
10(2):343-355, June 1983.
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R181
Newborn Hypothyroid Screening: The
Private Sector.
Form: Journal article.
Author: Wilson, D.P.; Coldwell, J.G.
Source: American Journal of Diseases of
Children. 139(7): 662-663, July 1985.
R182
Effects of Cost-Sharing on Users of a State's
Health Service Program.
Form: Journal article.
Author: Wolfson, J.; Kapadia, A.S.;
Decker, M.; Sear, A.M.; Roht, L.H.






Management of Women Referred to Early
Pregnancy Assessment Unit: Care and Cost
Effectiveness.
184
Obstetric Care in the Netherlands:
Manpower Substitution and Differential
Costs.
Form: Journal article.
Author: Bigrigg, M.A.; Read, M.D.
Source: British Medical Journal.
302(6776):577-579, March 9, 1991.
Abstract: British researchers assessed the
efficiency of a district general hospital's early
pregnancy assessment unit in the care of
women with bleeding or pain in early
pregnancy. Subjects consisted of 1141 women
referred with bleeding or pain in early
pregnancy during the first year of the unit's
operation and in the six months prior to its
introduction. The length of hospital stay
required for diagnosis and treatment served as
the main outcome measure. Results indicate
that before the unit was established, the mean
admission time was one and a half days for
women who required no treatment and three
days in women requiring evacuation of the
uterus. These times were reduced to two
hours as an outpatient and one day respectively
for most women after the unit was established.
Between 318 and 505 women were estimated
to have been saved from unnecessary
admission, and 233 had their stay reduced; the
associated saving was between 95,000 pounds
and 120,000 pounds in one year. The early
pregnancy assessment unit improved the
quality of care and also produced considerable
savings in financial and staff resources. 2
tables, 1 figure, 4 references.
Form: Journal article.
Author: Butter, I.; Lapre, R.
Source: International Journal of Health
Planning and Management. 1(2): 89-1 10,
January-March 1986.
Abstract: Trends in the Netherlands indicate
an expanded role for obstetricians in hospital-
based prenatal and natal care, as well as a shift
in postnatal care away from hospitals to
domiciliary care. While general practitioners
are present at a steadily declining share of total
births, midwives continue to play a central role
in supporting over 40 percent of all births and
attend nearly two-thirds of all home births,
which is the preferred delivery option for more
than a third of childbearing women in the
Netherlands. The shift of births into hospitals
and postnatal care out of hospitals produces
opposite effects on obstetric expenditures. The
average cost of hospital births exceeds the
average cost of postclinical births (women who
give birth in a hospital while receiving most of
their pre- and postnatal care outside) by about
2000 Dutch florins (Dfl) and that of home
births by about Dfl2500. The average per
diem charge of hospitalization in 1982 was
Dfl530 (for mother and infant) compared to a
weighted average of Dfl247 for a day of
domiciliary maternity care. The cost of
hospitalization for the average length of stay
for obstetric patients (8.4 days) was Dfl4452,
while home-based maternity care costs were
estimated (for 9 days) at Dfl2228. Cost
differences are primarily associated with
variation in location of care and only
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secondarily associated with variation of the
provider of care, underscoring the importance
of contrasting styles of obstetric management
and their influence on costs. In the context of
these observed transitions, researchers
concluded that the increasing popularity of
clinical deliveries constitutes a pivotal force
whose impact to date appears to have been
neglected by planners and health care decision
makers. 4 figures, 4 tables, 39 references.
185
Cost-Effectiveness and Obstetric Services.
possibility of cesarian section, provided an
unbiased indicator of case-mix, which was
used to adjust cost per delivery. The first
stage of the study involved a logistic
regression of the probability of a cesarean
section on a set of clinical indicators. The
second stage was an ordinary least squares
regression. The results suggest that cost
management should focus on staff levels and
mix more than on practice patterns, and care
management should focus on practice patterns
in relation to their influences on outcomes. 4
figures, 6 tables, 18 references.
Form: Journal article.
Author: Finkler, M.D.; Wirtschafter, D.D.
Source: Medical Care. 29(10): 95 1-963,
October 1991.
Abstract: Researchers used two risk-
adjustment strategies to model the cost
effectiveness of obstetric services for eight
hospitals under the management of the
Southern California Kaiser Permanente
Medical Care Program. The study focused on
what levels and mixes of obstetric service
professionals were cost effective and which
obstetric practice patterns were cost effective.
The analytical process involved five steps: (1)
Estimating all direct resource costs used in
producing labor, delivery, and postpartum
obstetric services; (2) developing a case-
specific expected cost indicator; (3) risk
adjusting observed costs for each medical
center by employing the expected cost
indicator; (4) selecting a risk adjusted measure
of health outcomes; and (5) comparing risk
adjusted costs (RAC's) to risk adjusted rate
outcome (RAO's). To identify cost effective
medical centers, researchers matched labor,
delivery, and postpartum obstetric services
(RAC's) per delivery and risk adjusted
perinatal mortality rate outcome (RAO) against
each other for each hospital. Risk adjusted
maternal length of stay, including the
186
Cost-Effectiveness of a Self-Care Program.
Form: Journal article.
Author: Friedman, L.H.; Oberg, B.J.;
Dansby, M.M.; Sanders, J.; Leonard, S.;
Davis, B.
Source: Nursing Economics.
6(4): 173-178, 204, July-August 1988.
Abstract: Nursing professionals at a Texas
hospital investigated the cost effectiveness of
implementing a self-care program in a high-
risk postpartum cesarean section unit.
Postpartum patients who could read and speak
English or Spanish were invited to participate.
Program objectives included having the patient
(1) perform activities related to daily self-care,
(2) act as primary caregiver for her newborn
to facilitate the total care concept in
preparation for discharge, (3) perform and
follow identified treatments and medication
regimes with instructional aids and nurse
assistance, and (4) effectively document all
self-care and baby-care on a bedside form.
Patients who participated received self-care
educational materials. To evaluate cost
effectiveness, researchers collected data for 4
months preintervention and 4 months
postintervention. Data elements examined
included percent occupancy, census, average
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daily acuity, length of stay on the self-care
unit, actual unit expenditures, and quality of
care. Census is an indicator of the average
daily number of patients on the unit. Acuity
scores reflect the amount of nursing time
required to adequately care for a patient.
Analysis of acuity data indicated a decrease
from a mean of 3.5 hours to a mean of 3.2
hours of nursing time required to care for a
patient. This converts to a 9 percent savings
in direct patient care hours. Monthly
expenditures remained the same for salaries
and services, after allowing for inflation; cost
of supplies increased but the increase was
attributable to the purchase of equipment
unrelated to the self-care program. A review
of all data elements supports implementation of
self-care protocols as cost effective without
compromising quality of patient care.
Researchers noted no significant increase in
expenditures between preintervention and
postintervention. A reduction in acuity,
coupled with a reduction in excessive length of
stay, may indicate a cost savings when
evaluated over a longer time period. 3
figures, 3 tables, 20 references.
187
Antenatal Care of Low Risk Obstetric
Patients by Midwives: A Randomized
Control Trial.
Form: Journal article.
Author: Giles, W.; Collins, J.; Ong, F.;
MacDonald, R.
Source: Medical Journal of Australia.
157(3): 158-161, August 3, 1992.
Abstract: To assess the practicality,
acceptability to patients, and salary costs of the
antenatal care of low risk obstetric patients by
midwives, researchers conducted a randomized
controlled trial at the antenatal clinic at
Westmead Hospital, a teaching hospital of the
University of Sydney (Australia). From
January 1989 until November 1990,
researchers randomly allocated to one of two
groups 89 women who (1) were booking for
full antenatal care at Westmead Hospital; (2)
were classified as low risk (i.e., had no
preexisting medical or surgical conditions and,
if multiparous, had previously had
uncomplicated pregnancies resulting in normal
vaginal deliveries); and (3) had English as
their first language (these were expected to be
the least easily satisfied group of patients).
Group one (42 patients) had their antenatal
care provided by registered midwives. Group
two (41 patients) had their antenatal care
provided by an obstetrician (either a visiting
medical officer or staff specialist) in a routine
hospital antenatal clinic. Patients in the
midwives' clinic were seen by an obstetrician
at their first visit to the antenatal clinic and
again at 30 weeks and at 40 weeks. The
midwife and obstetrician clinics each lasted 4
hours, during which an average of 60 patients
were seen in the doctors' clinic and 32 were
seen in the midwives' clinic. The midwives'
clinic was staffed by four midwives (average
salary A$16.60 per hour). One of the doctors'
clinics was staffed by three midwives, one
visiting medical officer obstetrician (A$135.50
per hour), one affiliate obstetrician (A$88.50
per hour), a registrar (A$23 per hour), and a
resident (A$17 per hour). The other doctors'
clinic was staffed by a staff specialist
obstetrician (A$50 per hour), a registrar, three
midwives, and a resident. While in the
postnatal ward, patients completed a
questionnaire concerning their impressions of
the care they received during their pregnancy.
Main outcome measures were the salary costs
of each clinic and the patients' levels of
satisfaction; other considerations included
maternal and neonatal indicators, delivery
details and analgesic requirements. The major
differences found were a per patient seen/per
hour salary cost of A$101 at the midwives'
clinic, A$140 at the staff specialist's doctors'
clinic, and A$314 at the visiting medical
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officer's doctors' clinic; this results in a salary
cost saving at the midwives' clinic of 28
percent over the staff specialist's doctors'
clinic, and 68 percent over the visiting medical
officer's doctors' clinic. Compared to patients
seen in the doctors' clinic, patients whose care
was provided by midwives showed a higher
level of confidence and a perception that they
received a significantly more comprehensive
amount of information. When asked which
clinic they prefer to attend in the future, 98
percent of the midwives' group wished to
return to the midwives' clinic and 66 percent
of the doctors' group wished to change to the
midwives' clinic. 4 tables, 19 references.
188
Charges for Comprehensive Obstetric Care
at Teaching and Nonteaching Hospitals: A
Comparison.
Form: Journal article.
Author: Gordon, G.S.; Sefcik, S.E.;
Lo Gerfo, J. P.
Source: Western Journal of Medicine.
155(6) :6 16-620, December 1991.
Abstract: Researchers compared total charges
for prenatal and obstetric care at a major
teaching hospital and faculty group practice
with those at three nonteaching centers in
western Washington. The patients, all of
whom were enrollees of an employee-based
health maintenance organization (HMO), gave
birth between January 1, 1986 and December
31, 1987 (425 births). Investigators used
charges as a proxy for costs and included all
outpatient, inpatient, and physician charges.
In a teaching hospital, average per patient
outpatient/physician charges for all patients,
vaginal deliveries, and cesarean deliveries
were $2,022, $1,855, and $2,857 respectively,
while inpatient charges were $2,630, $2,323,
and $4,167 respectively; in a nonteaching
hospital these per patient charges for
outpatients were $1,992, $1,770, and $2,644
respectively while inpatient charges were
$2,538, $1,998, and $4,127 respectively. In
the teaching system, patients were cared for by
faculty and house staff; in the nonteaching
settings, they received care from private
physicians. All four settings are located in a
similar geographic region and have similar
costs for labor and for living expenses.
Investigators obtained data from the health
plan's computerized billing records.
Researchers found no significant differences in
total charges between the teaching setting
($4,652 each for 90 births) and the
nonteaching setting ($4,530 each for 355
births) for all deliveries. In the teaching
setting, vaginal deliveries were slightly more
expensive ($4,178 each for 75 births versus
$3,768 for 250 births in the nonteaching
setting), as were cesarean deliveries ($7,024
each for 15 births versus $6,771 for 85
births), respectively. The rate of cesarean
deliveries was lower in the teaching setting (17
percent versus 25 percent), partially
accounting for the similarity in total charges.
The length of stay was similar in the teaching
hospital (3.29 versus 3.14 days). Results
suggest that the academic medical center as a
total system of care can provide obstetric care
as cost-effectively as nonteaching systems
under the constraints of prepaid care. 3 tables,
28 references.
189
Cost-effectiveness Analysis of Three Staffing
Models for the Delivery of Low-risk
Prenatal Care.
Form: Journal article.
Author: Graveley, E.A.; Littlefield, J.H.
Source: American Journal of Public Health.
82(2): 180-184, February 1992.
Abstract: Researchers analyzed the
comparative cost-effectiveness of three low-
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risk prenatal clinic staffing models: (1)
Physician-based; (2) mixed staffing (physician,
nurse practitioner, registered nurses, and
nurses aides); and (3) nurse-based (a clinical
nurse specialist with physicians available for
consultation). The three observed clinics
served predominantly Hispanic clients of low
socioeconomic status. Subjects were 156
women who had delivered at a county hospital
over a 3-month period in 1989. Clinic one
used the physician-based model, under which
women saw the same physician for all their
prenatal care and counseling and received a
standard clinic appointment. Fees were
charged on a sliding scale, according to the
client's ability to pay. Clinic two used the
mixed staffing model, under which each
patient saw a nurse aide, a registered nurse for
prenatal teaching, and the nurse practitioner
and/or contract physician at each visit. All
women received an 8 a.m. appointment; the
charge for prenatal care and counseling was
$50 unless the woman was unable to pay.
Clinic three used the nurse-based model, under
which three clinical nurse specialists delivered
total prenatal care, including referrals to
county agencies. The client received a
standard clinic appointment. Fees were
charged on a sliding scale, according to the
client's ability to pay. The study analyzed
four broad categories of patient variables: (1)
Demographic, (2) physiological, (3)
satisfaction with care, and (4) cost. The
Kessner Index assessed the adequacy of
prenatal visits. Researchers interviewed
women to assess maternal satisfaction with
access to care, using a patient satisfaction tool
consisting of 27 statements addressing
accessibility, affordability, availability,
acceptability, and accommodation. The
financial officer for each clinic provided data
on (1) number of staff, (2) hourly wages, (3)
number of prenatal appointments made and
kept, and (4) number of hours spent delivering
prenatal care. Data analysis indicated no
differences in outcomes for the maternal-
neonatal physiological variables, although
newborn admission to the neonatal intensive
care unit (NICU) approached statistical
significance among the clinics: 35 percent of
clinic two's clients' babies were admitted to
NICU, compared to 21 percent for clinic one
and 22 percent for clinic three. Clinic three
(staffed by clinical nurse specialists) had the
greatest client satisfaction and the lowest cost
per visit. 6 tables, 18 references.
190
Safe Motherhood Initiative: Proposals for
Action.
Form: Paper.
Author: Herz, B.; Measham, A.R.
Source: Washington, DC, World Bank,
52 p., May 1987.
Availability: World Bank, 1818 H Street,
NW., Washington, DC 20433.
Abstract: In developing countries, maternal
mortality is often the leading cause of death of
women of childbearing age. A total of
500,000 women worldwide each year die of
pregnancy-related complications; 99 percent of
these deaths occur in developing countries.
The risks are generally greater for (1) very
young women and those over age 35; (2)
women in their first pregnancy or after their
fourth; (3) women with preexisting health
conditions; (4) those who are poor,
malnourished, and uneducated; and (5) women
who live in rural areas without access to health
care. Seventy-five percent of maternal
mortality results from direct obstetric deaths,
especially from hemorrhage, sepsis, toxemia,
obstructed labor, and illegal or primitive
abortion. Improving the income, education,
health, and nutritional status of women of
childbearing age could significantly improve
maternal mortality rates. Access to family
planning information and services could
ultimately prevent 25-40 percent of maternal
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mortality. There are three major factors to
consider in any plan addressing this problem:
(1) Prevention of complications, (2) routine
care, and (3) backup measures for high-risk
and emergency cases. Screening techniques
could identify the high-risk population among
pregnant women and allow concentration of
resources where they are most needed. A
strategy to provide these three elements should
use a 3-pronged approach: (1) Stronger
community-based care including screening and
referral methods, provision of prenatal care,
and access to family planning services; (2)
stronger referral facilities, including hospitals
and health centers to provide care for
complicated deliveries and obstetrical
emergencies, and clinical and surgical methods
of family planning; and (3) an alarm and
transport system to transfer women with high-
risk pregnancies from communities to referral
facilities. Of two cost models presented here
to implement such an approach, the second
(involving a $1 per capita per annum
expenditure rather than a $2 one) is more cost
effective. The costs associated with
administering a safe motherhood initiative are
staff ($115,000), transportation ($25,000),
inservice training and supervision ($30,000),
equipment and supplies ($60,000), health
education ($10,000), and monitoring and
evaluation ($10,000). 11 tables, 54
references.
191
Certified Nurse-Midwives and Physicians:
Perinatal Care Charges.
Form: Journal article.
Author: Krumlauf, J.; Oakley, D.;
Mayes, F.; Wranesh, B.; Springer, N.;
Burke, M.
Source: Nursing Economics. 6(l):27-30, 46,
January-February 1988.
Abstract: To examine costs in health care
provision, researchers reviewed billing charges
for perinatal care by physicians (MD's) and
certified nurse midwives (CNM's).
Investigators compared hospital and
professional fee charges for a matched sample
of 29 CNM and 29 MD clients and their
babies who received care at a Michigan
hospital. Researchers designed a data
collection form to record data extracted
retrospectively from hospital billing records,
and obtained billing data from the obstetric,
pediatric, anesthesia, radiology, and pathology
service departments for professional fee
charges. Collection of billing data began 4-5
months after delivery and covered the period
from the start of care through 2 months after
delivery for mothers and 2 weeks after birth
for the babies. The CNM and MD groups
were similar demographically. Analysis of
charges showed that the mean total charges to
MD clients were higher, with mean charges of
$4,117 to MD clients and $3,569 to CNM
clients. This difference approached statistical
significance. Between-group analyses of total
charges showed that the charges to CNM and
MD clients were essentially the same for
professional services ($984 versus $994,
respectively) but significantly different for
hospital services ($2,585 versus $3,123,
respectively). Regarding bill charges related
to labor, delivery, and immediate postpartum
care, the average for the CNM group was
$1,480; for the MD group, $1,882. The
difference could not be accounted for by length
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of stay. Results indicate that MD's tended to
use services or delivery locations with higher
associated charges. 5 tables, 7 references.
192
Effect of Prenatal and Infancy Nurse Home
Visitation on Government Spending.
Form: Journal article.
Author: Olds, D.L.; Henderson, C.R.;
Phelps, C; Kitzman, H.; Hanks, C.
Source: Medical Care. 31(2): 155-174,
February 1993.
Abstract: Researchers analyzed the net cost
of a prenatal and infancy nurse home visitation
program from the perspective of government
spending to determine whether improvements
in maternal and child health translated into
government savings (averted expenditures for
other government services and increased tax
revenues from participation in the workforce).
Between April 1978 and September 1980, a
randomized trial of a prenatal and infancy
nurse home visitation program found that, in
contrast to comparison services, home
visitation improved a wide range of maternal
and child health outcomes among poor,
unmarried, and teenaged women bearing first
children in a semirural county in upstate New
York. The trial had as its goals (1) improving
the outcomes of pregnancy; (2) improving the
quality of care that parents provide their
children (and the children's subsequent health
and development); and (3) improving the
mother's personal life-course development
through completing educations, finding work,
and planning future pregnancies. As part of
the trial, researchers interviewed 500
primiparous women through a no-cost
antepartum clinic and enrolled 400 women
before their thirtieth week of pregnancy.
There were four treatment conditions: (1)
Screening of infants at ages 1 and 2 years for
developmental and sensory problems, with
referral to specialists (treatment one); (2) free
transportation to regular prenatal and well-
child care clinics and to screening and referral
(treatment two); (3) visitation by a nurse home
visitor during pregnancy and the benefits given
to the first two groups (treatment three); or (4)
the same benefits as the third group and
continued nurse visitation until the children
were age 2 years (treatment four). Data came
from medical and social service reviews and
periodic maternal interviews addressing (1)
family structure, (2) psychological
characteristics, (3) health conditions, (4) health
habits, (5) availability of informal support, and
(6) childhood history. A cost benefit analysis
compared the most relevant government costs
for families in the nurse visitation program and
those given the comparison services.
Government costs included (1) nurse salaries
($1,049 for treatment three, $3,277 for
treatment four, and zero for comparison
services); (2) costs of services to which nurses
linked families (e.g., Special Supplemental
Food Program for Women, Infants and
Children (WIC)) ($934 for treatment three,
$747 for treatment four, and $808 for
comparison services); and (3) costs of taxicab
service ($30 for treatment three, $32 for
treatment four, and $13 for comparison
services). Government cost benefits were
presumed to accrue through improved maternal
and child functioning (i.e., reduced costs to
Aid to Families With Dependent Children
(AFDC), Medicaid, Food Stamps, and Child
Protective Services), reduction in subsequent
pregnancy among low-income women, and tax
revenues generated by women's working.
Data analysis indicated that for low-income
families, the cost of the program was
recovered and a dividend accrued of $180 per
family. The net cost of the program for the
sample as a whole was $1,582 per family. An
appendix provides details of cost calculations.




Cost-Effectiveness Analysis of Prenatal Care
Delivery.
Form: Journal article.
Author: Seiner, K.; Lairson, D.R.
Source: Evaluation and the Health
Professions. 8(1):93-108, March 1985.
Abstract: Researchers performed a cost-
effectiveness analysis (CEA) to evaluate the
relative efficiency of three alternative prenatal
care programs in rural, low-income areas of
Texas. Investigators compared both the actual
cost per visit and the predicted capacity cost
per visit, the latter determining which model
type has the potential to be most effective.
The study retroactively examined costs and
encounter data for the three clinics for 1981.
Estimating the costs of care included
enumeration, measurement, and valuation of
each clinic's capital and operating costs, both
fixed and variable; separating maternity from
medical costs; and allocating maternity to
prenatal care. Other specific costs determined
included those related to manpower, utilities
and maintenance, medical and office supply,
janitorial needs, consultation, employee travel,
depreciation of equipment and furniture,
miscellaneous costs (insurance,
communication, data processing, equipment
repair, recruitment), and administrative
headquarters costs. Researchers derived the
cost-effectiveness (CE) ratio by dividing the
sum of the prenatal costs ($73,186; $14,237;
and $82,770; respectively) by the total number
of prenatal visits (2,494; 432; and 2,460;
respectively) during the year. The lowest
average cost was $29.34 at the Raymondville
clinic; average costs at the other two clinics
were $32.96 for Littlefield, and $33.65 for
Plainview. The Raymondville clinic had the
lowest cost per visit when using both actual
and adjusted capacity data. After considering
specific criteria, such as (1) type of routine
and ancillary services provided, (2) utilization
of space, (3) input mix of personnel, and (4)
quality of care rendered, researchers attributed
cost per visit differences primarily to the mix
of medical personnel. Specifically, the use of
certified nurse midwives in conjunction with
physician backup proved more cost-effective
than salaried physicians alone. Figures are not
given for the cost-effectiveness of use of nurse
midwives and physician backup versus salaried
physicians alone. 3 tables, 10 references.
194
Economic Evaluation of Daycare in the
Management of Hypertension in Pregnancy.
Form: Journal article.
Author: Twaddle, S.; Harper, V.
Source: British Journal of Obstetrics and
Gynaecology. 99(6):459-463, June 1992.
Abstract: In 1989, researchers in Scotland
evaluated the efficacy of day care in the
management of hypertension in pregnancy as
compared to inpatient management with prior
domiciliary visits. Researchers hypothesized
that, since the incidence and outcomes of
hypertensive pregnancies were similar in two
maternity teaching hospitals, it would be
possible to study the different modes of
management for mild hypertension for cost
minimization. Researchers recruited 100
consecutive patients with hypertension from
the Glasgow Royal Maternity Hospital daycare
unit and 100 consecutive inpatients from both
Glasgow Royal Maternity Hospital and
Aberdeen Maternity Hospital. Additionally,
the study included 100 women seen by the
domiciliary midwife service in Aberdeen
Maternity Hospital during the time taken to
recruit the 100 inpatients. Data came from
each subject's case records and included
demographics, obstetric and medical history,
history of hypertension in the current
pregnancy, and all hypertensive-related
resource use and maternal and fetal outcome.
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Researchers calculated actual costs for each
element of hypertension related care; however,
they calculated a single set of unit costs so that
any differences in costs were a result of
different resource use and not different
hospital operating characteristics. Via a
structured interview, researchers elicited
women's views on the care they received, their
preferences for day care or inpatient care, and
costs they incurred in terms of loss of
earnings, out of pocket expenses, and activity
disruption. Researchers measured (1)
pregnancy outcomes in terms of maternal
hypertensive complications, (2) gestation at
delivery, (3) mode of delivery, (4)
birthweight, (5) Apgar scores, (6) admission
rates, and (7) length of admission to special
care baby unit. Data analysis found no
significant difference in any of the measured
pregnancy outcomes between the two
hospitals. Domiciliary midwife visits and
daycare were very popular with the patients.
Day care management of hypertension in
pregnancy was more cost efficient than
inpatient care with prior domiciliary visits for
most women, but less efficient for women with
transient or previous hypertension. An
appendix offers cost calculations for different
systems of care. 10 references.
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Comparative Analysis of Newborn Outcome
in a Hospital-based Birthing Center.
Form: Journal article.
Author: Waskerwitz, S.; Fournier, L.;
Jones, P.; Meier, W.
Source: Clinical Pediatrics. 24(5):273-277,
May 1985.
Between 1979-1981, researchers at Rush-
Presbyterian-St. Luke's Medical Center
(Chicago, Illinois) compared a cohort of 123
hospital-based birthing center low-risk
deliveries with 100 control low-risk deliveries
born during the same period in the medical
center's traditional labor and delivery setting.
The center, which is staffed by attending
physicians and certified nurse midwives,
provides low-risk, full-term mothers with a
simulated home environment, with family
members present, for labor, delivery, and
immediate neonatal care. To be eligible to
select an alternate birthing site, couples must
(1) have a maternal age between 19 and 35,
(2) be part of an intact family, (3) attend
birthing center classes, (4) have an absence of
risk factors (using the Hollister classification
as a basis), (5) have at least 12 years formal
education, and (6) have agreement from the
obstetrician and prospective pediatrician to
participate in the process. Parents of babies in
the control group were matched for the same
characteristics. Analysis of the babies' status
at birth, 24 hours, and 72 hours revealed no
difference in immediate morbidity. Morbidity
was assessed based on (1) respiratory distress,
(2) cyanosis, (3) apnea, (4) abdominal
distention, (5) vomiting, (6) arrhythmias, (7)
murmurs, (8) convulsions, (9) tremors, (10)
hypotonia, (11) jaundice, (12) plethora, and
(13) congenital malformation. Classification
of immediate morbidity was determined need
and rapidity of treatment. Cost of
hospitalization was reduced by an average of
$340 per baby, mainly due to the length of
time the mother spent hospitalized (average
4.21 days) or in the birthing center (average
1.28 days). 4 tables, 9 references.
Abstract: Researchers reviewed medical
records of babies born in a hospital-based
birthing center to determine whether a birthing
center alternative to traditional hospital care of




Comparative Costs of a Cooperative Care
Program Versus Inpatient Hospital Care for
Obstetric Patients.
Form: Journal article.
Author: Woods, J.R.; Saywell, R.M.;
Benson, J.T.
Source: Medical Care. 26(6): 596-606,
June 1988.
Abstract: Researchers compared the cost of
obstetric care delivered in a cooperative care
unit with the cost for similar patients treated in
a traditional inpatient maternity unit between
March 1985 and February 1986. Researchers
sought to determine (1) the average hospital
cost per patient for obstetric care delivered in
a cooperative care setting versus a hospital
inpatient setting; (2) whether, or to what
extent, there is a cost difference between the
two types of care; and (3) the sources of
potential cost savings. The cooperative care
unit was located in an adjoining hotel; eligible
well mothers and their newborns stayed in the
hotel room and relied on care partners for
most of their routine care. The study sample
contained 1,683 consecutive obstetric patients
representing 23 distinct ICD-9-CM diagnoses
(576 cooperative care patients and 1,107
hospital inpatients). Cooperative care unit
patients were (1) women who have had an
eventful normal delivery or an uncomplicated
Cesarean section; (2) did not require
laboratory tests, intravenous (IV) care, or
administration of narcotics; and (3) were self-
selected for co-op care. Researchers
calculated the average hospital cost per case by
multiplying an adjusted ratio of department
cost to charges (direct and indirect costs per
hospital service unit; e.g., labor and delivery,
anesthesiology, and laboratory) by each
patient's recorded charge. The analysis
indicates that cooperative care patients had
significantly lower total hospital costs
($1,368.12 versus $1,508.11). The cost
savings persisted even when researchers
controlled for case severity. The only
exception was for obstetric patients requiring
intra-abdominal surgery (i.e., delivery by
Cesarean section or delivery followed by a
related open surgery procedure such as repair
of current obstetric laceration of bladder and
urethra, repair of umbilical hernia, or
destruction or occlusion of fallopian tubes)
($2,041.05 for co-op care per person versus
$1,952.73 for hospital care per person).
Compared with hospitalization patients, co-op
care patients (1) who had a normal delivery
had $131.69 less costs per case, (2) who had a
complex delivery had $94.96 less costs per
case, and (3) who had surgery had $88.32
higher costs per case. For fiscal year 1986,
hospital cost savings for the 576 patients who
used the cooperative care unit totaled $80,640,
or approximately $105,000 in total patient
charges. The majority of the savings came
from a reduction in routine nursing services
that is directly attributable to the use of care
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Cost Implications of Routine Antenatal
Administration of Rh Immune Globulin.
Form: Journal article.
Author: Adams, M.M.; Marks, J.S.;
Koplan, J. P.
Source: American Journal of Obstetrics and
Gynecology. 149(6):633-638, July 15, 1984.
Abstract: Researchers examined the cost
implications of a program of routine antenatal
administration of Rh immune globulin for
primiparous women. Using existing clinical
and demographic data to identify the principal
variables that contribute to an assessment of
the benefits, risks, and costs, they determined
which variables are most important in
evaluating this program. They also compared
the alternative policy of routine antepartum
and postpartum administration of Rh immune
globulin for primiparous women with the
policy of only postpartum administration. The
risks of maternal antepartum sensitization were
the number of subsequent pregnancies in which
Rh hemolytic disease of the newborn occurs.
The benefits of an antepartum Rh immune
globulin program were the incidence, cost, and
morbidity of cases of Rh hemolytic disease of
the newborn that could be prevented. The cost
of the program was the cost of antepartum
administration of Rh immune globulin.
Researchers used decision analysis on the
hypothetical experience of a cohort of 10,000
Rh-negative primiparous women through their
second delivery. To account for racial
differences in the frequency of
Rh-incompatible pregnancies, researchers
performed separate analyses for white, black,
and Asian women. The probabilities assigned
to the branches of the decision tree were based
on published data; when several probabilities
were plausible, sensitivity analyses were
performed. The decision node was for
antepartum administration of Rh immune
globulin at 28 weeks gestation in a mean dose
of 300 grams to all Rh-negative primiparous
women or no antepartum program. The
chance nodes included (1) the probability of
Rh incompatibility, which was 0.6 for white,
0.7 for black, and 0.95 for Asian; (2) since
previous studies estimated that 0.3 to 1.9
percent of unsensitized women become
sensitized during the third trimester,
researchers selected 0.005, 0.010, and 0.016
as the range of probabilities for sensitivity
analysis for antepartum sensitization; (3) the
probabilities of first delivery with no maternal
sensitization, 1.0 assuming that all sensitized
Rh-negative women with Rh-positive infants
would receive Rh immune globulin
postpartum; (4) the probability of first delivery
with maternal sensitization, 1.0 assuming that
all pregnant women who were sensitized
before birth did not receive Rh immune
globulin postpartum; (5) since previous studies
estimated that 59 to 76 percent of white and
Asian women and 50 to 73 percent of black
women with one previous delivery expected to
have future births, researchers used 0.76,
0.65, and 0.59 for white and Asian women
and 0.73, 0.60, and 0.50 for black women as
sensitivity analyses for the probabilities of
primiparous women having a second delivery;
and (6) the probability of Rh hemolytic disease
of the newborn at second delivery, 0.40 for no
disease, 0.20 for mild disease, and 0.40 for
moderate/severe disease. When the hospital,
pediatrician, and obstetrician charges were
combined, the estimated excess charges per
case were $1,170 for mild cases and $6,454
for moderate/severe cases. The estimated
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charge for antenatal Rh immune globulin was
$40 including administration, with a cost range
of $30 to $70. The number of births of
second-order infants with Rh hemolytic disease
of the newborn and the costs per case averted
by an antepartum program for 10,000
Rh-negative primiparous women were 14 white
infants and $28,571 per case, 18 black infants
and $22,222 per case, and 35 Asian infants
and $1 1,429 per case. The cost of the
antepartum program was $400,000. The costs
without the program were $63,936 for white
infants, $84,468 for black infants, and
$156,594 for Asian infants. For all races, the
costs incurred by an antepartum program were
more than double the costs averted.
Sensitivity analyses showed that the most
crucial factor influencing the benefits of
routine antepartum administration of Rh
immune globulin was the probability of this
event. Another factor affecting the program's
benefits was the rate of antepartum Rh
sensitization among primiparous women.
Results indicated that if the program were
restricted to primiparous women at high risk
for antepartum Rh sensitization, its benefits
might exceed its costs.
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Cost-effectiveness of Prenatal Screening and
Immunization for Hepatitis B Virus.
Form: Journal article.
Author: Arevalo, J. A.; Washington, A.E.
Source: Journal of the American Medical
Association. 259(3):365-369,
January 15, 1988.
Abstract: Researchers evaluated the
cost-effectiveness of screening pregnant
women for hepatitis B virus (HBV) and
subsequently immunizing the neonate at risk.
They used a decision analysis model and data
from published sources, chart review, and a
Delphi survey to determine outcome
probabilities and costs. The decision tree
compared two strategies: (1) To screen
pregnant women for the presence of hepatitis B
surface antigen (HBsAg), or (2) not to screen
pregnant women. The baseline rate of HBsAg
prevalence in the U.S. population was 0.2
percent. The researchers also analyzed the
subgroups of population defined by the Centers
for Disease Control (CDC) as high-risk
groups. CDC high risk groups were defined
as cases with the following prevalences: (1)
National prevalence, 0.2 percent; (2) medical
personnel, 1 percent; (3) CDC recommended
screening groups, 4 percent; (4) very high-risk
groups, 7 percent; and (5) highest risk groups,
15 percent. Neonates of mothers who are
HBsAg positive should receive hepatitis B
vaccine and hepatitis B immune globulin
(HBIG) at birth and repeated hepatitis B
vaccine at ages 1 and 6 months. The
specificity and sensitivity of the HBAg
immunoassay test (Auszyme) were
conservatively estimated at 97.5 percent and
98 percent, respectively. The probability of
neonatal transmission of HBV focused on
vertical transmission varying from 12.5
percent to 90 percent, depending on the
hepatitis B e antigen (HBeAg) status of the
mother. Researchers calculated a transmission
rate of 0.425 in the face of a true-positive
HBsAg test result and performed a sensitivity
analysis that varied the probabilities between
20 to 60 percent. Efficacy of immunization
ranged from 85 to 95 percent; 90 percent
efficacy was selected for baseline analysis.
Acute hepatitis in neonates born to mothers
whose serology was positive for HBsAg,
negative for HBeAg, and positive for the
antibody to HBeAg will develop clinical acute
neonatal hepatitis at a rate of 2 to 3 percent; a
median probability of 2.5 percent was selected.
Death from complications of chronic liver
disease for neonates was estimated at 25
percent, with the median age of death at 45
years of age. Probability of chronic liver
disease varied from a low of 10 percent to a
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high of 40 percent. For diagnoses in 1984 and
1985, the average number of hospitalizations
for hepatocellular carcinoma, chronic active
hepatitis, and cirrhosis were 4, 3, and 3 with
average costs of $7,500, $4,500, and $5,900,
respectively. The average cost of the
screening test for HBsAg was $20 in 1985
dollars. The cost of immunization was
estimated at $50, which included three
vaccines and $15 for the initial HBIG in the
hospital. The researchers also added a $35 fee
for the second visit to the physician for the
second vaccine and $20 for the HBsAg
serology test at 12 to 18 months of age to
confirm immunization efficacy.
Hospitalization costs for acute neonatal
hepatitis were $2,500 per hospitalization per
case (1985 dollars). The average cost of total
care of chronic liver disease was estimated at
$27,512 per case. The indirect costs, which
included lost productivity and lost wages from
development of chronic liver disease and
premature death, were discounted at a rate of 4
to 6 percent using 1985 as the base year.
When considering direct and indirect costs,
routine screening and immunization would be
cost-effective at a prevalence of 6 percent,
significantly lower than the national prevalence
of 0.2 percent. At an annual national birth
rate of 3.5 million births, a national policy of
routine screening of all pregnant women would
result in an annual net savings of more than
$105 million. In the high-risk groups, as
many as 140 cases of acute national hepatitis
and as many as 1 ,400 cases of chronic liver
disease would be prevented yearly per 100,000
pregnant women screened, at a net annual
savings of over $765 million.
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Screening for HBsAg in Pregnant Women:
A Cost Analysis of the Universal Screening
Policy in the Province of Quebec.
Form: Journal article.
Author: Audet, A.; Delage, G.; Remis, R.S.
Source: Canadian Journal of Public Health.
82(3): 191-195, May-June 1991.
Abstract: Canadian researchers conducted a
cost analysis of a universal prenatal screening
policy for hepatitis B virus infection in
pregnant women. They estimated (1) the
model parameters (prevalence of HBsAg
among pregnant women, number of
HBsAg-positive pregnant women by ethnic
origin, HBIG and vaccine efficacy,
immunization costs, costs of followup, cost
and performance of the HBsAg test, and rate
of perinatal transmission of hepatitis B virus
from carrier mothers by ethnic group) and (2)
cost of screening in Quebec (total cost of
screening policy, cost per carrier mother
detected, and cost of preventing an infant from
becoming a chronic carrier). Results indicate
that a universal screening policy in the
province of Quebec (87,000 births per year)
would cost about $473,000 per year and the
prevention of one chronic carrier, $8,915.
The cost varied greatly according to the ethnic
origin of the mother and the cost of the
serologic test. (Screening Asians is most cost
effective and screening Caucasians is least cost
effective.) Strategies to reduce the cost of the
serologic test could greatly reduce the cost of




Study of Various Tests to Detect
Asymptomatic Urinary Tract Infections in
an Obstetric Population.
Form: Journal article.
Author: Bachman, J.W.; Heise, R.H.;
Naessens, J.M.; Timmerman, M.G.
Source: Journal of the American Medical
Association. 270(16): 1971-1974,
October 27, 1993.
Abstract: Researchers compared rapid
screening techniques for detecting
asymptomatic urinary tract infections (AUTI)
in pregnant women on the initial prenatal visit.
They sought (1) to determine the prevalence of
AUTI in the obstetric population of the
Department of Obstetrics and Gynecology and
Family Medicine at the Mayo Clinic in
Rochester, Minnesota; (2) to compare the
efficacy of urinalysis, urine dipstick testing,
and Gram's staining with the results of
standard urine culture; (3) to determine the
patient costs for detecting positive cases; and
(4) to determine whether there is a highly
effective method for screening AUTI on the
same day. They also sought to assess
same-day testing in followup visits by (1)
comparing the value of urinalysis with urine
dipstick testing and (2) determining the
prevalence of pyelonephritis. Subjects
included 1,047 pregnant women. The criteria
for the study were (1) for AUTI, a culture of
100,000 or more of a single uropathogen per
milliliter; (2) for pathogens, staphylococcus
coagulase-negative specimens and
staphylococcus aureus were not considered
uropathogens, but staphylococcus
saprophyticus was acceptable; (3) for mixed
cultures, mixed cultures with one predominant
organism of more than 100,000 uropathogens
per milliliter; and (4) patients taking antibiotics
at the time of the urine study were excluded.
All mixed cultures received treatment by
clinicians. Urine culture, urinalysis sediment
microscopy, urine Gram's staining, and urine
dipstick were performed on the initial
specimen at a cost per positive test of $25,
$15, $15, and $1, respectively. The cost
figures assume that the screening test was done
on all subjects, with subsequent urine cultures
performed for a positive screening result. Of
the 1,047 patients enrolled in the study, 24 had
asymptomatic bacteriuria on the initial visit
(prevalence 2.3 percent). When examining the
components of the dipstick test, the test
identified 12 of 24 patients; the sensitivity was
the highest (50 percent) with high specificity
(96.9 percent), when either leukocyte activity
was found or nitrites were present. When
using leukocyte counts greater than 10 as the
criterion for a positive test, urinalysis detected
only 6 of the 24 patients with positive cultures
(sensitivity 25 percent, specificity 99 percent).
By using the presence of bacteria on urinalysis
as an alternative, sensitivity improved to 75
percent, but the positive predictive value
decreased to 4.2 percent and specificity
decreased to 59.7 percent. Gram's staining
was the only test that simultaneously provided
sensitivity and specificity values of 80 percent
or greater. Gram's staining identified 22 of 24
patients with AUTI (sensitivity 91.7 percent
and specificity 89.2 percent). The cost of
identifying a positive culture was lowest using
the urine dipstick test. The total costs of the
urine dipstick test ranged from $1,122 to
$2,147 for the study population. In followup
visits, urine dipstick tests detected 19
infections and urinalysis detected three
(positive predictive value, 5 percent compared
with 3 percent, respectively). The use of the
presence of nitrites as the criterion for a
positive test with followup by urine culture
resulted in total costs averaging $127 per
positive culture. When either leukocyte
activity or nitrites were used as indicators for
further assessment, the incremental cost per
additional positive culture was $750 due to the
additional true-positive result and 29
false-positive results. Urine Gram's staining
112
Screening for Maternal Infections and Conditions
identified almost twice the number of positive
cultures as urine dipstick tests, with an
incremental cost per positive culture of $1,603
for borderline positive and $1,790 for positive.
There were large numbers of negative cultures
with positive bacteria on urinalysis with costs
per patient population ranging from $15,830
(for greater than 50 leukocytes) to $26,705
(for bacteria present or leukocytes greater than
20). The cost of doing urine cultures on all
the subjects would be $26,175 and the cultures
would have detected all 24 patients with
bacteriuria. Urine dipstick testing for nitrites
identified half of all patients with urinary tract
infections and was superior to urinalysis on
followup visits. Although Gram's staining was
more expensive, it was more accurate for
AUTI than urinalysis or urine dipstick testing.
Urinalysis was more expensive and detected
fewer positive cultures. Leukocyte
measurement correlated poorly with AUTI.
in 80 cases of Rh(D) alloimmunization treated
from 1982 to 1986. Neonatal intensive care
accounted for 80.1 percent of the additional
health care expenses; an extra 512 hospital
days for such care constituted 65.7 percent of
the total treatment expense. The cost per case
prevented ($1,495) was 2.7 times less than the
cost per case treated ($3,986). 2 tables, 8
references.
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Preventing Neonatal Herpes: The Value of
Weekly Viral Cultures in Pregnant Women
With Recurrent Genital Herpes.
Form: Journal article.
Author: Binkin, N.J.; Koplan, J. P.;
Cates, W.




Prevention of Rh(D) Alloimmunization: A
Cost-benefit Analysis.
Form: Journal article.
Author: Baskett, T.F.; Parsons, M.L.
Source: Canadian Medical Association
Journal. 142(4):337-339, February 15, 1990.
Abstract: The PJi Programme of Nova Scotia
was established in 1964 for the prevention and
treatment of Rh(D) alloimmunization. The
program's effectiveness in preventing the
condition has been established previously in a
study showing that 88 percent of expected
cases were prevented. Because of increasing
budget restraints in health care, researchers
examined the cost-effectiveness of the program
by comparing the cost of prevention (office
administration fees, program staff salaries and
the price of Rh immune globulin) with the cost
of health care services required in addition to
standard obstetric procedures and neonatal care
Abstract: Using the technique of decision
analysis, researchers determined the benefits,
risks, and costs of preventing neonatal herpes
infection among offspring of women with
recurrent herpes. They examined two
strategies: (1) Maintaining a weekly history,
examination, and virology, and (2) maintaining
a weekly history and examination only. The
study model follows the hypothetical
experience of a cohort of 3.6 million women,
approximately the number of women
delivering live-born offspring in 1981 in the
United States. Assuming that 95 percent of
the cohort would receive routine prenatal care
during the last 3 months of pregnancy, the
researchers estimated that 5 percent of these
women (3,420,000) would report a history of
recurrent genital herpes, or approximately
171,000 women eligible for screening. The
first strategy involves taking weekly cultures
from women with recurrent herpes from week
32 to delivery. Women who have positive
results from an examination at delivery or
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whose culture before delivery was positive and
all women with positive results from an
examination in the week before delivery would
have a cesarean delivery, unless a subsequent
culture was negative. Those with both a
negative culture and normal examination
results would be allowed to deliver vaginally.
The second strategy would screen women with
a history of recurrent genital herpes by history
and physical examination but without viral
cultures. All women with lesions at delivery
would have cesarean deliveries. At the last
visit before delivery, 25 percent of women
with recurrent genital herpes would be
shedding virus in the week before delivery; 12
percent would have no signs or symptoms and
their episodes would be detectable by culture
only. Thus, 22 percent of the women would
have signs or symptoms while 78 percent
would not (3 percent with subclinical shedding
plus 75 percent with no shedding). For cost
analyses, the researchers assumed that each
woman would average eight cultures before
delivery and each would cost $30. They
assumed that each excess hospital day for
maternal complication would cost $300. Based
on the estimates in the model, 21,323 women
would have symptomatic recurrent infection at
delivery. Because symptoms and signs would
be detected by examination, both strategies
would diagnose the 18,125 at risk for
transmitting the virus to offspring. An
additional 2,906 women would have
subclinical viral shedding at delivery, 2,470 of
whom would be expected to deliver vaginally.
Weekly cultures would identify 612 (24.8
percent) of the 2,470 women at risk of
transmitting infection, while examination
would identify none. The cost of screening
alone would be $41 million. The cost of
cesarean deliveries performed for this
indication and their resulting morbidity would
be an additional $20 million. Weekly viral
cultures would diagnose 25 percent of women
with subclinical recurrent infection at delivery.
The cost per case averted would be
approximately $1.8 million. In a cohort of 3.6
million women, researchers estimated that
screening during the last 4 to 8 weeks of
pregnancy would avert 11.3 neonatal deaths
and 3.7 cases of severe retardation, but 3.3
women would die as a result of cesarean
deliveries necessitated by culture results. The
authors recommend that future screening
recommendations should consider not only the
number of cases averted but also the
effectiveness of screening and the costs in both
maternal lives and medical care dollars.
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Maternal Age and Screening for Gestational
Diabetes: A Population-Based Study.
Form: Journal article.
Author: Coustan, D.R.; Nelson, C;
Carpenter, M.W.; Carr, S.R.; Rotondo, L.;
Widness, J. A.
Source: Obstetrics and Gynecology.
73(4):557-561, April 1989.
Abstract: The American College of
Obstetricians and Gynecologists (ACOG)
recommended screening for gestational
diabetes, using a 50-gram, 1-hour glucose
challenge (threshold for further testing 140
milligrams/dL or higher), for all pregnant
women aged 30 or older and for younger
women with risk factors. Since there was
disagreement about the value of historic risk
factors in screening, researchers from the
Women and Infants Hospital of Rhode Island
and Brown University evaluated the sensitivity
and cost-effectiveness of various screening
plans. They collected demographic and
historic data on 6,214 pregnant women
representing a population of universally
screened individuals between July 1, 1984 and
December 30, 1986 in four large obstetric
practices. All four groups of obstetricians
practiced universal screening using a 50-gram,
1-hour glucose challenge at 24 to 28 weeks
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gestation at any time of the day. Venous
blood was drawn from an antecubital vein and
glucose was measured in plasma on an
autoanalyzer using the hexokinase method of
analysis. Over 90 percent of the patients were
screened at some time prior to parturition. A
screened test value of 130 mg/dL or higher
required a 100 gram, 3-hour oral glucose
tolerance test (GTT). Each woman was asked
to fill out a questionnaire at the time of
screening to obtain information on (1) medical
history, (2) height and weight, (3) past
obstetric history, (4) family history, (5)
previous diagnosis of gestational diabetes, (6)
glycosuria during pregnancy, and (7) last
menstrual period. The questionnaire results
were available for 98.2 percent of the
individuals screened. Using the National
Diabetes Data Group-ACOG criteria, 125 (2
percent) of the 6,214 pregnancies were
complicated by gestational diabetes; 44 of the
gestational diabetics had no risk factors.
Seventy patients (56 percent) diagnosed with
gestational diabetes were under the age of 30.
Among these 70 pregnant women with
gestational diabetes under 30, 1.9 percent had
positive risk factors and 1 percent had no risk
factors. Of the 125 diagnosed with gestational
diabetes, 13 (10 percent) manifested screening
test values of 130-139 mg/dL; their condition
would have gone undetected if a threshold of
140 mg/dL had been used. If the ACOG
recommendations had been followed in the
study population, 44 patients (35 percent)
would have gone undiagnosed. A 1-hour,
50-gram screening test is assumed to cost
$2.45 and a 3-hour, 100-gram oral GTT is
assumed to cost $11. With the current ACOG
protocol, the number of cases diagnosed per
1,000 patients would be 13 (sensitivity 0.65) at
a cost of $190 per case. With universal
screening, if the patient is 25 years of age or
older, younger if risk factors present, with a
threshold of 140 mg/dL then the number of
cases diagnosed per 1,000 would be 17
(sensitivity 0.85) at a cost of $192 per case.
With universal screening if the patient is 25
years of age or older, younger if risk factors
present, with a threshold of 130 mg/dL then
the number of cases diagnosed per 1 ,000
patients would be 19 (sensitivity 0.95) at a cost
of $215 per case. With universal screening
and a threshold of 140 mg/dL then the number
of cases diagnosed per 1,000 would be 18
(sensitivity 0.90) at a cost of $222 per case.
With universal screening and a threshold of
130 mg/dL then the number of cases diagnosed
per 1,000 would be 20 (sensitivity 1.0) at a
cost of $249 per case. In comparing the cost
and sensitivity of the various protocols, the
lower the cost per case, the greater chance that
cases may be missed. When comparing the
least and most expensive cost per case, $190
and $249, there is a 31 percent increase in cost
but a 35 percent increase in diagnostic
sensitivity. Using the ACOG
recommendations, 35 percent of gestational
diabetes would go undiagnosed, with little cost
savings. The authors also suggest that
sensitivity could be improved by performing
the screening test on fasting rather than fed
subjects.
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Cost-effectiveness of HIV Screening of
Pregnant Women in Hospitals of the Paris
Area.
Form: Journal article.
Author: Gales, C.L.; Moatti, LP.
Source: European Journal of Obstetrics and
Gynecology and Reproductive Biology.
37(l):25-33, October 1990.
Abstract: In the context of an epidemiologic
multicenter study about perinatal transmission
of HIV, researchers systematically screened
7,600 pregnant women during their first
prenatal visit to one of nine maternity clinics
in Paris between August 1987 and July 1988.
Among those screened, 2145 had already been
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tested and 45 were known to be HIV positive.
During the first 6 months (period 1), 5660
tests were performed and 17 pregnant women
tested positive for HIV. The total cost of
screening has been estimated between 720,000
and 775,000 French francs, resulting in a
mean cost per infected pregnant woman of
about 42,000 to 45,000 French francs. A
similar calculation over the following 5 months
(period 2) gave a mean cost of between
165,000 and 178,000 French francs. Since the
women had to answer a short questionnaire
about risk factors prior to screening, cost and
effectiveness of a selective screening strategy
could be simulated. The preference of
systematic screening to selective screening
enabled the discovery of two HIV positive
cases in each period, the marginal cost, i.e.,
cost per extra pregnant woman found to be
HIV positive was 303,320 to 327,540 French
francs for period 1, and 572,240 to 619,000
French francs for period 2. Although these
figures seem high, an estimation of the
cost-effectiveness does not allow the
researchers to conclude whether it is in
society's interest to devote the funds necessary
to move away from selective screening
towards systematic screening. 3 tables, 2
figures, 13 references.
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Source: AIDS and Public Policy Journal.
6(2): 98- 103, Summer 1991.
Abstract: Researchers developed a
methodology for analyzing the costs and
benefits of a human immunodeficiency virus
(HIV) screening program for pregnant women
in high-risk regions of the U.S. The program
focuses on voluntary confidential screening
followed by voluntary educational counseling
of pregnant women who test positive for HIV
in New York City. Screening effectiveness is
measured by (1) the number of tests and the
associated costs required to identify one
HIV-positive woman, (2) the number of cases
prevented by the screening program followed
by counseling, and (3) the cost of such a
screening program per case of acquired
immunodeficiency syndrome (AIDS)
prevented. The costs associated with the
screening program include (1) the cost of
testing the population using the enzyme
immunoassay (EIA) test, (2) the cost of
additional testing of EIA positive women using
the Western blot (Wb) test, and (3) the cost of
counseling positive Wb-tested women.
Researchers assumed resource costs of $6 for
an EIA series, $50 for a Wb, and an additional
$65 in counseling costs for each pregnant
woman who tests positive. The model
incorporates false-positive and false-negative
test results, the population seroprevalence, the
transmission probability between an infected
pregnant woman and her child, and the
efficacy of the information on seropositivity
and seronegativity in preventing the
transmission of AIDS in the general
population. In a population of 100,000
pregnant women, one of every 100 pregnant
women is HIV positive. Screening results
would detect 904 of every 1 ,000 (96 infected
women will be told that they are not infected
and 10 healthy women will be told that they
are infected with HIV). The screening cost
per infected woman would be $7.95 if 100
were tested, $6.87 if 1,000 were tested, and
$6.76 if 10,000 were tested. Total screening
cost is inversely proportional to the prevalence
rate. The model assumes that high-risk
pregnant women are less likely to participate
in the program. To measure the impact of the
differences in attitude toward screening on the
effectiveness of the program, researchers
compared the cost per infected woman detected
from the mixed population with the
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corresponding cost of the homogenous model.
Researchers estimate that the screening
program will actually detect 129 HIV-positive
pregnant women, from a pool of 142
HIV-positive individuals who come for
screening at a cost of $1,918 per case. The
test will miss 13 HIV-positive cases, and 4
uninfected individuals will be falsely told that
they are infected. Researchers assert that the
benefits of voluntary screening of pregnant
women residing in high-risk regions of the
country for detection of HIV infection are (1)
the birth of infected children can be prevented
and (2) that an HIV-positive woman will
become aware of her infection, which may
help her prolong her life and prevent others
from becoming infected. The costs associated
with detecting an infected pregnant woman are
highly dependent of the seroprevalence rate of
HIV-positive women in that population. The
study model can determine the minimum
threshold of seropositivity that will justify
screening of the population of pregnant women
for HIV infectivity. 5 tables, 23 references.
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Congenital Toxoplasmosis: To Screen or
Not to Screen?
Form: Journal article.
Author: Joss, A.; Chatterton, J.;
Ho-Yen, D.O.
Source: Public Health. 104(l):9-20,
January 1990.
Abstract: Researchers performed a reanalysis
of the relative costs of a congenital
toxoplasmosis screening program in light of
improvements in the cost efficiency of
screening techniques. The question was
whether a screening program would be more
expensive than paying for the costs of caring
for the casualties. A cost-benefit analysis
published in 1984 firmly concluded that
screening would not be cost beneficial.
Instead there was a proposal of a health
education program to alert pregnant women to
sources of infection. Since there is little
evidence that the public awareness has
improved, and since there is now also less
public tolerance for allowing preventable
disease to progress undiagnosed and unchecked
in utero, the current study was undertaken.
Researchers compared the present day
quantifiable cost to society of the 73 cases of
congenital toxoplasmosis which are estimated
to occur annually in Scotland with the cost of
preventing the disease by screening and
treatment. Investigators examined the cost and
feasibility of two methods: (1) Blood tests for
all women in the second month of pregnancy,
and, if susceptible, again in the fifth, seventh,
and ninth months; and (2) two blood tests for
all women, the first during the first trimester
and a second, if necessary, in the eighth month
(the timing precludes the option of
termination). The analysis included advances
in laboratory techniques, including
enzyme-linked immunosorbent assays (ELISA)
and immunosorbent agglutination assays
(ISAGA). Preventable costs included the cost
of inpatient care in an acute care hospital at
707 pounds per person in 1987-88. The
weekly cost of institutional care in an average
mental deficiency unit in Scotland was 268
pounds. The additional expense to the family
of raising a handicapped child was estimated at
34 pounds per week and the cost of special
education was 6,751 pounds annually. The
total cost of possible outcomes of mental
retardation, visual handicaps, and neonatal
illnesses of congenital toxoplasmosis included
64,000 pounds for minimum outcomes,
674,000 pounds for central outcomes, and
2,637,000 pounds for maximum outcomes.
The cost of screening depends on its scale and
whether inhouse or commercial tests are used.
For the group of women (1) who gave 3
specimens that were evaluated by commercial
kits, total screening costs were 538,000
pounds, total costs of true maternal infection
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were 623,000 pounds, costs of 0.02 percent
false positives were 643,000 pounds, and costs
of 0.36 percent false positive were 973,000
pounds; (2) who gave 3 specimens that were
evaluated by inhouse kits, total screening costs
were 253,500 pounds, total costs of true
maternal infection were 339,000 pounds, costs
of 0.02 percent false positives were 358,000
pounds, and costs of 0.36 percent false
positive were 689,000 pounds; (3) who gave 2
specimens that were evaluated by commercial
kits, total screening costs were 424,000
pounds, total costs of true maternal infection
were 467,000 pounds, costs of 0.02 percent
false positives were 487,000 pounds, and costs
of 0.36 percent false positive were 817,000
pounds; and (4) who gave 2 specimens that
were evaluated by inhouse kits, total screening
costs were 189,500 pounds, total costs of true
maternal infection were 233,000 pounds, costs
of 0.02 percent false positives were 252,000
pounds, and costs of 0.36 percent false
positive were 583,000 pounds. The estimated
cost of a health education campaign on
toxoplasmosis was 86,000 pounds. Results
indicate that a cost effective prevention
program should cost less than 674,000 pounds,
given the infection rate of 2 to 2.5 pregnant
women per thousand. Combining the
diagnostic and therapeutic costs, results show
that 80 percent of preventable costs could be
saved by surveillance and that the cost of
screening should be less than 539,000 pounds.
As likely screening costs in most of the
schemes considered are now less than the
preventable costs, the researchers conclude that
a screening program should be adopted.
Tables present data on (1) cost of preventable
outcomes of congenital toxoplasmosis in
Scotland; (2) costs of screening and treatment
for congenital toxoplasmosis; and (3)
combined costs of screening, treatment, and
confirming fetal infection. 4 tables, 37
references.
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Source: Obstetrics and Gynecology.
74(5):808-814, November"l989.
Abstract: In 1984, the Immunization
Practices Advisory Committee advocated
hepatitis B surface antigen screening of
pregnant American women having identifiable
epidemiologic risk factors for being hepatitis B
surface antigen carriers. In 1988, they
broadened the recommendation to include all
pregnant women, regardless of risk status. A
researcher examines the implications of this
broader policy. In two scenarios examined,
the first uses a public hospital model, in which
all pregnant women are tested and the expected
carrier rate is 1 percent. In the second
scenario, women from the general population
who have no risk factors are screened, and a
carrier rate of 0.1 percent is expected in this
group for whom the 1988 recommendation was
targeted. However, not all carriers transmit
infection. Over 35 percent of pregnant
carriers will be hepatitis B e antigen-positive.
Researchers used the following assumptions in
the cost analysis: (1) 95 percent of hepatitis B
e antigen-positive pregnancies will result in
infection of the neonate, (2) 20 percent of
hepatitis B e antigen-negative pregnancies will
result in infection of the neonate, (3)
symptomatic acute hepatitis will occur in 2.5
percent of all transmitted infections, (4) 85
percent of hepatitis B e antigen-positive
pregnancies will result in chronic carriers, (5)
5 percent of hepatitis B e antigen-negative
pregnancies will result in chronic carriers, (6)
10 percent of carriers in the population without
risk factors are hepatitis B e antigen-positive,
(7) 20 percent of carriers in the population
from a public hospital are hepatitis B e
antigen-positive (which includes the influence
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of ethnic groups with higher hepatitis B e
antigen positivity rates), (8) there is 90 percent
patient compliance with treatment, (9)
prophylaxis is 90 percent effective, (10) the
cost of hepatitis B surface antigen screening is
$20 per test, (11) the cost of initial prophylaxis
is $31.67 ($15 hepatitis immunoglobulin (Ig)
plus $16.67 vaccine), and (12) the cost of
followup is $108.33 ($33.33 for remaining two
doses of vaccine plus $35 for an extra visit and
$40 for postvaccination serology). The cost
per case prevented was $12,016 in the public
hospital model and the cost per case prevented
in a general population, with a lower carrier
rate and a lower frequency of hepatitis B e
antigen positivity, was 15 times as high, over
$181,556. In the cost-efficacy analysis
published by Arevalo et al., the projected costs
for treating acute hepatitis and chronic carriers
were $2,500 and $23,512 respectively. In the
public hospital scenario, 7 cases of acute
hepatitis and 170 cases in chronic carriers
were prevented. Because the direct treatment
cost of these 177 patients is over $4 million,
the screening and prophylaxis cost of
$2,129,167 seems justifiable. On the other
hand, the cost of hepatitis B surface antigen
testing of pregnant women without risk factors
is $180,000 per case, or 15 times the cost of
preventing a case in neonates of mothers with
risk factors; these additional costs will
substantially increase the cost of the screening
program and will also prevent less clinically
important hepatitis. In the general population
with no risk factors scenario, to save the direct
treatment costs of $2.5 million (approximately
6 cases of acute hepatitis and 105 chronic
carriers), hospitals have to spend $20,129,167
in screening and prophylaxis. Results indicate
that the major cost considerations in screening
are the following: (1) The hepatitis B surface
antigen carrier rate in the population to be
screened (because the major cost is screening),
(2) the percentage of carriers who are hepatitis
B e antigen-positive, (3) the efficacy of
prophylaxis in hepatitis B e antigen-negative
cases, and (4) compliance. Costs go up if the
overall carrier rate or percentage of carriers
who are hepatitis B e antigen-positive is lower,
if compliance is poorer, or if prophylaxis is
less (or even not) effective in hepatitis B e
antigen-negative carrier pregnancies. 3 tables,
47 references.
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Comparison of Prevention Strategies for
Neonatal Group B Streptococcal Infection:
A Population-Based Economic Analysis.
Form: Journal article.
Author: Mohle-Boetani, J.C.; Schuchat, A.;
Plikaytis, B.D.; Smith, J.D.; Broome, C.V.
Source: Journal of the American Medical
Association. 270(12): 1442-1448,
September 22-29, 1993.
Abstract: Researchers explored options for
preventing neonatal group B streptococcal
(GBS) disease by (1) developing a prevention
strategy for selective intrapartum antibiotics
that does not require prenatal GBS screening,
(2) using decision analysis models and clinical
economic analyses to compare the
cost-effectiveness and cost-benefit of three
strategies, and (3) using 1990 rates of neonatal
GBS disease from multistate population-based
active surveillance to predict the impact of
these prevention strategies on disease and
medical costs in the United States. They
constructed a decision tree to evaluate
outcomes and costs of neonatal GBS disease
for three prevention strategies compared with
no prevention strategy. The three strategies
included (1) intrapartum antibiotics
administered to colonized women with labor
complications; (2) an alternative strategy in
Atlanta, Georgia, that does not require
screening but uses epidemiologic criteria and
labor complications to target intrapartum
antibiotics; and (3) maternal GBS vaccination.
Researchers estimated the potential impact of
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each strategy on disease and costs in the
United States by using data from multistate
population-based surveillance. The decision
tree for the first prevention strategy included
(1) screened in prenatal care; (2) colonized
GBS carriers; (3) labor complications (fever of
99.5 degrees Fahrenheit, preterm labor at less
than 37 weeks, or membranes ruptured for
more than 12 hours previous to labor onset);
(4) intrapartum antibiotics; and (5)
anaphylactic reaction. The decision tree for
the second strategy included (1) high-risk
(teenaged or black patient); (2) labor
complications (fever of 99.5 degrees
Fahrenheit, preterm labor at less than 37
weeks, or rupture of membranes for more than
12 hours); (3) intrapartum antibiotics; and (4)
anaphylactic reaction. The decision tree for
the third strategy included (1) vaccinated,
baseline coverage; (2) adverse reactions; (3)
infant at greater than or equal to 34 weeks
gestation; and (4) infant with protective
antibody titers. Researchers analyzed direct
medical costs, excluding all nonmedical costs,
indirect morbidity and mortality costs, or
intangible costs. They included costs for
adverse reactions to antibiotics and vaccination
($1,200 per patient), discounted at a 5 percent
rate, and societal costs, which reflected costs
and benefits to society as a whole rather than
to specific patients, payers, or providers. The
baseline cost per patient for early-onset is
$33,800 whereas late-onset is $83,070. All
three strategies had a benefit-cost ratio greater
than one and positive net benefits. A
threshold analysis showed that population size
will affect the dollar amounts but not the
cost-saving threshold; the second strategy is
applicable only to the Atlanta area due to the
specific demographic risk factors. Intrapartum
antibiotic prophylaxis of high-risk women
identified by screening could prevent
approximately 3,300 cases (47 percent of
neonatal disease) annually in the United States
and could save approximately $16 million in
direct medical costs. Chemoprophylaxis of
high risk women identified using
epidemiologic criteria could potentially be
equally effective (3,200 cases prevented) and
would avoid the logistical difficulties of
screening. The net savings would be
approximately $66 million. Vaccinating 80
percent of pregnant women with a vaccine that
prevents 80 percent of cases among infants
born at or after 34 weeks of gestation would
prevent approximately 4,100 neonatal cases
annually with a net savings of $131 million.
Universal prenatal screening for GBS and
chemoprophylaxis of colonized women with
labor complications is likely to be
cost-beneficial in the United States. 5 figures,
4 tables, 33 references.
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Cost-effectiveness of Prenatal Testing for
Chlamydia Trachomatis.
Form: Journal article.
Author: Nettleman, M.D.; Bell, T.A.
Source: American Journal of Obstetrics and
Gynecology. 164(5, Part 1): 1289-1294,
May 1991.
Abstract: Researchers investigated the cost
effectiveness of strategies for screening
pregnant women for chlamydia trachomatis.
Potential complications of a chlamydial
infection in a pregnant woman include
conjunctivitis and pneumonia in her infant,
epididymitis in her sexual partner, and her
own risks of postpartum endometritis or
salpingitis and ectopic pregnancy. Researchers
assigned dollar charges to all potential
conditions and evaluated four strategies: (1)
Neither test nor treat; (2) culture all pregnant
women and treat if the culture is positive; (3)
perform a direct antigen test in all women and
treat if the result is positive; and (4) perform a
direct antigen test in all women, confirm
positive tests with culture, and treat only if the
culture is positive. Results showed that
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screening for chlamydia trachomatis was not
cost effective unless the direct antigen test
costs less than $3.90 (or prevalence exceeded
8.7 percent) and the strategy involved direct
antigen testing of all women and use of culture
to confirm positive direct antigen. Direct
antigen testing of all pregnant women would
be cost effective if the test cost less than $6.30
or the prevalence of infection exceeded 6
percent; however, the positive predictive value
of the test was only 51 percent. Culturing was
not cost effective until the prevalence of
infection exceeded 14.8 percent. If a direct
antigen test cost $8 and culture cost $25, the
excess cost of performing a direct antigen test
in all women and confirming positive results
with culture would be $2.09 per pregnant
woman. Screening all pregnant women for
chlamydia is not cost effective, but the excess
cost is modest when direct antigen tests are
used. 1 figure, 4 tables, 33 references.
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Effectiveness and Cost Benefit of a Proposed
Live Cytomegalovirus Vaccine in the
Prevention of Congenital Disease.
Form: Journal article.
Author: Porath, A.; McNutt, R.A.;
Smiley, L.M.; Weigle, K.A.
Source: Reviews of Infectious Diseases.
12(l):31-40, January-February 1990.
Abstract: To evaluate the cost benefit and
effectiveness of a proposed live human
cytomegalovirus (CMV) vaccine in preventing
a leading cause of congenital deafness and
mental retardation, researchers developed a
model to compare routine immunization,
selective immunization of those women
screened and found to be seronegative, and no
immunization. Outcomes of interest were
symptomatic congenital infection at birth
(SCI), newborn death, and long-term
neurologic sequelae. Assumptions used to
frame the decision for analysis include (1) the
entire lifetime of offspring is considered the
time frame for episodes of illness, (2)
congenital CMV infections occur at a constant
level in an endemic mode, (3) immunization
will not affect herd immunity, (4) each female
vaccinee is assumed to become pregnant at
least once after immunization, (5)
immunization of an initially seropositive
mother does not modify the chance of
congenital or perinatal CMV infection in her
offspring, (6) vaccine strain and natural CMV
strains are equally capable through reactivation
of causing symptomatic congenital and
perinatal infection, (7) severe vaccine reaction
in the recipient may occur, and (8) increased
risk of abortion due to primary maternal CMV
infection. Baseline probabilities for the model
were obtained from published data; when data
were not available best estimates were used.
Probabilities include (1) a baseline
seroprevalence range of 55-70 percent for
young women in the United States; (2) about
33 percent of maternal CMV infections are
transmitted to the fetus; (3) the rate of primary
congenital infection resulting in symptomatic
illness is 10 percent (case fatality rate is 25
percent), early multisystem involvement with
permanent sequelae among SCI infants is 85
percent, permanent late sequelae (usually
hearing impairment) is 15 percent, and
perinatally acquired CMV pneumonia is 2
percent (10 percent of which may be fatal); (4)
there is an 80 percent immunogenicity of the
vaccine, with a reduction in infectivity of 90
percent for both wild and vaccine-associated
reactivations; and (5) the rate of vaccine-
induced severe adverse effect is 1/10,000
women. Baseline cost data include (1) costs of
screening for CMV antibody ($6 per person);
(2) cost of the vaccine ($8 per person); (3)
treatment of severe adverse effects ($3,900 per
person); (4) hospitalization costs for people
with SCI or perinatal pneumonia ($127,000
and $7,200 per person, respectively); and (5)
costs of special education and institutional care
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for the mentally retarded, deaf, and blind
($53,000 per year per person). Results show
that the difference between routine and
selective immunization, which are similar in
terms of effectiveness and cost savings, is
largely dependent on the potential of maternal
adverse effects. The presence of human
immunodeficiency virus (HIV) will preclude
routine CMV immunization, and will
necessitate screening for both HIV and CMV.
More than half of the cases of SCI and
long-term sequelae are vaccine preventable.
When direct costs alone are considered,
routine immunization of healthy women aged
15-25 is cost beneficial even in populations
with CMV seroprevalence as high as 87
percent. In populations with 55 percent to 70
percent seroprevalence, for every 100,000
women immunized, more than 24 cases of
symptomatic congenital CMV infection at birth
and a similar number of cases with late
sequelae (mainly deafness) would be prevented
yearly. Such immunization would result in a
net annual saving of $2.5 million. Selective
immunization becomes the strategy of choice
when the cost of adverse effects exceeds
$60,000. The lower the seroprevalence, the
greater the cost benefit, but routine
immunization of healthy women age 15-25 is
cost beneficial even in populations with CMV
seroprevalence as high as 87 percent. 3
figures, 6 tables, 36 references.
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Screening for Gestational Diabetes:
Analysis by Screening Criteria.
Form: Journal article.
Author: Reed, B.D.
Source: Journal of Family Practice.
19(6):75 1-755, December 1984.
Abstract: A researcher evaluated a previously
studied glucose screening test (GST) for
gestational diabetes using six screening test
criteria for appropriateness and cost
effectiveness as a widespread screening tool.
The test consisted of a serum glucose level
determination in a pregnant patient 1 hour
after ingesting 50 g of a glucose solution.
Serum glucose values over 150 mg/dL were
considered abnormal, and patients with such
values were then tested with a 3-hour oral
glucose tolerance test (OGTT). The researcher
determined price per case detected and number
of cases missed when using this test or the
OGTT either on all prenatal patients or on a
selected subset of patients. Cost per case
detected and number of cases missed were,
respectively, as follows: (1) GST for all
patients; if positive, OGTT: $684 per case
detected, 5 cases missed; (2) GST only for
patients with risk factors; if positive, OGTT:
$683 per case detected, 15 cases missed; (3)
OGTT all patients with risk factors: $938 per
case detected, 12 cases missed; (4) OGTT all
patients: $976 per case detected, cases
missed; and (5) GST all patients over age 25:
$386 per case detected, 6 cases missed (three
cases were missed in those screened and three
in those not screened). Results support the
advisability of screening all pregnant patients
over age 25 for gestational diabetes with the
1-hour glucose screening test. Performing this
test on that population will detect about 79
percent of the cases (99 percent confidence
limit and a confidence interval of 60.6-97.3
percent) at the lowest cost per case detected.
2 tables, 17 references.
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Economic Evaluation of Maternal Screening
to Prevent Congenital Syphilis.
Form: Journal article.
Author: Stray-Pedersen, B.
Source: Sexually Transmitted Diseases.
10(4): 167-172, October-December 1983.
Abstract: Researchers applied benefit-cost
analysis to a model of first-trimester screening
for syphilis where approximately ten new cases
of early infections are identified and treated
per 50,000 pregnancies. The analysis
employed a model requiring the identification
of a detailed list of factors and the assignment
of the actual dollar values to the different
items concerned. The calculations refer to
Norway and were calculated in 1979 U.S.
dollars with a discount rate of 7 percent, but
the model can be applied for evaluation of
similar preventive programs elsewhere. The
procedures for the prenatal serologic screening
included blood samples routinely collected at
the first antenatal visit being tested by the
standard tests for syphilis; the Wassermann CF
test, the Venereal Disease Research Laboratory
(VDRL) flocculation test, and the Meinicke
flocculation test. The cost of the preventive
program was $229,016 (1979 U.S. dollars) for
the 50,000 subjects and their children, which
included the cost of the prenatal screening and
the cost of the treatment and followup program
for newly infected mothers and their children.
Economic benefits of a prenatal screening
program for congenital syphilis included
$660,720 in direct costs averted and $217,200
in indirect costs averted. Total benefits of the
preventive program were $877,920; total
benefits of preventing one case were $87,792.
The average cost of the serologic tests was
calculated from the laboratory expenses by
assessment of the cost of every item used in
the performance of the tests and the share of
the salaries, including benefits, of the medical
and technical staff, and 40 percent to cover
administration and expenditures for electricity,
fuel, and housing. The cost of the screening
was estimated to be $4.60 per participating
woman, while the benefit-cost ratio was 3.8.
Thus, the economic benefits were nearly four
times the cost of the program. Principally,
this ratio may be considered as a constant
value independent of the size of the population
screened. However, the total savings to
society, or the overall effect of the preventive
policy, may also be calculated as the net
benefit (benefit minus cost), which is directly
dependent on the number of participants. In
Norway, with an annual pregnant population
of 50,000 women, this value approximated
$650,000 yearly. However, if the indirect cost
is completely excluded from the analysis, the
program still gives a favorable benefit-cost
ratio of 2.9 and a net benefit of $430,000. 3
figures, 2 tables, 13 references.
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Author: Stray-Pedersen, B.; Jenum, P.
Source: Scandinavian Journal of Infectious
Diseases. 84(Supplement): 86-96, 1992.
Abstract: Researchers in Norway applied
benefit-cost analyses to strategies aimed at
preventing congenital toxoplasmosis: (1)
Health education of pregnant women on
avoiding toxoplasma infection, and (2)
serological surveillance in pregnancy combined
with prenatal diagnosis and chemotherapy. In
Norway, approximately 40 fetuses each year
are infected with congenital toxoplasmosis; of
these 6 percent will die in utero or during
early childhood, 16 percent will require
institutional care, 15 percent will be visually
handicapped and require special education, and
15 percent will be moderately retarded and
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require support to live in the community. The
serological surveillance in pregnancy combined
with prenatal diagnosis and chemotherapy
involves identification of women at risk
through testing a routine blood sample for
toxoplasma antibodies (IgG and IgM classes);
of these, only 0.05 percent will have
serological evidence of recent infection that
may have been acquired during the first few
weeks of gestation. These cases require
prenatal diagnosis (ultrasound and
amniocentesis) and the consideration of
therapeutic abortion or therapy. Women who
are seronegatives (85 percent) need to be
repeatedly tested during the second and third
trimester. Recently infected women (0.15
percent) will receive repeated prenatal
examinations and therapy; their infants will
receive Spiramycin therapy and will be
followed with repeated clinical,
ophthalmologic, radiologic, and serologic
examinations. Infected infants will receive
pyrimethamine, sulfadiazine, and folinic acid
during the first year of life. The health
education program, which can reduce the risk
of exposure and prevent infections in
pregnancy, has minimal monetary costs (20
Norwegian krone (NOK)) because it uses
already existing channels and means of
information aimed at the pregnant population.
The average cost per participating woman of
(1) basic screenings is NOK 202; (2) second
and third trimester screening is NOK 131; (3)
followup, treatment, and special examination
of a risk mother is NOK 4,500; (4) followup
and treatment of a high-risk infant is NOK
1,300; and (5) followup and treatment of a
congenitally infected infant during the first
year of life is NOK 3,500. The authors
conclude that the best and most rational
approach, and the program which will prevent
the most cases and save the most money for
society, is a combination of each program.
Compared with the results of any of the two
strategies alone, the benefits of the combined
program will increase significantly, while the
cost (NOK 165 per participating woman) will
add only fractions to that of the serological
screening program used alone. The benefits of
the strategies are influenced by many uncertain
factors such as (1) the discount rate, (2) the
incidence of infection, (3) the intrauterine
transmission rate, (4) the outcome of
pregnancy, (5) the prognosis of the offspring,
(6) the sensitivity of the screening tests and (7)
the effectiveness of the program. After
applying a sensitivity analysis, both programs
were found to be of economic benefit to
society at an incidence of maternal
toxoplasmosis of 1-1.5 per 1,000. 1 figure, 4
tables, 20 references.
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Cost-effectiveness of Intrapartum Screening
and Treatment for Maternal Group B
Streptococci Colonization.
Form: Journal article.
Author: Strickland, D.M.; Yeomans, E.R.;
Hankins, G.
Source: American Journal of Obstetrics and
Gynecology. 163(1, Part l):4-8, July 1990.
Abstract: Using decision analysis methods,
researchers attempted to determine what the
annual costs of screening and treatment for
intrapartum prophylaxis for group B
streptococci infections would be in the United
States and how sensitive the analysis is to
changes in test accuracy and costs.
Early-onset neonatal group B streptococci
infection occurs in 2 cases per 1 ,000 live
births in the United States and is associated
with a mortality rate greater than 20 percent.
The annual cost of group B streptococci
infection in the United States is conservatively
estimated at more than $500 million and nearly
2,000 neonatal deaths, excluding the costs of
long-term neurologic handicaps. Intrapartum
chemoprophylaxis with ampicillin is effective
in curtailing transmission of group B
124
Screening for Maternal Infections and Conditions
streptococci from mother to infant once
identification of maternal group B streptococci
colonization has occurred. Only screening
tests that allow group B streptococci
colonization detection in under 2 hours were
used in the analysis. Five tests were
evaluated: (1) The gram stain test reported by
Sandy, (2) the latex test reported by Isada, (3)
the latex test reported by Brady, (4) the gram
stain test reported by Holls, and (5) the gram
stain, test reported by Feld. The screening test
reported by Brady showed very high-
performance results, and its use in the United
States population as a whole (with a group B
streptococci prevalence of 10 percent and a
birth rate of 3.5 million) could avert 1,230
neonatal deaths from group B streptococci
annually at a total savings of $1,100 per
neonatal death averted. In a higher-risk
population such as women with preterm labor,
premature rupture of the membranes, or
intrapartum fever, the screening test program
reported by Brady could avert 7 deaths and
save an average of $216,000 for every 10,000
women in the cohort. Findings suggest that in
the United States intrapartum screening for
group B streptococci is cost-effective and
offers the potential to avert a significant
number of neonatal deaths and postpartum
infections. 1 figure, 3 tables, 25 references.
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Cost-Effectiveness of Antepartum
Prevention of Rh Immunization.
Form: Journal article.
Author: Torrance, G.W.; Zipursky, A.
Source: Clinics in Perinatology.
11 (2):267-281, June 1984.
Abstract: To demonstrate the application of
economic appraisal, researchers examine the
question of whether an antepartum program of
administering anti-D gamma-globulin to
prevent Rh isoimmunization is sufficiently cost
effective to warrant its use. They argue that
the decision to fund antepartum prophylaxis
must consider circumstances in the specific
area under consideration (e.g., Province of
Ontario, Canada): (1) Availability and cost of
anti-D gamma-globulin, (2) prevalence of the
Rh factor and of Rh disease in the population,
(3) pregnancy rates, (4) effectiveness of
treatment of Rh disease of the newborn and the
associated costs and outcomes, (5) methods
and costs of finding and treating potential
Rh-negative pregnant women, and (6) the
relative merit of competing claims for the
limited funds and resources available.
Assumptions included that, according to
Ontario birth statistics, 1,000 antepartum
injections prevent 8 isoimmunizations, which if
not prevented would subsequently cause 5.8
cases of Rh disease of the newborn leading to
0.73 more perinatal deaths (a loss of 14.2
life-years). In 1983, the net costs to the health
care system in Canadian dollars were C$2,700
per isoimmunization prevented, C$3,700 per
case of Rh disease prevented, C$29,500 per
life saved, and C$1,500 per year of life gained
and per quality-adjusted life year (QALY)
gained. Restricting the program to women
with homozygous Rh-positive husbands was
not cost effective because the laboratory costs
of determining each husband's Rh factor more
than offsets the savings from the fewer
antepartum treatments. Treating primiparae
was more than twice as cost effective as
treating multiparae; the costs per QALY
gained were C$900 and C$2,400, respectively.
These costs were substantially less than costs
reported for other health care programs
currently employed. Thus, in comparison with
other health care expenditures, researchers
conclude that a comprehensive antepartum
prophylaxis program for all Rh-negative
pregnant women in the Province of Ontario is
sufficiently cost effective to warrant its use. 1




Screening for Asymptomatic Bacteriuria in
Pregnancy: A Decision and Cost Analysis.
Form: Journal article.
Author: Wadland, W.C.; Plante, D.A.
Source: Journal of Family Practice.
29(4) -.372-376, October 1989.
Abstract: Researchers used decision and cost
analysis to compare the utility of screening
pregnant women for asymptomatic bacteriuria
(AB) with not screening. Data used were
based on published reports and average
charges for services. Cost estimates per
woman included (1) dip slide, $12; (2) urine
culture, $32; (3) amoxicillin treatments, $5 per
week; (4) followup cultures, $108; (5)
amoxicillin for the 20 percent of women who
remain positive, $1; (6) nitrofurantoin therapy
for the 12 percent of women who still remain
positive, $3.01; (7) treatment for yeast
vaginitis, $1.83; and (8) inpatient
hospitalization for pyelonephritis and
outpatient evaluation, $3,672.44. Researchers
based costs on 1988 charges at the Medical
Center Hospital of Vermont or the University
Health Center, projected for the expected
results of outpatient screening, possible
suppressive therapy, and risks of
pyelonephritis. Screening is based on the
combined sensitivities and specificities of the
MacConkey and CLED (cysteine-lactose-
electrolyte-deficient agar) panels of the
dip-slide culture. Under the baseline
assumptions, the risk of pyelonephritis is
estimated at 2 cases per 100 screened women
versus 3.5 cases per 100 unscreened women.
The anticipated cost of screening 100 women
is $9,939, compared with $12,824 for not
screening 100 women. Screening is cost
effective unless (1) the cost of screening is
above $26, (2) the length of hospitalization for
pyelonephritis is fewer than 2.2 days, (3) the
risk of AB falls below 2 percent, (4) the risk
of pyelonephritis with AB falls below 13
percent, or (5) the efficacy of treatment in
preventing pyelonephritis falls below 38
percent. Based on the decision and cost
analyses, there is a clear advantage to screen
and treat all obstetric patients for AB to
prevent pyelonephritis. 4 figures, 1 table, 13
references.
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Cost Efficacy of Routine Screening for
Diabetes in Pregnancy: 1-h Versus 2-h
Specimen.
Form: Journal article.
Author: Weiner, C.P.; Fraser, M.M.;
Burns, J.M.; Schnoor, D.; Herrig, J.;
Whitaker, L.A.
Source: Diabetes Care. 9(3):255-259,
May-June 1986.
Abstract: Undetected gestational diabetes
mellitus (GDM) is associated with a twofold to
fivefold increase in perinatal morbidity and
mortality. Widespread screening of pregnant
women (resulting in identification and
treatment) should reduce these rates.
Researchers examined 798 women during a
13-month period of universal glucose challenge
testing (GCT). A total of 2.8 percent of the
population had an abnormal oral glucose
tolerance test (OGTT). Thirty percent of those
with an abnormal OGTT were under age 25.
Researchers compared the specificity of a 1-h
GCT (50-g carbohydrate load) using a
threshold of either 140 or 150 mg/dL with that
of a 2-h specimen using a threshold of 118
mg/dL to determine whether the cost of
screening could be reduced. Investigators
obtained 1-h and 2-h specimens in 347 of these
women. A 34 percent reduction in the number
of followup OGTT's required would have been
achieved if a 2-h specimen had been used as
the index instead of a 1-h specimen (P less
than .05). As a result, the cost per patient
identified with GDM would have declined 23.5
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percent, from $866 to $662. Researchers
cannot comment about the actual false-negative
rate of either the 1-h or 2-h GCT because only
select women underwent an OGTT. To assess
validity of the 2-h threshold, researchers
performed an OGTT in an additional 190
women if either the 1-h or 2-h screen was
abnormal. The results were confirmatory:
The 2-h screen would have reduced the cost
per case identified by 32 percent in this small
group. Screening on the basis of past medical
history clearly lacked sensitivity and cost
efficacy in comparison with the GCT. 6
tables, 9 references.
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Screening for Syphilis in Pregnancy: An




7(1): 37-42, February 1985.
and postage costs, and marginal costs. It was
assumed that all women attending antenatal
care by 26 weeks would be screened. Under
various assumptions, the total cost savings
from discontinuing screening ranged from
170,479 pounds to 325,493 pounds annually,
with an average savings of 252,713 pounds
annually. Benefits in terms of cost savings to
the National Health Service resulting from the
screening program ranged from 1,870,705
pounds to 6,975,587 pounds per year, with an
average savings of 5,121,950. When other
benefits to society were considered, estimated
total benefits ranged from 3,243,845 pounds to
14,121,160 pounds per year, with an average
savings of 8,322,610 annually. The
benefit/cost ratio ranged from 9.20 to 1 to
82.83 to 1 with a best estimate of 32.93 to 1.
Results suggest that, on economic grounds,
there is a strong argument for continuing to
screen routinely for syphilis in pregnancy. 1
table, 19 references.
Abstract: The substantial decline in the
incidence of syphilis (especially among
women) in Western countries since 1945 has
led some to question the desirability of
continuing routine antenatal serological
screening for syphilis in pregnancy. No
routine figures are available in England with
regard to the incidence of maternal syphilis.
A researcher estimated the incidence of
syphilis in pregnancy for 1981 by sending out
a postal questionnaire to all Special Clinics in
England. He calculated the costs and benefits
of the screening program by means of a
computer-aided program that included a
sensitivity analysis. The pathological analysis
for syphilis as currently carried out by the
West Midlands Regional Transfusion Service
was computed at an average cost per test that
included materials and labor, time required to
take a sample, clerical time in completing
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Revised Conservative Estimate of the
Incidence of FAS and Its Economic Impact.
Form: Journal article.
Author: Abel, E.L.; Sokol, R.J.
Source: Alcoholism: Clinical and
Experimental Research. 15(3):514-524,
May-June 1991.
Abstract: Researchers conducted a new
analysis of the incidence of fetal alcohol
syndrome (FAS) and its economic impact,
basing evaluation on prospectively gathered
data from consecutive pregnancies. This more
conservative analysis reflects the researchers'
concern over possible inclusion of false
positives in their previous estimate ($321
million) of total annual costs for FAS and now
puts the overall rate in the western world at
0.33 cases per 1,000. The estimate among
whites is 0.29 per 1,000 compared with 0.48
per 1,000 for African Americans; estimates for
Native Americans are not included due to the
absence of prospectively gathered data on FAS
for this group. Retrospective studies suggest
larger disparities. Both prospective and
retrospective studies may be influenced by
examiner bias, especially for minorities since
they are often evaluated against standards
derived for whites. Based on estimates and the
number of African American and white
children born annually, researchers estimate
that 1,200 children are born with FAS each
year in the United States. This is a probable
lower limit based on considerations of
ascertainment and absence of relevant
information for other minorities such as Native
Americans. In calculating economic costs,
researchers adjusted estimates to consider costs
that would be incurred whether cases were
FAS or not, and also include estimated costs
for anomalies in FAS cases not considered in
previous estimates. Based on these
considerations, they estimate the incremented
annual cost of treating this disorder at $74.6
million. Approximately 75 percent of this
economic cost is associated with care of FAS
patients with mental retardation. 7 tables, 85
references.
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Author: Calhoun, B.C.; Watson, P.T.
Source: Obstetrics and Gynecology.
78(5, Part 1):73 1-734, November 1991.
Abstract: From September 1987 to October
1988, researchers compared the hospital
charges of a cocaine-abusing population of
pregnant women delivering at a Portland,
Oregon, hospital with the charges of a matched
control group delivering at the same hospital.
The study compared 91 mother-infant pairs
testing positive for cocaine at delivery with a
screened drug-free control population matched
for socioeconomic status, age, and parity.
None of the subjects had medical insurance,
adequate prenatal care, or a referring primary
physician. Researchers reviewed patient charts
and assessed clinical outcomes and hospital
charges for labor, delivery, postpartum, and
nursery care. Researchers assessed differences
between the control and study groups with a
paired, 2-tailed Student t-test, a noncorrected
chi-square test, and a Mann-Whitney test for
statistical significance. Data analysis indicated
that maternal use of cocaine during pregnancy
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contributed substantially to perinatal morbidity.
The control group contained a significantly
higher proportion of Southeast Asians, but was
otherwise statistically similar to the study
group in terms of background. Study group
mothers were more likely to smoke and to
have had fewer prenatal visits than control
group mothers. Study group mothers were
more likely to deliver prematurely and to have
low birthweight or growth-retarded infants
with (1) Apgar scores less than 7 at 5 minutes,
(2) signs of cocaine exposure, (3) neonatal
intensive care use, and (4) extensive
hospitalization. There was a substantial cost
difference between study group subjects and
control group subjects. 2 tables, 21
references.
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Drugs, Alcohol, Pregnancy, and the
Neonate: Pay Now or Pay Later (Editorial).
Form: Journal article.
Author: Chasnoff, I.J.
Source: Journal of the American Medical
Association. 266(1 1): 1567-1568,
September 18, 1991.
Abstract: A physician discusses the medical
costs associated with infants born to drug- and
alcohol-dependent women and asserts that the
most cost effective way of handling the
situation is to fund more prevention programs
aimed at these women. Previous studies
indicate that about 1 1 percent of infants born
in the U.S. have been exposed to some illicit
substance at some time during gestation and
that 2.4 to 4.5 percent of pregnant women use
cocaine during pregnancy. Estimated
additional medical costs resulting from this
situation range from $385 million to $3
billion. It has been shown that providing
prenatal care and helping cocaine or alcohol
addicted women to abstain during pregnancy
significantly reduces the incidence of
prematurity, low birthweight, small head
circumference, and other perinatal
complications. The author advocates (1) a
nationwide, comprehensive survey of this
problem to improve assessment; and (2) the
design of public education programs which can
help prevent drug use during pregnancy. 21
references.
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Hospital Costs for Cocaine-Exposed Infants.
Form: Journal article.
Author: Chiu, T.; Vaughn, A.J.;
Carzoli, R.P.
Source: Journal of the Florida Medical
Association. 77(10): 897-900, October 1990.
Abstract: During November 1988-October
1989, researchers conducted a retrospective
study at the University Medical Center at
Jacksonville (Florida) to estimate the cost of
treatment for 207 infants from cocaine-exposed
pregnancies (151 African American and 56
white infants). Researchers reviewed the
billing records for the patients. The sample
was composed of infants either showing a
positive urine test for cocaine or having a
maternal history indicating cocaine abuse to
the extent that the mother was referred to
social services. Twenty-five infants (12
percent) were admitted into the neonatal
intensive care unit (NICU) and 82 infants (88
percent) into the normal nursery. Average
stay for a cocaine-exposed infant in NICU was
21.5 days (range 3-125 days). Average stay
for a cocaine-exposed infant in the normal
nursery was 6.7 days as compared with 2-3
days for normal infants, primarily because
cocaine-exposed babies were detained in the
normal nursery until discharge either to the
parents or a foster home, depending on the
outcome of Florida Department of Health and
Rehabilitative Services (HRS) investigation of
each baby's home situation. Approximately 45
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percent of total days spent by babies in the
normal nursery were due to social hold
pending clearance for discharge by the HRS.
Total charges for the 12-month period
amounted to $1,057,921, or $5,110 per
cocaine-exposed patient; for a control group
matched by birthweight but with a maternal
history that was negative for cocaine abuse,
total charges were $520,251 or $2,513 per
patient. Average costs per cocaine-exposed
patient were $36,481 for NICU (compared
with $17,721 for a control infant) and $1,225
for normal nursery (compared with $424 for a
normal full-term infant). Laboratory fees
accounted for the largest percentage (41.5
percent; $15,147) of the total cost of
hospitalization in the NICU ($36,481), while
rooming charges were the major factor in the
excess normal nursery charges for cocaine-
exposed infants (50.8 percent; $401). 1
figure, 3 tables, 10 references.
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Cost-benefit/Cost-effectiveness Analysis of
Smoking Cessation for Pregnant Women.
Form: Journal article.
Author: Marks, J.S.; Koplan, J. P.;
Hogue, C; Dalmat, M.E.
Source: American Journal of Preventive
Medicine. 6(5):282-289, September-
October 1990.
Abstract: Researchers estimated the cost-
effectiveness of a smoking cessation program
for pregnant women to reduce low birthweight
and perinatal mortality. They defined a cost-
effective program as either improving health
outcome and saving money or delivering a
health benefit at an acceptable cost. Staff
assessed the low birthweight and perinatal
mortality attributable to maternal smoking
during pregnancy, and then examined the costs
of a smoking cessation program (e.g., booklets
and additional personnel costs). The study
estimated costs (using the 1986 dollar as the
base currency) and outcomes for the
population of women in the United States who
deliver babies each year. Assuming the
program would cost $30 per participant and
that 15 percent of participants would quit
smoking, researchers determined that a
program offered to all pregnant smokers would
shift 5,876 low birthweight infants into the
normal birthweight range, and would cost
about $4,000 for each low birthweight infant
prevented. Since infants born to smokers are
at 20 percent greater risk for a perinatal death,
a smoking cessation program could prevent
338 deaths at a cost of $69,542 for each
perinatal death averted. Compared with the
costs of caring for these low birthweight
infants in a neonatal intensive care unit,
smoking cessation programs would save
$77,807,054 or $3.31 per $1 spent. Assuming
a life expectancy of 75 years per additional
survivor, discounted at 4 percent, the costs are
$2,934 per year of life gained. The cost per
perinatal death averted ranges from $36,210 to
$136,659 depending on the relative risk of
LBW used in the calculation. The ratio of
savings to costs increases to more than six to
one when the equation includes reducing long-
term care for infants with disabilities
secondary to low birthweight in the benefits
from smoking cessation programs. The
authors conclude that physicians, third-party
payers, managed-care organizations, and
public health programs should offer this
preventive service to all pregnant women who




Maternal Smoking During Pregnancy and
Expenditures on Neonatal Health Care.
Form: Journal article.
Author: Oster, G.; Delea, T.E.;
Colditz, G.A.
Source: American Journal of Preventive
Medicine. 4(4):216-219, July-August 1988.
Abstract: Researchers estimated expenditures
on neonatal care based on the relationship
between maternal smoking during pregnancy
and the increase of low birthweight (LBW).
They combined estimates of the relative risk of
LBW by maternal smoking status in each of
three LBW groups with data on the prevalence
of maternal smoking during pregnancy. The
study examined the attributable risk of LBW in
each group. Researchers multiplied estimates
by the total number of United States live births
in 1983 in each LBW group to yield estimates
of the number of LBW's attributable to
maternal smoking during pregnancy.
Researchers used the probabilities of admission
to a neonatal intensive care unit (NICU) for
infants in each group to calculate the number
of NICU admissions due to maternal smoking.
They determined the marginal (or additional)
cost per NICU admission, with all costs
expressed in 1983 dollars. Researchers
multiplied estimates of the additional cost per
NICU admission by the number of NICU
admissions due to maternal smoking to yield
estimates of the additional cost of neonatal care
attributable to maternal smoking in each LBW
group. Summation of the costs across LBW
groups yielded the additional costs of neonatal
care attributable to maternal smoking during
pregnancy. Researchers multiplied the number
of live births in each LBW group by the
probability of NICU admission for infants in
that group to determine the total number of
NICU admissions. The total cost of NICU
care in 1983 came from multiplying that
estimate by the mean charge per NICU
admission. Results indicated maternal
smoking during pregnancy was responsible for
14.5 percent of all low weight births in 1983.
The study found that 6.6 percent of all
admissions to NICU's resulted from maternal
smoking, representing 8.5 percent of total
national expenditures on NICU services. The
average cost of neonatal care was $288 higher
for infants born to smokers than those born to
nonsmokers. 1 table, 31 references.
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Neonatal Costs of Maternal Cocaine Use.
Form: Journal article.
Author: Phibbs, C.S.; Bateman, D.A.;
Schwartz, R.M.
Source: Journal of the American Medical
Association. 266(11): 1521-1526,
September 18, 1991.
Abstract: Researchers examined the added
neonatal cost and length of hospital stay
associated with fetal cocaine exposure in a
large, public, inner-city hospital from 1985 to
1986. Three hundred fifty-five cocaine-
exposed infants were compared with a random
sample of 199 unexposed infants. Regression
analysis was used to control for the
independent effects of maternal age, smoking,
alcohol consumption, prenatal care, race,
gravidity, and sex of the infant. All infants
were routinely tested for illicit substances,
records were reviewed for maternal histories
of substance abuse, and all known cocaine-
exposed singleton infants were included. The
main outcome measures included (1) cost and
length of stay until each infant was medically
cleared for hospital discharge, and (2) cost and
length of stay until each infant was actually
discharged from the hospital. Results indicate
that neonatal hospital costs until medically
cleared for discharge were $5,200 more for
cocaine-exposed infants than for unexposed
infants (a difference of $7,957 versus $2,757).
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The costs of infants remaining in the nursery
while awaiting home and social evaluation or
foster care placement increased this difference
by more than $3,500. Compared with other
forms of cocaine, fetal exposure to crack was
associated with much larger cost increases
($6,735 versus $1,226). Exposure to other
illicit substances in addition to cocaine was
also associated with much larger cost increases
($8,450 versus $1,283). At the national level,
these individual medical cost estimates add up
to about $500 million. The magnitude of these
costs indicates that effective treatment
programs for maternal cocaine abusers could
yield savings within their first year of










Source: Family Planning Perspectives.
18(5):221-226, September-October 1986.
Abstract: A researcher (1) reviewed 12
studies that estimated public costs attributable
to teenage childbearing; (2) derived a formula
for making national, state, and local estimates
of the cost to the public of teenage
childbearing from this review; and (3) applied
the formula to United States data.
Calculations yielded a single-year cost for
1985 of $16.65 billion paid through three
programs (Aid to Families with Dependent
Children, $8.32 billion; food stamps, $3.42
billion; and Medicaid, $4.91 billion) for
women who first gave birth as teenagers.
Calculations also showed that the public will
pay an average of $13,902 over the next 20
years for the family begun by each first birth
to a teenager in 1985 and $5.16 billion over
the same period for the families of all
teenagers experiencing a first birth in 1985. If
all teenage births were delayed until the
mother was age 20 or older, potential savings
to the public would be $5,560 for each birth
delayed and $2.06 billion for the entire cohort
of teenagers who would otherwise have had a
first birth in 1985. Estimates of public outlays
for teenage childbearing are time-consuming
but not difficult, and should be readily
available to policy makers and program
planners throughout the United States. 1
figure, 2 tables, 38 references.
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Planning Programs for Pregnant Teenagers:
First You Define the Problem.
Form: Journal article.
Author: Burt, M.R.; Sonenstein, F.L.
Source: Public Welfare. 43(2):28-36,
Spring 1985.
Abstract: Researchers explored critical issues
affecting teenage pregnancy and parenting by
collecting data from 21 federally funded care
programs established in 1982 for pregnant and
parenting teens by the Office of Adolescent
Pregnancy Programs, Department of Health
and Human Services. Analyses are based on
1,054 clients entering a project either pregnant
or with a baby and having at least one
followup after the baby's birth. From client
records, researchers noted the teens' entry
characteristics, data on service delivery,
information on pregnancy outcome and
educational and vocational achievement,
employment and welfare status, and followup
data on repeat pregnancies. Findings showed
that (1) those who fund programs would be
better advised to support nonhospital programs
that have good interagency links to local
hospitals, since any one program structure can
work as well as another; (2) girls who were
pregnant when they entered a program
received more services than those who already
had one or more children; and (3) girls on
welfare received more services than those who
were not. The shorter the length of followup,
the more services the client received. Service
costs for 12 months' support to a pregnant or
parenting teen varied widely depending on
client type, from $5,283 for a teen who was
not receiving support from Aid to Families
with Dependent Children (AFDC) and who
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entered the program pregnant and delivered in
the program, to $9,592 for an entry mother on
AFDC. Public agencies planning similar
programs must (1) develop interagency
coordination with great care, allowing
adequate time; and (2) establish clear
guidelines for case management, for tracking
clients, and for keeping adequate client
records. Programs must address the needs of
the teenage parent as well as the pregnant teen.
School dropouts are an underserved group;
they would benefit from special efforts at the
state or local level. 3 tables.
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Teenage Welfare Receipt and Subsequent
Dependence Among Black Adolescent
Mothers.
Form: Journal article.
Author: Duncan, G.J.; Hoffman, S.D.
Source: Family Planning Perspectives.
22(1): 16-20, 35, January-February 1990.
Abstract: Researchers examined teenage
welfare receipt and subsequent dependence
among black adolescent mothers. Rather than
using a statistical model to distinguish state of
dependence from heterogeneity, researchers
used a set of parental and sibling measures to
adjust directly for family and neighborhood-
based heterogeneity. Data used were from the
1985 cross-year file Panel Study of Income
Dynamics (PSID) on women who were
observed both throughout their teenage years
and in their twenties to investigate the extent
to which welfare receipt affects their future
economic independence. Subjects include 316
black women between 14 and 26 who were
both members of PSID households and
members of households where 1985 interviews
were conducted. Researchers first observed
the subjects between the ages of 14 and 19 so
births could be compared with data on possible
receipt of Aid to Families with Dependent
Children (AFDC) and so their family
conditions could be measured as of age 14.
Births were considered to be out-of-wedlock if
they occurred prior to the mother's twentieth
birthday and the mother's first marriage. A
birth was considered to accompany AFDC if
AFDC income was reported in either of the
first two years following the child's birth. Of
the 316 young black women, 131 had at least
one out-of-wedlock birth before age 20, and 82
had at least one out-of-wedlock teenage birth
accompanied by receipt of AFDC. The
sample of black teenagers was divided into
four categories for analysis: (1) Those who
had at least one teenage out-of-wedlock birth
that was accompanied by AFDC receipt, (2)
those who had at least one teenage out-of-
wedlock birth that was not linked to AFDC
receipt, (3) those who had no out-of-wedlock
births but at least one marital birth during their
teenage years, and (4) those who had no
teenage births. The first category was divided
into (1) AFDC benefit levels in the state of
residence, (2) age of the mother at the time of
her first birth, and (3) whether the teenage
mother lived with a parent or independently in
the year following the birth. Regression
analyses determined that black teenage mothers
who receive benefits through AFDC around
the time they give birth are more likely to be
receiving AFDC at age 26 than are other black
teenage mothers or women who do not have a
teenage birth, even after adjustments are made
for differences in parental background and the
economic accomplishments of siblings. The
average earned family income at age 26 among
the mothers who had received AFDC as
teenagers was $8,600, half that of the other
groups (between $15,900 and $17,700) even
when transfer income is included. Black
teenage mothers who receive benefits through
AFDC around the time they give birth are also
more likely to have a lower earned family
income and a lower total family income.
Findings suggest that AFDC receipt around the
time of nonmarital teenage birth may be an
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independent cause of future economic
problems. 2 tables, 5 references.
229
Socioeconomic Consequences of Teen
Childbearing Reconsidered.
Form: Journal article.
Author: Geronimus, A.T.; Korenman, S.
Source: Quarterly Journal of Economics.
107(4): 1187-1214, November 1992.
Abstract: Researchers present new estimates
of long-term socioeconomic disadvantages for
mothers and children of teenage childbearing.
The new estimates take into account
unmeasured family background heterogeneity
by comparing sisters who timed their first
births at different ages and by using a within-
family estimation to control family background
heterogeneity. The researchers present
conventional cross-sectional estimates using the
same data and compare the two types of
estimates to gauge the degree to which
differences in family background of mothers
contribute to the large cross-sectional
associations between teenage childbearing and
socioeconomic status of mothers later in life.
Researchers analyzed samples of sisters from
three data sets: (1) The National Longitudinal
Survey Young Women's Sample (NLSYW),
(2) the Panel Study of Income Dynamics
(PSID), and (3) the National Longitudinal
Survey Youth Sample (NLSY). Researchers
grouped socioeconomic indicators into primary
outcomes and secondary outcomes. The
primary outcomes were total family income,
income-to-needs-ratio (1981 U.S. poverty
threshold), poverty status, and welfare status.
The secondary outcomes were whether or not
a woman completed high school, whether she
completed at least one year of postsecondary
schooling, her current employment status, and
her marital status. Results indicate large
differences in indicators of socioeconomic
status according to the age at which a woman
times her first birth. For most direct measures
of long-term economic well-being, results from
the NLSYW and the NLSY samples suggest
that unmeasured family background
heterogeneity biases traditional cross-sectional
estimates. In the NLSYW sample in 1982,
among women aged 28 to 38, those who had
first births after age 19 lived in families with
over 40 percent higher income. Total family
income in 1981 dollars was $18,045 for teens
and $25,258 for nonteens in the cross-sectional
data and $19,339 for teens and $21,870 for
nonteens in within-family data in the NLSYW
sample; $15,684 for teens and $24,873 for
nonteens in the cross-sectional data and
$16,876 for teens and $23,090 for nonteens in
within-family data in the PSID sample; and
$11,864 for teens and $21,670 for nonteens in
the cross-sectional data and $12,649 for teens
and $17,101 for nonteens in within-family data
in the NLSY sample. Approximately 20
percent of the women who became teenage
mothers were on welfare in 1982 compared
with approximately 5 percent of women who
had first births at older ages. Nearly 90
percent of older mothers had graduated from
high school in 1982, versus 66 percent of
women who were teenage mothers. Women
who had births after age 19 were more than
twice as likely as teen mothers to have
completed at least one year of postsecondary
schooling. Women who were teenage mothers
were also less likely to be married as of their
1982 interviews. The differences in primary
socioeconomic outcomes as a result of teenage
birth remained substantial when differences in
measured individual attributes and family
background were examined. The differences
in secondary socioeconomic outcomes were not
as dramatic as outcomes for more direct
measures of economic well-being. The
mechanisms whereby teen childbearing is
associated with lower family income are sister
differences in fertility timing, age, urban
residence, education, and current marital
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status. In two of the three data sets examined,
sister comparisons suggest that biases from
family background heterogeneity were
important, and therefore that earlier studies
may have overstated the consequences of teen
childbearing. Previous estimates of the effects
of teen childbearing have failed to adequately
control for family background differences
among women who have births at different
ages.
230
Socioeconomic Costs of Teenage
Childbearing: Evidence and Interpretation.
Form: Journal article.
Author: Geronimus, A.T.; Korenman, S.
Source: Demography. 30(2) :28 1-290,
May 1993.
Abstract: Researchers discuss their 1992
study on the socioeconomic costs of adolescent
childbearing through a sibling approach as a
matched comparison study group, which the
authors feel provides a more complete set of
match characteristics than matching measured
or observable family background
characteristics. The authors assert that a
recent replication of this 1992 study by
Hoffman et al. in 1993 supports their principal
conclusions that (1) standard cross-sectional
estimates of the consequences of adolescent
childbearing are biased by failure to control
adequately for family background differences
between women who have first births as
teenagers and those who have first births at
later ages, and (2) previous estimates are likely
to have exaggerated the costs of adolescent
childbearing. The authors are concerned that
Hoffman et al. gives the impression that
within-family estimates (i.e., sister differences)
derived from the Panel Study of Income
Dynamics (PSID) or the National Longitudinal
Study of Youth (NLSY) are preferable to those
based on the National Longitudinal Survey of
Young Women (NLSYW). Hoffman et al.
states that because the PSID and NLSY within-
family estimates are larger than the NLSYW
estimates, the weight of the evidence suggests
that the effects of adolescent parenthood on
subsequent socioeconomic status are likely to
be sizable, although smaller than has often
been assumed. The authors take exception
with 1993 Hoffman et al.'s suggestion that
PSID estimates are preferable and that the
NLSYW estimates are outliers since (1) the
precision of the within-family estimates is not
high in any of the samples; and (2) the greater
number of sibling pairs is obtained at the cost
of including some very young women
(between 21 and 25 years of age), which
impacts the study purpose of long-term
followup and outcome measures and produces
overpessimistic assessments of socioeconomic
status. When testing the NLSYW sampling
restriction in PSID data, the authors feel that
Hoffman et al.'s standard error is large; the
PSID within-family point estimates remained
much larger than the corresponding estimates
from the NLSYW. The authors assert that
Hoffman et al.'s hypothesis that genuine
cohort differences may exist between the
NLSYW sample and the PSID sample (since
more adolescent births are currently more
likely out-of-wedlock births, the cohort may
suffer larger costs) is speculation without any
empirical test. The within-family effect of an
adolescent birth on the probability of being
married at followup appears smaller in the
PSID and NLSY than in the NLSYW sample.
The authors also state that the sibling sample
from the PSID and NLSY data sets are
unrepresentative because (1) they overrepresent
the unmarried, (2) sister samples overrepresent
large families, and (3) sibling samples
exaggerate any problems associated with
attrition. A comparison of the cross-sectional
estimates for the NLSYW, PSID, and NLSY
on the effect of an adolescent birth on
income/needs found that the NLSYW sisters
subsample appears to yield more representative
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coefficient estimates than the PSID and the
NLSY. Given the difficulty of accounting for
selection into adolescent childbearing across
and within populations, and within families,
the authors believe that the size of any true
effects of adolescent births on socioeconomic
status must be considered an open question. 1
table, 8 notes, 40 references.
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Reevaluating the Costs of Teenage
Childbearing.
Form: Journal article.
Author: Hoffman, S.D.; Foster, E.M.;
Furstenberg, F.F.
Source: Demography. 30(1): 1-13,
February 1993.
Abstract: To distinguish the effect of teen
childbearing from that of family background,
researchers used data from the Panel Study of
Income Dynamics (PSID) and compared
teenage mothers with their sisters. The PSID
is a national survey of American families
conducted since 1968 by the Institute for
Social Research. The sample includes 856
sisters (428 sister pairs) between ages 21-33 in
1987; for each pair, one sister had a teenage
birth and the other did not. For each woman,
researchers gathered information on (1) age at
first birth, (2) educational attainment, (3)
marital and fertility history, (4) family income,
and (5) receipt of Aid to Families With
Dependent Children (AFDC). The sample
appears to be nationally representative; the
age, race, marital status, education, and
fertility distributions of the sisters correspond
closely to Census Bureau estimates. The
statistical technique used was a fixed-effects
model. Analysis showed that accounting for
unobserved family background reduces, but
does not eliminate, the estimated consequences
of early childbearing; statistically significant
and quantitatively important effects of teenage
parenthood remain for high school graduation,
family size, and economic well-being. Results
showed that postponement of first birth until at
least age 20 would result in (1) a high school
graduation level of 71.6 percent (vice 54
percent for teen mothers), (2) a college
graduation level of 25.9 percent (vice 13.6
percent for teen mothers), (3) a poverty level
of 15.6 percent (vice 28.4 percent for teen
mothers), (4) 57.9 percent in the middle class
(vice 22.1 percent for teen mothers), (5) 16.6
percent receiving AFDC (vice 27.9 percent for
teen mothers), (6) 61.9 percent married at first
birth (vice 50.6 percent for teen mothers), (7)
81 percent ever married (vice 74.6 percent for
teen mothers), and (8) family size of 1.61
children (vice 2.05 for teen mothers).
Postponing childbirth from age 18 to age 22
results in a 25 percent increase in the income-
needs ratio. The weight of the empirical
evidence suggests that the effects of teen
parenthood are smaller than has often been
assumed but may still be sizable. 4 tables, 19
references.
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Reevaluating the Costs of Teenage
Childbearing: Response to Geronimus and
Korenman.
Form: Journal article.
Author: Hoffman, S.D.; Foster, E.M.;
Furstenberg, F.F.
Source: Demography. 30(2):29 1-296,
May 1993.
Abstract: In response to a commentary,
researchers assert that early childbearing is
harmful to already disadvantaged women and
that educational attainment and economic well-
being are reduced by an adolescent birth, even
after controlling for effects of family
background. In research on adolescent
childbearing and its effects on socioeconomic
status, Geronimus and Korenman estimated
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fixed-effect models in which they compared
socioeconomic outcomes for sisters who had
first births at different ages. Using data from
the National Longitudinal Survey of Young
Women (NLSYW), Geronimus and Korenman
reported that the effects of early childbearing
were smaller than previous estimates and
statistically insignificant for a range of
outcomes, including economic status and
probability of high school graduation.
Hoffman, et al. replicated Geronimus and
Korenman's NLSYW analyses using a similar
methodology applied to three major data sets
and four samples, including a nationally
represented sample of young women from the
Panel Study of Income Dynamics (PSID) and
from the National Longitudinal Study of Youth
(NLSY). All replications show statistically
significant and negative effects of adolescent
childbearing on economic status and on the
probabilities of being officially poor and of not
graduating from high school. The effect on
the probability of acquiring some
postsecondary education is consistently
negative, but not always statistically
significant. Hoffman, et al. identified several
reasons why the NLSYW results might differ
from the others: (1) The NLSYW sisters
sample might be unrepresentative because of
selective inclusion of older women; (2) a
smaller sample of sisters was obtained in the
NLSYW than the PSID, 456 versus 210; and
(3) women between 20 and 24 years of age at
the baseline were underrepresented in the
NLSYW sisters sample, relative to the full
NLSYW sample and the Census data.
Geronimus and Korenman argue that the
effects of adolescent childbearing diminish
over time and as the adolescent mothers move
from early to later adulthood, they may catch
up with the later childbearers. Hoffman, et al.
assert that (1) the smaller estimated effect of
an adolescent birth on economic status in the
NLSYW could be evidence of a life-cycle
effect; and (2) the estimated effects of
adolescent birth increase with the inclusion of
additional years of data as indicated in 56
sister pairs, one who had an adolescent birth
and one who had not. Out of the 56 childless
sisters, 85 percent had graduated from high
school and 32 percent had postsecondary
schooling as compared to 64 percent and 23
percent, respectively for the adolescent birth
sister. Geronimus and Korenman argue that
NLSYW is the preferred sample because it is
the only sample in which the cross-sectional
estimate of the effect of an adolescent birth on
economic status is the same for the subsample
of women with sisters and for the full sample
of all women. Hoffman, et al. suggest further
study on whether the effects of adolescent birth
differ for women with or without sisters.
Hoffman, et al. also assert that since
Geronimus and Korenman offer no explanation
for their sample and why it appears only in the
NLSYW, the sample is simply used as a
convenient, albeit unorthodox, way to support
their findings. Hoffman, et al. suggest that it
is premature to conclude that the effects of
adolescent childbearing on creation and
perpetuation of social disadvantage are small.
1 table, 9 notes, 11 references.
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Process, Costs, and Outcomes of
Community-Based Prenatal Care for
Adolescents.
Form: Journal article.
Author: Kay, B.J.; Share, D.A.; Jones, K.;
Smith, M.; Garcia, D.; Yeo, S.A.
Source: Medical Care. 29(6):53 1-542,
June 1991.
Abstract: From January 1981 through June
1988, researchers compared differences in care
provided by a community-based prenatal care
program designed specifically for adolescents
relative to traditional prenatal care (not
adolescent-focused) delivered at a university
medical center. Researchers evaluated the
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resulting costs and pregnancy outcomes of the
two programs in terms of (1) average number
of prenatal visits per client, (2) percentage of
clients beginning prenatal care during the first
trimester of pregnancy, (3) percentage of
clients with full-term births, (4) percentage of
clients with low-birthweight births, (5)
percentage of clients with maternal
complications, (6) percentage of clients' infants
needing neonatal intensive care, (7) value of
resources consumed in delivering prenatal
care, and (8) differences in postpartum
pregnancy rates and use of contraceptives.
Researchers compared 180 adolescent clients
of The Young Adults' Health Center in
Ypsilanti, Michigan, (study group) with a
sample of adolescent clients of the University
of Michigan Women's Hospital (control
group). The samples were matched for age
and year of delivery. There were no
significant medical or socioeconomic
differences between the two samples, except
that study group clients were significantly
more likely to be without insurance coverage.
The teen-focused program provided health
services and peer education stressing
pregnancy prevention and comprehensive
primary health care. Four indexes described
(1) the clients' medical history, (2) medical
factors that put them at risk during the
pregnancy, (3) pregnancy outcome
complications, and (4) complications to the
newborn. The programs were significantly
different as measured by the mean number of
(1) prenatal visits, (2) nonscheduled outpatient
visits, (3) nonstress tests, (4) ultrasounds, and
(5) inpatient days during pregnancy. There
were no statistically significant differences in
(1) gestational age, (2) birthweight, (3)
percentage of infants needing neonatal
intensive care, and (4) percentage of clients
with maternal complications. The average cost
of resources consumed during prenatal care for
the study group was 41 percent that of the
control group. Compared with the control
sample, study group clients were significantly
more likely to have ceased smoking during
pregnancy and to use contraceptives and
significantly less likely to become pregnant
again after delivery. 5 tables, 14 references.
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Teenage Pregnancy and Parenthood in
Illinois: Estimated 1979-1983 Costs.
Form: Journal article.
Author: Reis, J.
Source: Journal of Adolescent Health Care.
8(2): 177-187, March 1987.
Abstract: A researcher estimates the 1979-
1983 public and private costs of teenage
pregnancy and teenage parenthood in Illinois.
The analyses include estimates of (1) the cost
associated with the care of the 1983 cohort of
44,000 pregnant Illinois adolescents; (2) the
costs of care for approximately 100,000
adolescents giving birth between 1979 and
1983; (3) the costs of resources consumed by
these mothers and their children for the first 5
years of the child's life; (4) the financial
contribution of individuals and business; and
(5) federal, state, county, and municipal taxes
for the care rendered. Data came from public
records, national and local surveys, and
knowledgeable professionals. The unit costs
per person for 32 categories of service were
adjusted according to whether the service was
1 time (e.g., birth) or ongoing (e.g., nursing
home care). The unit costs were weighted
according to the number of individuals
involved and the duration of services provided.
The total base costs ($784 million), a 21
percent federal income tax penalty which is
applied to those services receiving full or
partial federal government support based on
the sources of revenue ($39 million), and
medical costs shifting to business ($29 million)
were calculated. Estimates of the total cost of
services consumed were apportioned according
to corporate, state, federal, municipal, and
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private individuals as sources of revenue. An
additional amount was added to the estimated
costs through an 18 percent cost-shifting
penalty and was applied to the proportion of
services paid for by corporations. As of 1983,
Illinois businesses and citizens paid $848
million for services rendered to the 5-year
cohort of 94,000 teenage mothers and their
137,483 children. This sum includes $152
million annually for business and $696
annually for individuals. Each Illinois
household paid an average of $84 out of
pocket, $81 dollars in higher state and federal
taxes, and $37 in higher prices due to business
pass-through, for a total of $202 per year per
household. The $152 million paid by business
subdivided into annual fees of $42 million for
employee medical costs related to teenage
pregnancy, $28 million in medical cost
shifting, and $82 million in higher state and
federal taxes. The ratio of the costs of curative
and support services for pregnant and
parenting teens relative to services to prevent
pregnancy in sexually active teenagers is
$808,304 million for curative/support services
to $39,600 million for prevention. Three











Source: Statistical Bulletin Metropolitan
Insurance Company. 69(3): 18-25,
July-September 1988.
Abstract: Cesarean birth rates climbed to an
all-time high in the United States in 1986 at
24.1 per 100 deliveries. Metropolitan Life
Insurance Company statisticians studied the
costs associated with a Cesarean childbirth in
1986 and compared them to charges for a 1.5
year period (1982-1983). For both
Metropolitan Life and other insurance carriers,
Cesarean rates were highest in the South and
lowest in the Midwest. Average charges for a
C-section in 1986 totaled $5,270, with the
Pacific region having the highest costs
($6,600). The Middle and South Atlantic
regions were the only other areas to exceed the
national average; the lowest was in the East
South Central region of the United States (less
than $5,000). The Pacific and Middle Atlantic
areas had the highest average charges in both
study periods. In the East North Central
region, the average charge changed from 7
percent above the national average to 3 percent
below it. The District of Columbia and
Nevada led in total costs, with C-section
charges at 33 percent above the national total.
The lowest average C-section charge was
$3,680 in Montana for 13 cases (30 percent
below the national average). Other states with
lower charges included North Carolina, South
Dakota, Virginia, Minnesota, Maine,
Wyoming, Iowa, and South Carolina.
Hospital costs for room, board, and ancillary
fees averaged $3,240 in 1986. Physician fees
averaged $2,030 and varied extensively
between regions and states. Total charges for
a C-section in 1986 were 28 percent higher
than those in 1982-1983 ($5,270 versus
$4,130). Physician charges increased the most
(by 59.8 percent), rising from $1,270 to
$2,030. Room and board charges decreased
by 4.3 percent across the country but with
large fluctuations among different states.
More public health education is needed to
reduce the rate of cost increase for C-sections.
2 figures, 3 tables, 15 references.
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Source: Statistical Bulletin Metropolitan
Insurance Company. 67(3):2-10,
July-September 1986.
Abstract: The highest proportions of
Cesarean (C) section deliveries are reported in
the Northeastern and Southern regions of the
United States, according to a study by the
Metropolitan Life Insurance Company. The
lowest were in the West and Midwest. Many
researchers believe that the differences are not
due to geographic differences in the
distribution of high-risk populations. The
study was based on 8,636 C-sections paid for
by the insurance company in a 1.5-year period
in 1982-1983. The lowest total charge
occurred in the South ($3,780), the area that
contributed the largest proportion of cases and
reported the second shortest length of hospital
stay. The highest was in the West ($4,550).
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The average total charge in 1982-1983 for a
Cesarean birth was $4,130. The highest
average charge for C-section delivery was in
the company's Pacific division, at close to
$5,000. The Middle Atlantic division had the
second highest charges, at close to $4,960.
The East North Central division average was 7
percent above the national average. Total
charges for a Cesarean birth differed by as
much as 182 percent among states. The
District of Columbia led in charges, 30 percent
above the national average, followed by
California, Illinois, and New York ($5,300,
$5,300, and $5,290, respectively). The lowest
total charge was in Utah ($2,940, or 29
percent below the national average). Other
states with low charges included Kentucky,
Mississippi, and Iowa. Ancillary charges
averaged three-fifths of the total hospital bill
.
Physician charges varied extensively, both
among geographic areas and individual states,
with the average physician charge for a C-
section of $1,270. California and New York
had the highest physician charges ($1,890 and
$1,780). 2 figures, 1 table, 9 references.
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Hospital Utilization and Mortality Levels for
Patients in the Arizona Health Care Cost
Containment System.
Form: Journal article.
Author: Burns, L.R.; Wholey, D.R.;
Abeln, M.O.
Source: Inquiry. 30(2): 142-156,
Summer 1993.
Abstract: Researchers examine the experience
of Arizona's experimental Medicaid program,
the Arizona Health Care Cost Containment
System (AHCCCS), in achieving hospital
utilization levels and morbidity outcomes
comparable to those patients with private
insurance. They evaluated severity-of-illness
at hospitalization, hospital utilization (total
charges, length of stay, charges per day), and
inpatient mortality for AHCCCS beneficiaries
compared to privately insured patients. The
subjects included 121,874 discharges of
patients with 1 1 different conditions from
nonfederal general hospitals in Arizona during




repair/replacement, and large bowel resection),
three pediatric diagnoses (pediatric pneumonia,
bronchitis/asthma, and esophagitis/digestive
disorders), and two maternity diagnoses
(cesarean section and vaginal delivery).
Patient characteristics and outcomes for 11
selected conditions, which included number of
discharges, number of mortalities, mortality
rate, length of stay (mean and standard
deviation), and hospital charges (mean and
standard deviation), respectively were (1)
3,915, 99, 0.025, 5.40 (3.5) days, $6,192 and
$4,970 for pneumonia; (2) 979, 39, 0.040,
8.64 (8.09) days, $21,629 and 23,016 for
aorta repair/replacement; (3) 3,415, 135,
0.039, 6.08 (3.65) days, $10,792 and $7,345
for myocardial infarction; (4) 2,847, 64,
0.022, 11.04 (10.29) days, $18,893 and
$27,039 for large bowel resection; (5) 2,319,
45, 0.019, 4.15 (7.70) days, $5,163 and
$5,581 for gastrointestinal bleeding; (6) 1,960,
69, 0.035, 4.79 (5.15) days, $5,391 and
$6,901 for dehydration; (7) 3,389, mortality
not available, 3.79 (2.76) days, $3,930 and
$4,040 for pediatric pneumonia; (8) 6,749,
mortality not available, 2.94 (4.24) days,
$3,283 and $3,122 for bronchitis/asthma; (9)
3,485, mortality not available, 2.62 (2.79)
days, $2,169 and $2,883 for esophagitis/
digestive disorders; (10) 20,456, mortality not
available, 4.11 (3.92) days, $5,140 and $3,338
for cesarean section; and (11) 72,360,
mortality not available, 1.64 (1.65) days,
$2,027 and $1,490 for vaginal delivery. After
controlling for severity of illness and the
specific hospital used, as well as several
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patient, hospital, and physician factors,
regression analysis and the Acuity Index
Method (AIM) suggested that the AHCCCS
program achieved comparability with private
health insurance in hospital charges, length of
stay, charges per day, mortality, and inpatient
care. There was less comparability between
AHCCCS and private insurance for patients
with maternity diagnoses. AHCCCS women
undergoing vaginal delivery experience
significantly lower hospital charges and shorter
hospital stay. AHCCCS patients undergoing
cesarean section experienced significantly
higher charges and longer stays.
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Source: Drug Intelligence and Clinical
Pharmacy. 20(7-8): 592-593,
July-August 1986.
Abstract: To compare the respective
efficacies of piperacillin and cefoxitin in
preventing postoperative infection associated
with cesarean section and the cost of failure
associated with each regimen, researchers
randomly assigned 263 patients at the
University of California Los Angeles (UCLA)
Medical Center to receive either piperacillin or
cefoxitin for prophylaxis in cesarean section.
Piperacillin is an extended-spectrum penicillin
and cefoxitin is a second-generation
cephalosporin; both were selected because of
their known in vitro and in vivo activities
against common obstetric pathogens. The two
study groups did not differ significantly for
number of patients, mean age, mean weight,
duration of surgery, or duration of
postoperative hospitalization. Criteria used to
evaluate the efficacy of the regimens included
(1) febrile morbidity, (2) duration of
hospitalization, (3) administration of systemic
antibiotics postoperatively, and (4) wound
healing and evidence of infection at the
operative site. A satisfactory prophylactic
response was defined as no bacterial or clinical
infection at the operative site for 4-6 weeks
postoperatively. Although both drugs were
considered effective, piperacillin achieved a
level of 98 percent satisfactory prophylaxis
compared with only 91 percent for cefoxitin.
To determine whether piperacillin's clinical
excellence is associated with cost savings,
researchers calculated the total costs of
prophylactic failure in cesarean section;
compared the average failure rates associated
with ampicillin (23 percent), cephalothin (18
percent), cefoxitin (9 percent), and piperacillin
(2-3 percent) based on 100 patients. Total
costs of prophylactic failure were calculated
based on 100 patients: Ampicillin, $140,833;
cephalothin, $91,848; cefoxitin, $79,074; and
piperacillin, $26,358. Because of its high
failure rate, ampicillin was the most expensive
antibiotic and piperacillin was the least
expensive. 14 references.
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Effect of Health Coverage for Uninsured
Pregnant Women on Maternal Health and
the Use of Cesarean Section.
Form: Journal article.
Author: Haas, J.S.; Udvarhelyi, S.;
Epstein, A.M.
Source: Journal of the American Medical
Association. 270(l):61-64, July 7, 1993.
Abstract: Researchers examine the effect of
health coverage for uninsured, low-income
pregnant women on maternal health and the
use of cesarean section. Researchers
hypothesized that the Healthy Start program
would be associated with an increase in the use
of cesarean section for uninsured women
relative to women with insurance. The
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Healthy Start program was funded by the state
of Massachusetts to provide health insurance to
uninsured low-income women (including
women with incomes below 185 percent of the
federal poverty level) who are not eligible for
Medicaid. The program covered prenatal
visits, in-hospital care, laboratory, and
pharmacy services. To avoid selection bias,
researchers assessed the change in maternal
outcomes and rates of cesarean section for all
uninsured women in 1984, and for all women
who were uninsured or covered by Healthy
Start in 1987. The uninsured mothers were
compared to two concurrent control groups,
those with private insurance and Medicaid
beneficiaries. Researchers focused on adverse
maternal conditions that fit three criteria: (1)
Clinical face validity, (2) data sensitivity
(diagnoses that would be noted at the time of
delivery in a discharge abstract), and (3)
importance (cause of morbidity). Subjects
were all in-hospital, single-gestation births:
57,257 in 1984, and 64,346 in 1987.
Researchers used a logistic regression to
compare rates of adverse maternal outcome
and cesarean section, to calculate the
difference in rates between the uninsured and
each concurrent control, to examine the
interpayer differences in rates between 1984
and 1987, and to measure the effects of
Healthy Start. Compared with women who
received inadequate prenatal care, women who
received satisfactory prenatal care were less
likely to have severe pregnancy-induced
hypertension, placental abruption, and a
hospital stay greater than their infants. In
1984, uninsured women had higher rates of
adverse maternal outcome than privately
insured women (5.5 percent and 5.1 percent,
respectively; interpayer difference 0.4 percent)
and received fewer cesarean sections (17.2
percent and 23.0 percent; interpayer difference
5.8 percent). Between 1984 and 1987, there
was no statistically significant change in the
interpayer difference in adverse outcome
relative to women with private insurance.
However, the interpayer difference in cesarean
sections between the uninsured and the
privately insured was reduced by 2.3 percent,
although the uninsured continued to undergo
fewer cesarean sections (22.4 percent and 25.9
percent). Similar results were observed when
the uninsured women were compared with
women with Medicaid. Findings suggest that
the provision of health insurance alone to low-
income pregnant women may not be associated
with an improvement in maternal health.
Expanded coverage was associated, however,
with an increase in the rate of cesarean
section. 2 tables, 24 references.
240
Acute Childbirth Morbidity: Its
Measurement Using Hospital Charges.
Form: Journal article.
Author: Hage, M.L.; Helms, M.J.;
Dudley, A.; Stead, W.W.; Hammond, W.E.;
Neyland, C; Hammond, C.B.
Source: American Journal of Obstetrics and
Gynecology. 166(6, Part 1): 1853-1862,
June 1992.
Abstract: Researchers at Duke University
Medical Center in North Carolina performed
an analytic descriptive analysis of acute
childbirth morbidity, comparing patients
delivered by primary cesarean section with
those delivered vaginally. Investigators
combined all primary cesarean deliveries and
vaginal deliveries from July 1, 1981-June 30,
1986 with maternal and infant charge data,
analyzing 7,256 patients. Investigators
performed a description of the charges for the
associated diagnoses and used a morbidity
index to identify differences in predicted
median hospital charges with 95 percent
confidence intervals. Results showed that the
ratio of mean primary cesarean delivery to
mean vaginal delivery total charges was 2.5:1.
The magnitude of the mean hospital charges
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was inversely related to the frequency of the
indication, with the lowest charges associated
with dystocia and the highest with multiple
pregnancy. Antepartum risk factors (increased
maternal age, patient referral) were associated
with increases in maternal and infant morbidity
as measured by the morbidity index. Chronic
maternal hypertension resulted in decreased
maternal morbidity but increased infant
morbidity when primary cesarean delivery was
used. Although preterm delivery was
associated with large increases in charges, it
was not significantly altered by using primary
cesarean delivery. Risk factors associated with
management of abnormalities of labor were
associated with decreases in maternal and
infant morbidity when primary cesarean
delivery was used. Analysis of acute
childbirth morbidity, as measured by hospital
charges, showed marked variation of diagnosis
and risk-specific charges for patients delivered
by primary cesarean section. Specific dollar
figures were not stated for hospital charges. 5
figures, 2 tables, 19 references.
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Patient Costs in the Prevention and
Treatment of Post-cesarean Section
Infection.
Form: Journal article.
Author: lams, J.D.; Chawla, A.
Source: American Journal of Obstetrics and
Gynecology. 149(4): 363-366, June 15, 1984.
Abstract: Researchers compared the cost to
the patient of commonly used therapeutic and
prophylactic agents in a theoretical model
population of 450 women who were delivered
by cesarean section. Assumptions included a
35 percent incidence of postcesarean febrile
morbidity, with a reduction to 20 percent if all
women who underwent cesarean section
delivery received antimicrobial prophylaxis,
and hospitalization of 6 days postpartum in the
absence of febrile morbidity. One
prophylactic and four therapeutic regimens
were compared: (1) Cefazolin intravenous
prophylaxis, (2) ampicillin and gentamicin, (3)
clindamycin and gentamicin, (4) cefoxitin, and
(5) moxalactan. Daily bed charges were $155;
the minimum additional cost to the patient for
use of gentamicin was $132.90. Treatment
assumptions and costs used in the ampicillin
and gentamicin calculation included (1) 80
percent of patients would respond; (2) 15
percent would require additional clindamycin;
(3) 5 percent would require 10 days (as
opposed to the standard 6) of ampicillin and
gentamicin, additional clindamycin, and
additional heparin; and (4) a test for blood
urea nitrogen and a urinalysis. Treatment
assumptions and costs used in the clindamycin
and gentamicin calculation included (1) 90
percent of patients would respond; (2) 5
percent would require additional ampicillin; (3)
5 percent would require 7 days (as opposed to
the standard 6) of clindamycin and gentamicin,
additional ampicillin, and additional heparin;
and (4) a test for blood urea nitrogen and a
urinalysis. Treatment assumptions and costs
used in the cefoxitin calculation included (1)
90 percent of patients would respond; (2) 5
percent would require additional clindamycin;
and (3) 5 percent would require additional
clindamycin, ampicillin, and heparin.
Moxalactum and cefazolin intravenous
prophylaxis had no special assumptions. A
summary of costs to patients of each treatment
plan (i.e., bed charges, drug costs, laboratory
tests, and pharmacology consultation costs)
gives the cost per patient versus the average
cost of infection: Ampicillin/gentamicin,
$1,243 versus $881; clindamycin/gentamicin,
$1236 versus $859; cefoxitin, $1,109 versus
$503; moxalactan, $1,194 versus $743. For
cefazolin intravenous prophylaxis, all
infections treated with ampicillin and
gentamicin cost $1,135; all infections treated
with cefoxitin, $1,059. Cost of the drug alone
on a per gram, per dose, or per day of therapy
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basis was not an accurate way to estimate the
cost eventually paid by the patient. The
therapeutic efficacy, frequency of
administration, and need for ancillary services
for each treatment regimen significantly affect
the patient's costs. Researchers conclude that
(1) antibiotic prophylaxis is clearly cost-
effective for patients who are at increased risk
of postcesarean section infection and may even
be so for all women who have cesareans; (2)
the least expensive drugs do not necessarily
result in the lowest cost for the patient; and (3)
the high cost of peripartum infectious
morbidity should prompt renewed attention to
antepartum and intrapartum nonpharmacologic
methods of preventing infection in these
patients. 2 tables, 9 references.
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Economic Incentives in the Choice Between
Vaginal Delivery and Cesarean Section.
Form: Journal article.
Author: Keeler, E.B.; Brodie, M.
Source: Milbank Quarterly.
7 1(3): 365-404, 1993.
Abstract: Within the context of an economic
model of obstetric decision making,
researchers discuss the prevalence and the
effects of economic incentives in the choice
between vaginal delivery and cesarean section.
A 1989 U.S. survey found that the average
charge for a cesarean section was $2,850
greater than the average for a vaginal delivery
(Health Insurance Association of America,
1989). Although most of the price difference
can be traced to the 2 to 3 extra days of
inpatient care, the average physician fee for a
cesarean section was more than $500 greater
than the fee for a vaginal delivery. Ignoring
financial costs, a cesarean section is best if the
price in terms of morbidity and risk to mother
of the operation is less than the discomfort and
risks to the mother and child of a prolonged
vaginal delivery. Economic incentives and
choices exist among physicians, hospitals,
health maintenance organizations (HMO's),
insurers, and expectant mothers. The rise in
malpractice premiums has contributed to the
shift to more cesarean sections. There are also
opportunity costs of waiting for labor to
progress depending on the expected length of
labor and on physicians' ability to structure
their practice to make efficient use of that
time. The 1992 direct cost estimates in the
U.S. were $809 for the package of prenatal
and postnatal care and vaginal delivery, and
$1,066 for the total cesarean package. The
1989 survey by the Health Insurance
Association of America showed that physician
charges for cesarean section in 1989 were
$2,053 compared with $1,492 for vaginal
delivery. In 1986, average Medicaid
reimbursement for vaginal delivery was $554,
and for cesarean section was $767. The
percentage markup for cesarean section is
similar to private insurance. Private insurance
pays physicians the highest fees and has the
highest rates of cesarean sections. Cesarean
section rates in HMO's are comparable to
private insurance rates; however, salaried
HMO physicians have no financial incentive to
manage deliveries. Self pay and indigent
mothers have the lowest rates of cesarean
section. The effects of competition on
obstetricians include (1) a low fertility rate as
the baby boomers near the end of their
childbearing years, (2) an increase in the
supply of obstetricians per population, (3) a
homogenous package-type pricing structure,
(4) growing interest in natural births, and (5)
increased use of HMO's. The treatment
decision may be affected indirectly by
incentives to use tests and procedures that are
complementary to cesarean section, e.g.,
electronic fetal monitoring. Hospital
incentives are similar to those of obstetricians
since they also profit more from cesarean
sections and they have to balance immediate
gains against reputation. Obstetric services are
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expensive because of the unpredictable nature
of labor and economies of scale. The cost per
day of obstetrics cases exceeded the average
by $275 to $600 in the New York City area
because obstetric cases used nursing staff and
the delivery or operating room heavily and the
lengths of stay were short. Hospital charges
for C-section averaged $5,133 in contrast to
$2,842 for vaginal delivery. When physician
fees of $1,492 for vaginal delivery and $2,053
for cesarean were added, the cesarean section
total of $7,196 was 66 percent more expensive
than the vaginal delivery total of $4,334.
HMO's and managed care insurance plans
have incentives to minimize the cost of
services, but they must provide adequate care
to preserve their reputation. Obstetrician-
midwife teams save money inside and outside
of the HMO setting. Telephone surveys and
cost analysis in an HMO revealed that (1)
maternity patients accepted midwife care
despite little prior knowledge of midwives; (2)
the midwife reduced inpatient costs, but not
costs associated with prenatal care; (3) use of a
midwife did not affect perinatal outcomes; and
(4) physicians and midwives can work together
as teams. Mothers' incentives include
financial costs and preferences for care. In a
1989 insurance survey, one-third of the people
with work-related group insurance were in an
HMO or preferred provider organization and
two-thirds had conventional insurance. The
median out-of-pocket limit was $1,000; only
20 percent with a limit greater than $2,000
would be likely to pay 20 percent coinsurance
on the full $3,000 of difference. Because of
limited resources to pay for the care of
mothers who are on Medicaid or who are
uninsured, mothers, physicians, and hospitals
all have incentives to keep costs down.
Consequently, the cesarean rates of the
indigent or those on Medicaid are low. In the
United States and abroad, most studies have
found a correlation between income and
cesarean rates. The authors suggest that, to
make more informed decisions and have better
management of childbirth and insurance
reform, everyone needs better estimates for the
true health, satisfaction, and financial costs of
labor and postpartum morbidity following
vaginal delivery and cesarean section.
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Reducing the Incidence of Infection After
Caesarean Section: Implications of
Prophylaxis With Antibiotics for Hospital
Resources.
Form: Journal article.
Author: Mugford, M.; Kingston, J.;
Chalmers, I.
Source: British Medical Journal.
299(6706): 1003-1006, October 21, 1989.
Abstract: Researchers sought to estimate the
cost effectiveness of routinely giving
prophylactic antibiotics to reduce the incidence
of wound infection after cesarean section.
They based estimation of cost effectiveness on
a retrospective overview of 58 controlled trials
and on evidence about costs derived from data
and observations of practice. Trials included
in the overview were from obstetric units in
several different countries, including England.
Other participating countries were not named
in the source document. The costing study
was based on data from the John Radcliffe
Maternity Hospital, Oxford, England. A total
of 7,777 women were included in the 58
controlled trials comparing the effects of
giving prophylactic antibiotics routinely at
cesarean section with either treatment with a
placebo or no treatment. Cost estimates were
based on data on 486 women who had
cesarean sections between January and
September 1987. Researchers found that the
chance of wound infection is likely to be
reduced by about 50-70 percent by giving
antibiotics routinely at cesarean section.
Forty-one women who had cesareans were
coded by the Oxford obstetric data system as
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having developed wound infection (8.4
percent). The additional average cost of
hospital postnatal care for women with wound
infection (compared with those who had
cesareans but no infection) was estimated at
716 pounds; introducing routine prophylaxis
with antibiotics would reduce average costs of
postnatal care by between 1,300 pounds and
3,900 pounds per 100 cesareans (at 1988
prices), depending on the cost of the antibiotic
and its effectiveness. Results suggest that
giving antibiotics routinely at cesarean section
will not only reduce rates of infection after
cesarean but also reduce costs. 3 tables, 17
references.
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Cesarean Delivery for Women Presenting
With Genital Herpes Lesions: Efficacy,
Risks, and Costs.
Form: Journal article.
Author: Randolph, A.G.; Washington, A.E.;
Prober, C.G.
Source: Journal of the American Medical
Association. 270(l):77-82, July 7, 1993.
Abstract: Researchers assessed the effect of
cesarean delivery on neonatal and maternal
morbidity and mortality and their associated
costs for two populations of women with
genital herpes simplex virus (HSV) and
recurrent HSV type 2 (HSV-2) lesions at
delivery: (1) Those with a history of genital
herpes, and (2) those without a history of
genital herpes. Researchers created a model of
maternal-to-neonatal transmission using
decision analysis concepts, varying the
preventive efficacy of cesarean delivery, and
establishing ranges and probabilities from
medical literature. In comparison with a
baseline nonintervention strategy of standard
delivery for all women in the cohort,
investigators examined (1) the number of
cesarean deliveries performed solely because
of the presence of active genital herpetic
lesions, and (2) the number of neonatal
infections resulting after cesarean delivery for
all women in each population. Estimations of
lesions and viral shedding at delivery were
derived from measuring (1) the prevalence of
genital HSV-2 in pregnant women, (2) the
incidence of HSV-2 infection in pregnant
women, (3) lesions at delivery, and (4)
shedding of HSV at delivery. Researchers
used a 20 percent seroprevalence rate of HSV-
2 antibodies to estimate the prevalence of HSV
genital infections for 1 million women
delivering annually and 75 percent for
asymptomatic infection, and 25 percent for
symptomatic infection. Researchers estimated
(1) a baseline rate of 0.07 percent for rate of
acquisition of HSV-2 in pregnant women
(range of 0.045 to 0.1 percent); (2) that
approximately 70 percent of women with
primary symptomatic outbreaks in the last 28
days of delivery would still have lesions
present at delivery without antibodies; (3) that
of women with first-episode nonprimary
infections, 44 percent would excrete virus
from a lesion at delivery; and (4) that of
women with first-episode primary infection, 60
percent of women would excrete virus from a
lesion at delivery. Researchers estimated
maternal and neonatal outcomes through
examining (1) transmission rates from mother
to neonate, baseline 50 percent and range 20 to
80 percent; (2) neonatal HSV infection, 43.8
percent; (3) rate of cesarean delivery, baseline
15 percent; (4) morbidity from cesarean
delivery, 28.5 percent; (5) mortality from
cesarean delivery, .015 percent; and (6) the
efficacy of cesarean delivery in preventing
neonatal HSV infections, 80 percent.
Researchers used the Binkin and Koplan
method to analyze the costs and benefits
between cesarean and vaginal deliveries. The
difference in cost, including complications, is
$3,725, per patient adjusted using the
Consumer Price Index for Medical Care. The
extra cost for hospital care was estimated at
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$25,000 per neonatal herpes infected patient.
The estimated lifetime cost of long-term care
for a severely disabled child requiring
institutionalization is $250,000 and $125,000
for a moderately disabled child requiring home
assistance. Long-term costs were discounted
at a rate of 4 percent per year. The cost-
utility ratio was used to determine quality-
adjusted life-years (QALY) discounted at 4
percent per year. In women with a history of
recurrent genital HSV, cesarean delivery
prevents 9 neonatal infections per 1 million
births at a cost of 5,979 excess cesarean
deliveries and one maternal death. The total
cost of cesarean delivery as a strategy to
prevent neonatal HSV transmission from
women with recurrent genital HSV lesions at
delivery is more than $2.5 million per case of
neonatal HSV averted, with a cost of $203,000
per QALY gained. The cost per case of
neonatal HSV averted for women with genital
HSV lesions at delivery who have no history
of genital HSV is a saving of $38,000 with a
saving of $2,600 per QALY gained. Since
cesarean delivery for women with no history
of genital herpes simplex virus who have
lesions at delivery has low maternal costs per
neonatal benefit and saves money, women who
present with their first clinical episode of
genital herpes at delivery should have a
cesarean section performed. However, the
current practice of genital herpes at delivery
for women with a history of genital herpes
lesions that recur at delivery results in high
maternal morbidity and mortality at substantial
financial expense, underscoring the urgency of
examining alternative management strategies.
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Preterm Premature Rupture of Membranes:
A Randomized Study of Home Versus
Hospital Management.
Form: Journal article.
Author: Carlan, S.J.; O'Brien, W.F.;
Parsons, M.T.; Lense, J.J.
Source: Obstetrics and Gynecology.
81(l):61-64, January 1993.
Abstract: Researchers compared length of
latency period, gestational age at delivery, and
safety in a carefully selected group of women
with preterm premature rupture of the
membranes (PROM) randomized to home
versus hospital management. Study subjects
were 55 women admitted to Tampa (Florida)
General Hospital between March 1989 and
March 1991 who had preterm PROM (before
37 weeks' gestation) and had not entered labor
within 72 hours after rupture. Subjects gave
informed consent to their participation and
were limited to women with (1) a singleton
gestation, (2) no clinical evidence of intra-
amniotic infection, (3) cephalic presentation,
(4) at least one vertical pocket of amniotic
fluid greater than 2 cm, (5) cervical
examination estimated at less than 4 cm
dilation by inspection, and (6) Hillsborough
County residency. After 72 hours of hospital
care, physicians randomized subjects to either
home or hospital management. The two
groups underwent nearly identical surveillance
that included staying in bed with pelvic rest
and periodic rescanning. Health professionals
recorded oral temperature and pulse every 6
hours and charted fetal movements.
Researchers collected information from weekly
nonstress tests, blood tests, ultrasound tests,
and sterile speculum examination. Data
analysis indicated there were no significant
differences in clinical characteristics, perinatal,
or neonatal outcome between the groups.
There was a significant difference in total
maternal charges, with the home management
group having lower costs. 5 tables, 14
references.
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Conservative Management of Placenta
Previa: A Cost-benefit Analysis.
Form: Journal article.
Author: D'Angelo, L.J.; Irwin, L.F.
Source: American Journal of Obstetrics and
Gynecology. 149(3): 320-326, June 1, 1984.
Abstract: Researchers compared an outpatient
expectant mode of managing placenta previa
with a more aggressive, inpatient expectant
mode over a relatively short time period within
a single institution. From July 1979 to
December 1981, researchers reviewed the
records of a community-based tertiary care
hospital for cases of placenta previa. Cases
selected for analysis were those that required
cesarean section and met strict criteria.
Researchers were able to separate patient care
into two distinct management groups. The 18
outpatient subjects had bed rest at home, office
followup, and hospitalization for significant
bleeding episodes. The 20 inpatient subjects
rested in the hospital until delivery and
received fetal monitoring, drugs, and blood
transfusions when necessary. Researchers
collected maternal data regarding age,
gravidity, obstetric gestational age at first
bleeding and at delivery, days of
hospitalization, and units of blood transfused.
Neonatal data included gestational age,
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birthweight, Apgar scores, neonatal hospital
days, and neonatal morbidity and mortality.
Data analysis indicated the aggressive inpatient
expectant protocol resulted in statistically
significant improvement in perinatal outcome
as compared with the outpatient expectant
regimen. Inpatient group infants had a mean
of nearly 2.5 weeks greater estimated neonatal
gestational age than outpatient group infants.
There were two cases of neonatal death in the
outpatient expectant group and none in the
inpatient expectant group. There were
approximately 12 fewer hospital days for
neonates in the inpatient expectant group
compared to those in the outpatient group and
12 additional hospital days for inpatient
mothers compared to outpatient mothers.
Analysis revealed that the twofold increase in
maternal hospital costs in the inpatient group is
counterbalanced by a nearly threefold increase
in neonatal care costs in the outpatient
expectant group. Overall hospital costs for
maternal-neonatal pairs were 69 percent higher
in the outpatient expectant group. 3 tables, 7
references.
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Cost Effectiveness of Stopping Preterm
Labor With Beta-Adrenergic Treatment.
Form: Journal article.
Author: Korenbrot, C.C.; Aalto, L.H.;
Laros, R.K.
Source: New England Journal of Medicine.
310(1 1):691-696, March 15, 1984.
Abstract: Researchers retrospectively
compared the costs of maternal and neonatal
medical care after beta-adrenergic drug
treatment (given to arrest preterm labor) with
expected costs associated with no gestational
delay. Preterm labor was defined as
occurrence of contractions leading to cervical
change or premature rupture of the membranes
between the 20th and 37th weeks of
pregnancy. Researchers studied a total of 41
1
patient records from one hospital. Analysis
showed that the treatment arrested labor for at
least 3 days in 61 percent of patients; gestation
was extended by approximately 14 weeks in
infants with the earliest gestational age at
treatment (20-25 weeks) and by approximately
2 weeks in those with the latest gestational age
(36-37 weeks). Researchers based costs on
hospital charges and physicians' fees,
including high-risk obstetric outpatient
charges, obstetric prenatal and delivery
inpatient charges, and pediatric inpatient
charges. Treatment provided between 26-33
weeks of gestation was clearly cost effective,
resulting in expected savings of $11,240 (1981
dollars) per birth. After 33 weeks there was
no substantial difference in expected costs with
or without treatment. Between 20-25 weeks of
gestation, expected costs per surviving infant
were $39,000 lower with treatment than
without treatment; however, the number of
mothers who were not treated at this early
stage of gestation (three patients) was too small
to permit statistical significance. When
researchers considered the improved survival
of infants after prenatal treatment, treatment
before 25 weeks was also cost effective. For
labor at 20 to 25 weeks of gestation, the mean
maternal charges for patients receiving
treatment were about $5,000 more than
charges for patients who were not receiving
tocolytic drugs. Since premature infants have
a lower rate of survival, neonatal daily charges
between infants of 20 to 25 weeks of gestation
were high ($1,220), but their mean hospital
stay was short (6 days) giving the impression
that these neonatal charges did not differ from
those of term births. Results indicate that the
increased costs of prenatal medical care were
offset by decreased costs of neonatal medical
care when treatment was given before 34
weeks of gestation. 2 figures, 5 tables, 10
references.
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Evaluation of the Cost-Effectiveness of
Home Monitoring of Uterine Contractions.
Form: Journal article.
Author: Kosasa, T.S.; Abou-Sayf, F.K.;
Li-Ma, G.; Hale, R.W.
Source: Obstetrics and Gynecology.
76(1, Supplement) :71S-75S, July 1990.
Abstract: The Hawaii Medical Services
Association, the major health insurance carrier
and Blue Shield fiscal intermediary in Hawaii,
initiated a study to determine the cost-
effectiveness of ambulatory uterine monitoring.
Maternal and neonatal costs were calculated on
79 patients who were at high risk for preterm
birth. These risk factors included preterm
labor in the current pregnancy, previous
preterm labor, previous preterm delivery,
multiple gestation, or uterine anomaly. All
subjects were placed on the Term Guard
uterine monitoring system (produced by Tokos
Medical Corporation in Santa Ana, California)
between 24 and 36 weeks' gestation. Overall
costs were calculated using actual costs for
services provided: (1) Ambulatory monitoring
costs of $60 per day, (2) maternal costs for
inpatient tocolysis of $900 per day, and (3)
neonatal intensive care unit (NICU) costs of
$1,500 per day. Regression analyses used to
calculate the cost of preterm deliveries in the
absence of monitoring were derived from 192
patients who were admitted with preterm labor
for inpatient tocolysis and who delivered
preterm infants during the period study. Cost
assumptions for the monitored group were
based on preterm delivery rates of actual
patients in the institution who had not used the
monitor. Subjects in both groups were
matched for gestational age at the occurrence
of preterm labor. Women on the home
monitor recorded uterine activity in two
separate, daily 1-hour sessions during which
they assumed their routine activities. The
uterine activity data were stored and
transmitted after the second monitoring period
to a Tokos Perinatal Nursing Center.
Detection of any increased frequency of
uterine contractions above a baseline set by the
patient's physician was followed by a call to
the physician and subsequent evaluation.
Subjects were contacted at least once a day and
were questioned about any symptoms
associated with preterm labor. At the end of
the study, 79 patients had completed 3,189
days on the monitor. Thirty-six patients (45.6
percent) did not have preterm labor. The cost
of monitoring this group ranged from $600 to
$700; the daily monitoring resulted in an
average loss to the insurance carrier of $3,300
per patient or $118,800 total. In contrast, 43
patients (54.4 percent) experienced preterm
labor and yielded a cost savings from the home
uterine monitor. Earlier detection of preterm
labor and better management of oral tocolysis
in this group resulted in earlier initiation of
maternal tocolytic therapy, which ultimately
decreased the preterm birth rate and
hospitalization days in the neonatal intensive
care unit. Cost analysis of this group
demonstrated a decrease in cost ranging from
$500 to $68,000, with an average savings of
$24,000 per patient, or an overall savings of
$1,032,000. Conservative analysis of the costs
of inpatient maternal and NICU care resulted
in an average savings per patient 7.2 times
larger than the average loss in each subject, or
a net savings of $1 1 ,500 per patient. The total
group of high-risk patients resulted in a net
savings to the insurance carrier of $913,200,
suggesting that the use of the ambulatory
uterine activity monitoring system significantly





Controlled Trial of a Preterm Labor
Detection Program: Efficacy and Costs.
Form: Journal article.
Author: Main, D.M.; Richardson, D.K.;
Hadley, C.B.; Gabbe, S.G.
Source: Obstetrics and Gynecology.
74(6):873-877, December 1989.
Abstract: Between May 1, 1983 and May 30,
1986, researchers assessed the impact of a
preterm birth prevention patient education
program on 943 indigent African American
inner-city women. Patients were women
attending the obstetric clinic of the Hospital of
the University of Pennsylvania at or before 18
weeks' gestation. A nurse specialist used the
Papiernik-Creasy scoring system to assess each
patient's risk of spontaneous preterm birth.
Researchers randomly allocated 198 high-risk
women to a Preterm Labor Detection Clinic
(PLDC) and 178 high-risk women to a high-
risk control group; 567 women with lower risk
scores served as low-risk controls. Starting at
22 weeks' gestation, women in the PLDC
program received comprehensive patient
education from a nurse specialist and a weekly
or biweekly cervical examination from a
physician. Women in both control groups
were not informed of their status, and both
groups received prenatal care in standard
obstetric clinics. Overall, women in the two
high-risk groups were comparable with respect
to age, gravidity, parity, number of previous
early and late abortions, previous preterm
births, and gestational age at first visit.
Results showed no significant differences
between the high-risk groups with respect to
mean gestational age at delivery, mean
birthweight, or percentage delivery before
term as a result of preterm labor or premature
rupture of membranes (PROM). Evaluations
of inpatient charges ($5,846 for high-risk
controls versus $5,687 for PLDC participants)
revealed no significant differences due to
participation in this program, although
outpatient clinic use and charges were
increased significantly for PLDC patients.
The cost per PLDC participant was $1,125, as
compared with $542 per high-risk control
participant. Failure of this program to reduce
preterm birth may relate to the relatively low
overall rate of women presenting in preterm
labor with advanced cervical dilation. High
rates of PROM and fetal death occurred in all
three study groups. 6 tables, 7 references.
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Cost/Health Effectiveness of Home Uterine
Activity Monitoring in a Medicaid
Population.
Form: Journal article.
Author: Morrison, J.C.; Pittman, K.P.;
Martin, R.W.; McLaughlin, B.N.
Source: Obstetrics and Gynecology.
76(1, Supplement) :76S-8 IS, July 1990.
Abstract: Researchers instituted an intensive
system of preterm birth prevention using home
uterine activity monitoring in 130 public
assistance (Medicaid) patients who were at
high risk for preterm birth. Patients were
stratified into three groups: (1) Group A
patients had not experienced preterm labor
before monitoring began and subsequently did
not develop preterm labor during the
pregnancy; (2) group B patients had no labor
before the monitoring began but subsequently
did develop an episode of early labor; and (3)
group C patients experienced preterm labor,
received effective tocolytic therapy, or began
this therapy before discharge. A retrospective
review of the subjects' pregnancy outcomes
was conducted, and these data were exposed to
a model for projected patient care cost. The
occurrence of preterm delivery for failed
tocolysis or advanced cervical dilatation was
less than 10 percent. The incidence of preterm
labor in the at-risk group was 46 percent. The
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mean prolongation from the first episode of
preterm labor was 4.9 weeks in group B and
7.4 weeks in group C. Based on a cost-
analysis model, the costs of monitoring and
actual preterm births for groups A, B, and C
were (1) $417,160; (2) $399,810; and (3)
$781,090, respectively. The projected charges
due to preterm birth that would have occurred
if monitoring had not extended the pregnancy
for groups A, B, and C totaled (1) $291,000;
(2) $824,700; and (3) $3,318,000,
respectively. This yielded a projected savings
of $2,835,640 or $21,813 per patient. 5
tables, 3 figures, 24 references.
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Cost Effectiveness of Preventing Preterm
Delivery in Twin Pregnancies.
Form: Journal article.
Author: Papiernik, E.; Keith, L.G.
Source: Acta Geneticae Medicae et
Gemellologiae. 39(3):361-369, 1990.
Abstract: As an extension of previous work
on the risk of prematurity (delivery at less than
37 weeks' gestation) in singletons and on the
social cost of twin births, researchers in
France performed an analysis of the cost
effectiveness of preventing premature delivery
in twin pregnancies, which have an increased
rate of premature births. They assessed the
cost of prevention in terms of early diagnosis
of twin pregnancies through ultrasound
screening and of an extra 1 1 weeks of work
leave to expectant mothers of twins. The
study specifically looked at very low
birthweight (VLBW) infants born at less than
31 weeks and weighing less than 1,500 grams.
Statistics show that 10.7 VLBW children (a
total of 15.3 children for all birthweights) in
every 1,000 births of twins are handicapped.
Researchers obtained data from 321 twin
deliveries (excluding fetuses less than 500
grams) followed at Hopital Antoine Beclere,
Clamart, France, between 1982-1988. Costs
estimated included (1) the cost for a single
screening ultrasound of each pregnant woman
between 10-20 weeks gestation; (2) work leave
if all expectant mothers of twins were
employed, by week of work leave beginning at
gestation week 24; (3) the cost per neonatal
intensive care unit (NICU) hospital day; and
(4) approximation of the long-term costs for
each handicapped child. One scan in France
cost 300 francs (F) ($50); mean compensation
for 1 week of work leave was about 2,000 F
($333); mean cost for a NICU day was about
6,000 F ($1,000); and the monetary value of
lifelong support of a handicapped person was
estimated at about 7,000,000 F ($1,100,000).
When researchers compared the cost of
prevention and additional work leave to the
social cost involved in the transfer of
newborns to NICU's and in supporting
handicapped children, they concluded that the
total cost of prevention (26,000,000 F or
$4,300,000) corresponds to one-third of the
long-term costs associated with lack of
prevention (78,000,000 F or $12,400,000). 7
tables, 16 references.
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Prolonged Use of Tocolytic Agents in the
Expectant Management of Placenta Previa.
Form: Journal article.
Author: Tomich, P.G.
Source: Journal of Reproductive Medicine.
30(10):745-748, October 1985.
Abstract: Researchers studied the effects of
the prolonged use (greater than 7 days) of
tocolytic agents, along with other established
procedures of conservative, expectant
management, in women with either total or
marginal-partial placenta previa. From
January 1979-December 1983, 45 patients at
the Loyola University Perinatal Center
(Illinois) fulfilled study criteria: (1) The
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placenta previa was present at the time of
delivery; (2) the sole indication for cesarian
section was the presence of the placenta previa
with a mature infant, excessive bleeding, or
other placenta previa complications; (3)
patients were hemodynamically stable on
admission; (4) vaginal bleeding on admission
was less than 50 ml/hr; and (5) the estimated
gestational age at admission was less than 37
weeks. Researchers used two regimens of
tocolytic agents during the study period. From
January 1979-December 1981, researchers
administered isoxsuprine until delivery.
Starting in January 1981, researchers
administered ritodrine until delivery.
Prolonged use of the tocolytic agents, along
with expectant management, extended the
gestational age by more than 21 days in 56.2
percent of the total placenta previa cases and
66.7 percent in the partial-marginal cases.
There were no significant differences between
the groups that received isoxsuprine and
ritodrine. The prolonged use of tocolytics was
not associated with any undue side effects
requiring discontinuation of the regimen.
Three patients had abnormal glucose tolerance
tests normalized by diet. The prolonged
antepartum maternal hospitalization resulted in
an estimated cost savings of $16,110 for the
total placenta previa group and $20,240 for the
marginal-partial group in comparison with the
costs if the delivery had occurred on admission
(estimated costs of $51,000 and $49,300,
respectively). 5 tables, 12 references.
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Therapeutic Efficacy and Cost-effectiveness
of Aggressive Tocolysis for Premature Labor
Associated With Premature Rupture of the
Membranes.
Form: Journal article.
Author: Weiner, C.P.; Renk, K.;
Klugman, M.
Source: American Journal of Obstetrics and
Gynecology. 159(1):2 16-222, July 1988.
Abstract: Researchers conducted a
randomized trial comparing bed rest with
tocolysis to determine the therapeutic efficacy,
safety, and cost-effectiveness of tocolysis for
the treatment of preterm labor after membrane
rupture. One hundred-nine women
participated over a 26-month interval at the
University of Iowa hospital. Sixty percent of
the randomized group of women comprised the
tocolysis group. Treatment groups did not
differ significantly in terms of gestational age
at membrane rupture, gestational age at
delivery, birthweight, maternal or fetal
infectious morbidity, respiratory distress
syndrome, necrotizing enterocolitis, or
perinatal mortality. Investigators observed an
increase in the duration of intrauterine time
after onset of uterine contractions in women
receiving tocolysis versus those receiving bed
rest only (105.2 +/- 157 hours versus 62.1
+ 1-11 hours). This prolongation was not
associated with a significant reduction in the
total cost per surviving infant (tocolysis,
$38,593 versus bed rest, $43,158). The cost
difference was artifactual. Women who
received tocolysis had a near-significant
increase in hospital costs (bed rest, $4,399;
tocolysis, $4,883; p = 0.076) and a significant
increase in physician fees (bed rest, $939;
tocolysis, $1,419; p = 0.005). There were no
significant cost differences between treatment
groups for the neonates for either the hospital
or the physician. The number of very
premature infants born (less than 28 weeks'
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gestation) was unequal in the two groups (12
in the bed rest group and 5 in the tocolysis
group) and therefore skewed results. Before
28 weeks' gestation, tocolysis was associated
with a significant increase in intrauterine time
after onset of regular contractions (p = 0.05).
However, there was no identifiable perinatal
benefit garnered from the additional 5 days.
After 28 weeks there were no significant
differences between treatment groups in terms
of intrauterine time after onset of regular
contractions and total cost per surviving infant.
Because tocolysis does not improve perinatal
outcome and can itself be associated with
major maternal morbidity, it should be avoided
after 28 weeks' gestation. Before 28 weeks'
gestation tocolysis may greatly increase
intrauterine time, but the benefit of
prolongation is not clear. 1 figure, 7 tables,
15 references.
(3) regional or general anesthesia, (4) cerclage,
(5) recovery in the day care unit, (6) bed rest
at home for 24-74 hours following surgery, (7)
telephone followup, and (8) a chart review of
the pregnancy outcome. The inpatients
followed the same course as those in the
outpatient group, but after surgery, they
remained in the postanesthesia care unit under
observation for about 1 hour and in the
hospital on general rest for several days.
Researchers reviewed both groups' charts for
outcomes for the mothers and infants. Data
analysis indicated 45 outpatients and 48
inpatients completed pregnancy. The fetal
outcomes were similar for both groups, with
no significant differences in the number of
complications (e.g., respiratory problems, low
birthweight, and postpartum fetal icterus) for
newborn infants. The average cost of the
procedure for outpatients was $546 and for
inpatients was $1,174. 3 tables, 4 references.
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Safety of Outpatient Cerclage.
Form: Journal article.
Author: Wetchler, B.V.; Brick, J.
Source: Journal of Reproductive Medicine.
35(3):243-246, March 1990.
Abstract: Researchers compared anesthesia
techniques and maternal and fetal outcomes in
101 women who underwent scheduled
McDonald cerclage for cervical incompetence.
Researchers examined (1) 50 outpatients
prospectively and (2) 5 1 inpatients
retrospectively and concurrently. All subjects
had histories of at least one pregnancy loss in
the second trimester and were found to have
dilation of the cervix without contractions
during the current pregnancy. All subjects
underwent cerclage as an elective procedure
between the thirteenth and twenty-fifth week of
pregnancy. The outpatients underwent (1)
sonography, (2) preoperative laboratory
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Source: Statistical Bulletin Metropolitan
Insurance Company. 69(4):24-32,
October-December 1988.
Abstract: An estimated $16 billion was spent
on maternity care costs in the United States in
1986, when maternity care for an
uncomplicated delivery of a normal infant cost
an average of $2,923. The highest average
charge for normal delivery was in the Pacific
division of Metropolitan Insurance Company,
at $3,470. The Middle Atlantic division had
the second highest charges, followed by the
New England states. The states in the middle
of the country registered the lowest delivery
costs for a normal delivery. Between-state
costs varied by as much as 135 percent. The
highest total charge ($4,210) was in the
District of Columbia, and the lowest ($1,790)
was in North Dakota. The average physician
cost for a normal birth was $1,210 across the
country. Actual hospital charges averaged
$1,690 and differed by as much as 57 percent
among states. Hospitals in the South,
including Mississippi, Tennessee, Alabama,
Arkansas, and Georgia, charged the highest
ancillary fees (laboratory, X rays, delivery
room charges, etc.), ranging from 74-79
percent of the hospital bill (the average was 64
percent nationwide). Metropolitan areas
tended to have higher total and component
health care costs than nonmetropolitan areas,
and the charges for a variety of common
surgical procedures are higher in California
than in almost any other state. These
differences have been attributed to a number of
factors, including the availability of newer and
more sophisticated diagnostic and treatment
tools, the socioeconomic and demographic
composition of the area, medical care
consumption preferences, the tendency for
greater use of less expensive general
practitioners in rural areas, the greater use of
specialists in urban areas, and possibly also
malpractice premiums. 2 figures, 2 tables, 6
references.
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Outreach as Case Finding: The Process of
Locating Low-Income Pregnant Women.
Form: Journal article.
Author: Brooks-Gunn, J.;
McCormick, M.C.; Gunn, R.W.; Shorter, T.;
Wallace, C.Y.; Heagarty, M.C.
Source: Medical Care. 27(2): 95- 102,
February 1989.
Abstract: Researchers document the process
of case finding to enroll women in prenatal
care in an urban, disadvantaged community.
The following assumptions were made
concerning the outreach: (1) Community
networks are the source of many referrals to
the health care system, (2) indigenous workers
are more likely to locate pregnant women than
are middle-class service providers, and (3)
community workers would be more likely to
canvass the neighborhoods than would clinic
workers who have become accustomed to
being in the clinic. Between 1982-1983, two
full-time and two part-time female community
residents (all without white-collar work
experience or current employment) searched
for pregnant women for 1 year in Central
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Harlem, receiving a salary and a $10
commission for each woman they found who
enrolled for antenatal care. To document their
outreach efforts, the workers kept daily logs of
their activities and participated in debriefing
sessions. From the logs, researchers
abstracted information on (1) time actually
spent searching for pregnant women, (2)
search strategies, (3) individual differences in
search strategies, and (4) effort expended to
locate pregnant women. Results indicated
outreach workers spent more than half of their
time in the field, contacted 20-25 women per
day, and used a variety of strategies to locate
women. Welfare offices and clinic settings
were the locations where the outreach workers
spent the most time, followed by apartment
buildings and the streets. Strategies included
advertising the program via flyers
(emphasizing the free health care and stressing
the need to take care of the baby's health) that
were placed all around the community. A
total of 52 women entered the Harlem Hospital
Medical Center health care system through the
outreach process, with outreach workers
identifying 104 pregnant women not already
receiving prenatal care. Based on results of
the process analysis, recommendations for
improving the outreach process include (1)
selecting workers who enjoy acting on their
own initiative, are able to supervise
themselves, and have the perseverance to
continue in the face of constant rejection; (2)
providing workers with formal training in
selling; and (3) providing quick and continuous
feedback and incentives to maintain
motivation. The cost of the outreach effort
was approximately $44,000. 1 table, 25
references.
257
Evaluation of the Impact of Maternity Care
Coordination on Medicaid Birth Outcomes
in North Carolina.
Form: Journal article.
Author: Buescher, P. A.; Roth, M.S.;
Williams, D.; Goforth, CM.
Source: American Journal of Public Health.
81(12): 1625-1629, December 1991.
Abstract: Researchers assessed the effect of
maternity care coordination services on birth
outcomes in North Carolina, in 1988 and
1989, by comparing women on Medicaid who
did and who did not receive such services.
The study linked health program data files,
including Medicaid claims paid for maternity
care coordination, to 1988 and 1989 live birth
certificates. Researchers compared very-low-
birthweight, low-birthweight, infant mortality,
and newborn medical care costs. They
examined the effect of maternity care
coordination on prenatal participation in the
Special Supplemental Food Program for
Women, Infants and Children (WIC).
Researchers matched birth records to claims
paid for maternity care coordination to identify
births that required the service. Researchers
summarized prenatal visit records from the
public health department client information
system and matched them to the birth records
to identify those births that received prenatal
clinic care in health departments. Linking
birth records identified women receiving WIC
service during the prenatal period. Linking
death records to birth cohorts provided
statistics on infant mortality rates. Data
analysis indicated maternity care coordination
was effective in reducing low birthweight,
infant mortality, and newborn medical care
costs among babies born to women in poverty.
Women on Medicaid with maternity care
coordination were significantly more likely to
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receive WIC services than those without the
maternity care coordination. 5 tables, 7
references.
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Paying for Maternity Care in the United
States.
Form: Journal article.
Author: Gold, R.B.; Kenney, A.M.;
Singh, S.
Source: Family Planning Perspectives.
19(5): 190-193, 195-206, September-
October 1987.
Abstract: Researchers illustrate how the
current system of programs and policies
through which maternity care is financed in the
United States has left 14.6 million women of
reproductive age uncovered by private or
public insurance programs for maternity care,
and make suggestions about how to improve
the situation. Some 3.7 million women, many
of them young and with modest incomes, have
a baby each year. About 8 women in every
100,000 die from complications associated
with childbearing, and 20 percent of newborns
(770,000 annually) are born with a health
problem. Thirty-four percent of pregnant
women are getting inadequate prenatal care.
The average bill for having a baby is estimated
at $4,300; it is $2,900 even if the pregnancy is
uncomplicated, the delivery normal, and the
infant is healthy. With complications it can go
much higher; a cesarean birth with an
extremely immature infant can cost $27,050.
Other topics examined include private health
insurance (who has it and what it covers);
waiting periods before coverage is effective;
government programs such as the Civilian
Health and Medical Program of the Uniformed
Services (CHAMPUS) and Medicaid; federally
financed clinics; women without insurance;
and uncompensated care. Suggestions are
given for improving maternity care financing
and taking the next steps toward better care.
Congress and 8 states (Illinois, Maine,
Maryland, Massachusetts, Minnesota, New
York, Ohio, and Wisconsin) have already
taken steps to extend insurance coverage and
services to pregnant women and their children.
The Alan Guttmacher Institute has suggested
further measures; 15 are listed in the article.
These include uniform coverage for services,
expansion of Medicaid services, giving states
incentives to offer health care providers
reasonable reimbursement, strengthening
community-based services, and improving
coordination among public programs providing
or financing prenatal care. Researchers
conclude that adequate and effective financing
of prenatal care would help with the country's
current problems and would probably cost
society as a whole no more than the current
system does. 2 figures, 13 tables, 108
references.
259
Cost Effectiveness of Prenatal Care in
Reducing Low Birth Weight in New
Hampshire.
Form: Journal article.
Author: Gorsky, R.D.; Colby, J. P.
Source: Health Services Research.
24(5):583-598, December 1989.
Abstract: Researchers calculated the cost
effectiveness of adequate prenatal care in
reducing the low birthweight (LBW) rate for
each of three socioeconomic groups of women:
(1) Those with less than 12 years of education,
(2) those with 12 years, and (3) those with
more than 12 years. Researchers used data on
prenatal care, birthweight, infant survival, and
mother's level of education from birth and
death certificates collected by the New
Hampshire Bureau of Vital Records and Health
Statistics for the 1981-1984 birth cohort.
Variables calculated from birth and death
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certificate information include prenatal care
inadequacy, birthweight, mother's level of
education, survival rates of very low
birthweight (VLBW; under 1,500 grams) and
medium low birthweight (MLBW; 1,500-2,499
grams) at 1 month and 1 year. Researchers
analyzed (1) initial hospitalization costs
($13,616 per low birthweight infant); (2)
number of rehospitalized infants (38.3 percent
for VLBW infants and 19 percent for MLBW
infants); (3) ^hospitalization costs ($372 x
16.2 days for VLBW infants and $372 x 12.5
days for MLBW infants); (4) number of
infants with long-term morbidity (18.9 percent
of 1 -month survivors); (5) long-term morbidity
costs ($1,405 per year); and (6) total cost of
LBW (sum of the costs of initial
hospitalization, rehospitalization, and long-
term morbidity). Target LBW rates for each
group were those actually achieved by New
Hampshire women receiving adequate prenatal
care within respective education groups. The
estimated total cost associated with low
birthweight births among the 1981-1984 cohort
of New Hampshire resident births was more
than $38 million. With universal adequate
prenatal care (estimated to cost $2.5 million),
the LBW costs would be less than $32 million,
resulting in a cost savings of $4 million ($1
million a year). For each additional dollar
spent on prenatal care, $2.57 in medical care
costs would be saved. 9 tables, 19 references.
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Prenatal, Delivery, and Infant Care under
Medicaid in Three States.
Form: Journal article.
Author: Howell, E.M.; Brown, G.A.
Source: Health Care Financing Review.
10(4): 1-15, Summer 1989.
Abstract: Researchers analyzed Medicaid
services and expenditures for care during the
prenatal, delivery, and post-delivery periods in
California, Georgia, and Michigan.
Investigators used uniform data from the
Health Care Financing Administration's
(HCFA) Medicaid Tape-to-Tape project, 1983-
1984, which contains person-based information
on all services covered by Medicaid since 1980
in several states. Researchers estimated that
the 144,540 Medicaid-financed births in the
three states in 1983 represented about 17
percent of all Medicaid births nationally in
1983. Data studied are from 12,045
Medicaid-financed deliveries in the three states
in October 1983. Percentages of all births in
the states studied that were financed by
Medicaid were 16 percent in Georgia, 23
percent in California, and 24 percent in
Michigan. More than 50 percent of
expenditures for the study population were for
delivery hospitalization; less than 12 percent
were for prenatal care. Up to 41 percent of
total delivery payments were for high-cost
deliveries (those over $4,000). From 33-41
percent of total Medicaid expenditures for Aid
to Families with Dependent Children were for
pregnancy, delivery, and newborn care in
1983. Average fee-for-service charges and
Medicaid payments for prenatal care ranged
from $904 in Michigan to $454 in Georgia.
Average charge per delivery hospitalization
ranged from $2,559 in Georgia to $4,150 in
Michigan. Average total expenditures for care
during all three periods were $3,933 in
Georgia, $4,632 in California, and $4,816 in
Michigan. For the measures observed, the
Medicaid programs of these three widely
differing states provided very similar care for
pregnant women and infants during 1983. 6
figures, 10 tables, 13 references.
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Prenatal Care and Low Birthweight:
Effects on Health Care Expenditures.
Form: Book chapter.
Corporate Author: Institute of Medicine,
Division of Health Promotion and Disease
Prevention, Committee to Study the Prevention
of Low Birthweight.
Source: IN: Preventing Low Birthweight.
Washington, DC, National Academy Press,
pp. 212-237, 1985.
Availability: National Academy Press, 2101
Constitution Avenue, NW., Washington, DC
20418.
Abstract: In Prenatal Care and Low
Birthweight: Effects on Health Care
Expenditures, The Committee to Study the
Prevention of Low Birthweight attempted to
determine prenatal costs by (1) identifying a
target population of high-risk pregnant women,
(2) estimating additional public fiscal outlays
required to provide them with more complete
prenatal care services than they currently
obtained, (3) assessing direct medical care
expenditures resulting from a low-weight birth
for 1 year, and (4) comparing the additional
public fiscal outlays for adequate prenatal care
of the target group mothers with the potential
savings in single-year medical care costs that
might result from the reduction in low
birthweight rate. The target population
included the total national cohort of women
between ages 15-39 who received public
assistance and who had less than 12 years'
education (an estimated 1,399,000 women).
These women were projected to have 110,601
pregnancies at risk for low birthweight, of
which 12,719 would result in a low
birthweight infant (an 11.5 percent rate). The
committee estimated the cost for professional
services associated with prenatal care at about
$400 per infant. The estimated cost for a
newborn's hospitalization in neonatal intensive
care was $13,616 (adjusted to 1984 dollars);
for rehospitalization in the first year, $372.
The committee calculated that an additional
$12 million would be required to provide the
target population of high-risk women with
prenatal care beginning in the pregnancy's first
trimester. If only a 10 percent low
birthweight rate were achieved by providing
prenatal care to high-risk pregnant women,
total initial hospitalization costs would be
$150.6 million, a cost savings of $22.6
million. At a 10 percent low birthweight rate,
rehospitalization cost savings are projected at
$1.6 million. Providing this population with
increased prenatal care services would cost
more initially, but would decrease the overall
fiscal outlays of governmental agencies for the
care of low birthweight infants born to high-




Medicaid Expenditures for Maternity and
Newborn Care in America.
Form: Journal article.
Author: Kenney, A.M.; Torres, A.;
Dittes, N.; Macias, J.
Source: Family Planning Perspectives.
18(3): 103-1 10, May-June 1986.
Abstract: The Alan Gutmacher Institute
(AGI) conducted a survey to determine (1)
1985 Medicaid expenditures for maternity care
and neonatal intensive care given to critically
ill newborns; and (2) the number of women
receiving public funding in 1985 for prenatal,
postnatal, and delivery care on a state-by-state
basis. In November 1985, AGI contacted the
head of the agency administering the Medicaid
program in each of the 50 states and the
District of Columbia, requesting the total
number of Medicaid patients obtaining
prenatal, postnatal, and delivery services and
the expenditures for these services. Most
states provided information for 1985 fiscal
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year or calendar year. Data provided for more
than 1 year were annualized. Thirty-five states
and the District of Columbia provided
aggregate data on maternity care or at least
one component of maternity care (usually
physician services); an additional seven states
furnished information on reimbursement rates.
Eighteen states provided acceptable data on
neonatal intensive care. Estimates were made
for the eight states that provided no
information by applying state reimbursement
rates to use data. Results showed that
approximately 542,000 low-income women
have a Medicaid-subsidized delivery each year.
The federal and state governments spend
almost $1.2 billion annually for maternity care
(including prenatal, postpartum, and newborn
care). Medicaid pays for about 10 percent of
the nation's maternity care bill, although it
subsidizes deliveries for about 15 percent of all
women who give birth. Only the highest
payments under Medicaid (e.g., Tennessee's
$3,500) are close to the charges for maternity
care in the open market, resulting in a
significant disinclination for physicians and
hospitals to accept Medicaid patients.
Medicaid payments for neonatal intensive care
average about $11,800 per infant. Although
only about 6 percent of all newborns whose
deliveries are subsidized by Medicaid require
neonatal intensive care, the care adds about 30
percent to all Medicaid expenditures for
maternity care.
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Prenatal Care and the Low Birth Weight
Infant.
Form: Journal article.
Author: Leveno, K.J.; Cunningham, F.G.;
Roark, M.L.; Nelson, S.D.; Williams, M.L.
Source: Obstetrics and Gynecology.
66(5): 599-605, November 1985.
Abstract: Researchers assessed human and
economic consequences of low birthweight
linked to lack of prenatal care for indigent
women. During a 6-month period, researchers
collected data on women delivering babies at a
Texas hospital, noting those who did and did
not seek prenatal care at the clinic.
Researchers collected and computerized
maternal and infant data prospectively.
Maternal data included (1) maternal age, (2)
race, (3) parity, (4) gestational age, (5) route
of delivery, and (6) pregnancy complications.
Infant data included (1) sex, (2) birthweight,
(3) Apgar scores, (4) neonatal morbidity, (5)
mortality, (6) length of stay in the neonatal
intensive care unit, and (7) hospital charges.
To assess costs, researchers retrieved
computer-generated hospital bills. The study
excluded physician fees but included patient
charges for (1) daily nursery board, (2)
medications, (3) procedures, (4) laboratory
tests, (5) x-rays, and (6) operating room time.
Data analysis indicated that 4,619 women
delivered 4,653 babies during the study period.
A total of 84 percent of the women obtained
prenatal care. The perinatal mortality for
those without prenatal care was 73 per 1 ,000
compared to 16 per 1,000 in women with
prenatal care. Women who sought prenatal
care had significantly decreased incidence of
low birthweight infants compared to those who
did not seek prenatal care. Low birthweight
infants born to women with prenatal care had
significantly better perinatal survival and less
frequent respiratory distress and
intraventricular hemorrhage. Infants born to
166
Economics and Prenatal Care
clinic mothers used fewer neonatal intensive
care days and had shorter hospitalizations.
Failure to obtain prenatal care related to a 50-
percent increase in cost per infant. In this
study, the largest neonatal costs incurred for
an infant were in excess of $150,000, and
costs in excess of $100,000 were not
uncommon. Given 3.5 million annual births,
of which 6 percent were low birthweight, and
the 3 percent of mothers who did not receive
prenatal care, excess neonatal intensive care in
1984 dollars approached $75 million. 2
figures, 6 tables, 31 references.
264
Blessed Events and the Bottom Line:
Financing Maternity Care in the United
States.
Form: Monograph.
Corporate Author: Alan Guttmacher
Institute.
Author: Lincoln, R.; Johnson, J.H.; eds.
Source: New York, NY, Alan Guttmacher
Institute, 59 p., 1987.
Availability: Alan Guttmacher Institute, 111
Fifth Avenue, New York, NY 10003. (212)
254-5656.
Abstract: Blessed Events and the Bottom
Line: Financing Maternity Care in the United
States presents facts and statistics on the
current system of financing maternity care and
discuss how it leaves approximately 15 million
women of reproductive age uncovered by
private or public insurance programs for such
care. Chapters include (1) Introduction; (2)
Having a Baby in America; (3) Paying for
Maternity Care (Private Health Insurance,
Government Programs, and Women Who
Have No Insurance); and (4) Conclusions and
Recommendations. Details include
demographic information, sources of
information, and implications presented in
tables, graphs, and illustrations. The typical
pregnant woman in the United States has a
family income of $20,000. Pregnancy
expenses account for 20 percent of a year's
income on average (the average bill is $4,300).
Families having babies are usually young, just
starting careers, or employed in low-paid
service or part-time work. Twenty-seven
percent of hospital admissions are for delivery,
yet the continuing preventive care needed for
maternity care is not the aim of most crisis-
oriented health insurance plans. Government
coverage includes CHAMPUS insurance for
civilian dependents of the military (1 million
women) and Medicaid insurance primarily for
those on welfare (4 million women). Twenty-
six percent of women of reproductive age have
no maternity coverage; many become eligible
when they get pregnant, leaving 15 percent
uninsured. A total of 550,000 deliver each
year at public expense; they are more likely to
be poor, black, teenage, or unmarried, and to
have had little or no prenatal care.
Recommendations include legislation to fund
prenatal care for all who need it; finding a
way to remove the stigma felt by Medicaid
recipients; and coordinating existing programs
or providing a system of consistent prenatal,
obstetric, and infant care nationally. The only
new expense would be relatively inexpensive
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Source: Washington, DC, Health Insurance
Association of America, 12 p., 1989.
Availability: Health Insurance Association of
America, P.O. Box 41455, Washington, DC
20018.
Abstract: In 1989, the Health Insurance
Association of America (HIAA) conducted a
survey to determine the cost and cost-related
issues of maternity and newborn care,
including prenatal care, hospitalization, and
other medical expenses for mother and infant.
Researchers surveyed 173 community
hospitals, 70 childbirth centers, and 153
licensed midwives. Researchers tabulated data
based on an average 2-day stay for a normal
delivery and a 4-day stay for a cesarean
delivery in metropolitan and nonmetropolitan
areas according to four United States
geographical regions, Northeast, South,
Midwest, and West. Results indicated that (1)
the cost per person in the United States for a
normal pregnancy and delivery averages
$4,334; (2) the average national hospital cost
for a normal delivery, excluding physicians'
and other practitioners' fees is $2,842; (3) the
average cost of a midwife's services is $994;
(4) cesarean section costs an average of $7,186
($5,133 for hospital charges, and $2,053 for
physicians' fees); (5) a normal delivery based
on a one-day stay in a birth center costs
$2,111; (6) a one-day stay in a hospital costs
$3,233; (7) amniocentesis is the diagnostic
procedure most frequently performed on
pregnant women; and (8) five of the
commercial health insurers that write the
largest volume of group coverage in the United
States paid $1.4 billion in maternity care
claims. Birth centers comprise less than 0.5
percent of all deliveries and cost on average
$2,111 for a 1-day stay, which includes
laboratory tests, childbirth education, home
visits, and prenatal and postnatal visits.
Factors that contribute to the increasing cost of
maternity care include (1) the overall increase
in the cost of health care and the cost-of-living
index; (2) increases in cesarean deliveries, 17
percent from 1980 to 1987; (3) changes in
maternal age, more adolescents and women in
later childbearing years, and subsequent
greater risk of a complicated delivery and need
for more diagnostic tests; (4) new
technologies, such as neonatal intensive care
units, which have average daily costs of $985
per patient and account for approximately 40
percent of uncompensated care; (5) a hostile
malpractice environment resulting in an
increasing number of diagnostic tests; and (6)
the increasing annual loss in revenue by
community hospitals for uncompensated care.
2 figures, 7 tables, 10 references.
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Perinatal and Economic Impact of Prenatal
Care in a Low-Socioeconomic Population.
Form: Journal article.
Author: Moore, T.R.; Origel, W.;
Key, T.C.; Resnik, R.
Source: American Journal of Obstetrics and
Gynecology. 154(l):29-33, January 1986.
Abstract: Reductions in publicly funded
prenatal care programs from 1981-1984
resulted in an increase in unregistered patient
deliveries from 7.8 percent to 14.9 percent of
births at the University of California San
Diego (UCSD) Medical Center. To assess the
economic and perinatal impact of the
increasing number of deliveries of women
without prenatal care, researchers studied 100
consecutive (UCSD) Medical Center patients
with fewer than three prenatal visits. The
study matched each patient by age, parity, and
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week of delivery with a control patient who
received care in a state-funded perinatal
project, the Comprehensive Perinatal Program.
Researchers reviewed the maternal and
newborn medical records of each of the pairs
of subjects. Data analysis indicated the
provision of prenatal care did not appreciably
reduce the incidence of maternal complications
or morbidity associated with labor and
delivery. However, infants of women with no
prenatal care experienced significantly greater
perinatal morbidity and mortality, primarily
related to increased prematurity. The
difference in maternal hospital charges
between the no care group and the
Comprehensive Perinatal Program patients was
small ($59 higher in the no care group).
Neonatal charges, however, were strikingly
higher for infants in the no care group ($3,487
versus $697 for program patients). The total
excess costs for delivery of 400 women
receiving no care per year in the study hospital
was $877,600. 5 tables, 15 references.
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Access to Obstetric Care in Rural Areas:
Effect on Birth Outcomes.
Form: Journal article.
Author: Nesbitt, T.S.; Connell, F.A.;
Hart, L.G.; Rosenblatt, R.A.
Source: American Journal of Public Health.
80(7):814-818, July 1990.
Abstract: Researchers investigated the extent
to which local availability of obstetric (OB)
services related to perinatal outcomes.
Researchers examined the characteristics of
rural communities in which the majority of
women delivered at a facility other than their
local hospital (outflow). Using outflow as a
proxy for access to care, researchers assessed
whether there were any differences in the
outcome or cost of care for women living in
communities with diminished OB access
compared to women who had ready access to
local OB care. Researchers used data on all
deliveries of women whose primary residence
was in a rural area of Washington and who
gave birth during 1986. By comparing the
place of residence with the location of the
hospital of delivery, they determined what
proportion of all obstetrical deliveries occurred
in facilities outside a woman's local hospital
cachement area. They collected hospital
discharge data from 33 rural hospital service
areas, categorizing the data by the extent to
which patients left their local communities for
OB care (low outflow and high outflow).
Telephone surveys with hospital administrators
and directors of nursing determined the
availability of OB services in each of the
communities and the number and specialty of
all physicians providing OB services in each
hospital during 1985, 1986, and early 1988.
Researchers used diagnosis related groups
(DRG's) as proxies for OB outcome
(complicated or uncomplicated birth and
premature or term neonate). Data analysis
indicated women from communities with
relatively few OB providers in proportion to
number of births were less likely to deliver in
their local community hospital than women in
rural communities with greater numbers of
physicians practicing OB in proportion to
number of births. Women from the high
outflow communities had a greater proportion
of complicated deliveries, higher rates of
prematurity, and higher costs of neonatal care
than women from communities where most
patients delivered in the local hospital. 2




Expanding Medicaid Coverage for Pregnant
Women: Estimates of the Impact and Cost.
Form: Journal article.
Author: Torres, A.; Kenney, A.M.
Source: Family Planning Perspectives.
21(1): 19-24, January-February 1989.
Abstract: Researchers estimate 361,000
pregnant women will be newly eligible for
Medicaid coverage when all states raise the
income ceiling for such coverage to 100
percent of the federal poverty level by 1990,
as mandated by Congress. Since the first
provision expanding the Medicaid income
ceiling, researchers have suggested several
methodologies to help states calculate the costs
of increasing coverage to 100 percent of
poverty. All of them have based their
estimates of the size of the newly eligible
Medicaid group on data from the annual
Current Population Survey, which includes
data on the health insurance status of the
United States population by sex, age, and
poverty status. According to the methodology
for projecting the effects of recent
Congressional changes in the Medicaid
program, about 64 percent of the 361,000
soon-to-be-covered women would be otherwise
uninsured, at least for maternity care, and for
the rest Medicaid would be the payer of last
resort. Some states may choose to cover
pregnant women with incomes from 100
percent to 185 percent of poverty. Doing so
would make another 552,000 women eligible.
Researchers estimate that the overall federal
and state expenditures to provide maternity and
newborn care (excluding neonatal intensive
care) to all newly eligible women below 100
percent poverty to be $654 million per year,
about 87 percent of which would cover
services to uninsured women. The federal
government would pay about 59 percent of
Medicaid expenditures for the newly eligible
women, and the states would pay about 41
percent. 2 tables, 33 references.
269
Does Prenatal Care Decrease the Incidence
and Cost of Neonatal Intensive Care
Admissions?
Form: Journal article.
Author: Wilson, A.L.; Munson, D.P.;
Schubot, D.B.; Leonardson, G.; Stevens, D.C.
Source: American Journal of Perinatology.
9(4):281-284, July 1992.
Abstract: Researchers conducted a study to
examine the potential effects of expanded
Medicaid coverage for low income women in
South Dakota. Statewide birth data for 1983
to 1985 were examined to determine the
relationship between prenatal care and
admissions to neonatal intensive care units
(NICUs) and the related costs. An NICU
sample was formed from infants who (1) were
discharged live following more than 7 NICU
days, (2) were referred to an out of state
tertiary center, or (3) died following NICU
admission. Inadequate care (no prenatal care,
only last trimester care, or less than five visits)
was received by 1 1 percent of the total birth
cohort and by 1 8 percent of the infants in the
NICU sample. Infants with inadequate care
had a NICU admission rate of 5.10 percent
versus 2.86 percent for those with adequate
prenatal care. The hospital billings for infants
in the NICU sample with inadequate care were
significantly higher than were those for infants
with adequate care. Assuming that economic
resources limit access to prenatal care, the
projection can be made that had all women
with inadequate prenatal care received
Medicaid-covered adequate prenatal care,
expenditure for this care would yield more
than a two to one return in savings in NICU
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Spontaneous Abortion in Primary Care: A
Report From ASPN.
Form: Journal article.
Corporate Author: Ambulatory Sentinel
Practice Network.
Source: Journal of the American Board of
Family Practice. 1 ( 1 ) : 1 5-23
,
January-March 1988.
Abstract: The Ambulatory Sentinel Practice
Network (ASPN) conducted an observational
study of usual primary care of spontaneous
abortion. Forty-nine practices in 18 states and
4 Canadian provinces reported and audited 171
spontaneous abortions from November 1982
through December 1983 and March through
December 1984. Clinicians reported weekly,
using a card designed for rapid completion. A
questionnaire was completed retrospectively by
two persons in each practice to determine
complications experienced at the time
spontaneous abortion was diagnosed and in the
30 days following diagnosis of spontaneous
abortion. There were 226 spontaneous
abortions reported in the 25-month study
period. ASPN spontaneous abortion patients
were predominantly white, between ages 20-
34, and insured. Contrary to recommendation
in some texts, 40 percent were managed
completely in the office and/or at home, and
5 1 percent had a dilatation and curettage (D
and C). Spontaneous abortions occurring later
in pregnancy were more likely to (1) be
managed in the emergency room or hospital,
(2) receive consultation, and (3) have a D and
C. Patients managed with a D and C had a
greater frequency of excessive blood loss at
diagnosis, but otherwise they did not differ in
terms of complications at diagnosis or
followup from those who did not. Adverse
psychological consequences were subjectively
observed by ASPN clinicians in 24 percent of
women, exceeding any other category of
complications. Charges for six selected
services related to managing spontaneous
abortions were estimated at (1) $88 per
spontaneous abortion managed out of hospital
without D and C, (2) $497 per spontaneous
abortion managed out of hospital with D and
C, (3) $828 per spontaneous abortion managed
in hospital without D and C, and (4) $1,248
per spontaneous abortion managed in hospital
with D and C. Management of all
spontaneous abortions in a hospital with D and
C, instead of the management observed in this
study, could add $145 million per year to
health care expenditures in the United States.
4 figures, 4 tables, 35 references.
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Impact of an Instant Pregnancy Test Kit on
the Operations of a Major Hospital Casualty
Department.
Form: Journal article.
Author: Baber, R.J.; Bonifacio, M.;
Saunders, D.M.
Source: Australian and New Zealand Journal
of Obstetrics and Gynaecology.
28(2): 134-136, May 1988.
Abstract: Since failure to diagnose ectopic
pregnancy in a hospital emergency department
may lead to unnecessary admissions and
perhaps unnecessary operations, researchers
sought to determine the impact of an instant
pregnancy test kit on emergency department
staff diagnostic accuracy, rates of patient
admission to the hospital, operative
procedures, and related economic factors.
Researchers at the Royal North Shore Hospital
of Sydney, Australia, retrospectively examined
the records of 100 patients on whom a Tandem
Beta HCG test was performed during January-
April 1986, and compared them with the
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records of 73 patients who received both a
Tandem Beta HCG test and a Test Pack Serum
HCG instant pregnancy test kit in the same
casualty department during January-April
1987. Tandem Beta HCG test performance
requires 2 hours and was performed during
office hours; the mean time needed to receive
pregnancy test results was 1.61 days. The
instant pregnancy test requires 3 minutes and
was performed 24 hours a day. Results
revealed a 100 percent correlation between the
Tandem Beta HCG and Test Pack Serum HCG
tests. Ectopic pregnancy was diagnosed with
increased accuracy in 1987 (8 provisionally
diagnosed and 7 surgically proven) compared
with 1986 (32 provisionally diagnosed and 5
surgically proven). A total of 24 patients were
admitted to the hospital in 1986 who would not
have been if they had been known not to be
pregnant. Instant pregnancy testing
significantly improved the accuracy of
provisional diagnoses and appeared to help in
reducing the number of surgical procedures
performed. Based on an analysis of potential
cost savings that may have been achieved in
1986 had the instant pregnancy test been
available, a combination of careful clinical
assessment plus the appropriate application of
an instant pregnancy test kit could result in a
total cost saving to the hospital of over
$41,000 per annum. 3 tables, 5 references.
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Cost of Ectopic Pregnancy Management:
Surgery Versus Methotrexate.
Form: Journal article.
Author: Creinin, M.D.; Washington, A.E.
Source: Fertility and Sterility.
60(6):963-969, December 1993.
Abstract: Researchers examined the costs
associated with the management of ectopic
pregnancy (EP) in a local hospital and
projected annual potential cost savings of
methotrexate (MTX) therapy. They reviewed
records of patients treated for EP in 1991.
Surgical professional fees were $1,647 per
case; other direct costs were determined from
billing statements. Indirect costs, such as lost
productivity, were estimated based on
published data indicating the likelihood of
employment and average salary based on age.
Disability was 28 days for laparotomy, 7 days
for laparoscopy, and 4 days for MTX
treatment. The cost analysis compared two
management policies: (1) Surgical
management, exam under anesthesia,
culdocentesis, dilation and curettage (D and
C), and/or laparoscopy, and then
salpingostomy or salpingectomy via
laparotomy; or (2) medical management for
patients eligible for MTX treatment and
appropriate surgical treatment. Costs for
failure of MTX included the cost of MTX
treatment, the average total direct cost for
laparotomy in patients not eligible for MTX,
and a total of 28 days of disability. Potential
annual national cost savings from MTX
treatment were then extrapolated using national
statistics on the incidence of EP. Fifty EP's
were treated with an average direct cost of
$7,972 per case. Direct and indirect costs
totaled $662,180; direct costs were $525,464
and indirect costs were $136,716 (lost wages
$93,553, lost value of household management,
$43,163). The cost of MTX treatment in 1992
was $1,495 per case based on the protocol for
a single-dose MTX including emergency room
visit, endovaginal ultrasound (US), D and C,
before and after treatment blood tests, MTX,
and followup visits. Direct and indirect costs
for MTX treatment for those who were eligible
totaled $488,720; direct costs were $387,160
and indirect costs were $101,560. With one
MTX treatment failure (93 percent success
rate), the direct costs would total $397,561 and
indirect costs $103,904 for a total of
$501,465. MTX treatment had a cost savings
of 24 percent compared with surgical
management. Fifteen (30 percent) of the cases
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would have been eligible for MTX treatment
with a total cost savings of greater than
$160,000. The potential annual national cost
savings would be in excess of $282 million
given a 95 percent success rate and over $265
million with a 90 percent success rate. Results
indicate that MTX will not only reduce
morbidity but also the substantial cost of
treating ectopic pregnancy.
330
Impact of Public-Sector Expenditures for
Contraceptive Services in California.
Form: Journal article.
Author: Forrest, J.D.; Singh, S.
Source: Family Planning Perspectives.
22(4): 161-168, July-August 1990.
Abstract: For a state-level analysis in
California, researchers adapted a methodology
previously used to calculate the number of
unintended pregnancies averted nationally
through publicly funded contraceptive services.
The approach involved (1) identifying
contraceptive users who rely on publicly
supported services, (2) calculating the number
of unintended pregnancies and their outcomes,
(3) estimating public sector costs, and (4)
estimating public sector savings. Of the
526,300 women who obtained reversible
contraceptives through publicly funded
providers in California in fiscal year (FY)
1989, 87.5 percent relied on family planning
clinics and 12.5 percent received care from
private physicians reimbursed by MediCal.
Researchers estimated that 136,800 unintended
pregnancies, which would result in
approximately 36,000 births, 85,100 abortions
and 15,700 miscarriages, were averted each
year because publicly funded contraceptive
care was available from clinics and private
physicians in California. Federal and state
expenditures of $46 million for contraceptive
services in California in FY 1989 resulted in
an estimated savings of $232-$509 million
(averaging $353 million) in public costs for
abortions, prenatal and maternity care, and
welfare and supplementary nutritional
programs during the first 2 years after a birth.
These savings represent an average of $7.70
saved for each dollar spent to provide
contraceptive services. If none of the women
used contraceptives, an additional $925 million
in public expenditures would be needed for
women who would become pregnant,
equivalent to $20.10 for each dollar spent in
FY 1989 for family planning services. The
above savings/cost ratio is 75 percent higher
than that previously estimated for the United
States as a whole. 4 tables, 10 references.
331
Public-Sector Savings Resulting From
Expenditures for Contraceptive Services.
Form: Journal article.
Author: Forrest, J.D.; Singh, S.
Source: Family Planning Perspectives.
22(1) :6- 15, January-February 1990.
Abstract: Almost one in four United States
women who use a reversible method of
contraception rely on a publicly funded source
of care, either a family planning clinic or a
private physician reimbursed by Medicaid.
The approach used by researchers to analyze
savings from public sector contraceptive
services involved (1) identifying contraceptive
users who rely on publicly supported services;
(2) calculating the number of births, abortions,
and miscarriages; (3) estimating public sector
costs; and (4) estimating public sector savings.
In 1982, 4.1 million women using reversible
birth control methods relied on a family
planning clinic. According to three scenarios
of alternative contraceptive use patterns, if
publicly funded services were not available,
these women would have between 1.2 million
and 2.1 million unintended pregnancies a year,
181
Family Planning and Women's Reproductive Health
substantially more than the current level of
approximately 400,000 per year. If these
women relying on publicly funded services
used no method of contraception at all, they
would be expected to have more than 3.5
million unintended pregnancies in 1 year. In
fiscal year (FY) 1987, federal and state
governments spent $412 million on
contraceptive services for women who
otherwise might not have been able to obtain
them. If these services had not been available,
the additional public costs for medical care,
welfare, and supplementary nutritional
programs during the first 2 years after a birth
or for publicly funded abortions would have
totaled $1.2-$2.6 billion. These savings
represent an average of $4.40 saved for every
dollar of public funds spent to provide
contraceptive services. Researchers estimated
savings from availability of public sector
family planning services in FY 1982 to be
between $0.6 billion and $2.5 billion. 7
tables, 52 references.
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Cost Effectiveness of an Accurate and Rapid
Assay for Serum Human Chorionic
Gonadotropin in Suspected Ectopic
Pregnancy.
Form: Journal article.
Author: Gennis, P.; Gallagher, E.J.;
Andersen, F.; Hain, L.
Source: American Journal of Emergency
Medicine. 6(l):4-6, January 1988.
Abstract: Researchers at the Adult
Emergency Department and the Women's
Health Center of the Bronx Municipal Hospital
(New York) studied the cost effectiveness and
clinical utility of a simple, rapid, and accurate
pregnancy test in the evaluation of suspected
ectopic gestation. All women of childbearing
age presenting to either clinical site between
the hours of 9 a.m. and midnight during July
and August 1985 (237) were screened for
study eligibility. Entry criteria were a chief
complaint of lower abdominal pain and a
serum human chorionic gonadotropin (hCG)
level determination requested by the examining
physician. During the first month of the
study, the usual hCG test (Hybritech Tandem-
E qualitative serum assay) was performed by
the hospital laboratory on a routine basis.
During the study's second month, two blood
samples were taken from each patient. One
was sent to the hospital laboratory for the
routine hCG test and one (the Tandem Icon
hCG qualitative serum assay) was performed
by trained medical students at the bedside.
The medical students were able to report a
result to the examining physician in 15
minutes. Daily comparisons of the qualitative
and quantitative hCG determinations were
made. Followup information was obtained for
all patients with detectable levels of hCG. The
disposition and final diagnosis were obtained
in each case by chart review or direct phone
contact with the patient. Compared with the
usual quantitative serum assay, the bedside
performance of the Tandem Icon qualitative
serum assay procedure was associated with a
significant decrease in culdocenteses (7 versus
22), pelvic ultrasound examinations (13 versus
20), and hospital admissions (15 versus 24),
with a net projected institutional reduction in
health care costs of approximately $123,000
annually. Specific cost figures for the net
costs for the usual quantitative serum assay,
were not mentioned in the source document.
The reduction in procedures and admissions
occurred primarily in nonpregnant women. 3
tables, 7 references.
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333
Accessibility of Abortion Services in the
United States.
change in this proportion between 1985 and
1988. 5 tables, 1 figure, 30 references.
Form: Journal article.
Author: Henshaw, S.K.
Source: Family Planning Perspectives.
23(6):246-252, 263,
November-December 1991.
Abstract: The author discusses abortion
services' accessibility and related issues.
Abortion services are provided in hospitals,
doctors' offices and various types of clinics,
but about two-thirds of procedures are
performed in specialized abortion clinics.
While this system appears to work well for
most women, some women seeking abortion
face obstacles related to distance, cost,
harassment and special medical conditions.
Nine percent of nonhospital abortion patients
must travel more than 100 miles and 18
percent travel 50 to 100 miles for services.
The average woman having a first-trimester
nonhospital abortion paid $251 in 1989. Fees
were higher in facilities with small abortion
caseloads. An abortion at 10 gestational weeks
in a hospital cost an average of $1,757.
Charges for abortions at 16 weeks averaged
$509 in abortion clinics, compared with
$1,539 in hospitals for curettage and $2,246
for instillation procedures. Only 43 percent of
all abortion facilities offer services past 12
weeks, and 27-37 percent of nonhospital
facilities say they do not treat patients who test
positive for the human immunodeficiency virus
(HIV), the virus that causes AIDS. Women
who need special services such as an
administration of Rh immunoglobulin, general
anesthesia or HIV testing usually pay extra for
these services. In addition, 85 percent of
nonhospital facilities that serve 400 or more
abortion patients a year reported some form of
antiabortion harassment in 1988, most
commonly picketing; there was virtually no
334
Cost-Benefit Analysis of Selective Screening
Criteria for Chlamydia Trachomatis
Infection in Women Attending Colorado
Family Planning Clinics.
Form: Journal article.
Author: Humphreys, J.T.; Henneberry, J.F.;
Rickard, R.S.; Beebe, J.L.
Source: Sexually Transmitted Diseases.
19(l):47-53, January-February 1992.
Abstract: Health care personnel screened
women attending family planning clinics in
Colorado during 1988 for Chlamydia
trachomatis infection, using enzyme
immunoassay (EIA). Researchers analyzed
cervical specimens from 11,793 women
attending 22 family planning clinics, and used
patient history and physical examinations to
assess risk factors for infection. A total of
913 patients (7.7 percent) had positive culture
results for Chlamydia trachomatis.
Multivariate analysis showed that infection was
significantly related to endocervical bleeding,
cervical mucopurulent discharge, a new sexual
partner in the last 3 months or multiple
previous sexual partners (greater than 3) in the
last year, pregnancy, the use of oral
contraceptives, and age. Researchers observed
increased odd ratios for the combination of
endocervical bleeding and mucopurulent
discharge and sexual history that included
partners over the previous year as well as the
most recent 3 months. Health care workers
used a combination of these criteria to
selectively screen women attending Colorado
family planning clinics on an ongoing basis.
Researchers conducted a cost-benefit analysis
employing a model used by Trachtenberg et al.
They conducted a telephone survey of three
Colorado hospitals to determine the average
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costs attributable to conditions of untreated
Chlamydia trachomatis infections, including
outpatient treatment for pelvic inflammatory
disease and inpatient treatment such as
surgery. Cost of the test was $5.50; cost of
treatment was $16 per treated client. Adoption
of criteria with the greatest predictive value to
detect Chlamydia trachomatis infection resulted
in annual expenses of $82,500 for selective
screening and estimated total health care
expenses of $1,220,000. Universal screening
would cost $203,500, with an associated total
health care cost of $607,000. Researchers
estimated total health care costs in the absence
of screening at $1,370,000. Analysis showed
a significant financial benefit associated with
universal screening over either selective
screening or no screening for Chlamydia
trachomatis in this population. 4 tables, 27
references.
335
Costs of Family Planning Services: A
Critique of the Literature.
Form: Journal article.
Author: Janowitz, B.; Bratt, J.H.
Source: International Family Planning
Perspectives. 18(4): 137-144, December 1992.
Abstract: Researchers reviewed studies that
estimate the costs of family planning methods,
examined problems that arise in comparing
cost estimates from different studies, and
discussed steps that could lead to greater
comparability of cost information. To
examine the variation in costs, the authors
compiled a summary of costs per couple-year
of contraceptive protection for studies carried
out in 13 countries and converted cost
estimates to 1988 U.S. dollars. All output
measures were converted to couple-years of
protection. Sterilization costs ranged from
$2.50 to $8.90 per couple-year; intrauterine
device (IUD) costs ranged from $4.68 to
$19.11; and one couple-year of oral
contraceptives ranged from $6.05 to $25.54.
For community-based distribution (CBD) and
social marketing programs, program costs
were prorated among methods, and per-unit
costs were multiplied by the number of units
needed to yield one couple-year of protection.
Costs for one couple-year of oral
contraceptives ranged from $4.70 to $29.30;
condom costs ranged from $6.60 to $50.53 per
couple-year. Researchers defined costs by
opportunity cost, market price of the inputs,
and quantity. However, the researchers felt
that the lack of a standard approach or format
for gathering cost data was an obstacle to cost
comparability. Six types of methodological
issues contribute to the difficulty of comparing
estimates: (1) Exclusion of some costs, such
as indirect costs, from estimates; (2) varying
methodologies for allocating time and
overhead; (3) inconsistent treatment of capital
costs; (4) classification of training as a capital
or a recurrent cost; (5) treatment of free
components; and (6) difference in exchange
rates and comparative value of resources in
different countries. All programs produced
two basic types of results: (1) Contraceptive
services to protect the user against unintended
pregnancy, and (2) demand creation for family
planning or for particular methods or brands.
Differences in program output also undermine
the comparability of cost estimates including
(1) multiservice versus single-purpose
programs, (2) services provided by other
organizations, (3) program maturity and level
of demand, and (4) content of service delivery
programs. The cost of one program's output
may contrast due to differences in program
settings including (1) level of demand and
program capacity, and (2) level of demand and
competing services. Steps to increase
comparability of costs estimates include (1) a
standard costing approach to be developed and
adopted by donors and programs, (2) program
characteristics that are clearly understood, (3)
comparisons of cost per couple-year of
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protection should be considered invalid due to
disparate cost calculations that vary with each
program, and (4) special studies should be
conducted where reliable cost estimates do not
exist. 5 tables, 24 references.
336
Distribution of Contraceptives in Factories
in St. Lucia.
Form: Journal article.
Author: Landry, E.G.; Louisy, R.;
George, A.
Source: Journal of Health Administration
Education. 5(1): 105-1 17, Winter 1987.
Abstract: Researchers began a program in
1982 in 24 factories in St. Lucia, the Virgin
Islands, to test two alternative systems for
delivering family planning services. Research
objectives included testing the knowledge and
use of contraceptives among the female
employees and evaluating the cost-effectiveness
of the two different systems. Treatment Group
A received services from a trained nurse who
visited factories in this group twice a month.
The nurse performed routine gynecological
examinations, provided counseling about the
use and side effects of the available
contraceptives (the pill, condoms, and foam),
sold contraceptives to participants, and held
periodic group meetings to discuss family
planning topics. Treatment Group B received
services from a trained employee who
answered basic questions about available
contraceptives, sold them to participants, and
referred clients to the project nurse or a local
family planning clinic. Preintervention and
postintervention surveys were conducted for
both groups (190 and 267 for A and B,
preintervention; 228 and 319, respectively,
postintervention). Mean age was similar for
both treatments and on both surveys (25-26
years). Researchers measured program
achievement by couple-months of protection
(CMP) provided to each treatment group.
They conducted a cost-effectiveness analysis
(CEA) to measure the cost of replicating the
project on a local level and to compare the
cost of the two systems. In a 3-year period,
the cost per CMP by treatment group ranged
from $10.10 to $13.57 in Group A and from
$5.39 to $10.32 in Group B. The study
demonstrated an increase in contraceptive
prevalence as a result of bringing family
planning services to the workplace within
Group B. Contraceptive prevalence in Group
A factories slightly decreased. The overall
cost per CMP was $1 1.37 in the first year to
$6.10 in the second year. The cost per CMP
was $11.11 for Group A and $6.91 for Group
B. The program was acceptable and cost-
effective. The St. Lucia Family Planning
Association has adopted the Group B activities
as a part of its community-based services. 1
figure, 7 tables, 4 references.
337
Benefit-Cost Analysis of Family Planning
Services in Iowa.
Form: Journal article.
Author: Levey, L.M.; Nyman, J. A.;
Haugaard, J.
Source: Evaluation and the Health
Professions. 1 1 (4) :403-424, December 1988.
Abstract: Researchers conducted an analysis
of publicly funded family planning services in
Iowa to provide tangible estimates based on
local data of the value of these services in
averting unplanned and unwanted births to
women who voluntarily use them. The study
reports methods that can be applied by other
states to evaluate their own family planning
programs. Researchers measured benefits as
the cost savings in public expenditures avoided
by providing family planning services to low-
income and marginal-income women.
Researchers used Iowa data for Aid to
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Families with Dependent Children (AFDC),
food stamps, and Medicaid payments to
calculate benefits. They adjusted total benefit
savings to reflect the impact of family planning
services on preventing births. The adjusted
savings were accrued over 1-year and 5-year
time frames and for four age groups (14-19,
20-29, 30-34, and 35-44). In the base year,
the cost of providing family planning services
in Iowa to the more than 56,000 women who
used them was $3.1 million, or $59 per user.
Results showed that the benefits of family
planning services were highest for teenagers
who would become eligible for public
assistance programs upon the birth of a child.
For persons already receiving government aid,
benefits are greater than costs for 14-19-year-
olds and 20-25-year-olds, and decline over the
four age groups. Five-year projections showed
that costs averted for teenagers are greater by
a multiple of 6.6 over their 1-year savings
compared to a multiple of about 3.3 in the
other age groups. Benefits of family planning
in Iowa generally outweighed the costs, except
in the short term for women over age 29.
Overall, the Iowa study showed a first-year
savings of $2.50 for every dollar spent in 1983
for family planning services. 7 tables, 9
references.
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Source: Economic Inquiry. 26(l):353-359,
January 1988.
model in terms of the general theory of
fertility control, and (3) discusses policy
implications. Michael's model suggests that a
couple's fertility control decisions are based on
a comparison of the costs and benefits
associated with each additional child over time.
The Michael's abortion demand equation, a
linear specification, estimates the abortion rate
per thousand pregnancies in women aged
15-44 as the dependent variable and relates this
variable to (1) the average price of abortions,
(2) women's average income, (3) marital status
and percentage of women who are unmarried,
(4) employment status and labor force
participation rate, (5) percentage of Roman
Catholics in each state, (6) a dummy variable
to control for differential tastes, and (7) a
dummy variable to control for Medicaid
funding. Since the price of abortions is
determined simultaneously with the abortion
rate, the equation was estimated using a
2-stage least squares regression. Results
showed that the fundamental law of demand
holds for abortions at a 0.05 level of
significance for price and at a 0.01 level of
significance for income. The price elasticity
of demand of -0.81, which is inelastic, was
consistent with the elasticities of other health
services. The positive elasticity with respect
to income was 0.79, which shows that abortion
is a normal good. The demand for abortions
was positively related to the labor force
participation of women and to being
unmarried. Catholic religion, education, and
the poverty status of women were not
statistically significant to the demand for
abortions. 13 references.
Abstract: A researcher conducted an analysis
to evaluate economic aspects of the demand for
abortions. The author (1) empirically
estimates the demand for abortions using the
economic model of fertility control developed
by Michael (1973), (2) outlines Michael's
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339
Elective Hysterectomy: Benefits, Risks, and
Costs.
Form: Journal article.
Author: Sandberg, S.I.; Barnes, B.A.;
Weinstein, M.C.; Braun, P.
Source: Medical Care. 23(9): 1067-1081,
September 1985.
Abstract: Researchers evaluated the effect of
hysterectomy alone or hysterectomy and
bilateral salpingo-oophorectomy (hysterectomy
and oophorectomy) versus alternative medical
management on life expectancy, quality of life,
and direct medical costs. They approximated
dollar costs of medical care by charges,
adjusted to 1983 dollars according to the
medical component of the Consumer Price
Index. Using techniques of decision analysis
and available data on sequelae, researchers
found that gains in life expectancy and quality
of life can be expected when women aged 30-
60 undergo hysterectomy for a benign
neoplasm, disorders of menstruation, acquired
abnormal anatomy, cervical disease, or
endometriosis, owing primarily to prevention
of reproductive tract cancers, which outweighs
the impact of operative mortality. However,
women who have relatively high operative risk
or low expected cancer risks beyond thresholds
estimated in sensitivity analyses suffer losses in
life expectancy. Women under age 35 not
treated with replacement estrogens following
hysterectomy and oophorectomy can expect net
losses in life expectancy with surgical
intervention due to increased risks of heart
disease and osteoporosis. The net discounted
costs of hysterectomy alone and hysterectomy
with oophorectomy range from about $1,200
to $3,800 under the different combinations of
age and indication examined. Cost
effectiveness ranged from about $7,900 per
additional quality-adjusted life year for the
youngest women with acquired abnormal
anatomy to $43,000 in the oldest women
undergoing hysterectomy for benign cervical
disease. For women in the reproductive years
who wish to preserve their potential to bear
children, sterilization may be an unacceptable
consequence of elective hysterectomy in the
quality of life. 1 figure, 4 tables, 45
references.
340
Economic Evaluation of Transcervical
Endometrial Resection Versus Abdominal
Hysterectomy for the Treatment of
Menorrhagia.
Form: Journal article.
Author: Sculpher, M.J.; Bryan, S.;
Dwyer, N.; Hutton, J.; Stirrat, G.M.
Source: British Journal of Obstetrics and
Gynaecology. 100(3):244-252, March 1993.
Abstract: Researchers evaluated the relative
health service cost of transcervical endometrial
resection versus abdominal hysterectomy for
the treatment of menorrhagia and the value
women attach to their health state before and
after surgery. They used a randomized,
controlled trial of 200 women requiring
surgical treatment of menorrhagia between
January 1990 and May 1991; after
withdrawals, 97 women underwent
hysterectomy and 99 underwent endometrial
resection. Researchers used the EuroQol
Group 1990 health questionnaire to determine
the change in women's valuation of their
health state 1 month prior to their operation, 2
weeks after, and a minimum of 4 months after
surgery. The EuroQol used a visual analogue
scale resembling a thermometer running from
to 100. Data included all health service
resources, valued at 1991-1992 UK unit costs,
used for treatment up to 4 months after the
operation: (1) pre-operative, (2) operative, (3)
post-operative, (4) in-patient hotel, (5)
complications, (6) retreatment, and (7) general
practice. Mean with standard deviation (SD)
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and median costs in British pounds per case
for endometrial resection were pre-operative
15.69 (23.25), 10.95; operative 221.06
(27.92), 218.20; post-operative 2.62 (16.61),
0.12; in-patient hotel 236.38 (74.51), 226;
complications 4.81 (26.64), 0.00; retreatment
80.47 (233.69), 0.00; general practice 3.82
(5.40), 0.00; and total costs 560.05 (261.22),
459.77. Mean with standard deviation (SD)
and median costs in British pounds for
hysterectomy were pre-operative 15.79
(23.48), 10.95; operative 275.47 (32.82),
266.98; post-operative 6.42 (20.46), 2.43; in-
patient hotel 720.07 (114.79), 678;
complications 28.41 (128.83), 0.00;
retreatment (not applicable); general practice
11.16 (10.21), 10.40; and total costs 1,059.73
(198.04), 993.76. Total health service costs
were significantly higher among abdominal
hysterectomy patients (mean 1,059.73) than
among endometrial resection patients (mean
560.05) with a mean difference of 499.68
British pounds (95 percent confidence interval,
432 to 567 British pounds). This significant
difference existed under alternative
assumptions about the difference in lengths of
stay in hospital between the two treatment
groups and the hotel cost per in-patient day.
On a scale of to 100, relative to a month
before surgery, there was a statistically
significant difference in favor of endometrial
resection between the 2 groups in the increase
in value women attach to their state at 2 weeks
after surgery (mean difference 11.2; 95
percent confidence interval, 0.6-21.7) but not
at a minimum of 4 months after surgery (mean
difference 7; 95 percent confidence interval,
-17.4 to 3.4). On the basis of health service
resource cost up to 4 months after surgery,
endometrial resection had a cost advantage
over abdominal hysterectomy. However,
given the fact that a subgroup of women
required retreatment due to resection failure
and that this study considered a relatively short
period of followup, the authors suggested that
the long term costs and benefits of endometrial
resection need to be evaluated before
widespread diffusion is justified.
341
Routine Intravenous Pyelograms Before
Hysterectomy in Cases of Benign Disease:
Possibly Effective, Definitely Expensive.
Form: Journal article.
Author: Simel, D.L.; Matchar, D.B.;
Piscitelli, J.T.
Source: American Journal of Obstetrics and
Gynecology. 159(5): 1049-1053,
November 1988.
Abstract: Researchers examined whether
preoperative intravenous pyelography (IVP)
diminishes the risk of operative ureteral injury
and its cost-effectiveness, and under what
circumstances preoperative IVP is justifiable.
They performed a cost-effectiveness study,
based on decision analysis techniques using a
tree-structured model to represent the choices,
chances, and valued outcomes associated with
the use of IVP before hysterectomy in cases of
benign disease. The two choices were to
obtain an IVP or not to obtain an IVP. The
chances in the model were quantified as
probabilities: (1) The risk of having a fatal
complication (1 in 75,000), (2) the risk of
operative ureteral injury among patients
without IVP (injury or no injury), and (3) the
risk of a ureteral injury with IVP (injury or no
injury). In the group with IVP, the risk of
operative ureteral injury was diminished by the
test efficacy of the pyelogram. Outcomes
were valued in terms of both cost and overall
effectiveness. Overall effectiveness was based
not only on test efficacy but also on
probability of ureteral injury without the test
and the probability of a fatal complication
from the test. Estimates of risk and test
efficacy were obtained from the literature or
from opinions provided by practicing
gynecologists and used to calculate the
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marginal cost-effectiveness ratio. Sensitivity
analyses were performed to examine the
impact that changes in the estimates may have
on the marginal cost-effectiveness ratio. The
preoperative test efficacy was estimated at 25
percent and sensitivity analyses were
performed over a broad range of test efficacy.
At a baseline ureteral incidence injury rate of
0.5 percent (with a range of 0.1 to 2.5
percent), the marginal cost-effectiveness ratio
indicates 833 pyelograms would be obtained to
prevent a single injury and approximately
$3.33 million would be spent to prevent a
single death. Estimating a real dollar charge
of $200 per intravenous pyelogram charged to
the patient suggested that $166,600 will be
spent avoiding a single ureteral injury. As the
probability of an injury increases, the marginal
cost-effectiveness ratio was less dependent on
the test efficacy and was more modest.
Sensitivity analyses indicated that the marginal
cost-effectiveness ratio varies from 4,225
pyelograms to prevent one injury when the
risk in low to 402 pyelograms when the risk of
injury is high. Since abnormal ureteral
anatomy probably predicts ureteral injury, the
authors suggested selectively obtaining
preoperative pyelograms only when the
probability of an abnormality is high.
342
Public Benefits and Costs of Government
Funding for Abortion.
state analysis by The Alan Guttmacher Institute
(AGI) shows that the opposite is true. For
every tax dollar spent to pay for abortions for
low-income women, about $4 is saved in
public medical and welfare expenditures. The
savings are in public expenditures that
otherwise would have to be incurred because
of the babies that these women would have
borne. On the basis of earlier research, it was
assumed that 20 percent of Medicaid-eligible
women who could not obtain abortions would
give birth. Public costs examined in the AGI
analysis include Medicaid expenditures for
prenatal care, delivery, and postnatal care for
the mother, and for newborn care, neonatal
intensive care, and pediatric care for the child
for the first 2 years of life; as well as
expenditures for Aid to Families with
Dependent Children (AFDC), food stamps,
and the Special Supplemental Food Program
for Women, Infants and Children (WIC)
during those first 2 years. With no restrictions
on public funding of abortions, the net savings
in medical and social welfare costs would
amount to $340-$415 million over the
following 2 years. The net saving in the
Medicaid program would be at least $194
million and in the social welfare programs, at
least $146 million. The benefit-to-cost ratio
varies from about 9:1 in Massachusetts to 2:1
in Hawaii and Pennsylvania. Public funding
of abortion saves money and helps ensure that
low-income women have control over their
childbearing. 3 tables, 33 references.
Form: Journal article.
Author: Torres, A.; Donovan, P.; Dittes, N.;
Forrest, J.D.
Source: Family Planning Perspectives.
18(3): 11 1-1 18, May-June 1986.
Abstract: In state referenda to end public
funding of abortions for low-income women,
one of the most successful tactics of abortion
foes has been to charge that abortion funding
increases the burden on taxpayers. A state-by-
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343
Cost-Based Decision Analysis for Chlamydia




Washington, A.E.; Halldorson, S.
Source: Obstetrics and Gynecology.
71(1): 101-108, January 1988.
Abstract: Antibody-based methods to
diagnose Chlamydia trachomatis infection of
the cervix have recently made population
screening programs possible for this frequently
asymptomatic and epidemic problem.
Researchers constructed a decision model,
using medical care costs as utilities, to
determine the total costs of screening versus
not screening in California state-funded family
planning clinics, and to determine the
prevalence of infection at which screening
could be expected to pay for itself. The test
used for Chlamydia screening would be a
direct-smear fluorescein-labeled antibody test
(MicroTrak) that would cost $6.75 per test
(cost quoted to the Office of Family Planning),
with specificity of 98 percent and sensitivity of
90 percent. Approximately 400,000 women
per year are served by the California Office of
Family Planning. Cost of treatment for a
positive test was estimated at $16 per patient
and $20 for each partner. Analysis showed
that the screening program would eradicate
33,516 Chlamydial infections each year in
400,000 women with a Chlamydia prevalence
of 9.8 percent. This would produce a net
savings of $6 million in the first year, with
annual savings eventually increasing to over
$13 million, from the prevention of
Chlamydia-associated pelvic inflammatory
disease and other long-term sequelae such as
tubal infertility and ectopic pregnancy. A total
of $63.8 million (in 1986 dollars) could be
saved in the first 5 years of such a statewide
screening program. In populations with
infection prevalence of 2 percent or more,
such screening will pay for itself and can be
considered cost effective. Screening of
asymptomatic women for Chlamydia should be
carried out in most American family planning
clinics. 3 figures, 4 tables, 39 references.
344
Ectopic Pregnancy in the United States:
Economic Consequences and Payment
Source Trends.
Form: Journal article.
Author: Washington, A.E.; Katz, P.
Source: Obstetrics and Gynecology.
81(2):287-292, February 1993.
Abstract: Researchers conducted a study to
(1) estimate the annual direct and indirect costs
of ectopic pregnancy in the United States and
(2) examine trends in payment source. To
estimate direct medical care costs and to
determine payment sources, investigators
analyzed hospital discharge data, including
hospital bills, for 1982-1989 from a San
Francisco hospital, and California statewide
hospital discharge data for 1983-1987.
Researchers examined national labor data to
compute indirect cost. Analysis showed that
the total cost of ectopic pregnancy in 1990 was
estimated at nearly $1.1 billion, of which
direct costs of hospitalization and other
medical treatment contributed 77 percent.
Average hospital costs were estimated at
$6,079 per person, hospitalization-related
physician fees at $3,254 per person, and
average outpatient costs $149, for a total direct
cost per person of $9,482. Of the total
indirect costs ($250.5 million), 67 percent was
attributed to the value of lost wages and the
remainder to the lost value of household
management. Public payment sources covered
the largest portion of ectopic pregnancy-related
direct costs among women under age 19 (35
percent), but private insurance covered the
190
Family Planning and Women's Reproductive Health
largest portion among women ages 20-29 (32
percent) and women over age 30 (43 percent).
In general, the proportion of payments made
by private insurance has decreased, while the
proportion of payments made by public pay
sources, health maintenance organizations, and
preferred provider organizations has increased.
Findings suggest that ectopic pregnancy results
in a substantial economic burden, with an
increasing share of direct costs being borne by
public pay sources. Appropriate use of cost-
effective management approaches can reduce
costs, while preventive measures that decrease
the risk of ectopic pregnancy can both save
resources and spare human suffering. 2
figures, 4 tables, 14 references.
345
Gynecological Services Utilization by
Contraceptive Clients: A Cost Analysis.
Form: Journal article.
Author: Zapka, J.G.; Averill, B.W.;
Pastides, H.
Source: Journal of American College Health.
32(2): 66-72, October 1983.
the average number of specified visits as
identified in the study. Eighty-four percent of
the study population were women aged 18-22
and 91 percent were white. There were 1,483
visits for gynecologic services for the total
sample, including the subsample of college
seniors (the class of 1981). Twenty-eight
percent of the sample were seniors, 24 percent
were juniors, 21 percent were sophomores,
and 25 percent were freshmen. The average
cost of contraception services per senior client
was $83.10; for pregnancy-related care and
followup (including abortion), the average cost
was $47.43; for other gynecological visits,
average costs were $100.51. The cost of
coded gynecologic services per patient for the
3.5-year period was $293.43. The study
demonstrated that diagnostic group-focused
analysis studies are feasible and accurate when
(1) a uniform reporting system is in place that
captures units of time spent, reports by
clinician type, and also by initial and followup
visits; (2) all assignments to diagnostic,
procedure, or symptom group are done in
medical records to ensure uniform coding; and
(3) the budgeting system permits cost center
assignment. 6 tables, 20 references.
Abstract: Researchers conducted a cost-
analysis of gynecologic service utilization in a
prepaid university health plan in
Massachusetts. They audited health records
for 495 women who had used a diaphragm for
contraception, and subsequently computed
costs for contraception and pregnancy-related
and other gynecological services. The cost
analysis procedure consisted of five different
methods: (1) The double-apportionment
method of allocating costs to revenue-
producing departments, (2) the compilation of
service units, (3) the identification of the
number of encounters for each specific
diagnosis or procedure performed, (4) the
separation of initial visits and followup visits
for the same episode, and (5) the
multiplication of the average cost per visit by
191









Source: Family Planning Perspectives.







Hysterectomy in a University Hospital:
Report of 82 Cases and Comparison With
Abdominal and Vaginal Hysterectomy.
Form: Journal article.
Author: Boike, G.M.; Elfstrand, E.P.;
DelPriore, G.; Schumock, D.; Holley, H.S.;
Lurain, J.R.
Source: American Journal of Obstetrics and
Gynecology. 168(6, Part 1): 1690-1697,
June 1993.
Form: Journal article.
Author: Baird, D.T.; Ledger, W.L.;
Glasier, A.F.
Source: Bailliere's Clinical Obstetrics and
Gynaecology. 4(3):639-650, September 1990.
R350
Cost Analysis of a Mucoadhesive Foam
Versus Conventional Treatment for
Postepisiotomy Patients.
R348
Prospective Comparison of Videopelviscopy
With Laparotomy for Ectopic Pregnancy.
Form: Journal article.
Author: Baumann, R.; Magos, A.L.;
Turnbull, A.
Source: British Journal of Obstetrics and
Gynaecology. 98(8):765-771, August 1991.
Form: Journal article.
Author: Bouis, P.; Hoffman, M.;
Newton, W.; Johnson, S.; Mack, M.
Source: Hospital Formulary.
21(12): 1226-1228, December 1986.
R351
Cost Effectiveness of Testing for Chlamydial
Infections in Asymptomatic Women.
Form: Journal article.
Author: Buhaug, H.; Skjeldestad, F.E.;
Backe, B.; Dalen, A.
Source: Medical Care. 27(8): 833-841,
August 1989.
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R352
Operative Laparoscopy in the Management
of Tubal Ectopic Pregnancy.
R356
Family Planning Clinics: Facing Higher
Costs and Sicker Patients.
Form: Journal article.
Author: Chatwani, A.; Yazigi, R.;
Amin-Hanjani, S.
Source: Journal of Laparoendoscopic
Surgery. 2(6):3 19-324, December 1992.
Form: Journal article.
Author: Donovan, P.
Source: Family Planning Perspectives.
23(5): 198-203, September-October 1991.
R353
Cost-benefit Analysis of Cephradine and
Mezlocillin Prophylaxis for Abdominal and
Vaginal Hysterectomy.
Form: Journal article.
Author: Davey, P.G.; Duncan, I.D.;
Edward, D.; Scott, A.C.
Source: British Journal of Obstetrics and
Gynaecology. 95(11): 1170-1 177,
November 1988.
R357
Patient Cost in the Treatment of
Postsurgical Female Pelvic Infection.
Form: Journal article.
Author: Faro, S.
Source: American Journal of Medicine.
78(Supplement 6B): 165-169, June 28, 1985.
R358
Cost-Effectiveness of Strategies to Evaluate
Postmenopausal Bleeding.
R354
Comparative Study of Operative
Laparoscopy Versus Laparotomy: Analysis
of the Financial Impact.
Form: Journal article.
Author: Davison, J.M.; Park, W.;
Penney, L.L.
Source: Journal of Reproductive Medicine.
38(5):357-360, May 1993.
Form: Journal article.
Author: Feldman, S.; Berkowitz, R.S.
Tosteson, A.
Source: Obstetrics and Gynecology.
8 1(6): 968-975, June 1993.
R359
Cost-effectiveness of Cefonicid Versus
Cefoxitin Prophylaxis for Cesarean Section
(Editorial).
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Public Funding of Contraceptive,
Sterilization and Abortion Services, Fiscal
Year 1990.
Form: Journal article.
Author: Gold, R.B.; Daley, D.








Source: International Journal of Technology
Assessment in Health Care. 7(4):485-499,
Fall 1991.
R361
Predictions of the Effectiveness of a Policy
of Screening for Chlamydia Trachomatis in




Source: British Journal of Family Planning.
17(2): 44-45, July 1991.
R365
Critical Analysis of 75 Therapeutic
Abortions.
Form: Journal article.
Author: Leschot, N.J.; Verjaal, M.;
Treffers, P.E.
Source: Early Human Development.
10(3):287-293, January 1985.
R362
Single-dose Cephalosporin for Prevention of
Major Pelvic Infection After Vaginal
Hysterectomy: Cefazolin Versus Cefoxitin
Versus Cefotaxime.
Form: Journal article.
Author: Hemsell, D.L.; Bawdon, R.E.;
Hemsell, P.G.; Nobles, B.J.; Johnson, E.R.;
Heard, M.C.
Source: American Journal of Obstetrics and
Gynecology. 156(5): 1201-1205, May 1987.
R366
Medical Radiodiagnosis and Pregnancy:




Source: Health Physics. 48(3):297-301,
March 1985.
R367
Public Funding of Contraceptive,
Sterilization and Abortion Services, 1982.
R363
Medicaid Cutoff and Abortion Services for
the Poor.
Form: Journal article.
Author: Henshaw, S.K.; Wallisch, L.S.
Source: Family Planning Perspectives.
16(4): 170-180, July-August 1984.
Form: Journal article.
Author: Nestor, B.; Gold, R.B.
Source: Family Planning Perspectives.
16(3): 128-133, May-June 1984.
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Evaluation of the Effect of Contraceptive




Source: Advances in Contraception.
9(1):1-11, March 1993.
R369
Partner Notification for Control of HIV:
Results After 2 Years of a Statewide
Program in Utah.
Form: Journal article.
Author: Pavia, A.T.; Benyo, M.; Niler, L.;
Risk, I.
Source: American Journal of Public Health.
83(10): 1418-1424, October 1993.
R370
Healthier Mothers and Children Through
Family Planning.
Form: Journal article.
Author: Rinehart, W.; Kols, A.;
Moore, S.H.




Benefit-Cost Analysis of Antimicrobial
Prophylaxis in Abdominal and Vaginal
Hysterectomy.
Form: Journal article.
Author: Shapiro, M.; Schoenbaum, S.C.;
Tager, I.B.; Munoz, A.; Polk, B.F.
Source: Journal of the American Medical




Induced Abortion: Chlamydia Trachomatis
and Postabortal Complications: A Cost
Benefit Analysis.
Form: Journal article.
Author: Skjeldestad, F.E.; Tuveng, J.;
Solberg, A.G.; Molne, K.; Dalen, A.;
Buhaug, H.
Source: Acta Obstetricia et Gynecologica
Scandinavica. 67(6):525-529, 1988.
R373
Patient Costs for Prophylaxis and Treatment




Source: American Journal of Obstetrics and





Randomized Double-Blind Comparison of
the Efficacies, Costs, and Vaginal Flora
Alterations With Single-Dose Ceftriaxone
and Multidose Cefazolin Prophylaxis in
Vaginal Hysterectomy.
Form: Journal article.
Author: Stiver, H.G.; Binns, B.O.;
Brunham, R.C.; Cheng, N.; Dean, D.M.;
Goldring, A.M.; Walker, J.B.; Tan, E.;
McLeod, J.
Source: Antimicrobial Agents and
Chemotherapy. 34(6): 1194-1 197, June 1990.
R375
Results of Establishing Medical Guidelines




Source: Contraception. 29(6):5 11-517,
June 1984.
R376
Cost-effectiveness of Gamete Intrafallopian
Transfer in Comparison With Induction of
Ovulation With Gonadotropins in the
Treatment of Female Infertility: A Clinical
Trial.
Form: Journal article.
Author: Wessels, P.H.; Cronje, H.S.;
Oosthuizen, A. P.; Trumpelmann, M.D.;
Grobler, S.; Hamlett, D.K.
Source: Fertility and Sterility.





Prenatal WIC Participation Can Reduce
Low Birth Weight and Newborn Medical
Costs: A Cost-benefit Analysis of WIC
Participation in North Carolina.
Form: Journal article.
Author: Buescher, P. A.; Larson, L.C.;
Nelson, M.D.; Lenihan, A.J.
Source: Journal of the American Dietetic
Association. 93(2): 163-166, February 1993.
Abstract: Researchers assessed the impact of
prenatal participation in the Special
Supplemental Food Program for Women,
Infants and Children (WIC) on low-birthweight
and Medicaid costs for newborn medical care
in North Carolina in 1988. They compared
average costs for newborn medical care for the
Medicaid recipients enrolled in WIC with
those for the non-WIC mothers to assess the
association of WIC participation and morbidity
in early infancy. Researchers linked Medicaid
and WIC data files to birth certificates for live
births in North Carolina in 1988 to (1) identify
Medicaid births; (2) identify women who
received WIC services during the prenatal
period; and (3) track all claims paid for any
service to the infant (e.g., inpatient,
outpatient, physician, medication) beginning
within 60 days of age. Each WIC participant's
identification number was matched to WIC
redemption files to determine the date when
WIC services began and the number and dollar
value of food vouchers redeemed during the
pregnancy. The WIC program cost was
calculated as the total value of all food
vouchers redeemed plus an administrative cost
estimated to be $8 per participant per month.
Within the group of Medicaid births,
researchers compared WIC-participants with
non-WIC participants by assessing the
association between prenatal WIC participation
and low birthweight and by statistically
controlling the groups for differences in (1)
age, (2) race, (3) marital status, (4) education,
(5) previous adverse birth outcomes, (6)
adequacy of prenatal care, (7) maternal
smoking, (8) maternal medical risk factors,
and (9) receipt of Medicaid case management
services. The study excluded births with no
prenatal care. Data analysis looked at whether
low birthweight differed by level or degree of
WIC participation. Results indicated that
maternal participation in prenatal WIC
programs in North Carolina improved rates of
low birthweight and very low birthweight and
reduced costs for newborn medical care. A
higher level of participation in WIC related to
better birth outcomes and lower costs for
newborn medical care. 4 tables, 15
references.
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Economic Costs of Nutrition Services for a




Source: Journal of Pediatric and Perinatal
Nutrition. 1(2): 35-48, Fall-Winter 1987.
Abstract: Using an economic framework,
researchers pilot tested methods of measuring
the economic costs of nutrition counseling for
an urban low-income prenatal population. The
nutritional counseling activities, which
included care from a nutritionist, nurse
practitioner, public health nurse, social
worker, and physician in one of the Alameda
County, California, Department of Health
Care Services Agencies, served as the source
of the cost data. The study clinic provided
prenatal services 3 days a week; the public
health nutritionist was in the clinic on 2 of the
3 days. Clinic protocols called for nutrition
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assessment and counseling for each patient at
the initial prenatal visit, and at least once
during each trimester. Additional nutrition
counseling was available for those assessed to
be at high risk. Nutrition services were
always integrated with the other components of
prenatal care. Costs for the prenatal women
were assessed by a structured interview using a
standardized questionnaire. The questionnaire
was pretested at the clinic during January 1984
and revised. Data were collected 1 day a
week for 24 weeks between February and
December 1984. All clients receiving nutrition
services during the observation days were
asked to participate in the study; there were no
criteria for exclusion. Direct costs identified
were personnel, space, materials used for
nutrition assessment and education, and the
client's travel and child care costs. Personnel
costs were measured through the observation
and recording of the time the nutritionist spent
in the various components of nutrition
services. The value of this time was calculated
by applying the minute rate of the mean salary
package for counseling nutritionists in the
county agency. In addition to the nutritionist,
personnel rates were also calculated for the
other health team members. The average cost
of nutrition services per pregnant woman was
$40.87, or total direct costs were $3,923.18
for the entire study group of pregnant women.
The costs for the nutrition services were
calculated separately from the initial prenatal
visit and the followup visits; services were
divided into chart review, assessment,
counseling, referrals, charting, and case
conferences. Estimated direct clinic costs of
nutritional services for 96 women in the study
group throughout pregnancy included
$1,062.72 for the nutritionist for initial
prenatal visits, $1,251.84 for followup prenatal
visits, and $760.56 for nutrition services
delivered by non-nutrition health care
providers. Space cost was calculated solely by
square footage as $36.10 per month, or $4.51
per day; total space cost for nutrition services
was $324.72. Other clinic direct costs for
nutritional services for the study group
included a sign language translator, $27.00,
and materials used for nutrition assessment and
education, $38.62. Direct costs for client
transportation provided by the clinic were
$36.36. Client direct costs for the entire
group included (1) other transportation costs
not included in the clinic-provided
transportation, $345.24, and (2) child care
costs, $76.12. The methods developed to
measure and value direct costs of prenatal
nutrition services were successfully pilot
tested. These methods can be used in future
studies for evaluating cost benefit and cost
effectiveness of nutrition services.
379
Economic Costs of Nutrition Services for a
Low-Income Prenatal Population: II.
Indirect and Intangible Costs.
Form: Journal article.
Author: Disbrow, D.D.
Source: Journal of Pediatric and Perinatal
Nutrition. 2(1): 17-26, 1988.
Abstract: Researchers conducted a pilot study
to explore a method of determining the value
of indirect costs for a low-income prenatal
population to obtain nutrition services. They
also considered intangible costs although these
costs were not measured or valued.
Investigators collected indirect cost data by
conducting structured interviews with pregnant
women who received nutrition services at a
county health department ambulatory care
center. The interview requested information
about the mode, cost, and time of travel to the
clinic and the cost of child care for older
children. The two primary intangible costs
related to nutrition care during pregnancy were
the anxiety women expressed over their
appearance and weight during pregnancy, and
their suffering from morning sickness.
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Researchers used the minimum wage ($3.35)
to calculate the value of the clients' time
unless the client had a job. They collected
complete data for 96 of the 100 women who
participated in the study. Mean indirect cost
per person for an initial visit was $7.85; for
two followup visits, $13.51. Total mean
direct costs for the clinic for the group were
$34.99, and for the client, $4.39; mean
indirect costs were $21.37. For a more
realistic estimate, making the value of the
clients' time $5.47 (mean wage of those
employed) and using $8.53 for all the value of
the clients' transporters' time, the indirect
costs were $3,220 (mean $33.54), with a total
economic cost of $7,000 (mean $72.92). 2
tables, 16 references.
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Source: American Behavioral Scientist.
28(4):543-558, March-April 1985.
Abstract: A researcher reports on progress
toward cost-benefit evaluations of potential
interventions for reducing iron deficiency
anemia in individuals in developing countries.
Costs of anemia reduction derive from the
dietary iron supplements and the system for
delivering them and ensuring that they are
consumed by appropriate populations.
Potential benefits include improved feelings of
well-being, higher work output, reduced
morbidity associated with iron deficiency, and
more effective learning among students.
Provided are a brief summary on the
prevalence and treatment of anemia; benefits
of anemia reduction, with special emphasis on
work output; and suggestions of the magnitude
of costs and benefits of hypothetical
interventions. For communities with a health
care delivery system in place, the costs might
only be for providing nutritional supplements
of iron in medicinal form or in dietary
fortification. The cost for 100-180 mg of
ferrous sulphate per day (in 1981) would be
about $1.50 or less per year. Even with
marginal processing and distribution costs
added, it would be about $3 per year. Work
output and productivity could increase from
30-75 percent. With wages of even $1 a day
(typical of developing societies), changes in
work output would raise output by $0.30 to
$0.75 a day, or the equivalent of $90-$225 a
year. That is, for $3 a year per person, it
might be possible to get increases in output
from $90-$225 a person. Preliminary
estimates of costs of supplementation where a
delivery system must be established range
from about $6-$25 a year per person,
depending on population density. Dietary
fortifications of salt and sugar with iron have
been estimated at only $0.07-$0.10 a year per
person. The very large potential benefits
relative to costs suggest that field trials and
more refined analyses would show a promising
cost-benefit result from a program of iron
supplementation. 43 references.
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Prenatal Participation in WIC Related to




Source: Public Health Reports.
101(6):607-615, November-December 1986.
Abstract: To determine if Supplemental Food
Program for Women, Infants and Children
(WIC) prenatal participation is associated with
a reduction in Medicaid costs within 30 days
of birth, researchers replicated in 1982 a 1980
evaluation of prenatal participation in
Missouri. Researchers used a file of 9,086
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Missouri Medicaid records matched with the
corresponding birth records. The 1980 study
found that WIC participation related to a
reduction in Medicaid newborn costs.
Between 1980 and 1982, the Missouri WIC
program expanded in number of counties,
number of participating mothers, and
proportion of Medicaid mothers on WIC. The
Missouri Medicaid program also changed the
hospital reimbursement procedures. The
current study used a 1982 WIC-Medicaid file
to verify the 1980 findings. The study
involved linking five separate data files: (1)
Medicaid, (2) birth certificates, (3) WIC
records, (4) NICU admissions, and (5) death
certificates. Data analysis confirmed the 1980
findings, with the 1982 results showing
slightly improved pregnancy outcomes for
WIC participants and slightly reduced benefit-
to-cost ratios compared with the 1980 findings.
In 1982, WIC participation related to an
increase in mean birthweight of 3 1 grams and
reductions in low birthweight rates and in
neonatal death rates. WIC apparently reduced
the incidence of low birthweight, respiratory
distress syndrome, and neonatal mortality.
Adjusted Medicaid paid claim amounts for
newborns averaged $76 less for WIC
participants than for non-WIC clients, a
statistically significant reduction. Mean
Medicaid costs for WIC newborns were
$1,250 compared with $1,326 for those
newborns whose mothers were not on WIC. 6
tables, 8 references.
382
WIC Prenatal Participation and Its
Relationship to Newborn Medicaid Costs in
Missouri: A Cost/Benefit Analysis.
Form: Journal article.
Author: Schramm, W.F.
Source: American Journal of Public Health.
75(8):851-857, August 1985.
Abstract: Researchers in Missouri examined
whether participation in the Special
Supplemental Food Program for Women,
Infants and Children (WIC) would relate to a
reduction in Medicaid costs within 30 days
after birth. To determine whether the
reduction in Medicaid costs would be greater
than the WIC costs for those women and
whether WIC would increase birthweight and
reduce low birthweight (LBW) among
Medicaid births, researchers linked (1)
Medicaid files, (2) birth certificates, (3) WIC
records, and (4) neonatal intensive care unit
(NICU) admissions. Researchers performed
the evaluation of WIC using 7,628 Missouri
Medicaid records matched with their
corresponding 1980 birth records.
Researchers divided the file into a WIC group
containing 1,883 records and a non-WIC
comparison group of 5,745 records.
Demographic analysis revealed little difference
between the two groups; however, the WIC
group had a lower percentage of metropolitan
births than the comparison group, which is
important because metropolitan medical costs
tend to be higher than nonmetropolitan medical
costs. Statistical analysis indicated WIC
participation related to a reduction in Medicaid
newborn costs of about $100 per participant.
There was no effect on mothers' Medicaid
costs. Reductions in LBW rates and NICU
admission rates among WIC infants provided
two possible reasons for the reduced Medicaid
costs associated with WIC food
supplementation. As WIC food costs
increased, both mean birthweight and newborn
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Medicaid savings also increased. Evidently
mothers who drop out of WIC or who enter
WIC late in pregnancy experience little or no







Author: Splett, P.L.; Caldwell, H.M.;
Holey, E.S.; Alton, I.R.
Source: Journal of the American Dietetic
Association. 87(2):204-208, February 1987.
Abstract: Researchers examined
comprehensive prenatal nutrition services
provided to low-income women in two urban
settings in terms of total costs, per client costs,
per visit costs, and cost per successful
outcome, using standard cost-accounting
principles. They studied outcome measures
using standard procedures based on written
quality assurance criteria. Data sources for
cost analysis came from the organizations'
financial management and reporting systems,
statistical systems for recording services
rendered, and evaluation system for outcome
measures from quality assurance audits. The
study population included 196 clients of a
county hospital program and 357 in a city
health department program. In these
programs, nutrition services were delivered for
a per client cost of $72 in the health
department setting and $121 in the hospital-
based prenatal care program. The total cost of
nutrition services in this study for 1982 was
$25,610 through the health department and
$23,714 at the hospital. Further analysis
illustrates that total and per client costs can be
misleading and that costs related to successful
outcomes are much higher. The three levels
of cost analysis reported provide baseline data
for quantifying the costs of providing prenatal
nutrition services to healthy pregnant women.
Cost information from these cost analysis
procedures can be used to guide adjustments in
service delivery to assure successful outcomes
of nutrition care. Accurate cost and outcome
data are necessary prerequisites to cost-
effectiveness and cost-benefit studies. 1
figure, 4 tables, 12 references.
384
Cholesterol-lowering Diets May Increase the
Food Costs for Danish Children: A Cross-
sectional Study of Food Costs for Danish
Children With and Without Familial
Hypercholesterolaemia.
Form: Journal article.
Author: Stender, S.; Skovby, F.;
Haraldsdottir, J.; Andresen, G.R.;
Michaelsen, K.F.; Nielsen, B.S.; Ygil, K.H.
Source: European Journal of Clinical
Nutrition. 47(ll):776-786, November 1993.
Abstract: Researchers compared food costs
for children under dietary treatment for
familial hypercholesterolemia with children
without known familial hypercholesterolemia
to evaluate Danish financial compensation
programs for children in dietary treatment for
familial hypercholesterolemia. The study
included four sets of dietary data from 135
Danish children: 30 children in treatment for
heterozygous familial hypercholesterolemia,
one group of 25 and one group of 40 school
children from Copenhagen, and 40 school
children from Jutland. The daily intake of
macronutrients and the daily cost of the diet
for each child were calculated from dietary
intakes and average prices of 365 different
food items. The prices used in the food cost
calculations, based on 1991 prices, came from
the Danish Bureau of Statistics household
budget survey and the prices collected in
supermarkets by two dieticians. Researchers
determined total costs by calculating the prices
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per weight unit, with corrections made for
food wastage during preparation and cooking.
Multiple linear regression models determined
the dependence of dietary cost per unit of
energy on (1) grams of fiber per unit of
energy, (2) percentage of energy from protein,
(3) percentage of energy from fat, and (4)
daily intake of energy. The mean and
standard deviations (SD) of percentages of
energy (E percent) from fat in the diet of
children with and without known familial
hypercholesterolemia were 23.6, 0.8 (SD) E
percent and 34.5, 0.5 (SD) E percent,
respectively. The dietary costs per unit of
energy in these two groups were 3.79, 0.12
(SD) Danish crowns (DKr) and 3.34, 0.05
(SD) DKr. Costs of the various food groups
expressed in DKr per 10 units of
energy/percentage of the daily cost for the
children with familial hypercholesterolemia
and Danish school children from Copenhagen
respectively, included: (1) Meat, 8.64/25
percent and 6.5/21 percent; (2) fruit, 4.47/13
percent and 1.82/6 percent; (3) milk products,
3.81/11 percent and 5.03/16 percent; (4)
vegetables, 3.76/11 percent and 2.04/7
percent; (5) bread, 3.26/9 percent and 2.36/8
percent; (6) fish, 2.02/6 percent and 1.35/4
percent; (7) juice, 1.98/6 percent and 0.27/1
percent; (8) soft drinks, 1.59/5 percent and
0.63/2 percent; (9) cake, 0.29/1 percent and
1.15/4 percent; (10) candy, 0.15/0 percent and
2.09/7 percent; and (11) other, 4.51/13
percent and 7.81/25 percent. Total costs for
the children with familial hypercholesterolemia
and Danish school children from Copenhagen,
respectively were 34.5 and 31.1 DKr per 10
units of energy. The cost per unit of energy
increased with decreasing fat energy
percentage of the diet for all children as one
group (r equals -0.37), as well as for the
group of children without familial
hypercholesterolemia (r equals -0.35).
Stepwise multiple regression analysis showed
that the differences in cost per unit of energy
between the groups could be explained by
differences in percentage of energy from fat.
The authors conclude that a reduction of
dietary fat from 35 percent to 25 percent may







Individualized Parenteral Nutrition in Low-
Birth-Weight Infants.
Form: Journal article.
Author: Dice, J.E.; Burckart, G.J.;
Woo, J.T.; Helms, R.A.




Cost Containment Using Cysteine HC1
Acidification to Increase Calcium/Phosphate
Solubility in Hyperalimentation Solutions.
Form: Journal article.
Author: Schmidt, G.L.; Baumgartner, T.G.;
Fischlschweiger, W.; Sitren, H.S.;
Thakker, K.M.; Cerda, J.J.
Source: Journal of Parenteral and Enteral
Nutrition. 10(2):203-207, March-April 1986.
R387
Summary Document of Nutrition
Intervention in Prenatal Care.
Form: Journal article.
Author: Trouba, P.H.; Okereke, N.;
Splett, P.L.
Source: Journal of the American Dietetic






Cost-effectiveness of the Matlab MCH-FP
Project in Bangladesh.
Form: Journal article.
Author: Attanayake, N.; Fauveau, V.;
Chakraborty, J.
Source: Health Policy and Planning.
8(4): 3.27-338, November 1993.
Abstract: Researchers evaluate the cost-
effectiveness of the Matlab Maternal and Child
Health-Family Planning (MCH-FP) project in
rural Bangladesh from 1986 to 1989 to assess
its economic viability. Between 1986 and
1989, there were five new interventions: (1)
Nutrition education and rehabilitation (NRU),
(2) maternity care (MAT), (3) vitamin A
capsule distribution (VAC), (4) control of
acute respiratory infections (ARI), and (5)
control of dysentery (DYS). Other projects
included (1) family planning program (FPP),
(2) expanded program of immunization (EPI),
(3) oral hydration therapy (ORT), (4) curative
services (CUR), and (5) expenditure on
research. The analysis of the cost structure is
at the activity level and confined to provider's
and recurrent cost. To apportion the
expenditure on salaries and wages among
activities, a time allocation study was
undertaken by administering a questionnaire
among all employees of the project.
Researchers measured three types of cost-
effectiveness indicators: (1) Cost per
birth/death averted, (2) average cost to
attend/perform/treat one case, and (3)
incremental cost to reduce/increase an
effectiveness indicator by one point. The
Matlab project allocated 40 percent of its total
expenditure on research over 4 years
($138,970; $156,614; $178,270; and
$262,945, respectively) and the rest on
delivery of services; total cost increased at a
real annual rate of 22.5 percent. The growth
rate in total costs for research was 23.7
percent and 21.6 percent for services. Among
the activities, family planning and maternity
services had the greatest increases, 14.3
percent ($59,827; $65,329; $74,860; and
$89,351) and 19.6 percent ($0; $25,542;
$28,111; and $36,550), respectively. All
services increased in cost, except NRU which
decreased by 0.1 percent. EPI was the most
efficient in cost per death averted (CPDA);
CPDA for measles is $201 per person and for
neonatal tetanus is $294. The CPDA from
ARI for neonates, which comprise
approximately 50 percent of the mortality
estimate, was $310. MAT seems to the least
efficient; it has averted a total of 42 direct
obstetric and neonatal deaths with a CPDA of
$2,158. However, cost per birth averted
(CPBA) by the Matlab project averaged $67
for a total of 4,343 births. The number of
births averted increased from 841 in 1986 to
1,343 in 1989 and decreased in CPBA from
$71 in 1986 to $60 in 1988. Incremental cost
varied among all interventions. For FPP, with
the increase in contraceptive prevalence rate
from 46.4 percent in 1986 to 56.5 percent in
1989, incremental cost decreased from
$35,747 in 1988 to $19,247 in 1989.
Incremental cost per contraceptive user
declined from $133 to $97. For NRU, while
the mortality rate declined from 4.4 percent in
1986 to 3.3 percent in 1989, incremental cost
to reduce it by one unit declined from
$114,553 in 1987 to $93,072 in 1989. The
average cost per case treated was calculated
for five activities. NRU increased to $400 per
case, ARI and DYS were approximately $40,
EPI was approximately $2 per immunization,
and ORT was $0.1 per oral rehydration
packet. The authors suggest restructuring the
present resource allocation pattern for the
activities which have already come close to
satiety level and continuing to use an enhanced
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cost-effectiveness methodology. 6 tables, 2
notes, 10 references.
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Evaluation of a Communications Program
to Increase Adoption of Vasectomy in
Guatemala.
Form: Journal article.
Author: Bertrand, J.T.; Santiso, R.;
Under, S.H.; Pineda, M.A.
Source: Studies in Family Planning.
18(6):361-370, November-December 1987.
Abstract: Researchers conducted a study to
test the impact of three communications
strategies (radio and male promoter, radio
alone, and male promoter alone) in increasing
the adoption of vasectomy in Guatemala and
measured the relative cost effectiveness of the
three strategies. The strategies were
implemented for a 1-year period in three
different semirural towns in the southern
coastal region of Guatemala, while a fourth
community served as a control. The radio
promotion consisted of six 30-45-second spots
and a series of 36 micro-programs of 10
minutes each, all dealing with family planning,
health, and vasectomy. The promoter was a
man who had been trained in family planning
methods and philosophy (with special emphasis
on male sterilization) and in interpersonal
communication techniques; he organized
groups of men in the community or workplace
to discuss family planning, and arranged for
interested men to have vasectomies.
Evaluation is based on a baseline and followup
survey among men in the four communities,
service statistics indicating the number of
operations performed in the communities since
1979, and data on the cost of producing and
implementing the communications program.
There was little change in knowledge or
attitudes that could be attributed solely to the
program (because changes in the treatment
areas were also observed in the control area,
possibly because of spill-over). However, the
number of operations performed in all three
treatment areas increased significantly. The
strategy employing the male promoter alone
generated the most operations at the lowest
cost. It resulted in 98 operations performed at
a cost of 3,806 quetzales, as opposed to 47
operations performed in the radio and
promoter group at a cost of 14,145 quetzales.
(One quetzal equaled one United States dollar
at the time of the study.) 2 figures, 6 tables,
17 references.
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Indonesian Family Planning Program: An
Economic Perspective.
Form: Paper.
Author: Chernichovsky, D.; Pardoko, H.;
De Leeuw, D.; Rahardjo, P.; Lerman, C.
Source: Washington, DC, World Bank,
185 p., March 1991.
Availability: World Bank, 1818 H Street,
NW., Washington, DC 20006.
(202) 676-1777.
Abstract: Indonesian Family Planning
Program: An Economic Perspective provides
Indonesian authorities with data they can use
to improve the cost-effectiveness of family
planning delivery in Indonesia. It examines
resource allocation, cost, funding institutions,
and output of the program at the grassroots
level in selected regions of three provinces:
West Java, the Special District of Yogyakarta,
and South Kalimantan. It is based on data
from the program's field operations collected
from November 1986-March 1987, and routine
service statistics of BKKBN (the Indonesian
National Family Planning Coordinating
Board). Availability of the medical
infrastructure to each eligible couple (ELCO)
varies greatly among regions. The value of all
resources allocated to family planning delivery
208
International Health
ranges from about 270 rupiahs (about $0.18)
per month per ELCO in densely populated
Tangerang to 630 rupiahs in sparsely populated
South Kalimantan. BKKBN bears about 50
percent of family planning delivery costs, the
Ministry of Health about 40 percent, and the
community the remaining 10 percent. It is
costliest (900 rupiahs per month) to maintain
an average user in South Kalimantan. The
cost is half that in Tangerang, the least costly
area.. The intrauterine device (IUD) is the
most cost-effective method in the long run,
followed by injectable birth control. Major
gains in cost effectiveness can therefore be
brought about by altering the contraceptive
method mix in favor of these more permanent
methods. However, implementing this new
mix would require capital investment and the
training of medical personnel that would strain
available resources. The report's chapters
include an overview of population and family
planning in Indonesia; study specifics; program
output; program design and delivery system;
field personnel and operations; program cost
and cost-effectiveness; worker productivity and
efficiency of field operations; and program
efficiency. 21 figures, 43 tables, 34
references.
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Source: Asian and Pacific Population Forum.
1(4): 1-8, 21-24, August 1987.
Abstract: In the mid 1980's Singapore
instituted a selective family planning policy
that encouraged poorly educated women to
prevent pregnancy and discouraged university
graduates from using family planning. The
policy's intent was to restructure the
population and the economy into a more skill-
intensive industrial society and to produce
effective leaders for the country's future
government. Monetary incentives were
offered to both groups of women for their
compliance with this policy, including grants
to low-income women agreeing to undergo
sterilization. Researchers performed a cost-
benefit analysis of this policy, considering
parameters of economic growth, marginal
value product of labor, and consumption
levels. They used a time horizon of 30 years
and a 10 percent discount rate, with the base
year of 1977-1978. The expected net present
value in Singapore dollars (in millions) of
preventing 1,000 births under those parameters
was estimated at $26.66 for the university
group and $-3.45 for the primary group under
high real growth (real growth was calculated
using yearly projections of costs and benefits
at base-year prices), and at $29.86 and $7.00,
respectively, under zero real growth. The
expected net present value for university
graduates under other parameters were almost
always positive, implying that the benefits of
preventing births among university graduates
outweighed the costs. The expected net
present value for primary school leavers was
often negative, suggesting that preventing the
birth of children who will not progress as far
academically could cost society more than it
gains. Two factors explain these results.
First, the cost of a university education is
considerably higher than the cost of a primary
school education. Second, the timing of the
flow of benefits differs between the two
groups. The authors conclude that although
university-educated people are more productive
than uneducated people during their working
years, the cost of educating them and the years
of work lost due to education outweigh the
benefits of their higher productivity. The
analysis shows that a selective birth control
program based purely on the potential high
productivity of the offspring of a particular
group need not necessarily be viable




Effectiveness and Cost-Effectiveness of
Postpartum IUD Insertion in Lima, Peru.
Form: Journal article.
Author: Foreit, K.G.; Foreit, J.R.;
Lagos, G.; Guzman, A.
Source: International Family Planning
Perspectives. 19(1): 19-24, 33, March 1993.
Abstract: Researchers assessed the
effectiveness of a postpartum family planning
service in contributing to higher contraceptive
prevalence and the cost-effectiveness of the
family planning program operating costs. The
subjects included 1,560 women giving birth in
1988-1989 at the largest hospital of the
Peruvian Social Security Institute (IPSS) in
Lima, Peru. Two randomly selected maternity
wards participated in the study, one as an
experimental group and one as a control.
Women could have an intrauterine device
(IUD), a TCu 380A, inserted immediately
after expulsion of the placenta or before
hospital discharge. Barrier methods were
offered to women who either did not want an
IUD or could not be attended by a physician
prior to discharge; oral contraceptives were
available to women not planning to breast
feed. Contraceptive counseling and temporary
methods were offered the experimental groups,
while a second ward, acting as a control
group, was discharged without being offered
comparable services. In the second half of the
study period, almost 90 percent of the
experimental group accepted family planning
prior to discharge, and 25 percent of women
received an IUD. Followup interviews were
conducted after 40 days and 6 months with
both the experimental and control groups. Of
the 1,560 women, 639 from the experimental
group were interviewed at 40 days and 238 at
6 months; 482 from the control group were
interviewed at 40 days and 201 at 6 months.
At 40 days, 44.7 percent of experimental
group and 25.9 percent of the women in the
control group were using a contraceptive
method and 27.5 percent of the experimental
group and 12.0 percent of the control group
were using an IUD. Six months after
delivery, 81.8 percent of the members of the
experimental group were using a contraceptive
method, with 40.3 percent using an IUD; by
comparison, 68.7 percent of controls were
using a method, and 27.4 percent an IUD.
Cost of initial physician training was $5,100
for fees, travel, and per diem; training for the
two patient educators cost $182 plus $6,000
per year for salaries and support costs. Costs
of postpartum IUD insertion associated with
the facility and consumable supplies were
estimated at $7.20 per insertion, plus $1.02 for
the cost of the device (donated by the U.S.
Agency for International Development).
Training costs were amortized over a 5-year
depreciation period. To compute unit costs,
researchers calculated that given a 35 percent
IUD acceptance rate among 17,250 women
delivering per year, 6,000 IUDs could be
inserted annually in postpartum services. The
total cost of inpatient IUD insertion was
estimated to cost $9.38 per person. IUD
insertion on an outpatient basis required two
visits. Cost of an outpatient consultation at
IPSS was estimated at $11.57, including costs
for facility, personnel, and consumable
supplies, so the two visits would cost $23.14
overall, plus $1.02 for the cost of the device.
Since outpatient clinics did not provide the
special family counseling offered by the
postpartum program educator, the total cost of
the outpatient postpartum IUD insertion was
$24.16. Comparing the inpatient and
outpatient insertion costs showed that every
inpatient insertion saved $14.78 and provided
special counseling not available through
outpatient services. The cost savings of the
postpartum service, when applied to the annual
maternity caseload for the study hospital,
yielded a net savings of $13,000 per year. If
the rate of in-hospital IUD insertions increased
to 35 percent, total savings could reach
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$71,700. Researchers estimated that if
postpartum IUD insertion was instituted
throughout Lima, Peru, potential annual
savings could reach $60,800 to $94,300,
depending on level of demand. Implementing
postpartum family planning services in all
IPSS hospitals in Lima could save 3 to 5
percent of the annual projected IPSS family
planning budget for Lima and free up 6
percent of the current outpatient delivery
capacity.
393
Costs and Benefits of Implementing Child
Survival Services at a Private Mining
Company in Peru.
Form: Journal article.
Author: Foreit, K.G.; Haustein, D.;
Winterhalter, M.; La Mata, E.
Source: American Journal of Public Health.
81(8): 1055-1057, August 1991.
Abstract: Researchers examined whether
expenditures for curative child health care
could be reduced through preventive
interventions and better prescription practices
while maintaining or improving quality of
care. The study site was a privately owned
Peruvian mine that provides medical coverage
to approximately 900 dependent children under
age 5. Researchers assessed baseline
conditions during 1986 and 1987. Data
included company records and household and
clinic surveys. The household survey included
220 miners' wives. The clinic survey involved
132 consultations with children under age 5.
In 1989, after the introduction of preventive
health services, researchers conducted a
followup to collect service statistics, a
campwide census, and a clinical survey of 206
visits by children under age 5 . Researchers
calculated wholesale costs of medications
prescribed at baseline and at followup. The
initial study found that despite considerable
outlays for medical services, few children
under age 5 were vaccinated and half of their
illnesses received no treatment. Children who
attended the clinic usually received
unnecessary medication. As a result of a
prospective cost-benefit analysis finding that
family planning and child survival services
could improve health status at costs that would
be compensated by savings from averted
services, the company (1) implemented
recommended services, (2) hired additional
staff to provide integrated maternal-child
preventive health care and family planning,
and (3) contracted for intensive training and
periodic on-site supervision. In less than 2
years, vaccination reached 75 percent, and
virtually all children under age 1 year were
enrolled in growth monitoring. Prescriptions
were reduced by 24 percent. Mothers
accepted well-baby services and had no
complaints about reduced medications. The
cost of the new services was $13,000 for the
first 2 years. There was a $6,800 savings in
pharmaceuticals prescribed for respiratory
infection and diarrhea. 2 tables, 5 references.
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Family Planning Programmes in Ten
Developing Countries: Cost Effectiveness by
Mode of Service Delivery.
Form: Journal article.
Author: Huber, S.C.; Harvey, P.D.
Source: Journal of Biosocial Science.
21(3):267-277, July 1989.
Abstract: Researchers assessed the cost
effectiveness of various modes of family-
planning service delivery based on the cost per
couple-year of protection (CYP). For this
commodity-based measure, the total number of
contraceptives distributed or sold in a program
is divided by the average number of each type
of contraceptive used per couple each year to
determine the number of CYP's provided by
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each program. The program expenditure is
then divided by total CYP's to obtain the cost
per CYP of the program in question.
Researchers used 1984 data for 63 projects in
10 countries (3 each in Africa and Asia, and 4
in Latin America). These projects provided
more than 4.8 million CYP's during the year
studied. Results showed that programs with
the highest volume of services delivered
corresponded to lowest average costs. Social
marketing (2.8 million CYP's) and sterilization
projects (960,000 CYP's) cost about $2 per
CYP, on average; highest costs were for full
service clinics and community-based
distribution projects ($13-$14 per CYP).
Costs of clinics combined with community-
based distribution services were approximately
$8-$9 per CYP, or between the two extremes.
Seventy-eight percent of the CYP's studied
were provided by the two most cost effective
delivery modes, social marketing (58 percent)
and clinics offering primarily sterilization (20
percent). This study demonstrates the use of a
simple but important tool to assist in planning
and management decisions related to cost
effectiveness of family planning service
delivery. 8 tables, 9 references.
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Cost-effectiveness of Family Planning in




Source: Health Policy and Planning.
1(2): 138-147, June 1986.
Abstract: Researchers conducted a cost-
effectiveness analysis of family planning in
India by estimating the average cost (AC) and
marginal cost (MC) of family planning
between 1956 and 1983 to identify long-run
trends. They used AC's and MC's to examine
the efficacy of reorienting the program during
the fiscal year 1966-1967 by making it target-
oriented and time-bound. Researchers used
data from the Year Books on the Family
Welfare Program pertaining to performance,
expenditure, and impact. The analysis
measured three variables: Cost per equivalent
sterilization, cost per couple protected, and
cost per birth averted. Considerable
fluctuations were evident with respect to the
number of equivalent sterilizations, especially
between 1968-1969 and 1977-1978, when the
number of sterilizations decreased from
2,089,000 to 1,878,000 and from 8,663,000 to
1,242,000, respectively. Some of the
variations in output were directly related to the
level of program expenditure, especially
between 1972-1973, when the Medical
Termination Programme (MTP) was
introduced and real marginal expenditures
increased by 101.492 million rupees. A
similar trend was noted in 1982-1983, when
real marginal expenditures increased by
342.768 million rupees. Program expenditure
and output in terms of equivalent sterilization
were closely related, supporting the view that
the output of the family planning program
varied directly with variations in program
expenditure. The MC and AC curves relative
to equivalent sterilizations showed lowest
points around 1959-1960 and 1967-1968. Cost
curves relating to cost per birth averted
showed slightly different patterns of the long-
run AC and MC; both decreased over time,
with the AC decreasing steadily to an apparent
minimum in 1979-1980. The AC showed less
sensitivity to short-term changes and implied
that the cost per equivalent sterilization was a
better indicator of operational efficiency. 5




Paying for Family Planning.
Form: Serial.
Author: Lande, R.E.; Geller, J.S.
Source: Population Reports. Series J:
Family Planning Programs. (39): 1-31,
November 1991.
public-private collaboration (social marketing,
employment-based services); (4) cost recovery,
such as instituting fees in public and private
nonprofit family planning clinics; and (5)
improvements in efficiency of service delivery,
promotion, and evaluation. 4 tables, 244
references.
Abstract: Paying for Family Planning
discusses the challenges and costs involved in
meeting the future needs for family planning in
developing countries. Estimates of current
expenditures for family planning in the
developing world are as high as $4.5 billion.
According to the United Nations Population
Fund, governments in developing countries
contribute 75 percent of the payments for
family planning, donor agencies contribute 15
percent, and users pay for 10 percent.
Although current expenditures cover the needs
of 315 million couples of reproductive age in
developing countries, this number of couples
accounts for only 44 percent of all married
women of reproductive age. Meeting all
current contraceptive needs would require an
additional $1-$1.4 billion. By the year 2000,
as many as 600 million couples could require
family planning, costing as much as $11
billion a year. While most of the
responsibility for covering these costs will
remain the domain of governments and their
donor agencies (governments spend only 0.4
percent of their total budget on family
planning and only 1 percent of all development
assistance goes toward family planning), the
authors suggest that a wide array of
approaches can be used to help meet added
costs. Detailed discussions are presented for
the following approaches: (1) Retail sales and
fee-for-service providers, which involve an
expanded role for the commercial sector and
an increased emphasis on marketing; (2) third-
party coverage, which means paying for family
planning services through social security
institutions, insurance plans, and the like; (3)
397
Cost Effectiveness of the APROFAM
Program for Voluntary Surgical
Contraception in Guatemala.
Form: Journal article.
Author: McBride, M.E.; Bertrand, J.T.;
Santiso, R.; Fernandez, V.H.
Source: Evaluation Review. ll(3):300-326,
June 1987.
Abstract: A study examined the relative cost
effectiveness of five alternative service
delivery methods for providing voluntary
surgical contraception (VSC) in Guatemala.
The study focused primarily on the relative
effectiveness of providing VSC in the
country's interior using fixed facilities with
local doctors or mobile teams. The VSC
program was administered by the Asociacion
ProBienestar de la Familia (APROFAM).
Service delivery modes included a surgical
center, private clinics, and APROFAM clinics.
Two types of cost data were used: Actual
expenditures and shadow pricing for items that
constituted inputs to the program but were not
charged to the contract. The coding procedure
for cost data consisted of coding each line item
from the monthly expenditure reports on a
series of variables, including the type of
resource it was and the type of service delivery
model for which it was used. The output
measure used in this cost effectiveness analysis
(CEA) was the total number of sterilizations
performed at each location by funding period.
The total cost of the VSC program between
March 1979 and June 1984 was Quetzales (Q)
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2,868,939. The retrospective CEA showed
that the mobile teams are relatively more
expensive ($201,302 and $324,002,
respectively) than using local doctors
($451,171 and $1,196,316, respectively). This
result was tempered by an analysis of the
monthly cost and service statistics using
statistical cost techniques. An alternative
analysis revealed that, at the margin, with the
given stock of capital the mobile teams are
relatively cheaper to use, and that the fixed
facilities need high demand levels (which are
unlikely to occur in the interior) to achieve
low costs at the margin. The alternative
analysis led to the funding agency retaining the
mobile team model. 3 figures, 7 tables, 12
references.
398
Cost-Benefit Analysis of the Mexican Social
Security Administration's Family Planning
Program.
Form: Journal article.
Author: Nortman, D.L.; Halvas, J.;
Rabago, A.
Source: Studies in Family Planning.
17(1): 1-6, January-February 1986.
Abstract: Researchers conducted a cost
benefit analysis of the family planning program
of the Mexican Social Security System (IMSS)
to test the hypothesis that IMSS's family
planning services would yield a net savings to
IMSS by reducing the load on its maternal and
infant care service. The study examined the
years 1972-1984. The study methodology
consisted of four components: (1) An annual
time series of IMSS cost for contraceptive
recruitment and supply; (2) computation of the
annual number of averted births based on the
CONVERSE model; (3) an estimate based on
empirical data regarding annual number of
averted IMSS treatments for incomplete
abortions; and (4) an annual time series of
IMSS expenditure per pregnant and postpartum
woman, per incomplete abortion treated, and
per child cared for during the first year of life.
In 1984, researchers conducted a field survey
of 37 IMSS hospitals and 16 clinics in 13 of
Mexico's 32 states to determine IMSS
expenditures on family planning services and
maternal and infant care. The survey
retrospectively and prospectively monitored
cost per minute or day and number of minutes
or days for family planning, first time and
subsequent visits of IUD and hormone
acceptors, and female and male sterilization.
Researchers looked at expenditure on pregnant
and postpartum women and IMSS expenditure
per case. The results indicated that the IMSS
family planning program considerably reduced
the demand on its maternal and infant care
services. The program averted a total of
3,556,700 births and 362,700 treatments for
incomplete abortion through 1985. The cost
per averted birth plus incomplete abortion
ranged from an average of 90,000 pesos (1983
currency) in the first year of operation to a
low of 5,800 pesos in 1983. Excluding any
financial input in 1985, the average cost per
averted birth and incomplete abortion during
1972 through 1985 was 9,700 1983 pesos or
about $65 . As a consequence of its family
planning program, IMSS was able to divert a
total of 318 billion pesos during 1972-1985
from maternal and infant care to payments for
pensions and general health services. 1 figure,




Potential Uses of Cost Analyses in Child
Survival Programmes: Evidence From
Africa.
Form: Journal article.
Author: Quails, N.L.; Robertson, R.L.
Source: Health Policy and Planning.
4(1):50-61, March 1989.
Abstract: Researchers determined how cost
analyses help international health care
specialists to monitor service delivery, evaluate
activities, plan for improvements in programs,
and arrange for adequate financing. They used
results from child survival programs in Africa,
with particular emphasis on evaluations of
selected national program components from the
Combatting Childhood Communicable
Diseases (CCCD) Project. The CCCD Project
emphasizes three categories of childhood
diseases, (1) vaccine preventable diseases
(EPI), (2) acute diarrhoeal diseases (ORT),
and (3) malaria, and delivers preventive health
services to children under 5 years of age in
Africa. Researchers studied overall total costs
and their distribution among sources of funds
and types of inputs on a CCCD Project in
Swaziland and Malawi in 1984-1985. The
total costs and cost per capita for the program
components of EPI were $1,588,776 and
$0.24 for Malawi and $412,542 and $0.60 for
Swaziland. The total costs and cost per capita
for the program components of ORT were
$396,842 and $0.06 for Malawi and $374,491
and $0.54 for Swaziland. The total costs and
cost per capita for the program components of
malaria were $1,324,661 and $0.20 for
Malawi and $162,219 and $0.24 for
Swaziland. Data on the costs per out-patient
for diarrhoeal disease treatment in Malawi (in
Kwacha) and in Swaziland (in Emalangeni)
included total cost, number of out-patient
cases, and average cost per case. The average
costs per case in Malawi clinics (in U.S.
dollars) were in Kamuzu, $1.07; in Mangochi,
$0.42; in Nathenje, $0.17; in Nankhumba,
$8.47; and in Chonde, $0.27. The average
costs per case in Swazi clinics (in U.S. dollars)
were $3.98 in Raleigh Fitkin; $4.83 in Good
Shepherd; $4.57 in Mankayane; $4.14 in
Emkhuzweni; $19.06 in Sitobela; $2.25 in
Balekane; $2.45 in Lavumisa; $3.18 in
Lomahasha; $3.49 in Lubuli; $3.34 in
Mafutseni; $4.14 in Ngonini Estates; and
$0.72 in Siphofaneni. Data on the costs per
immunization dose in Malawi (in Kwacha) and
in Swaziland (in Emalangeni) included total
cost, number of doses, and average cost per
dose. The average costs per dose in Malawi
clinics (in U.S. dollars) were in Kamuzu,
$1.67; in Dedza, $1.58; in Queen Elizabeth,
$0.56; in Mulanje, $0.69; in Nkhata Bay,
$4.12; in Kabadula, $2.13; in Kaphuka,
$1.50; in Chinteche, $2.08; in Kawale, $.46;
in Bembeke, $1.92; in Limbe, $0.10; in
Monkey Bay, $0.84; in Nankhumba, $0.88; in
Chonde, $0.27; in Phalombe, $0.10; in
Milonde, $0.55; in Mbamba, $0.39; and in
Maula, $0.35. The average costs per dose in
Swazi clinics (in U.S. dollars) were in King
Sobhuza II, $4.78; in Mbabane, $6.56; in
Raleigh Fitkin, $1.31; in Good Shepherd,
$1.45; in Mankayane, $4.55; in Emkhuzweni,
$1.94; in Havelock Mine, $3.83; in Sitobela,
$9.33; in Balekane, $1.71; in Lavumisa,
$0.91; in Lomahasha, $0.99; in Lubuli, $2.89;
in Mafutseni, $1.45; in Mliba, $2.28; in
Ngonini Estates, $5.01; in Siphofaneni, $1.63;
and in Siteki $3.45. A comparison of the cost
profiles for the full CCCD Project of Malawi
and Swaziland and of specific local health care
facilities within those countries indicated major
differences in personnel costs. The fully
vaccinated child costs for Malawi and
Swaziland were $11.48 and $50.57,
respectively. In comparison with Malawi,
Swaziland had a significantly higher cost per
dose, $2.58 versus $0.99 and a greater number
of doses required for full vaccination status.
The Swazi ratio of vaccine doses consumed to
vaccinations delivered for all types except
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tetanus, was 2.42; the Malawi ratio was 1.56.
Swazi programs had higher vaccine loss and
wastage rates. Researchers determined that
Swazi EPI officials needed to review policies
and practices on vaccine handling to improve
efficiency. Malawi had a larger number of
health care facilities, with more data
limitations, than Swaziland; however,
Malawi's operations and estimations for uses





Author: Rinehart, W.; Blackburn, R.;
Moore, S.H.
Source: Population Reports.
Series J: Family Planning Programs.
(34):92 1-951, September-October 1987.
Abstract: The authors examine family
planning in developing countries and discuss
how such services in the workplace make
sense for both employers and employees.
Large manufacturers and plantations in India
first offered family planning to workers in the
1950's. Now many large companies have
added family planning to other health services
in such locations as Indonesia, the Philippines,
Thailand, South Korea, Turkey, Egypt, and
Kenya. In some Latin American countries,
social security systems have provided family
planning for many workers. The type of
groups that run employment-based programs in
various countries include companies, labor
unions, government-sponsored social
marketing programs, and the military.
Services are offered in workplace clinics,
through referrals, in freestanding facilities, in
social security hospitals, and in community-
based clinics. Funding comes from
employers, governments, unions, family
planning associations, and the United States
Agency for International Development
(USAID). The most effective programs offer
supplies and services as well as information,
offer them directly at the workplace, and use
volunteer workers to distribute birth control
pills and condoms. Successful programs
require the full support of company
management. ElectroLima (an electric utility
in Peru) provides health care for almost 2,500
married women between ages 20-49. It found
that savings ($55,000) could exceed costs
($30,000) by more than two to one in the third
year of a program, for total savings of
$25,000. This type of favorable cost-benefit
projection can show managers that offering
family planning makes financial sense and also
contributes to employee health. 218
references.
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Health Spending, Delivery, and Outcomes in
OECD Countries.
Form: Journal article.
Author: Schieber, G.J.; Poullier, J.;
Greenwald, L.M.
Source: Health Affairs . 12(2): 120-129,
Summer 1993.
Abstract: Researchers analyzed and compared
health expenditures in 24 industrialized nations
between 1985 and 1991. They discussed
availability and use of inpatient medical care
and physician services and data on infant
mortality and life expectancy. The ratio of
health spending to gross domestic product
(GDP) ranged from 2.8 percent in Turkey to
10.5 percent in the U.S. in 1985 and 4.0
percent in Turkey to 13.2 percent in the U.S.
in 1991. Over the same period, the average
health-to-GDP Organization for Economic
Cooperation and Development (OECD) ratio
increased from 7.2 to 7.9 percent. Per capita
spending was calculated on the basis of GDP
purchasing power parities (PPP's) for 1985 to
216
International Health
1991. In 1985, per capita spending ranged
from $66 in Turkey to $1,711 in the U.S.,
with an OECD average of $855. By 1991, per
capita health expenditures ranged from $142 in
Turkey to $2,868 in the U.S., with an OECD
average of $1,305. Researchers analyzed five
additional measures of health spending
performance for Canada, France, Germany,
Japan, the United Kingdom and the U.S. based
on national currencies: (1) Compound annual
growth rates in nominal per capita health
spending, (2) real (medical price-adjusted) per
capita health spending, (3) real (GDP deflator-
adjusted) per capita health spending, (4) excess
health care inflation, and (5) the nominal
elasticity of per capita health spending relative
to per capita GDP. The U.S. had the highest
rates of growth in real health spending (5
percent), excess medical care inflation (2.3
percent), and highest nominal elasticity of
health spending relative to GDP (1.7). In
growth in nominal per capita health spending
and real per capita spending, the U.S. ranked
second (9 percent, slightly below the U.K. rate
of 9.9 percent) and third (2.7 percent, behind
Japan at 4.5 and France at 4.3), respectively.
Availability and use of services measures
included 1990 information on (1) inpatient
medical care, (2) beds per thousand
population, (3) inpatient days per capita, (4)
admission rates, (5) average lengths-of-stay,
(6) occupancy rates, (7) number of employees
per bed, (8) number of physicians per
thousand, and (9) physician contacts per
capita. The number of inpatient medical care
beds ranged from 2.1 beds per thousand in
Turkey to 16.7 beds in Iceland, 4.7 beds in the
U.S. (fourth lowest), and an OECD average of
9.0 beds. Days per capita ranged from 0.4
days per person per year in Turkey to 5.1 days
in Iceland, 1.2 days in the U.S. (fifth lowest),
and an OECD average of 2.7 days. The
percentage of population admitted to an
inpatient medical care facility varied from 5.6
percent in Turkey to 27.5 percent in Iceland,
13.7 percent in the U.S., and an OECD
average of 16.6. Average length of stay per
admission varied from 6.9 days in Turkey to
50.5 in Japan, 9.1 days in the U.S, and an
OECD average of 15.7 days. Occupancy rates
ranged from 56.9 percent in Turkey to 88.5
percent in the Netherlands, 69.5 percent in the
U.S, and an OECD average of 78.5. Number
of employees ranged from 0.8 in Austria and
Japan to 3.9 in Australia, 3.4 in the U.S.
(ranked second), and an OECD average of
2.0. Physicians-to-population ratios ranged
from 0.9 per thousand in Turkey to 3.8 in
Spain, 2.3 in the U.S, and an OECD average
of 2.4. Physician contacts per capita ranged
from 2.0 in Turkey to 12.9 in Japan, 5.5
contacts in the U.S., and an OECD average of
6.2. Health outcome measures for 1990
included (1) infant mortality, (2) life
expectancy at birth, and (3) life expectancy at
eighty. Infant mortality rates ranged from 4.6
deaths per thousand live births in Japan to 59.3
deaths in Turkey, 9.1 in the U.S., and an
OECD average of 9.7 deaths (7.5 excluding
Turkey). Male life expectancy at birth ranged
from 75.9 years in Japan to 64.1 years in
Turkey, 72 years in the U.S., and an OECD
average of 72.6 years. Female life expectancy
ranged from 81.9 years in Japan to 68.4 years
in Turkey, and 78.8 years in the U.S. and in
the OECD. Male life expectancy at 80 ranged
from 7.4 years in Iceland to 5.2 years in
Turkey, 7.1 years in the U.S., and 6.4 years
for an OECD average. Female life expectancy
at 80 ranged from 9.3 years in Canada to 5.9
years in Turkey, 9.0 years in the U.S., and 8
years for an OECD average. The authors
suggested that the lack of a coordinated and
comprehensive system for providing preventive
and prenatal care to the entire population
accounted for the lower scores for the U.S.
system; however, that the U.S. had a larger
pool of money with which to transform its
current system into one that meets other





Third World Family Planning Programs:
Measuring the Costs.
Form: Journal.
Author: Yinger, N.; Osborn, R.;
Salkever, D.; Sirageldin, I.
Source: Population Bulletin. 38(1): 1-36,
February 1983.
Abstract: This population bulletin is based on
papers presented at the International Workshop
on Cost-Effectiveness Analysis (CEA) and
Cost-Benefit Analysis (CBA) in Family
Planning Programs, held in August 1981 in St.
Michaels, Maryland. Researchers explain and
demonstrate the use of CBA and CEA in
evaluating Third World family planning
programs. CBA, which aids decisions on
alternate uses of investment funds (for
example, family planning versus new schools),
helped convince Third World governments to
adopt family planning programs because of
their economic value in overall development.
CEA is a technique that can show which
family planning delivery systems work best for
the money expended as measured, for
example, by cost per acceptor, per couple-year
of protection (CYP) against the risk of
pregnancy, or per birth averted. This is
increasingly necessary in the 1980's as funds
for family planning are being pinched in both
developing and donor countries. At the same
time, researchers estimate that annual
expenditures on family planning in the Third
World must rise from the current $1 billion to
$64 billion by the year 2000 if this population
is eventually to be stabilized. Researchers
present nine case studies from Brazil,
Colombia, Ghana, Haiti, India, Thailand, and
Zaire to demonstrate what CEA has revealed
about such issues as integration of family
planning with health services, use of
paramedical staff and community-based
distribution to promote contraceptive use, and
important factors to include to ensure
comparability of findings. CEA can be
improved to make it more useful in practice by
(1) including all inputs, (2) evaluating services
and methods, (3) relying less on cost per
acceptor, (4) considering user characteristics,
and (5) building the data needed into the
project at the planning stage. Little cost
information is included in the article and what
exists is not comparable among the different
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Form: Journal article.
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Evaluation of the Cost-Effectiveness of
Mobile Family Planning Services in Tunisia.
Form: Journal article.
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Source: Studies in Family Planning.
20(3): 158-169, May-June 1989.
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1983. United Nations, Department of
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New York, NY, United Nations,
pp. 229-247, 1984.
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Illegal Abortion: An Attempt to Assess its
Cost to the Health Services and Its
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Form: Journal article.
Author: Figa-Talamanca, I.;
Sinnathuray, T.A.; Yusof, K.; Fong, C.K.;
Palan, V.T.; Adeeb, N.; Nylander, P.;
Onifade, A.; Akin, A.; Bertan, M.;
Gaslonde, S.; Edstrom, K.; Ayeni, O.;
Belsey, M.A.
Source: International Journal of Health
Services. 16(3): 375-389, 1986.
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Form: Journal article.
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Wirima, J.J.; McFarland, D.A.;
Khoromana, CO.; Campbell, C.C.
Source: Transactions of the Royal Society of
Tropical Medicine and Hygiene.
84(4):496-498, July-August 1990.
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Form: Journal article.
Author: Phonboon, K.; Shepard, D.S.;
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Source: Bulletin of the World Health
Organization. 67(2): 181-188, 1989.
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Form: Journal article.
Author: Khan, A.R.; Begum, S.F.;
Covington, D.L.; Janowitz, B.; James, S.;
Potts, M.
Source: Journal of Biosocial Science.
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Form: Journal article.
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2(l):49-76, January 1988.
R425
Cost-effectiveness of the Expanded
Programme on Immunization in the Ivory
Coast: A Preliminary Assessment.
Form: Journal article.
Author: Shepard, D.S.; Sanoh, L.; Coffi, E.
Source: Social Science and Medicine.
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Complexity of the Equation.
Form: Journal article.
Author: Archambault, A.
Source: Journal of the Canadian Dietetic
Association. 49(2): 80-85, Spring 1988.
Abstract: Identifying and valuing costs and
benefits, measuring effectiveness, and
assessing quality of life are complex and
difficult issues. A researcher discussed these
issues in reference to Canadian studies on the
cost effectiveness of nutrition support and
stressed the need for further research to
improve cost effectiveness of nutrition support.
The paper presented definitions of the concepts
cost-benefit analysis (CBA) and cost-
effectiveness analysis (CEA) and outlined the
set of basic steps followed in CBA and CEA.
Detsky and Jeejeebhoy used cost-effectiveness
analysis to compare three strategies for
reducing incidence of severe nutrition-
associated complications in patients undergoing
major gastrointestinal surgery. These authors
used a decision tree reflecting the structure of
possible outcomes for three possible strategies:
(1) Treat all patients with parenteral nutrition
support (PNS) for 10 days before surgery; (2)
treat no patients with preoperative parenteral
nutrition support; and (3) perform a test that
stratifies patients, and treat only the high risk
patients. Comparison of the test strategy with
the strategy to treat all patients showed that
fewer patients would develop iatrogenic
complications (IC's), whereas more would
develop nutrition associated complications
(NAC's). Comparison of the test strategy with
the strategy to treat no patients showed that
fewer patients would develop NAC's whereas
more would develop IC's. This trade-off of
IC's for NAC's with the test strategy is the
key to the risk-benefit analysis. The results of
Detsky and Jeejeebhoy suggest that
preoperative PNS may prove to be very cost
effective in some clinical circumstances despite
its high cost. The author also discusses
measures of effectiveness used in economical
appraisal of health care programs for resource
allocation decisions. Outputs from health
programs and interventions can be measured
(1) in units inherent to the program or disease
treated, i.e., cases detected, cases prevented,
lives saved, or life years gained; (2) in
economic benefits associated with health
improvements, i.e., direct benefits in saving
health care costs, indirect benefits in
productivity gains because patients are well
and able to work, or intangible benefits of
reduction in pain and suffering to the patient
and family; and (3) the value of the health
improvement to the patient, family, or society
regardless of any economic consequences.
Approaches can be classified into three groups:
(1) Use of ad hoc numeric scales, assessing the
patient on aspects of his or her health; (2) use
of basic techniques for valuing health benefits,
including human capital and willingness to
pay; and (3) use of utilities and quality-
adjusted life-years (QALY's), giving utilities
cardinal values assigned to each health state,
values that reflect the quality of health states,
and values that allow morbidity and mortality
improvements to be combined into a single
weighted measure of QALY's gained. Detsky
et al. performed an economic evaluation of a
home parenteral nutrition (HPN) program by
measuring incremental costs and health
outcomes for 73 patients between 1970 and
1982. Over a 12-year time frame, HPN
resulted in a net savings in health care costs of
$19,232 per patient and an increase in survival
adjusted for quality of life of 3.3 years
compared with the alternative of treating these
patients in the hospital with intermittent
nutritional support when needed. Detsky et al.
estimated that HPN resulted in incremental
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costs of $48,180 per patient over 12 years, or
$14,600 per QALY gained. 1 figure, 11
references.
430
Modeling Resource Allocation for Child
Survival.
Form: Book chapter.
Author: Barnum, H.N.; Barlow, R.
Source: IN: Child Survival: Strategies for
Research. Mosley, W.H.; Chen, L.C.; eds.
New York, NY, Cambridge University Press,
pp. 367-387, 1984.
Availability: Cambridge University Press,
40 West 20th Street, New York, NY 10011.
Abstract: Modeling Resource Allocation for
Child Survival is a chapter in Child Survival:
Strategies for Research. The chapter presents
a framework to provide a direct assessment of
health interventions designed to raise the
probability of child survival in a hypothetical
community. Direct interventions are a
practical way to improve the rate of child
survival in developing countries. Despite
technical feasibility, resource constraints
restrict the adoption of projects; health
programs must therefore also be examined
with respect to economic feasibility. Questions
that arise include the cost effectiveness of
curative versus preventive care; indirect versus
direct health services; the choice of appropriate
population targets; the relative importance of
nutrition interventions; and identifying
constraining resources as well as estimating the
benefits to be derived from additional
resources. Salient features of the proposed
model include the use of interactive
simultaneous equations to model the causes of
death in a setting of multiple diseases, the
clear distinction between preventive activities
affecting morbidity and curative activities
affecting case fatality rates, and the separation
of the early childhood period into age
subgroups with distinct morbidity
characteristics. The optimization model also
distinguishes between program use and
program availability, and sets intervention
levels that tend to equilibrate use and
availability. The three types of structural
equations in the model generate the rates for
intervention use, marginal disease incidence,
and fatality. The interventions selected for a
hypothetical resource-poor community are
health promotion, breast feeding, latrines,
water, well-baby clinics, tetanus immunization,
iron fortification tablets for all women, and
outpatient services for infants in the first 28
days. Results indicate that inpatient care and
hospital deliveries are not cost effective, and
are not adopted by the optimization program
until community resources reach high levels.
Nutrition interventions deserve special
emphasis, and timing is crucial to the cost
effectiveness of prenatal care. 4 figures, 2
tables.
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Health Service Efficiency: Appraising the
Appraisers. A Critical Review of Economic
Appraisal in Practice.
Form: Journal article.
Author: Blades, C.A.; Culyer, A.J.;
Walker, A.
Source: Social Science and Medicine.
25(5):461-472, 1987.
Abstract: Researchers presented a critical
appraisal of the application of economic
evaluative techniques to problems of health
service efficiency. They focused largely on
the British literature and selected some
recurring issues, commented on them from a
theoretical point of view, and illustrated them
with examples of good and bad practice. The
paper is organized into four sections: (1) An
introduction, (2) treatments of cost, (3)
treatments of benefit, and (4) design and
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presentational issues. Treatments of cost
include (1) the concept of opportunity cost, (2)
the breadth of coverage of costs, (3) the
treatment of averted costs, (4) the art of
spotting and measuring marginal costs, and (5)
discounting. A study by Culyer and Maynard
(1981) discussed medical and surgical
alternatives in the treatment of duodenal
ulcers; inclusion of the cost of surgical
fatalities produced a range of cost per case for
the surgical option of 1,180 to 16,370 British
pounds, relative to a range for the medical
option of 1,020 to 1,240 pounds. Excluding
these costs brought the cost per surgical case
down to 950 to 1,370 pounds. In a marginal
cost analysis in the United States, in screening
for asymptomatic colon cancer (Neuhauser and
Lewicki 1975), while the average cost per case
detected using a protocol with six sequential
tests was only $2,451, the incremental cost per
case detected by performing a sixth test
(having already completed five tests) was $47
million. Most of the studies point out the
variety with which breadth is treated in
practice and urge analysts on to the greatest
possible breadth. One study that took a very
comprehensive view of the breadth of coverage
was that by Hagard et al. This study sought to
identify the costs and economic benefits of a
program for the mass screening of pregnant
women for early detection and abortion of
fetuses with neural tube defects. The costs of
the program were seen as falling primarily on
the health service but a significant portion of
costs (28 percent) also fell on patients.
Relevant marginal costs are often exceedingly
elusive and even sophisticated practitioners
have often failed to spot them, often as a result
of screening procedures. All studies urge the
discounting of costs and benefits. Discounting
is likely to make a difference in the relative
attractiveness of alternatives when the time
profile of costs is substantially different as
between the options. Benefits can be evaluated
through (1) cost-effectiveness analyses, (2)
cost-utility analyses, and (3) cost-benefit
analyses. Researchers discuss the output
measures and outcome measures as related to
monetary and nonmonetary assessment.
Design and presentation of studies should
encompass a variety of alternatives, sensitivity
and robustness in the data analyses, and
decision indexes for ranking and distribution of
costs and benefits. Researchers should also be
aware of quantophrenia, a condition
characterized by the quantified driving out the
important. 4 tables, 59 references.
432
Problems and Prospects in the Economic
Evaluation of Antenatal Care.
Form: Journal article.
Author: Buhaug, H.
Source: International Journal of Technology
Assessment in Health Care.
8(Supplement l):49-56, 1992.
Abstract: The author elaborates on (1) the
basic elements of an economic evaluation
(antenatal care, health status, resource use,
productive output, health outcome, net cost,
and comparison); (2) health outcomes and
effectiveness; and (3) changes in antenatal care
programs. He presents preliminary results
from a antenatal cost study being conducted in
Oppland, Norway to illustrate his views. The
average cost of routine antenatal care per
expectant mother was Nkr 2,840 with the first
visits accounting for more than 20 percent of
the average cost. The average number of
visits was 1 1 . Assuming that there is an
additional basic cost of each visit, close to 50
percent of the cost is due to the number of
visits only and not to the procedures being
performed. Thus, the cost of routine antenatal
care is only a small fraction of the total cost
associated with pregnancies. Average
outpatient cost per pregnant woman was Nkr
2,087 and the average cost per inpatient case
was Nkr 13,400. The average cost per
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delivery was Nkr 12,868. Loss of productive
output due to health problems during
pregnancy is the largest cost component. This
cost average per pregnant woman was Nkr
17,273. The range was Nkr 0-175,900 (278
days), yet fifty-two percent did not have a sick
leave during pregnancy. After reviewing this
study, he asserts that (1) economic evaluations
can be used to compare alternative antenatal
care programs in terms of cost and outcome,
(2) the cost of routine antenatal care is small
compared to the total cost associated with
pregnancy and childbirth, and (3) the main
problem in economic evaluations is related to
outcome measurement. 3 tables, 3 figures,
5 references.
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Measuring Costs and Financial Benefits in
Randomized Controlled Trials.
Form: Journal article.
Author: Bulpitt, C.J.; Fletcher, A.E.
Source: American Heart Journal.
119(3, Part 2): 766-771, March 1990.
Abstract: Researchers measured the costs and
financial benefits in randomized controlled
trials using three main types of evaluation:
(1) Cost-effectiveness analysis (CEA), (2) cost-
utility analysis (CUA), and (3) cost-benefit
analysis (CBA). The costs included direct
costs of medical-related care and indirect costs
of productivity losses or those associated with
illness, measured by loss of earnings.
Economic benefits were defined as when a
treatment program results in an increase in
earnings, measured in natural units, e.g.,
health effects and utility units, e.g., quality-
adjusted life years (QALY's). A CEA using
1987 prices in British pounds and measured in
biologic units (mm Hg) was done on the
results of a double-blind trial that compared
the use of verapamil and propranolol in the
treatment of patients with hypertension.
Verapamil (average dose 160 mg, twice daily)
lowered systolic blood pressure by 17.1 mm
Hg and diastolic by 17.3 mm Hg at a cost of
42 British pounds; propranolol (average dose
120 mg, twice daily) lowered systolic blood
pressure by 9.3 mm Hg and diastolic by 11.0
mm Hg at a cost of 16 British pounds. The
verapamil more effectively lowered systolic
blood pressure by 7.8 mm Hg and diastolic by
6.3 mm Hg at an additional cost of 26 British
pounds per dose. The marginal costs for
systolic and diastolic pressures were 2.46 mm
Hg and 2.43 mm Hg for verapamil and 1.72
mm Hg and 1.45 mm Hg for propranolol.
The CEA outcome indicated that 1 mm Hg
reduction was achieved at a cost of 3.33
pounds per mm Hg for systolic and 4.13
pounds per mm Hg for diastolic. The CUA
was 140 pounds per QALY for verapamil and
57 pounds for propranolol. The full cost of a
QALY with verapamil was 1,300 British
pounds. The CUA calculated the QALY's by
integrating the survival with a measure of
quality of life, the Health Status Index. A
CBA measured the consequences of
intervention in a hospital-based mental health
program in the United States The hospital-
based program proved less expensive at $797
per patient per year than a community-based
program. However, when the indirect benefit
of patient earnings was taken into account,
patients in the community-based program
earned twice as much as those in the hospital-
based program for a net benefit of $399 per
patient per year for community care.
Researchers also performed a CBA on the use
of naftidrofuryl in the treatment of acute
cerebral hemisphere infarction using 100
patients eligible for drug treatment. In the
treatment of acute cerebral hemisphere
infarction, the direct costs were $3,260
million, the indirect costs were $438 million,
and the present value of future earnings, with
a 6 percent discount rate, was $3,666 million.
Data from the United Kingdom indicated that
naftidrofuryl therapy reduced hospital stays by
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an average of 25 days, or freed resources of
550 British pounds. In a randomized
controlled 6-month trial of auranofin for the
treatment of rheumatoid arthritis, researchers
included quality of life measures. The Health
Status Index, on the Quality of Weil-Being
Scale showed a significant +0.02 improvement
with auranofin. The CBA showed an increase
in costs of $707 per year on placebo and
$1,563 per year on auranofin, or $856 in extra
costs. The investigators did not perform a
CUA on the auranofin trial. Results indicated
that economic evaluation is justified whenever
a more expensive treatment is expected to
produce greater benefit and that economic
analyses should consider quality of life and
health status as well as the more easily
identifiable economic outcomes.
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Comparison of the Effects of Per Case and
Per Diem Based Charges on the Distribution
of Hospital Costs Across Employer Groups.
Form: Journal article.
Author: Cline, K.E.
Source: Medical Care. 28(8):68 1-702,
August 1990.
Abstract: Using data generated by the
Experimental Hospital Case Mix Payment
Program of Blue Cross of Western
Pennsylvania, researchers (1) compared
employer group claims based on Patient
Management Categories (PMC's) (i.e., an
average cost per diagnostic case) with costs
based on an average cost per day and (2)
identified diagnostic, group, and hospital
characteristics that influence the differences in
a group's costs under the case mix versus the
per diem methodologies. A correlation of
differences between PMC's and the diagnosis-
related groups (DRG's) used by the federal
government revealed a correlation coefficient
of 0.98, statistically significant at the 0.0001
level. The PMC system classifies patients in
up to five categories, allowing for the presence
and degree of comorbidity. To compute total
PMC payments for a given hospital,
researchers calculated an average unit price by
dividing a hospital's fiscal year 1987 projected
Blue Cross inpatient expenses, excluding
capital and medical education costs, by its total
PMC units that were derived for Blue Cross
patients. The hospital's Blue Cross capital and
medical education costs were divided by its
budgeted Blue Cross admissions to develop a
capital and medical education cost per case. A
hospital's total PMC payment is therefore the
sum of its PMC unit price multiplied by its
total PMC units, and its capital and medical
education costs per case multiplied by its total
admissions for Blue Cross patients treated by
the hospital during fiscal year 1987.
Researchers simulated payments based on
PMC's for approximately 200,000 inpatient
Blue Cross claims submitted by 88 hospitals
for the 12 month period ending June 1987,
then distributed each hospital's total PMC
payments to groups (1) on the basis of each
group's total PMC units and its admissions and
(2) on the basis of a group's total patient days.
The analysis showed that changing the basis of
employer group costs from the traditional per
diem method to one based on diagnostic case
would substantially increase the costs of many
groups; 14 percent would pay at least 150
percent more ($12 million). In a model
explaining differences in employer group costs
between the two payment methods
($500,379,026 for costs based on PMC's and
$500,389,244 for costs based on adult days),
patient diagnosis was found to be the major
explanatory factor, contributing to two-thirds
of the total explained variation. For example,
for 671 groups experiencing more costs under
the PMC method, costs based on PMC's
exceed costs based on days by about $7
million. Results indicated that (1) a group's
total admissions, mean patient age, and gender
distribution and (2) a hospital's teaching status,
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location, patient capacity, occupancy rate, and
mean ancillary costs influence the differences
in a group's costs under the two methods.
2 figures, 6 tables, 5 references.
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Economic Evaluation and the Rational
Diffusion and Use of Health Technology.
Form: Journal article.
Author: Drummond, M.F.
Source: Health Policy. 7(3):309-324,
June 1987.
Abstract: A researcher discusses the 1986
European Community initiative on the
Methodology of Economic Appraisal of Health
Technology and its objective, to establish a
workshop consisting of members of
collaborating centers to review the state of the
art of economic appraisal of technologies as it
currently exists in Europe and to recommend
suitable methodologies. He addresses two
issues: (1) Improving the design and conduct
of economic evaluations to increase their
relevance to health care decision making at the
planning and clinical stages, and (2) devising
policies on the diffusion and use of health
technology to make fuller use of the economic
evaluations that are carried out. Empirical
studies support economic evaluation of
expensive and nonexpensive technologies
through cost benefit analysis. The major
principles for economic evaluation were set out
in a 10-point checklist of questions by the
Department of Clinical Epidemiology and
Statistics, McMaster Health Sciences Center,
Ontario, Canada: (1) Was a well-defined
question posed in an answerable form; (2) was
a comprehensive description of the competing
alternatives given (i.e., could one determine
who did what to whom and how often); (3)
was there evidence that the program's
effectiveness had been established; (4) were all
important and relevant costs and consequences
for each alternative identified; (5) were costs
and consequences measured accurately in
appropriate physical units prior to evaluation;
(6) were costs and consequences valued
credibly; (7) were costs and consequences
adjusted for differential timing; (8) was an
incremental analysis of costs and consequences
of alternatives performed; (9) was a sensitivity
analysis performed; and (10) did the
presentation and discussion of the results of the
study include all issues of concern to users.
Researchers calculated quality-adjusted life-
years (QALYs) by obtaining the utility values
of health states on a scale from (dead) to 1
(healthy), and then combining these utility
weights with the data on the years of life
gained. The cost-utility analysis, more general
than the cost effectiveness analysis, can be
used to evaluate health care interventions that
impact on the quality of life as well as the
quantity of life. Torrance and Zipursky
compared cost-utility results in reported cost
and adjusted cost (in 1983 U.S. dollars) per
QALY for the following selected programs:
(I) Phenylketonuria (PKU) screening, less than
zero; (2) post-partum anti-D to Rh-negative
mothers, less than zero; (3) antepartum anti-D
to Rh-negative mothers, $1,220 (1983 results);
(4) coronary artery bypass surgery for left
main coronary artery disease, $3,500 and
$4,200; (5) neonatal intensive care, 1000-1499
grams, $2,800 and $4,500; (6) T4 (thyroid)
screening, $3,600 and $6,300; (7) treatment of
severe hypertension (diastolic greater than or
equal to 105 mm Hg) in males age 40, $4,850
and $9,400; (8) treatment of mild hypertension
(diastolic greater than or equal to 95-104 mm
Hg) in males age 40, $9,880 and $19,100; (9)
estrogen therapy for postmenopausal symptoms
in women who had not had a hysterectomy,
$18,160 and $27,000; (10) neonatal intensive
care, 500-999 grams, $19,600 and $31,800;
(II) coronary artery bypass surgery for single
vessel disease with moderately severe angina,
$30,000 and $36,300; (12) school tuberculin
testing program, $13,000 and $43,700; (13)
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continuous ambulatory peritoneal dialysis,
$35,100 and $47,100; and (14) hospital
hemodialysis, $40,200 and $54,000. Possible
mechanisms for encouraging a rational
diffusion and use of health technology are
regulation by directive by central/regional
government and regulation by incentive.
Regulation by directive includes (1) planning
of facilities, specialist departments, and
specific technologies; (2) excluding
technologies from public financing; (3)
developing settlement policies for health
manpower; and (4) strengthening pre-market
controls for drugs and devices (safety,
efficacy). Regulation by incentive includes (1)
reforming budgetary programs within health
care institutions; (2) encouraging budgetary
reform within health care institutions; (3)
changing payment systems for health care
providers; (4) subsidizing specific
technological developments; (5) charging
patients; (6) encouraging competitive
arrangements; and (7) developing medical
audit and utilization review systems. A league
table lists costs and consequences of selected
medical procedures in terms of the present
value of extra cost per QALY gained in British
pounds: (1) Pacemaker implantation for heart
block, 700; (2) hip replacement, 750; (3) valve
replacements for aortic stenosis, 950; (4)
coronary bypass grafting (CABG) for severe
angina with left main disease, 1,040; (5)
CABG for moderate angina with 3 vessel
disease, 2,400; (6) kidney transplantation
(cadaver), 3,000; (7) heart transplantation,
5,000; (8) home hemodialysis, 11,000; (9)
CABG for mild angina with two vessel
disease, 12,600; and (10) hospital
hemodialysis, 14,000.
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Survey of Cost-effectiveness and Cost-
benefit Analyses in Industrialized Countries.
Form: Journal article.
Author: Drummond, M.F.
Source: World Health Statistics Quarterly.
38(4):383-401, 1985.
Abstract: This survey grouped studies under
six broad headings: (1) Burden of disease and
alternatives in public policy, (2) alternatives in
prevention, (3) alternatives in diagnosis, (4)
alternatives in therapy, (5) alternative locations
of care, and (6) alternatives in health service
organization. These topics are first discussed
briefly, and then, using one study from each
topic area, are discussed in detail. A number
of studies have sought to estimate the
economic burden of particular diseases on the
community, with a view to informing the
debate on priorities for investment in health
programs. An example of such cost of illness
studies is that by Cooper and Rice, who
estimated the costs of a number of disease
groupings in the United States in terms of the
direct resource outlays for prevention,
detection, and treatment, and the indirect costs
or loss in output due to disability and
premature death. Cooper and Rice calculated
that the total cost of illness in 1972 was $189
billion, of which $40 billion was for diseases
of the circulatory system, $27 billion for
accidents, and $17 billion each for diseases of
the digestive system and cancer. Tables
present data on (1) cost effectiveness of seven
programs for reducing perinatal mortality and
morbidity in France; (2) cost effectiveness of
programs to reduce cholesterol level in
children in the United States; (3) measures of
economic evaluation of neonatal intensive care,
according to birthweight class in Canada; (4)
alternative forms of care for the elderly in the
United Kingdom; (5) weekly costs of care by
dependency category in different care settings
in the United Kingdom; and (6) annual total
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costs per capita for elderly populations in the
United Kingdom. 1 figure, 5 tables, 73
references.
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Economic Analysis and Clinical Trials.
Form: Journal article.
Author: Drummond, M.F.; Stoddart, G.L.
Source: Controlled Clinical Trials.
5(2): 115-128, June 1984.
Abstract: Researchers propose criteria for
judging the appropriateness of including
economic analysis in a given trial, suggest how
that analysis could be phased in order to
minimize the work involved, and discuss the
wider implications for medical research of
more frequent attention to economic concepts.
Economic analyses should be built into clinical
trials when: (1) Sizeable amounts of scarce
resources are at stake; (2) responsibility is
fragmented; (3) the objectives of the respective
parties are at variance or unclear; (4) there
exist significantly different alternatives, such
as drug therapy versus surgery or hospital
versus home-based care; (5) the technology
underlying each alternative is well understood;
and/or (6) the results of the analysis are not
required before valid estimates of effectiveness
are available. The kinds of indications
medical researchers should use to assess
whether economic analysis should be built into
a given trial are: (1) Imminent resource
allocation decisions, if the results of the trial
are likely to be influential in deciding future
patterns of care, or pressures for the adoption
of the new therapy mean that this is likely to
be the last trial; (2) large resource
consequences, if the unit cost difference
between the alternatives is suspected to be
large, or the size of patient population is large;
and (3) prominence of resource considerations,
if questions of resource use are viewed to be
important either by the clinical investigators,
the research funding body, or those who fund
health care. Data requirements for economic
analysis include (1) health service resource use
both in the hospital and community sectors, (2)
the impact of the new treatment on other
community resource use, and (3) the impact of
the new therapy on health status. Key points
to consider when evaluating the data
requirements for economic analysis are (1)
performing a full economic evaluation that
considers not only the costs but also the
benefits of health care interventions; (2)
adopting a community-wide viewpoint; and (3)
ensuring that measurement of costs and
benefits is not exclusively in money terms, but
also in health effects or utilities. Phasing of
economic analysis in the development of a new
therapy should be performed in the following
stages: (1) Stage one, first explanatory trials
to make an estimate of the relative costs of the
alternatives being compared; (2) stage two,
during a selected trial, collect data, such as
length of hospital stay, use of hospital
resources and services, loss of productivity by
patient and family, and impact on family
resources; and (3) stage three, harvest the
economic information relevant to the policy
questions suggested by the medical results of
the trial. The authors maintain that phasing in
of the analysis avoids unnecessary work and
that general economics capability should be
built up in institutions where trials are carried
out, rather than tying the employment of






sociolegal (i.e., laws governing abortion and
surrogate mothering). 1 figure, 4 tables, 30
references.
Form: Journal article.
Author: Fuchs, V.R.; Perreault, L.
Source: Journal of the American Medical
Association. 255(1):76-81, January 1986.
Abstract: Researchers present systematic
estimates of the direct money costs of
reproduction-related health care in 1982: (1)
Obstetrical care, (2) infant care, (3)
contraception, (4) abortion, and (5) infertility
services. The estimates are constructed
primarily by multiplying estimated quantities
by estimated prices using data drawn from
sources ranging from national surveys to small
clinical studies. All prices and quantities are
for 1982, unless otherwise stated.
Expenditures for reproduction-related health
care amounted to $17.8 billion in 1982; this
was 5.5 percent of the total health care
spending of $322 billion. The reproduction-
related sector was dominated by obstetrical
care and infant care, which took 46 percent
and 37 percent respectively. Contraception
accounted for 13 percent, while abortion and
infertility services were 3 percent and 1
percent, respectively. Expenditures per
woman of childbearing age were $329.
Although only 39 percent of all women of
childbearing age were in their third decade in
1982, they accounted for approximately 66
percent of all births and 55 percent of
abortions. Factors influencing the proportion
of future reproduction-related health care
spending include (1) demographic (i.e., the
aging of the baby boom generation and the
smaller waves of women of childbearing age
coming behind the baby boomers); (2)
technologic (i.e., advances in electronic fetal
monitoring and ultrasound, new fertility drugs,
and improved surgical techniques affect the
level of spending); (3) economic (e.g.,
insurance coverage changes); and (4)
439
Setting Health Care Priorities in Oregon:
Cost-effectiveness Meets the Rule of Rescue.
Form: Journal article.
Author: Hadorn, D.C.
Source: Journal of the American Medical
Association. 265 (17):22 18-2225,
May 1, 1991.
Abstract: The Oregon Health Services
Commission recently completed work on its
principal charge: Creation of a prioritized list
of health care services, ranging from the most
important to the least important. Oregon's
draft priority list was criticized because it
seemed to favor minor treatments over
lifesaving ones. This reaction reflects a
fundamental and irreconcilable conflict
between cost-effectiveness analysis and the
powerful human proclivity to rescue
endangered life: The Rule of Rescue.
Oregon's final priority list was generated
without reference to costs. Therefore, the
author feels it is more intuitively sensible than
the initial list. However, the utility of the
final list is limited by its lack of specificity
with regard to conditions and treatments. An
alternative approach for setting health care
priorities would circumvent the Rule of Rescue
by carefully defining necessary indications for
treatment. Such an approach might be applied
to Oregon's final list in order to achieve better








Source: Journal of the American Medical
Association. 270(4):474-478, July 28, 1993.
Abstract: A researcher estimated the lifetime
cost of medical treatment for persons with
human immunodeficiency virus (HIV) from
onset of infection until death, assuming that an
individual is identified and treated for HIV
immediately following infection. Data from
interviews conducted in 1992 with 1,164 HIV-
positive respondents at 26 sites in 10 cities
(part of the acquired immunodeficiency
syndrome (AIDS) Cost and Service Utilization
Survey (ACSUS)) estimated the monthly cost
of treatment for persons in four stages of HIV
illness from the San Francisco Men's Health
Study (all T-cell counts multiplied by 10 to the
ninth power divided by L): (1) Symptomatic
AIDS based on the 1987 definition, (2) HIV
infection without AIDS with a T-cell count
lower than 0.20, (3) HIV infection without
AIDS with a T-cell count of at least 0.20 and
lower than 0.50, and (4) HIV infection without
AIDS with a T-cell count of 0.50 or higher.
The author multiplied estimates of the monthly
use of services received by respondents by the
cost of each service derived from the provider
survey. The products are estimates of the
monthly cost of medical care incurred by
patients in given stages of illness. This
process was employed for all costs except
prescription drugs. Since billing data from the
pharmacies were generally incomplete, the
costs for prescription drugs were obtained
directly from the provider survey. The weekly
costs for these drugs were $63 for HIVID,
$145 for Sporanox, $203 for Mepron, $50 for
Mycobutin, and $183 for Marinol. Long-term
care costs were estimated to be zero for
persons with HIV without AIDS because only
two of the 380 persons with HIV without
AIDS in the survey had spent any time in a
long-term care facility. The monthly estimate
for stage one is $2,764 per person ($1,890 for
inpatient monthly costs, $380 for outpatient
visits, $174 for home health care, $265 for
drug costs, and $55 for long-term care). The
estimate for stage two is $990 per month ($456
for inpatient monthly costs, $344 for outpatient
visits, $80 for home health care, and $110 for
drug costs). The estimate for stage three is
$430 per month ($119 for inpatient monthly
costs, $191 for outpatient visits, $21 for home
health care, and $99 for drug costs). The
estimate for stage four is $282 per month ($54
for inpatient monthly costs, $151 for outpatient
visits, $10 for home health care, and $67 for
drug costs). This study projects a mean
survival time of 25 months for a person with
AIDS. Multiplying these figures by the
average monthly cost of $2,764 yields an
estimate of $69,100 per person for the cost of
treatment from the time of AIDS diagnosis
until death. Multiplying the average monthly
costs by the mean monthly occupancy time in
stages two through four, 12.4, 44.0, and 67.3,
respectively, yields an estimate of $50,174 for
the cost of treating a person with HIV from
initial infection until a diagnosis of AIDS.
Adding the cost of AIDS diagnosis until death
yields an estimated lifetime cost of $119,274
for treating a person with HIV from the time
of infection until death. The author asserts
that the cost of treating a person with AIDS
has fallen as a result of a reduction in the use





DRGs: Nursing Documentation Contributes
to the Bottom Line.
Form: Journal article.
Author: Hines, G.L.
Source: Nursing Clinics of North America.
23(3):579-586, September 1988.
Abstract: Nursing documentation in the
medical record is an important source of
information for the medical record coder.
Coded data are necessary for quality
assurance, risk management, and research and
statistical purposes, as well as for proper
Diagnosis Related Groups (DRG) assignment
for third-party reimbursement. Researchers
used a Medicare reimbursement rate of $4,326
to calculate DRG payment. Facts gleaned
from nursing documentation, supported by
physician documentation and laboratory data,
can often result in increased reimbursement for
the hospital. Documentation is also important
for statistical purposes, quality assurance, and
risk-management monitoring. Examples of
items that should be documented include (1)
medication errors and drug reactions (e.g.,
coding for treating premature ventricula
reactions due to the patient's adverse effect to
a prescribed drug adds $2,558 in
reimbursement and coding for treating a
patient suffering from reaction to a drug given
in error adds $5,772 in reimbursement); (2)
intravenous filtration and phlebitis (e.g., not
coding infiltration loses $3,009 in
reimbursement and not documenting treatment
of phlebitis as a complication following
surgery loses $1,098 in reimbursement); (3)
complications to treatment (e.g., not
documenting hospital-acquired pneumonia
loses $1,098 in reimbursement and not
documenting malnutrition as a complication to
pneumonia loses $1,687 in reimbursement);
(4) respiratory distress (e.g., not coding
required use of a ventilator for a patient with
severe emphysema loses $10,413 in
reimbursement); and (5) obstetrics and
neonatology complications (e.g., not coding a
sepsis workup and treatment for a newborn
loses $3,114 in reimbursement and not coding
maternal drug use in pregnancy as part of the
delivery room record loses $1,358). DRG
methodology does not adequately describe the
differences in the severity of illness among the
patients within the DRG; nursing
documentation provides a way of grouping
patients to take into account the varying
amounts of nursing care required and support
applications for reimbursement at a rate above
the usual DRG rate.
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Cost Analysis in Family Planning:
Operations Research Projects and Beyond.
Form: Book chapter.
Author: Kenney, G.M.; Lewis, M.A.
Source: IN: Operations Research: Helping
Family Planning Programs Work Better.
Seidman, M.; Horn, M.C.; eds. New York,
NY, Wiley-Liss, Inc., pp. 411-429, 1991.
Availability: Wiley-Liss, Inc., 1 Wiley
Drive, Somerset, NY 08873.
(201) 469-4400.
Abstract: Cost Analysis in Family Planning:
Operations Research Projects and Beyond
addresses the relevance of cost analysis to
operations research (OR) projects on family
planning. The chapter (1) explains the
importance of cost analysis in OR projects; (2)
defines the financial, economic, and resource
costs involved; and (3) describes three
innovative approaches to cost analysis. With
overall increases in the demand for family
planning and declining government resources,
cost and resource allocation have become
increasingly important. Cost analysis within
OR projects allows programs to maximize the
impact of scarce resources and meet the
increasing demand for services. However,
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while the conceptual view of cost is
straightforward, the practical aspects of
measuring and defining cost are often difficult
and confusing. Regarding three concepts of
cost analysis (economic, financial, and
resource cost), complications that arise in
practice include nontraceable costs, the need
for quality control, the issue of measuring
demand, and the importance of the scale of
operation. While most cost analysis OR
projects employ data from controlled
experiments, such studies can have several
disadvantages: They can be costly, can blur
research and implementation costs, and the
findings may not carry over when implemented
on a large scale. Three recent methods for
measuring and analyzing costs that can
enhance OR projects include the multivariate
analysis (hedonic), the measurement of
economic costs and quality, and the cost-
benefit analysis (TIPPS). The chapter
concludes with seven suggested specific
initiatives that would enhance and expand the
scope of cost analysis in family planning and
make cost-effectiveness analysis more relevant
and appropriate for policy and program needs.
19 references.
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Costs and Benefits of Title XX and Title
XIX Family Planning Services in Texas.
Form: Journal article.
Author: Malitz, D.
Source: Evaluation Review. 8(4):5 19-536,
August 1984.
examined billing records to derive a sample
population and sent survey forms to providers
to determine when the patient first visited the
agency, the date of her last visit in FY 1981,
and methods of contraception she used before
her first visit and after her last visit. Sixty-
five of 78 providers returned the survey forms.
The final sample included 1,606 adolescents
(under age 19) and 1,605 adults (over age 20),
representing about 2.5 percent and 1 percent,
respectively, of the adolescent and adult Title
XX populations. Researchers estimated public
assistance costs for births averted and
compared them with the costs of the programs
to derive the cost-benefit ratio. Researchers
estimated that about 56,000 unwanted
pregnancies and 27,000 births were prevented
by the programs, as well as 22,000 abortions
and over 7,000 miscarriages. Cost savings
consisted of expenditures that would have been
incurred in the first year following birth in
TDHR's Aid to Families with Dependent
Children (AFDC), food stamp, and Medicaid
programs. Total first-year savings to TDHR
attributable to births averted by Title XX were
nearly $33 million (including $11.7 million for
adolescent services and $21.5 million for adult
services), or a net saving of nearly $16
million. Cost-benefit ratios were 1:2.44 for
adolescents, 1:1.73 for adults, and 1:1.93 for
all Title XX patients. For Title XIX patients,
the cost-benefit ratio was 1:3.04-1:3.29 for
adolescents, and 1:2.93 for adults. For every
dollar spent on family planning under Title
XIX, the TDHR saved about $3. Researchers
calculated net savings at $10.1 million.
4 tables, 9 references.
Abstract: The Texas Department of Human
Resources (TDHR) provided family planning
services to more than a quarter of a million
women in fiscal year (FY) 1981 through its
Title XX and Title XIX programs. In 1982,
TDHR commissioned a study to evaluate the
impact of these programs; one component was




Decision Analysis for Public Health:
Principles and Illustrations.
Form: Journal article.
Author: McNeil, B.J.; Pauker, S.G.
Source: Annual Review of Public Health.
5:135-161, 1984.
Abstract: Researchers present some of the
basic principles that underlie decision analysis
and their application to public health issues. A
decision analysis consists of five steps: (1)
Structuring the problem so that alternative
courses are defined, (2) estimating the
probability of each chance outcome, (3)
assigning a relative value or utility to each
potential outcome, (4) calculating the best
alternative using the principle of expectation to
average out and fold back the decision tree
model, and (5) performing a set of sensitivity
analyses wherein different assumptions are
varied to determine the robustness of the
conclusions. The techniques of decision
analysis include (1) building trees, (2)
Bayesian probability revision, (3) receiver
operating characteristic (ROC) analyses, (4)
utilities, (5) sensitivity analyses, and (6) costs.
The decision tree is the notation used to
represent the model, with events separated into
those requiring a choice and those occurring
by chance. Bayesian probability revision
relates to diagnostic sensitivity and specificity.
The ROC curve and the mathematics of
optimization are used to produce more reliable
results. Utilities are outcomes on decision
trees and can be assessed using hypothetical
lotteries, or binary scales to calculate the
expected utility of the gamble. Sensitivity
analyses examine the effects of changes in
single or multiple parameters, holding other
parameters constant. The repeated sensitivity
iterations test the robustness of the conclusions
and specify the optimal strategies for
combinations of assumptions. Costs, whether
direct, indirect, or induced, are accounted for
using present and future values of money and
discounted to reflect a real monetary growth
rate. Cost-benefit analyses evaluate strategies
by the difference between dollars expended
and dollars saved. Cost-effectiveness analyses
are defined on a single scale. The differences
in expected costs and expected effectiveness
are calculated as a marginal cost-effectiveness
ratio. Among secondary causes for
hypertension, renovascular disease (RVD) is
most common, with a prevalence of 4.5
percent. In considering RVD screening of the
hypertensive population, there are two
strategies. In strategy one, all patients are
screened for RVD with an intravenous
pyelogram (IVP) and, if this is abnormal,
further examinations are performed. Surgery
is then performed on all patients with
confirmed fibromuscular disease (FM) and to
those with arteriosclerotic disease (AS) who
are considered operable. The balance with AS
are treated medically. In strategy two, no one
is screened. Researchers found that in patients
with FM surgery the net change in quality-
adjusted life expectancy per surgical cure in
years discounted at 5 percent per annum at age
30 is -0.23 years among males, -0.45 years
among females and at age 50 is -0.62 years
and -0.43 years, respectively. The net
increase in cost per surgical cure in patients
with FM surgery at age 30 is $13,000 among
males, $9,000 among females and at age 50 is
$30,400 and $13,400, respectively.
Researchers found that in patients with FM
and AS surgery the net change in quality-
adjusted life expectancy per surgical cure at
age 30 is -1.39 among males, -0.99 among
females and at age 50 is -1.83 and -1.49,
respectively. The net increase in cost per
surgical cure in patients with FM and AS
surgery at age 30 is $10,600 among males,
$8,800 among females and at age 50 is
$12,800 and $10,900, respectively. In the
case of lead screening programs for children, a
decision analysis compared three strategies:
(1) Free erythrocyte protoporphyrin essay
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(FEP), (2) blood lead screening, and (3) no
screening. The marginal cost effectiveness
ratios compared FEP screening versus no
screening, blood lead screening versus no
screening, and blood lead screening versus
FEP screening. Dollar costs per case of
learning disability averted were $220 for FEP
screening versus no screening, $3,370 for
blood lead screening versus no screening, and
$20,940 for blood lead screening versus FEP
screening. Dollar costs per case of mental
retardation averted were $1,500 for FEP
screening versus no screening, $26,300 for
blood lead screening versus no screening, and
$2,010,000 for blood lead screening versus
FEP screening. An example of decision
analytic techniques in immunization practices
is the swine flu program for a general
population. Vaccine efficacy impacts on costs
by its reaction rates and its ability to immunize
against swine flu; the larger the percentage of
individuals accepting the vaccine, the greater
its net effects. A Delphi analysis indicated
that a likely acceptance rate was 67 percent for
members of the general population and 59
percent among high risk individuals and that
the probability of an epidemic was 0.10. If
the vaccine was offered in public programs at
an estimated administration cost of $0.50 per
person in the target group, the break even
acceptance rates for programs in which the
vaccine was offered to the general population 5
years of age and over, 25 years and over, and
just the high-risk group were 53 percent, 37
percent and 24 percent, respectively.
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Determining Optimal Screening Policies
Using Decision Trees and Spreadsheets.
Form: Journal article.
Author: Milsum, J.H.
Source: Computers in Biology and Medicine.
19(4) :23 1-243, 1989.
Abstract: A researcher describes the optimal
screening policies for specific disease or high-
risk conditions in order to minimize overall
expected cost or disutility function. The
author states that if an inexpensive
prescreening is available, by using some
readily available criterion or marker, then the
full screening process could be restricted to a
high-risk group. The model includes decision
trees set up for VP PLANNER, LOTUS 123,
or compatible software based on the
probabilities and costs of all possible
outcomes. Variables and parameters include
(1) the prevalence of the condition in the
population; (2) the proportion of the
population to be screened; (3) the sensitivity of
the screening test, assumed to be 0.95; (4) the
specificity of the screening test, assumed to be
0.80; (5) the true or false positives or
negatives respectively resulting from screening
with the given sensitivity and specificity; (6)
the prevalence in the high-risk screened group;
and (7) the prevalence in the unscreened
group. The author has assigned the following
costs for each of the screening outcomes: (1)
True positive, 100 units; (2) true negative,
units; (3) false positive, 50 units; and (4) false
negative, 1,000 units. If the costs range from
30 to 45 units per person, then the per capita
cost of the screening can be expected to
decrease as the screening population increases.
The cost ratio (cost for whole population
screened by the cost of true positive) is 0.3.
In the decision tree model formulation, when
the prevalence of the condition in the
population is 10 percent, the screened
population is 65 percent with a per capita cost
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of 33.96 and a prevalence of 0.142; the not
screened population is 35 percent with a per
capita cost of and a prevalence of 0.024.
For the screened population, the true positive
cost is 11.77, the true negative is 15.15, false
positive is 9.36, and false negative is 4.78.
The total cost for a true positive is 26.92 and
for a true negative is 22.64. For the not
screened population, the positive cost is 8.49
and the negative cost is 0. The total cost for a
positive is 25.05 and for a negative is 24.51;
total screening cost is 49.56. In the decision
tree model formulation when the prevalence of
the condition in the population is 5 percent,
the screened population is 35 percent with a
per capita cost of 38.30 and a prevalence of
0.109; the not screened population is 65
percent with a per capita cost of and a
prevalence of 0.022. For the screened
population, the true positive cost is 5.01, the
true negative is 9.55, false positive is 5.51,
and false negative is 1.98. The total cost for a
true positive is 14.57 and for a true negative is
22.08. For the not screened population, the
positive cost is 14.59 and the negative cost is
0. The total cost for a positive is 21.59 and
for a negative is 15.06; total screening cost is
36.65. In the decision tree with 5 percent
prevalence, the cost of false conditions rises
relative to the cost of true conditions. Overall
per capita cost falls because the true cases
were reduced by one-half, but the cost per
case is almost 50 percent higher than with 10
percent prevalence, 733 (20 x 36.65) versus
497 (10 x 49.7), which is due mostly to the
identification problem with the lower
prevalence. Determination of the proportion
of population to be screened minimizes overall
costs. The model includes computations of the
prevalences in the screened and nonscreened
sub-populations for different levels of
screening. The microcomputers afford
instantaneous complex calculations and
sensitivity studies. The generalized
implementation on a microcomputer
spreadsheet provides a user-friendly format for
sensitivity and optimization processes across
different parameter conditions.
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Ante-natal Screening: What Constitutes
Benefit?
Form: Journal article.
Author: Mooney, G.; Lange, M.
Source: Social Science and Medicine.
37(7): 873-878, 1993.
Abstract: Researchers discussed the
application of economic appraisal in prenatal
screening. In particular, they examined the
way in which economists to date have
attempted to measure and value the benefits of
prenatal screening. They argued that there are
problems with existing approaches particularly
in terms of the nature of women's utility
functions and which arguments are present in
these utility functions. They suggested that
policy makers are unlikely to take full account
of the results of such analyses until economists
better attempt to reflect measures of what
women want from prenatal screening. Three
separate but related approaches to the
assessment of the benefits of prenatal screening
programs are found in the economic appraisal
literature: (1) The resource savings method,
(2) the excess costs method, and (3) the
replacement method. The resource savings
method assumes that there is no replacement of
any aborted fetus. Therefore, the average
family size for any woman is reduced by
exactly one as a result of the existence of a
screening test which reveals an affected fetus
which she chooses to abort. The excess costs
method assumes that there is instantaneous
replacement of the affected fetus by a normal
fetus of the same gestational age. In this case,
family size is not affected. The replacement
method assumes that there is a delay in
possible replacement to allow for the normal
biological processes to occur. It also accepts
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in principle replacement rates of anything from
percent to above 100 percent. The logic of
the over 100 percent figure is that in a world
with an effective diagnostic test for, say,
Down's Syndrome, women may choose to
conceive and give birth when otherwise they
would not. 1 table, 22 references.
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Cost-Effectiveness Analysis in Pediatric
Practice.
Form: Journal article.
Author: Pantell, R.H.; Berwick, D.M.
Source: Pediatrics. 85(3):361-364,
March 1990.
Abstract: Two physicians present a
commentary on how physicians decide to
balance their responsibilities to an individual
patient with their social responsibility. They
examine the analytical methods used by Lieu et
al., which provide an example of decision
analysis applied to a common pediatric
problem. The steps used by Lieu et al. to
create the analysis include: (1) What
alternatives are considered in the decision
tree?; (2) what probabilities do the authors
use?; (3) which outcomes are included and
which are not?; (4) what costs are included
and how are they assessed?; and (5) is
sensitivity analysis thorough? All decision
analyses are arbitrarily bounded by the
selection of some initial set of options. Lieu et
al. consider four different clinical outcomes:
(1) Rheumatic fever, (2) rheumatic heart
disease, (3) suppurative complications of
pharyngitis, and (4) allergic reactions to
penicillin. However, they omit an infinite
number of other possible strategies. When
decision analysis enters the terrain of cost-
effectiveness analysis, as in the article by Lieu
et al., choices are made about how to assess
dollar costs and benefits. In Lieu et al.'s
article, direct medical costs are included, but
indirect costs such as patient time, work lost,
and some forms of institutional overhead are
not. These choices are subtle and important
and become even more complex when one
attempts to move from medical charges, which
may not reflect true costs, to more accurate
cost estimates. Because decision analyses
depend on many estimates that do not have
firm bases, it is customary to repeat the
calculations of cost, risk, and benefit many
times, letting the uncertain variables change
through their range of uncertainty. This
procedure is called sensitivity analysis, because
it allows one to explore the sensitivity of the
preferred choice within the range of current
uncertainty. Decision analysis is a tool to
support decision, not a replacement for
judgment. In the Lieu et al. article, it is the
authors' best guess that their preferred
strategy, antigen test alone, can prevent
rheumatic fever at a cost of $52,208 per case
prevented and severe rheumatic heart disease
at more than $1 million per case prevented.
The wisdom of these investments in prevention
is an issue that goes far beyond formal analytic
techniques. 13 references.
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Cost-Benefit Analysis of the Policy of
Prevention of Preterm Delivery.
Form: Book chapter.
Author: Papiernik, E.; Bretz, H.
Source: IN: Effective Prevention of Preterm
Birth: The French Experience Measured at
Haguenau. Papiernik, E.; Keith, L.G.;
Bouyer, J.; Dreyfus, J.; Lazar, P., eds.
White Plains, NY, March of Dimes Birth
Defects Foundation, pp. 207-214, 1989.
Availability: March of Dimes Birth Defects
Foundation, 1275 Mamaroneck Avenue,
White Plains, NY 10605.
Abstract: Cost-Benefit Analysis of the Policy
of Prevention of Preterm Delivery, a book
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chapter, relates details of a study occurring
between 1971 and 1982 that measured the
additional costs and specific benefits resulting
from a preterm birth policy in France.
Researchers at first did not include normal
costs associated with pregnancy and prenatal
care, but included costs and benefits resulting
from the changes in the number of prenatal
consultations (100 French francs (F) per
consultation), work leaves (80 F per day),
hospitalizations (1,000 F per day), and
newborn babies transferred to a pediatric
department or neonatal resuscitation unit
(2,320 F per day). Eventually all
consultations, additional work leaves, and
hospitalizations in the first two trimesters were
considered as a cost attributable to the preterm
delivery prevention program even though this
method overestimated the true cost (figures for
true cost were not stated). Investigators also
made similar choices in measuring intervention
benefits. The average number of prenatal
consultations increased dramatically, from 1.9
in 1971 to 5.9 in 1982, and the frequency of
work leaves prior to legally mandated
pregnancy leave increased from 24 percent to
48 percent. Based on 1982 francs and a fee of
100 F per consultation, the additional charge
for four consultations per 1 ,000 pregnancies
was 400,000 F. The prevention cost for 1,000
births was 1,467,000 F. The savings from the
reduction in the number of neonatal
hospitalizations was 903,430 F. This meant
that the immediate benefit in avoided
hospitalizations covered two-thirds of the
prevention cost. An estimated 240 life years
without handicap per 1,000 births were gained.
The monetary value for each year of life
without handicap gained by the program comes
to 543,370 F divided by 240, or 2,265 F.
3 tables.
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Utility-Based Model for Comparing the
Cost-effectiveness of Diagnostic Studies.
Form: Journal article.
Author: Patton, D.D.; Woolfenden, J.M.
Source: Investigative Radiology.
24(4): 263-271, April 1989.
Abstract: Researchers evaluate cost-
effectiveness models for the detection task of
diagnostic testing and suggest a utility-based
model for comparing the relative cost-
effectiveness of diagnostic procedures for both
the individual patient who is to have diagnostic
testing and a population for which policy
decisions regarding diagnostic testing have to
be made. The expected direct cost (EDC)
equals the base cost of the test plus the
expected cost of morbidity and mortality. The
effective cost (EC) of a diagnostic test is the
money spent per unit of diagnostic
performance. The unit of diagnostic
performance can be measured as diagnostic
utility (DU), or expected utility, the
probability-weighted sum of the utilities of the
four test outcomes, true positive (TP), true
negative (TN), false positive (FP), and false
negative (FN): DU equals U(TP)P(TP) plus
U(TN)P(TN) plus U(FP)P(FP) plus
U(FN)P(FN). The utility is a relative measure
taking on values between negative 1 (worst
possible outcome) and positive 1 (best possible
outcome). DU incorporates the clinical
decision analytic variables sensitivity (Se),
specificity (Sp), equivocal fraction (EF),
disease probability (P(D)), and outcome utility
(U). DU is not an inherent property of a
diagnostic test but of test-observer interactions
in a clinical setting. The model sets the
effective cost (EC) of a diagnostic test equals
actual direct cost (ADQ/DU. When DU
equals 1 (perfect test) EC equals ADC and the
patient benefits from the test dollar for dollar.
When DU is less than 1, EC exceeds ADC. If
DU approaches zero, EC becomes infinite and
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the test has no effectiveness at any cost. DU
depends strongly on P(D). If Se and Sp differ
significantly, then EC also depends on P(D),
and the effective cost of a test performed in
the wrong P(D) setting may be several times
its actual direct cost. The authors use two
studies to illustrate use of the model: (1)
Snow et al. and (2) Alderson et al. which
compare three tests for detecting metastatic
disease in the liver; a radionuclide liver scan,
a computed tomography (CT) study, and an
ultrasound study. They calculated expected
direct costs and diagnostic utility using 1983
base costs (CT $475, ultrasound $150, liver
scan $300). For an estimated mean associated
cost of $200 and a mortality cost of $200,000,
the expected direct cost of the CT scan is
$451.21 for no mortality and no morbidity;
$33.74 for morbidity with no mortality; $0.89
for morbidity with mortality; and $17.84 for
mortality. The outcome costs equal $503.68.
The morbidity and mortality costs in this case
added 6 percent to the base price. Based on
total calculations, the data from Snow et al.
indicate that group CT had the highest
diagnostic utility and ultrasound had the lowest
over all ranges of P(D). Taking into account
all costs, CT would have the lowest effective
cost of all three tests at low P(D), liver
scanning the lowest at midrange, and
ultrasound the lowest at high P(D) (confirming
test). The high base cost of CT scanning was
counterbalanced by its high performance, the
low performance of ultrasound by its low base
cost. The model requires the user to insert his
or her own sensitivity and specificity values
since the values differ from institution to
institution. When the data allows, the authors
suggest using a receiver operating
characteristic (ROC) curve for diagnostic tests
to obtain the optimum operating point. This
model of comparing effective costs compares
actual direct cost with clinical measures of test
performance and utility values that allow
expression of patient/doctor fears and
preferences.
450
Time Preference in Medical Decision
Making and Cost-Effectiveness Analysis.
Form: Journal article.
Author: Redelmeier, D.A.; Heller, D.N.
Source: Medical Decision Making.
13(3):212-217, July-September 1993.
Abstract: Researchers measured the time
preferences held by individuals toward
hypothetical health states, determined their
implicit discount rates, and tested whether
individuals' implicit discount rates conformed
to the assumptions of the standard medical
economic model of time preference. Subjects
included a random sample of 121 medical
students, house officers, and attending
physicians. The participants were contacted by
telephone and scheduled for a face-to-face
interview and questionnaire (80 percent
response rate). The questionnaire contained
detailed descriptions of three hypothetical but
realistic medical scenarios. The first scenario
described a strangulated internal hernia, having
a colostomy for 4 months, and subsequent
intestinal reattachment with colostomy closure.
The second scenario described herpetic
keratitis that caused 4 months of painless
bilateral blindness but no scarring or residual
complications. The third scenario described an
episode of psychiatric depression that resolved
after four months on medication. Participants
imagined that each event was destined to occur
at five sequentially different times in the
future: 1 day, 6 months, 1 year, 5 years, and
10 years, or 15 distinct prospects.
Researchers measured the disutility of each
prospect using two utility-elicitation
techniques: (1) Standard gamble, and (2)
categorical scaling. The standard gamble
required the respondent to indicate his or her
indifference probability relative to a gamble
between the event's occurring immediately and
the event's being prevented altogether. The
categorical-scaling technique required the
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respondent to indicate how bad a given
prospect was using a scale of to 100, where
represented the worst news and 100
represented the best. Discount rates were
estimated for each scenario separately for each
of the elicitation techniques. The final sample
of 1,394 implicit discount rates provided the
data for analyses in the exponential discount
model. To determine whether discount rates
were constant over time, investigators used the
paired t-test to evaluate proximal and distal
discount rates. They also used a paired t-test
to compare implicit discount rates for the
elicitation techniques. Of all the discount
rates, 62.1 percent equalled zero, 10 percent
were less than 0, and 15.7 percent were
greater than 0.10. Mean discount rates for
relatively proximal time intervals tended to be
larger than those for relatively more distant
intervals (0.041 versus 0.025, p less than
0.01). Mean discount rates for blindness
tended to be smaller than those for colostomy
or depression (0.023 versus 0.039 versus
0.037, respectively, p less than 0.005).
Hence, respondents' implicit discount rates are
not always small positive numbers that are
constant over time and the same for all
settings. The authors suggest that the
conventional exponential discount model may
not fully characterize the time preferences held
by individuals.
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Source: Ciba Foundation Symposium.
110:203-217, 1985.
Abstract: A researcher discusses the design
aspects of cost effectiveness analysis of
preventive care advances and its evolution
from an application of economic reasoning to
an accepted aid in decision making. The
design aspects reviewed include (1) the issues
of the perspective of the study, (2) the choice
of discount rate, (3) medical costs in added
years of life, (4) measurement of the costs of
institutionalization, (5) measures of health
effects that reflect changes in the quality as
well as the quantity of life, and (6) the proper
place of estimates of earnings. The Weinstein
and Stadon (1977) cost effective formula
included an analysis of prevention where costs
equal the medical costs of the preventive
measure; minus savings in acute medical care,
rehabilitation, and long-term institutional care;
plus costs of treating side effects of the
preventive measure; plus costs of ordinary
medical care during added years of life. In
this formula, the effects equal the lives or
years of life saved by prevention minus lives
or years lost to side effects. The effects
reflect gains and losses in quality of life as a
result of prevention expressed in terms of an
equivalent number of years of healthy life.
The costs and effects are discounted, summed,
and expressed in the form of a cost-
effectiveness ratio. The author suggests (1)
that the social perspective is preferable because
it does not represent any group's point of
view, no other perspective is predominant, and
all costs and effects are included; (2) that all
studies use 5 percent as the discount rate; (3)
that the formula be calculated both ways by
excluding and calculating medical costs in
added years of life; (4) that the relevant costs
of institutionalization are over and above the
costs if the same person lived a normal life;
(5) adoption of the quality-adjusted life year as
the standard for measuring health effects; and
(6) including earnings when the consequences
of a program can be measured in dollars, to
represent detail and amplification of health
effects, and excluding earnings when they
result in double-counting health effects. Other
issues that affect the comparability of studies
include: (1) Value on patients' time, which is
often excluded; (2) the assumption that not all
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patients comply with the prescribed regimen in
a prevention program, while studies of acute
care generally assume full compliance; and (3)
point estimates that are not comparable
estimates of precision, or uncertainty. The
author suggests that (1) probability
distributions be assigned to each of the
important parameters in a study, (2) a
probability distribution or standard error be
generated empirically for the cost-effectiveness
ratio, and (3) cost effectiveness studies be
more consistent in approach and more
standardized in assumptions so that valid
comparisons can be made.
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Framework of a Protocol for the Evaluation




Source: European Journal of Obstetrics,
Gynecology and Reproductive Biology.
28(Supplement): 69-77, 1988.
Abstract: Guidelines are presented for the
economic evaluation of prenatal screening
procedures. The topics addressed include (1)
the meaning of economic evaluation, (2) the
determination of priorities in evaluative
research, (3) the relative range of alternatives,
(4) the selection of the type of analysis, (5) the
measurement of costs and benefits, (6) the
assessment of costs and benefits, (7)
uncertainty, and (8) presentation of the results.
Economic evaluation can be defined as the
comparative analysis of alternative courses of
action in terms of both their costs and
consequences. One can establish priorities by
performing a global cost-effectiveness analysis
for each prenatal screening procedure under
consideration. Economic evaluation should
include a thorough comparison of competing
alternatives. Types of analysis include cost
analysis of a new procedure compared to
existing procedures, and cost per quality
adjusted life year. A societal viewpoint is
important when considering the relevant range
of costs and benefits; all relevant costs and
benefits of the procedure should be considered
in the analysis. Sources and methods of
valuation of costs and benefits should be
clearly stated. Costs are normally valued in
units of local currency, based on prevailing
prices of personnel, commodities, and
services. All current and future program costs
are normally valued in constant dollars of
some base year. In the absence of reliable
medical evidence for some technologies,
economists have applied sensitivity analysis to
a number of medical parameters. It is
important that results be presented in a way
that helps a decision maker appreciate their
relevance to his or her circumstances. It is
also important to (1) identify differences
between locations, (2) identify key value
judgments clearly in presentations, and (3)
recognize that there are other relevant factors
in decision making, such as equity in the
provision of services. 2 tables, 10 references.
453
Explaining Resource Consumption Among
Non-normal Neonates.
Form: Journal article.
Author: Schwartz, R.M.; Michelman, T.;
Pezzullo, J.; Phibbs, C.S.
Source: Health Care Financing Review.
13(2): 19-28, Winter 1991.
Abstract: The adoption by Medicare in 1983
of prospective payment using diagnosis-related
groups (DRG's) has stimulated research to
develop case-mix grouping schemes that more
accurately predict resource consumption by
patients. Researchers compared the DRG and
pediatric modified diagnosis-related groups
(PMDRG's), presenting a new method
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designed to improve case-mix classification for
newborns through the use of birthweight in
combination with DRG's to adjust the
unexplained case-mix severity. Investigators
added a continuous birthweight function to the
current DRG's for sick newborns, allowing
full exploitation of the strong correlation
between birthweight and resource consumption
by newborns. They used regression analysis
to compare the predictive power of the
models. Analytic models examined cell size
and explanatory power of the DRG's, the
PMDRG's, and the simplified grouping
scheme (BWDIS) developed by the authors
which uses birthweight and discharge status
only. By dividing cases into more and more
refined categories, one can classify nonnormal
neonates into case-mix groups that are
homogeneous across groups of hospitals.
However, there is a tradeoff between greater
explained variation and large numbers of small
cells. BWDIS model regressions reveal that
the current DRG's can be easily improved
without using any diagnostic information. The
use of the birthweight function as a DRG
adjuster is one improvement that would not
require additional groups, and it is objective.
The use of a continuous birthweight adjustment
for DRG's to better reflect case mix will allow
the current payment method to more accurately
reflect severity and thereby pay for care more
precisely. 3 figures, 7 tables, 14 references.
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Economic Evaluation of Neonatal Intensive
Care: Which Variables Have to be Known?
Form: Journal article.
Author: Sinclair, J.C.
Source: International Journal of Technology
Assessment in Health Care.
7(Supplement 1): 146-150, 1991.
Abstract: The author discusses health care
evaluation in economic terms and stresses that
this type of evaluation is fundamentally an
exercise about opportunity costs. Meta-
analysis demonstrated that the elements of an
economic evaluation include (1) a well-defined
question posed in answerable form, specifying
the alternatives for each comparison; (2) a
specific description of the competing
alternatives; (3) prior or simultaneous evidence
of the program's effectiveness; (4)
identification of the important and relevant
costs and consequences for each alternative;
(5) accurate measurement of the costs and
consequences; (6) credible valuation of the
costs and consequences; (7) adjustment of the
costs and consequences for differential timing;
(8) an incremental analysis of costs and
consequences of alternatives; and (9) a
sensitivity analysis. The evaluator's viewpoint
will affect the relevancy of different cost
categories such as operating costs, and
consequences such as effects, utilities, and
benefits. Most analyses can be classified into
five types of data analysis: (1) Cost analysis,
(2) cost minimization, (3) cost-effectiveness,






International Experience With Cost-
Effectiveness Analysis and Cost-Benefit
Analysis.
Form: Monograph.
Author: Sirageldin, I.; Salkever, D.;
Osborn, R.; Cebula, D.; Evenchik, A.;
Lewin, N.; Mandel, P.; eds.
Source: New York, NY, St. Martin's Press,
Inc., 534 p., 1983.
Availability: St. Martin's Press, Inc.,
175 Fifth Avenue, New York, NY 10010.
(800) 221-7945.
Abstract: Evaluating Population Programs:
International Experience With Cost-
Effectiveness Analysis and Cost-Benefit
Analysis examines cost-benefit analysis (CBA)
and cost-effectiveness analysis (CEA) of the
planning and evaluation of population and
policy programs, particularly in Africa, Asia,
and Latin America. Intended for population
and health program managers, planners, policy
makers, and social scientists working in the
field of population planning programs, the
papers in this book were written by
participants in the International Workshop on
Cost-Effectiveness and Cost-Benefit Analysis
of Population Planning Programs, which met
in August 1981. The volume has two parts,
the first of which covers methodological and
conceptual issues such as CBA/CEA
techniques and their applications to manpower
and population policies. Contents of the first
part include the main workshop background
paper; an overview of the literature of cost-
effectiveness as applied to family planning
programs; and other papers focusing on a
methodological or conceptual issue in the
application of CBA/CEA to population
activities. The second part examines the
application of CBA/CEA to family planning
programs. Presented are empirical findings
from 12 case studies in 9 countries (2 African,
2 Asian, and 5 Latin American). The
problems of program application included
issues of measurement, cost estimation, and
standardization of output measures. The book
includes numerous tables and figures;
references follow some chapters, and there are
four appendixes.
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Oregon Formula: Health Economists'
Dream or Stalinist Nightmare?
Form: Journal article.
Author: Stevenson, R.
Source: Archives of Disease in Childhood.
66(8): 990-993, August 1991.
Abstract: Under new arrangements for the
British National Health Service (NHS),
purchasers of health care must make contracts
with health care providers. That process will
make explicit choices about whether to treat or
not to treat a condition. The Oregon formula,
the only comprehensive system for making
such decisions, relates the cost of a medical
intervention to its benefits, measured in
quality-adjusted life years (QALY) gained.
Treatments are ranked according to the cost of
producing one QALY; the intention is to first
purchase the cheapest QALY's, then the
second cheapest, and so on until the budget is
exhausted. Procedures ranked below a cut-off
point will not be offered. Cost utility analysis
has much in common with cost effectiveness
analysis (which seeks to find the method of
least cost for achieving a well-defined
objective), but focuses directly on the welfare
of the patient by seeking alternative means of
producing QALY's. The Oregon system has
addressed the problem of scarce resources by
disallowing treatment for some conditions
(e.g., treatments for infertility and neonatal
care for very-low-birthweight infants).
Pediatric interventions rate highly in cost per
QALY ranking in many respects, and there are
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many areas where cost utility analysis in
pediatrics is unique because the infants cannot
make their own decisions. In pediatrics, the
decision to treat or not to treat can have
profound financial and nonfinancial
implications for parents and siblings as well as
for the health services. The author notes two
objections to a priority system based on
QALY's: (1) It does not adhere to principles
of equity within the NHS, and (2) the Oregon
system is vulnerable on operational grounds.
There is no consensus on how valuations of
health should be made and whose opinions to
take into account. (The Oregon Health
Commission used telephone interviews to
sample public opinion on valuations of health.)
A fully operational scheme requires the
evaluation of (1) all medical therapies; (2) a
large number of inputs to those treatments; (3)
choices between preventive and curative
medicine; (4) hospital, community and
alternative location care; and (5) changes in
costs and technology. To meet these data
requirements even partially would require a
huge (and costly) input from clinicians,
economists, accountants, and other health care
workers. Estimates of the costs of QALY's
gained are averages derived from statistical
samples of patients, but averages may not be a
good guide to the cost of gaining a QALY for
particular patients. One great concern is that a
rigid system of priorities, based on highly
imperfect estimates of the cost of gaining a
QALY, could negate clinical freedom to
pursue the best interests of individual patients.
A full-scale NHS implementation of the
Oregon approach seems premature in the
present state of the art of health care
evaluation. 11 references.
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Selective Screening: When Should




Source: Journal of General Internal
Medicine. 5(5, Supplement) :S47-S49,
September-October 1990.
Abstract: A researcher evaluated whether
screening to detect early disease should be
limited to screening of high-risk subjects, a
selective screening. He suggests that for a
selective screening program to be successful,
the screening test should have a high level of
accuracy, in addition to accurate discrimination
of who is at high risk. Identification of high-
risk subjects is done for the purpose of
carrying out secondary prevention, not to
detect risk factors causally related to the
disease. He proposes that, unlike primary
prevention, the purpose of screening for early
disease detection is not to modify the risk
factors, but to identify and treat individuals
with subclinical disease. The author uses a
hypothetical population of 2,000 individuals
uniformly distributed in terms of presence or
absence of two risk factors that has a total of
240 prevalent cases. Prevalence rates are
given for each stratum formed on the basis of
combinations of the two risk factors. The
prevalence rate ratio for each risk factor is
3.0. Three options are available: (1) Screen
all subjects in the population, (2) screen
subjects who are positive for only one of the
risk factors, or (3) screen subjects who are
positive for both risk factors. For all options,
it is assumed that the same test is being used
and that its sensitivity and specificity are both
90 percent. The sensitivity allows
identification of 90 percent of all the cases, or
216 out of the 240; however, the false-positive
rate is fairly high, since 176 (45 percent) of
the 392 test positives are not true cases. If the
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initial screening examination costs $200, the
cost per true case found in the entire
population is approximately $1,850. Another
strategy is to screen only those individuals who
are positive for one of the risk factors.
Screening for only one risk factor reduces the
population to be screened and the sensitivity of
the test (from 90 percent to 60 percent), but
the specificity increases for the more selective
group and the false positive rate is lower. On
the other hand, the false-positive rate also
decreases when only high-risk groups are
screened and as a consequence, there is a
reduction in cost per true case found by a
selective, compared with a nonselective
screening program. If the initial screening
examination costs $200, the cost per true case
found in when only one risk factor is present
is approximately $1,390 and when both risk
factors are present is $1,110. Even if risk
factors are independent and do not interact
with each other, when the high risk group is
defined by a combination of risk factors,
rather than by only one risk factor, program
sensitivity decreases further, although the
false-positive rate and the cost of the program
also decrease. Therefore, program sensitivity
in selective screening can be low even when
conditions are favorable, with a high disease
prevalence and a strong interaction between
risk factors. The distinction between test
accuracy and program accuracy presented in
the context of impact on cost/true cost
detection, reflects the gain in specificity and
loss in sensitivity for the total target
population. When two or more risk factors
are combined to define high-risk subjects, a
gain in program accuracy and a relative
reduction in cost/true case found develop if
there is additive interaction between these risk
factors. Although periodicity of screening is
hard to determine, it is a function of several
factors, including (1) the duration of the
detectable preclinical interval preceding the
critical point (the point in time beyond which
screening is less effective or ineffective), (2)
the accuracy of the screening examination, (3)
the severity of the disease, and (4) the risks
and costs associated with the screening
procedures. The author suggests that risk
factors that predict disease incidence should
not also be used as a criterion for periodicity
of screening and that if the durations of the
detectable preclinical intervals preceding the
critical point are the same for low-risk and
high-risk subjects, there is no reason the
second screening examination should be
offered after a longer period in low-risk,
compared with high-risk subjects. The
screening will capture only cases that have a
long detectable preclinical phase, which may
have a better outlook regardless of screening.
Selective screening for secondary prevention is
a function of current epidemiologic knowledge
of risk factors for disease occurrence, which
determines the quality of criteria to classify
subjects into high-risk or low-risk subsets of
the target population.
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Source: Journal of the American Academy of
Audiology. 2(3): 195-205, July 1991.
Abstract: A researcher presents a simple
model that permits the calculation of the
performance and cost of early identification
protocols regarding hearing loss. The author
asserts that the model is sufficiently general to
accommodate most early identification
strategies including those that meet the goal of
identification and habilitation by age 6 months.
The model measures protocol performance
using hit rate, false alarm rate, and selected
posterior probabilities. It calculates two
measures of the financial cost: One measure
reflects the cost of implementing the protocol,
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the other reflects the cost effectiveness of the
protocol. The parameters required by the
model are based on published clinical data and
include disease prevalence, hit rate/false alarm
rate of the individual tests in the protocol, and
test correlation. Because the model has the
ability to compare different early identification
protocols on the basis of cost and
performance, the model helps audiologists
design and select early identification protocols
that are optimal for their particular clinical
situation. The author concludes that the model
generates a quality and quantity of information
not available elsewhere. This information can
be combined with other important factors, not
considered in the model, to produce a
reasonable, defensible cost-benefit analysis.
3 figures, 1 table, 33 references.
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Principles of Cost-effective Resource
Allocation in Health Care Organizations.
Form: Journal article.
Author: Weinstein, M.C.
Source: International Journal of Technology
Assessment in Health Care. 6(1):93-103, 1990.
Abstract: A researcher examines the
applicability of the cost-effectiveness
framework to resource allocation in health care
organizations. The general cost-effectiveness
model is applicable when the following
conditions are met: (1) A well-defined
measure of effectiveness or program
performance; (2) a specified resource
constraint; and (3) a set of programs from
which to choose, each of which produces some
quantity of effectiveness and consumes some
of the constrained resource. The author
discusses the societal perspective of cost-
effectiveness analysis, where the constrained
resource is the total economic output of the
society, i.e., its net burden on the gross
national product (GNP). The components of
net economic costs in a societal cost-
effectiveness analysis are (1) direct health care
costs (or savings), (2) direct personal costs (or
savings), (3) direct nonhealth costs (or
savings), and (4) indirect costs (or savings).
Direct health care costs (or savings) include
costs directly related to the program or
technology, costs (or savings) of tests and
treatments induced (or averted) as a result of
clinical information obtained, costs required to
treat side effects and complications, savings
because of avoidance and subsequent
morbidity, and costs of treating conditions
during added years of life. Direct personal
costs (or savings) include transportation, home
care services, equipment and supplies used in
the home, and special foods. Direct nonhealth
costs (or savings) include property damage or
loss, crime and criminal justice costs, and
special education costs. Indirect costs (or
savings) include productivity gains or losses
and opportunity cost of time spent by patients
(e.g., travel, waiting for providers,
hospitalization). Costs and health
consequences that occur over time should be
discounted to present value and projected to
future value. The most important difference
between the societal perspective and the
limited health care sector is that costs and
savings not affecting the use of health care
resources are not included in the numerator of
the C/E ratio; nonhealth direct costs and
indirect costs and savings do not affect the
measure of cost from this perspective. The
difference in interpretation of the government's
interest versus the societal interest is that
health care costs not financed from public
funds would be excluded, as would direct
personal costs. The taxable portion of indirect
costs and savings (earnings) and nonhealth
costs that are publicly financed (e.g., special
education, disability) would be included. In a
government agency program, such as
Medicare, the cost of a technology or program
is its effect on the agency's budget. Costs not
covered by the agency's jurisdiction, personal
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costs, indirect costs and savings, and nonhealth
costs falling outside the agency's jurisdiction
would be excluded. In a managed care setting,
if the revenues are regarded as fixed, costs and
savings are those related to health care services
provided to members. Implied resource
constraint means that net income in the long
run must be positive, after considering the
opportunity cost of investment. Resource
allocation decisions in hospitals relate to the
mix of primary services offered, to the content
of care within an admission, and to the
acquisition of technologies for clinical use.
Consumer-based decisions about health
insurance, utilization of services paid partly or
fully out of pocket (because of deductibles,
copayments, or exclusions) and personal health
practices (diet, exercise, random monitoring,
self-help groups) must be made within the
limits of personal resources. T.H. Lee et al.
analyzed screening strategies for left-main
coronary artery disease. They calculated the
cost and effectiveness of five alternative
strategies: Observe only, three strategies
involving exercise electrocardiography but
differing according to the criterion for
proceeding to angioplasty (ST-segment
depression greater than 3 mm, 2 mm, or
1 mm, respectively), and angioplasty for all
patients. Costs included the cost of screening,
the expected cost of angioplasty, and the cost
of coronary artery bypass surgery for patients
found to have left-main coronary artery
disease. Effectiveness was measured in years
of life gained, attributable to the benefit of the
surgery. In 40 year olds, the strategy of
screening with a 3 mm threshold for
angiography resulted in a cost of $1,381 per
patient and a gain of 0.271 years of life
expectancy, for a ratio of $5,092 per year of
life gained. The more aggressive strategy of
screening with a 1 mm threshold for
angiography resulted in a cost of $3,077 per
patient and a gain of 0.356 years of life
expectancy, for an average cost of $8,637 per
year of life saved. In examining incremental
costs and gain in life expectancy, compared to
the 2 mm strategy, the 1 mm strategy adds
$785 per patient and yields only 0.004 years
of life, for a C/E ratio of $187,300 per year of
life saved. Therefore, the extra $785 per
patient may be better spent elsewhere in the
health care system. The incremental C/E ratio
for the screening strategy with a 3 mm ST-
segment threshold for angiography, as noted,
is $5,092 per year of life saved. The
incremental C/E ratios for the 2 mm and
1 mm strategies are $11,263 and $187,300,
respectively. Even though the 3 mm strategy
appears to be the most effective due to its low
incremental C/E ratio, it is not as aggressive
as the 2 mm strategy (the best buy at
$11,263). The author recommends that
analysts interpret C/E ratios correctly, always
perform sensitivity analyses, and measure





Comparison of Cost-Sharing Versus Free
Care in Children: Effects on the Demand
for Office-Based Medical Care.
Form: Journal article.
Author: Anderson, G.M.; Brook, R.;
Williams, A.
Source: Medical Care. 29(9): 890-898,
September 1991.
R461
Choosing Sample Sizes to Maximize
Expected Health Benefits Subject to a
Constraint on Total Trial Costs.
Form: Journal article.
Author: Baker, S.G.; Heidenberger, K.
Source: Medical Decision Making.
9(1): 14-25, January-March 1989.
R462
Health Gains From Screening for Infection
of the Lower Genital Tract in Women
Attending for Termination of Pregnancy.
Form: Journal article.
Author: Blackwell, A.L.; Thomas, P.D.;
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Author: Bose, C.L.; LaPine, T.R.;
Jung, A.L.
Source: Medical Care. 23(1): 14-19,
January 1985.
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Maternal Screening in Prevention of
Neonatal Infections: Current Status and




Source: Journal of Hospital Infection.
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Hysterectomy: The Initial Nashville,
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